URL: https://www.austlii.edu.au/cgi-bin/viewdoc/au/other/lawreform/VLRC/2015/32.html
Scraped: 2025-11-17 16:51:19
================================================================================

Cases & Legislation
Journals & Scholarship
Communities
New Zealand
Specific Year
Medicinal Cannabis [2015] VLRC 32
Medicinal Cannabis
REPORT AUGUST 2015
Published by the Victorian Law Reform Commission
The Victorian Law Reform Commission was established under the
Law Reform Commission Act 2000
as a central agency for developing law reform in Victoria.
© Victorian Law Reform Commission 2015.
This work is protected by the laws of copyright. Except for any uses
permitted under the
(Cth) or equivalent overseas
legislation, no part of this work may be reproduced, in any matter or in any
medium, without the written
permission of the publisher. All rights
This publication of the Victorian Law Reform Commission follows the
Melbourne University Law Review Association Inc,
Australian Guide to Legal
(3rd ed., 2010).
This report reflects the law as at 1 August 2015.
National Library of Australia
Cataloguing-in-Publication data
Medicinal Cannabis:
Report / Victorian Law Reform Commission 32
ISBN 9780994372314 (paperback)
Series: Report (Victorian Law Reform Commission) Subjects:
Cannabis—Law and legislation—Victoria. Cannabis—Therapeutic
use—Victoria.
Dewey Number: 364.177
Ordered to be published
Victorian Government Printer 2015
PP number 68, session 2014-2015.
The Hon. Philip Cummins AM
s p e c i a l i s t c o m m i s s i o n e r
Dr Ian Freckelton QC
c o m m i s s i o n e r s
Liana Buchanan Helen Fatouros Bruce Gardner
Dr Ian Hardingham QC
His Honour David Jones AM Eamonn Moran PSM QC Alison O’Brien
The Hon. Frank Vincent AO QC
c h i e f e x e c u t i v e o f f i c e r
Merrin Mason
r e f e r e n c e t e a m
Lindy Smith (team leader) Michael Adams
Sharyn Broomhead
Claire Leyden-Duval
c o v e r d e s i g n
t e x t l ay o u t
Medicinal Cannabis
AUGUST 201 5
Victorian Law
Reform Commission
333 Queen Street
+61 3 8608 7800
law.reform@lawreform.vic.gov.au
GPO Box 4637 Melbourne Freecall
www.lawreform.vic.gov.au
Melbourne Victoria 3000 1300 666 555
Victoria 3001 Australia
(within Victoria)
DX 144, Melbourne +61 3 8608 7888
......................................................................................................................................
vii Terms of
reference....................................................................................................................
ix Glossary
......................................................................................................................................
x Executive summary
................................................................................................................
xvi Recommendations
..............................................................................................................xxxiv
1. Introduction
...........................................................................................................................
Terms of reference
...........................................................................................................
The Commission’s process
...............................................................................................
The Commission’s approach
............................................................................................
Scope of the reference
...................................................................................................
Focus of inquiry
.............................................................................................................
Regulatory objectives
.....................................................................................................
............................................................................................................................
Expectations about
implementation............................................................................
A regulator
.................................................................................................................
An advisory body
.........................................................................................................
measures..........................................................................................................
developments.............................................................................................
Rescheduling of
cannabidiol.........................................................................................
trials.................................................................................................................
Regulator of Medicinal Cannabis Bill 2014
........................................................... 14
Draft Drugs of Dependence (Cannabis Use for Medical Purposes) Amendment Bill
...........................................................................................................................
Tasmanian parliamentary inquiry
..................................................................................
Norfolk Island licence to cultivate and export cannabis
................................................. 17
Structure of this
report..................................................................................................
2. The use of cannabis for medicinal
purposes.....................................................................
Introduction
...................................................................................................................
What is medicinal cannabis?
.........................................................................................
Scope of review
..................................................................................................... ..........20
Characteristics of medicinal
cannabis............................................................................
Use of medicinal cannabis
.............................................................................................
Personal accounts of conditions where cannabis has provided relief
............................... 23
Access..........................................................................................................................
Research support for efficacy
......................................................................................
Breadth and variety of data
.........................................................................................
Evidence-based medicine and the quality of evidence
....................................................... 31
The quality of cannabis
research...................................................................................
Determining efficacy
....................................................................................................
Issues for policy-makers
...............................................................................................44
Evidence of side
effects................................................................................................
3. Access to medicinal cannabis in ‘exceptional
circumstances’.......................................... 52
Introduction
...................................................................................................................
Exceptional circumstances
............................................................................................
The idea of
‘exceptionality’...........................................................................................
Compassion as a basis for
action..................................................................................
Eligibility criteria
............................................................................................................
Factors informing eligibility criteria
...............................................................................
Methods of determining eligibility
................................................................................
Proposed conditions and symptoms
.............................................................................
Recommendations
.......................................................................................................
Incorporating
flexibility.................................................................................................
Authorisation of
treatment...........................................................................................
Overview of proposed procedure
.....................................................................................
Residence requirement
.................................................................................................
Which practitioners?
....................................................................................................
Practitioner’s role
.............................................................................................................
procedures..........................................................................................................
Patients’ rights and
obligations.....................................................................................
Other participants
........................................................................................................
A new category of poison
............................................................................................
Implementation issues
...................................................................................................................
4. Current regulation of cannabis
..............................................................................................
Introduction
.................................................................................................................
Restriction of supply as a narcotic drug
..................................................................... 102
Single Convention on Narcotic Drugs 1961
................................................................ 102
Commonwealth Narcotic Drugs Act
...........................................................................
Victorian Drugs, Poisons and Controlled Substances Act
............................................ 106
Control of quality, safety and efficacy as a therapeutic good
................................. 107
Commonwealth Therapeutic Goods
Act..................................................................... 108
Approval by the Therapeutic Goods Administration
(TGA).......................................... 108
Victorian Therapeutic Goods
Act................................................................................
Approval of cannabis
products...................................................................................
Access to unapproved products
..................................................................................112
Implications for a Victorian medicinal cannabis scheme
.......................................... 114
A stand-alone Victorian scheme
.................................................................................
A comprehensive
scheme............................................................................................115
....................................................................................................................
5. Options for
reform............................................................................................................
Introduction
.................................................................................................................
Importation under amended Commonwealth
rules................................................. 121
.................................................................................................................
.................................................................................................................
.................................................................................................................
Exemption from prosecution for possession and use
................................................ 125
.................................................................................................................
.................................................................................................................
................................................................................................................
‘Grow your own’
.........................................................................................................
.................................................................................................................
.................................................................................................................
.................................................................................................................
Regulated not-for-profit production and distribution
............................................. 135
.................................................................................................................
.................................................................................................................
.................................................................................................................
Regulated distribution through dispensaries
............................................................ 138
.................................................................................................................
.................................................................................................................
.................................................................................................................
Government-enforced monopoly
...............................................................................
.................................................................................................................
.................................................................................................................
.................................................................................................................
Multiple licensed producers
........................................................................................
.................................................................................................................
.................................................................................................................
.................................................................................................................
6. Regulating
supply..............................................................................................................
Introduction
.................................................................................................................
Nature of Commonwealth/state collaboration
......................................................... 148
Cultivation and manufacture
......................................................................................
structure.......................................................................................................
Licensing cultivation
...................................................................................................
Licensing manufacture
...............................................................................................
..................................................................................................................................
Selection of licensees
...............................................................................................................
Distribution
..................................................................................................................
Government as single
purchaser.................................................................................
Distribution through pharmacies
................................................................................
7. Regulating the product
.....................................................................................................
Introduction
.................................................................................................................
Product control: form and regulation
........................................................................ 175
Quality control
.............................................................................................................
Objectives of quality control
.......................................................................................
Regulation of herbal medicines in Australia
................................................................ 176
Creating a framework for medicinal cannabis
quality.................................................. 178
Quality standards
.......................................................................................................
testing...........................................................................................................
Clinical testing of side effects
.....................................................................................
approval........................................................................................................
testing..............................................................................................................
............................................................................................................................
Post-market surveillance
.....................................................................................................
Forms of medicinal cannabis
.......................................................................................
Smoking should be avoided
.............................................................................................
Formulations and delivery
systems..............................................................................
Strains........................................................................................................................
Cannabinoid
content..................................................................................................
Whole-plant medicines versus isolated cannabinoids
.................................................. 195
8. Research and evaluation
..................................................................................................
Introduction
.................................................................................................................
Enabling research and drug
development.................................................................
Access to cannabis by researchers
........................................................................................
Treatment permits and clinical
trials............................................................................
Knowledge collection and information
provision..................................................... 202
Responsiveness to change
...........................................................................................204
Legal developments
...................................................................................................
Alternative supply options
..........................................................................................
Scheme evaluation
.......................................................................................................
9. Conclusion
..........................................................................................................................208
Appendix A. Advisory committees
......................................................................................
Appendix B. Submissions
.................................................................................................................
Appendix C. Consultations
...................................................................................................
Appendix D. Tables of legislative amendments
................................................................. 218
Bibliography...........................................................................................................................
On 19 December 2014 and pursuant to
section 5(1)(a)
Victorian Law
Reform Commission Act 2000
, the Victorian Attorney-General, the Hon. Martin
Pakula MP, referred to the Commission for review and report options for changes
to the law to allow people to be treated with medicinal cannabis in exceptional
circumstances. The reference was not in relation
to legalisation of cannabis
generally, nor in relation to legalisation of cannabis for medical purposes
generally; but rather, for
treatment with medicinal cannabis in exceptional
circumstances. Thus this report addresses as a central issue the proper
of what should constitute exceptional circumstances.
In its review the Commission heard many compelling stories of personal
suffering, and also received submissions emphasising the presently
proven scientific knowledge about the potential and risks of medicinal cannabis.
The report is driven both by personal compassion
and by medical
responsibility.
This report is necessarily a complex one. Because cannabis is a prohibited
drug in Victoria, any legalisation of it, including for
compelling personal
medical circumstances, must take into account the complex of legal,
administrative, medical and health considerations
applicable within Victoria and
also nationally and internationally. Where practicable, the Commission has
recommended the use of,
or adaptation of, existing administrative structures,
systems and protocols.
The options reviewed in the report demonstrate that, for effective and
sustainable reform to take place, there needs to be collaboration
between the
Victorian and Commonwealth governments. At the time of writing, the introduction
of Commonwealth medicinal cannabis legislation
appears possible. Any such action
would affect the options open to Victoria. Should this occur, I trust that the
discussion in this
report will provide helpful guidance in addressing the issues
that would arise under any national medicinal cannabis scheme.
I acknowledge and warmly thank everyone who contributed to the review by
making submissions and participating in public consultations.
The Commission
drew upon the expertise of many clinical and regulatory experts who generously
gave their time and ideas at advisory
committee meetings and private
consultations. Likewise, some two hundred members of the public attended
meetings that the Commission
held in Melbourne and across Victoria to discuss
the issues encompassed by the review. I attended a number of these
consultations
and was moved by the stories I heard.
Although I was closely involved at all stages, the review was led by Dr Ian
Freckelton QC, who was appointed Commissioner for this
purpose. I thank him for
the intellectual rigour and tireless dedication he brought to the task.
I would also like to thank my fellow Commissioners, all of whom worked on
this reference, for their contribution and expertise.
Finally, I am grateful for the hard work of the research team, led by Lindy
Smith and supported by research and policy officers Michael
Adams and Sharyn
Broomhead and research and executive associate Claire Leyden-Duval.
I commend the report to you.
The Hon. P. D. Cummins AM
Victorian Law Reform Commission
August 2015
Terms of reference
[Referred to the Commission pursuant to
section 5(1)(a)
Commission Act 2000
(Vic) by the Attorney-General of Victoria, the
Hon. Martin Pakula MP, on
19 December 2014.]
1 The Victorian Law Reform Commission is asked to review and report on
options for changes to the
Drugs, Poisons and Controlled Substances Act 1981
and associated Regulations to allow people to be treated with medicinal
cannabis in exceptional circumstances, and to make the recommendations
consequential amendments which should be made to the:
Therapeutic Goods (Victoria) Act 2010
• any other relevant legislation.
2 In conducting the review, the Commission is asked to consider:
• the operation of Victoria’s
Drugs, Poisons and Controlled
Substances Act 1981
and associated Regulations, and how this interacts with
Commonwealth law, functions and any relevant international conventions
• medical use of cannabis in other jurisdictions.
3 The Commission is asked to appoint expert panels to assist in its review,
specifically to examine:
• prescribing practices for medicinal cannabis, including eligibility
criteria for access to medicinal cannabis and the role
of doctors in managing
the use of medicinal cannabis by patients
• the regulation of medicinal cannabis manufacture and distribution,
including which forms of medicinal cannabis should be permitted
4 The Commission should report no later than 31 August 2015.
Cannabinoids
Substances that bind to biological receptors to produce
the pharmacological effects demonstrated by cannabis, including both natural
synthetic cannabinoids.
Any plant in the genus Cannabis and any product derived from
the plant, including dried cannabis (marijuana) and cannabis extracts.
Cannabis sativa
Cannabis indica
Cannabis ruderalis
Cannabis extract
Any concentrated form of cannabis in which the
chemical components of the cannabis plant have been extracted from the plant
using a solvent or infusion method (includes cannabis oil and
tinctures).
Cannabis oil
A liquid produced by
infusing cannabis leaves and flowers in a solvent (such as an oil or an alcohol)
to produce a concentrated extract,
which can be thinned using oil. Sometimes
known as ‘hash oil’.
Cannabis resin
The resin of the cannabis plant, contained in trichomes
on the flowering heads of the plant, and collected by being scraped or shaken
from the buds and flowers. The resin can also be separated from the plant using
Cannabidiol, a non-psychoactive cannabinoid found in the cannabis
Dried cannabis
The dried flowers, leaves and/or stems of the cannabis
A pharmaceutical formulation of synthetically produced THC
(specifically the isomer delta-9-tetrahydrocannabinol), available in the
States and Canada under the trade name ‘Marinol’.
Endocannabinoid
An endogenous substance that activates the same
receptors as phytocannabinoids.
Endocannabinoid system
A signalling system in the human body, comprising receptors, ligands
(endocannabinoids) and associated proteins and enzymes. The receptors
those activated by THC and other cannabinoids. The system
has a key role in controlling nervous system functions and many other aspects
of human physiology.
The Food and Drug Administration, a statutory agency of the
United States Federal Government responsible for regulation of pharmaceutical
products, among other activities.
Compounds found in plants which contribute flavour, aroma
and pigment and are thought to provide a range of health benefits.
Good Agricultural and Collection Practice.
Good Manufacturing Practice.
Hash/hashish
Cannabis resin which has been dried. Hash is often
compressed into blocks.
Health practitioner
An individual who practises a health profession,
as defined in the
Practitioner Regulation National Law (Victoria).
Varieties of cannabis which contain low levels of THC (generally
1 per cent or lower by weight), and are commonly used to produce
fibre (for use
in cloth, rope and so on) or hemp oil (made from pressed hemp seeds used in
cosmetics and, in some places, food).
Infused products
Cannabis products produced by the infusion of dried
or fresh cannabis in a solvent.
Medical practitioner
A person registered to practise in the medical
profession under the
Health Practitioner Regulation National Law (Victoria)
A synthetic cannabinoid that is chemically similar to THC
and mimics its effects, and is used pharmaceutically in the form of a capsule.
Nabilone is sold in the US under the trade name Cesamet.
A whole-plant botanical extract of cannabis, administered
as a mouth spray, containing THC and CBD in approximately equal proportions
comprising not less than 90 per cent of the total cannabinoid content, and which
may contain other trace cannabinoids. The trade
name for nabiximols is
Pharmaceutical grade
Describing a substance manufactured in
accordance with good manufacturing practice and a chemical purity standard
established by a
recognised publication.
Phytocannabinoid
Any plant-derived cannabinoid or plant-derived
substance which interacts with the endocannabinoid system or is similar in
to a cannabinoid.
Specialist medical practitioner
A person registered to practise in the medical profession in a recognised
specialty under the
Health Practitioner Regulation National Law
Standard for the Uniform Scheduling of Medicines and
6, contained in Schedule 1 to
The Poisons Standard 2015
, a legislative
instrument made under the
Therapeutic Goods Act 1989
Synthetic cannabinoid
Cannabinoids of synthetic origin, including
compounds which are not chemically identical to but mimic the effect of
cannabinoids found
in the cannabis plant.
Volatile compound found in the cannabis plant.
The Therapeutic Goods Administration, a division of the
Commonwealth
Department of Health.
Tetrahydrocannabinol, the principal psychoactive constituent (or
cannabinoid) of the cannabis plant. An isomer of THC, delta-9-
tetrahydrocannabinol,
sometimes referred to as dronabinol, is believed to be the
most active version of the compound.
Tetrahydrocannabinolic acid, the precursor chemical to THC. THCA
is converted to THC as fresh cannabis dries, and when cannabis is
subjected to
heat, such as by smoking, baking or vaporisation. THCA lacks the psychoactive
effects of THC but acts on the same receptors.
A solution of cannabis infused in alcohol, administered under
the tongue or taken orally.
Measure and adjust the dosage of a drug.
A device which heats dried cannabis or a cannabis extract to
a temperature at which a vapour containing cannabinoids is released.
Medical terms
Pain which lasts for a short time, provoked by a specific
disease or injury.
Acquired Immunodeficiency Syndrome, the final stage of HIV
AIDS is a chronic, potentially life-threatening condition which damages the
body’s immune system.
Alzheimer’s disease
A progressive, degenerative disorder that
attacks the brain’s nerve cells (neurons), resulting in loss of memory,
thinking and
language skills and behavioural changes. Alzheimer’s disease
is the most common cause of dementia among those aged 65 and older.
The moderation of painful stimuli so that they are no longer
painful, but still perceived. An analgesic is a substance which has this
Anti-convulsant
Preventing or arresting seizures.
Anti-emetic
Preventing or arresting vomiting.
Anti-inflammatory
Reducing inflammation, without affecting the
underlying cause.
An abnormal heart rhythm.
A group of diseases (the arthritides) involving inflammation
of a joint, resulting in pain, swelling and limited movement.
Weight loss and wasting occurring during a chronic
Cannabis use disorder
Recurrent use of cannabis causing clinically and
functionally significant impairment, such as health problems, disability and
to meet responsibilities at work, school or home. Symptoms listed in the
DSM-5 include disruptions in functioning, development of
tolerance, cravings for
cannabis and the development of withdrawal symptoms within a week
of ceasing use.
A cancer-producing substance or organism.
Chemotherapy
Treatment of disease (especially cancer) by means of
chemical substances.
Chronic pain
Pain which persists beyond the time of healing of
surgery, trauma or other condition, frequently without a clearly identifiable
Crohn’s disease
A type of inflammatory bowel disease affecting
the digestive tract, which can lead to abdominal pain, severe diarrhoea,
fatigue, weight
loss and malnutrition.
Dravet Syndrome
A rare form of severe, intractable epilepsy beginning
in infancy, causing frequent seizures. Children with Dravet Syndrome typically
experience poor development of language and motor skills, hyperactivity, and
difficulty relating to others. Also known as Severe
Myoclonic Epilepsy of
The 5th edition of the American Psychiatric Association’s
Diagnostic and
Statistical Manual of Mental Disorders
, published in 2013.
A chronic neurological disorder characterised by violent,
uncontrolled seizures and usually associated with some alteration of
consciousness.
Fibromyalgia
A feeling of well-being or happiness.
A condition of unknown cause, characterised by widespread pain, abnormal pain
processing, sleep disturbance, fatigue and often psychological
distress, and
often co-occurring with other rheumatic conditions.
A disease of the eye characterised by
increased intraocular pressure and damage to the optic nerve which produces
vision defects and
can result in blindness.
Human Immunodeficiency Virus, a
virus spread through bodily fluids that weakens a person’s immune system.
HIV can lead to AIDS.
Inflammatory bowel disease
One of a number of conditions which cause chronic or recurring immune
response and inflammation of the digestive tract. Includes Crohn’s
disease and ulcerative colitis.
Intractable
Resistant to treatment.
Intraocular pressure
The fluid pressure within the eyeball which
maintains its round firm shape. Abnormally high intrarocular pressure is a risk
for the development of glaucoma.
Lennox-Gastaut
A form of epilepsy which begins in childhood and causes frequent seizures of
varying types. It often results in some degree of impaired
intellectual
functioning or information processing, developmental delays and behavioural
disturbances.
Multiple sclerosis (MS)
A condition involving an abnormal response by
the body’s immune system directed against the central nervous system,
which attacks
nerve fibres and the fatty tissue that surrounds them, resulting
in the formation of scar tissue (sclerosis) around nerves and the
distortion and
interruption of nerve impulses. Symptoms vary but can include fatigue, numbness,
weakness, dizziness and vertigo,
pain, cognitive changes, difficulty walking,
spasticity, bladder and bowel problems and mood changes.
Myocardial infarction
Commonly known as a heart attack, a condition
where a coronary artery or one of its smaller branches becomes suddenly
Neurological
Concerning the nervous system and the diseases affecting
Neuropathic pain
Pain caused by damage to or dysfunction in the
peripheral or central nervous system.
Neuroprotective
Having the effect of protecting neurons from injury or
degeneration or restoring or regenerating them.
Palliative care
Medical care to improve the quality of life of
patients and their families facing life-threatening illnesses, including support
and pain relief.
Parkinson’s disease
A neurological syndrome, usually resulting
from a dopamine deficiency, as the consequence of changes to the basal ganglia,
characterised
by rhythmical muscular tremors and rigidity of movement.
Psychoactive
Affecting mental activity, behaviour or perception, such
A mental and behavioural disorder causing gross distortion
or disorganisation of a person’s mental capacity, affective response
capacity to recognise reality, communicate and relate to others. An
anti-psychotic is a substance used to treat psychotic disorders.
Psychotogenic
Capable of inducing psychosis.
Psychotropic
Synonym for psychoactive.
Post-traumatic stress disorder.
Schizophrenia
A chronic, severe and disabling brain disorder, which
can cause hallucinations, delusions, thought and movement disorders, along with
disruptions to normal emotions and behaviours and compromised cognitive
functioning. A diagnosis of a schizophreniform disorder may
be made if symptoms
of schizophrenia exist but have not been present for sufficient time for
schizophrenia to be diagnosed.
Stiff or rigid muscles, with unusual tightness or increased
muscle tone.
Tourette syndrome
A neurological disorder characterised by repetitive,
stereotyped, involuntary movements and vocalisations (tics).
Tachycardia
A faster-than-normal resting heart rate.
Botanical terms
In biological taxonomy, the classification one level above
A group of plants distinguished from other plants of its
category by a particular trait, such as a high yield, but not considered
separate variety.
Research terms
Clinical trial
A research study that prospectively assigns
participants to one or more treatments (interventions) to evaluate their effect
Crossover study
A study in which groups of participants receive two or
more treatments in a particular order. For example, the first of two groups
receive treatment A then treatment B, with the second group receiving treatment
B then treatment A.
Double blind
Where two or more parties (typically the investigator and
the participant)
do not know which participants have been assigned to which treatments.
Observational study
A study in which participants are assigned to
study groups and observed.
While treatments may be applied, participants are not assigned to particular
treatments.
Phase I clinical trials
A category of drug trial used by the FDA.
Phase I clinical trials are conducted with healthy volunteers, with the aim of
out the drug’s most frequent and serious adverse events and how
the drug is metabolised and excreted.
Phase II clinical trials
A category of drug trial used by the FDA.
Phase II clinical trials gather preliminary data on effectiveness (that is,
whether the
drug works for certain conditions), which may involve comparing the
drug’s effects with a placebo. Safety is also evaluated.
Phase III clinical trials
A category of drug trial used by the FDA.
Phase III clinical trials gather more information about safety and
effectiveness by studying
different dosages, populations and drug combinations.
The final stage before marketing approval is granted.
Placebo-controlled
Describing a study in which the effectiveness of
drug is compared with the effect of a placebo (a substance which resembles the
but does not contain the active ingredient).
Randomised study
Describing a study in which participants are assigned
to treatment groups by chance.
Pharmacological terms
Decarboxylate
Removal of a molecule of carbon dioxide from a
carboxylic acid, for example the conversion of THCA to THC.
Of a preparation, intended for administration via the mouth
and/or throat.
A derivative of opium.
A narcotic substance.
A chemical group or molecule on the surface of or inside a
cell which binds to a particular compound or chemical group (such as a
antigen or neurotransmitter).
Of a preparation, intended to be administered under the
Of a preparation, intended for administration via the
Transmucosal
Of a preparation, intended for administration via a
mucous membrane,
such as the nose or mouth cavity.
Executive summary
Introduction
1 This report completes the Victorian Law Reform Commission’s review of
law reform options that would allow people in Victoria
to be treated with
medicinal cannabis in exceptional circumstances. The Victorian Government has
made clear its intention to change
the law to this effect, and the Commission
has explored how it could be done, in accordance with terms of reference
provided by the
Attorney-General on 19 December
2 The terms of reference call for the Commission not only to review how
Victorian legislation could be amended, but also to consider
its interaction
with Commonwealth law and functions and international conventions. In addition,
they extend to an examination of
how a medicinal cannabis scheme could operate.
The Commission
was asked to examine prescribing practices, eligibility criteria, the role of
doctors, the regulation of manufacture and distribution,
and which forms of
medicinal cannabis should be permitted.
3 The Commission published an issues paper in March 2015, based on its
analysis of the current law and research into the use of cannabis
for medicinal
purposes overseas, and called for submissions. It then held a series of
consultations in Melbourne and regional centres
with members of the public,
health and legal professionals and government officials. It consulted by
telephone with regulators and
others involved with medicinal cannabis schemes in
other countries and, as required by the terms of reference, convened panels of
medical and regulatory experts.
4 The Commission’s conclusions are summarised below and its 42
recommendations are listed at page xxxiv–xl.
Medicinal cannabis
5 In the broadest sense of the term, ‘medicinal cannabis’ is
cannabis used for medicinal purposes, namely to cure or relieve
the symptoms of
medical conditions. The purpose for which it is used distinguishes
‘medicinal cannabis’ from cannabis
utilised as food or as a
recreational drug.
6 Between 80 and 100 cannabinoids and some 300 non-cannabinoid chemicals are
produced by the cannabis plant. The cannabinoids that
have been discovered to
have therapeutic properties are delta-9-tetrahydrocannabinol (THC) and
cannabidiol
(CBD), although claims in this regard have also been made in relation to a
number of other cannabinoids. THC is best known for its
psychoactive,
euphoriant qualities but has also been identified to have anti-emetic,
analgesic, anti-inflammatory and anti-
oxidant properties. To a certain degree CBD moderates the effects of THC, and
researched for its potential to treat epilepsy, schizophrenia and other
psychotic disorders, type II diabetes, inflammatory bowel
disease, gliomas and
drug dependency, among other conditions. A range of other non-psychoactive
cannabinoids are also showing promise
for the treatment of a range of
7 There are three main types of Cannabis—
—and multiple strains within each type. Many more
strains have been produced through cross- cultivation. The different strains
contain varying amounts of cannabinoids and therefore can have different effects
on the user. When consumed, certain cannabinoids
found in the cannabis plant are
understood to lock onto specific receptor sites in the body that interact with
the endocannabinoid
system. Non-cannabinoid chemicals such as terpenes are also
claimed to contribute to the medicinal effects of cannabis.
8 The effect on the user depends not only on the strain and chemical
composition of the cannabis but also on the form and the method
application. Cannabis that is used for medicinal purposes takes a variety of
forms and is administered in a number of ways.
Medicinal cannabis schemes in
other countries make the following forms available, in different combinations
and on different terms
and conditions:
• the dried flowering tops of the cannabis plant, taken through being
smoked, vaporised or infused in tea
• cannabis resin, collected and compressed from the flowering tops
• infused cannabis products, such as alcohol-based tinctures, edible
oils infused with cannabis and products made from these,
suppositories
• extracts of cannabis, containing concentrated extracts of
cannabinoids, taken orally, topically or by vaporisation
• raw, undried cannabis leaves, consumed as a food.
9 Some of these forms and delivery methods are employed by recreational users
10 In submissions and consultations, and indeed worldwide, the term
‘medicinal cannabis’ is variously interpreted, from
definition requiring specific medical intervention to a wide definition
comprehending therapeutic use by non-qualified
persons. As the terms
of reference do not define the term ‘medicinal cannabis’, the
Commission has adopted a broad approach in consideration
of the issues, and
which leads, for the reasons stated in this report, to the Commission’s
recommendations.
11 The Commission uses the term ‘medicinal cannabis’ to refer to
products containing cannabinoids that are derived from
the cannabis plant by any
process whatsoever— including drying, infusing and extracting—and
which are consumed with the
of achieving a therapeutic effect, namely curing or remediating the symptoms
of medical conditions. While it includes pharmaceutical
grade products that are
extracted from the cannabis plant, for the purposes of this report medicinal
cannabis is not taken to refer
to synthetic pharmaceutical products that mimic
the effects of cannabinoids in the body.
How medicinal cannabis is used in Victoria
12 A broad range of Victorians use medicinal cannabis for a variety of
conditions and symptoms, notwithstanding its prohibition under
Victorian and
Commonwealth law.
13 The Commission heard compelling stories about the dramatic improvements to
their health that some cannabis users have experienced.
Many spoke of the ways
in which cannabis had enabled them to stop using pharmaceutical drugs with
serious side effects, or to ‘get
their lives back’. People without
experience of medicinal cannabis told the Commission about the desperation they
felt in experiencing,
or watching a loved one experience, the pain and suffering
of a chronic illness, and expressed sincere hope that cannabis might be
effective for them and made legally available.
14 The majority of medicinal cannabis users and their relatives who spoke to
the Commission said they obtained it (at varying cost)
from people who
specialise in the unlawful cultivation and refining of cannabis for therapeutic
purposes—in Victoria and interstate.
Indeed, several such producers
attended the Commission’s consultations and some made written submissions.
They conveyed a detailed
knowledge of the cannabis plant, its varieties and
refined versions, and expressed strong views about its potential therapeutic
applications.
In addition, an expansive submission on behalf of the
‘cannabis community’ of Victoria provided an account of illicit
medicinal cannabis production and use in
Victoria.1 Users who presently access cannabis for medicinal purposes receive
significant advice and guidance from their suppliers,
including instructions on
strains, dosage and indications.
Evidence of efficacy
15 Cannabis has long been used by humans for therapeutic purposes, yet
scientific knowledge about how it affects the body is relatively
incomplete. A substantial body of clinical evidence now exists in relation to
the efficacy of certain forms of cannabis
for particular medical conditions,
although the evidence varies in its rigour. AMA Victoria acknowledges that there
evidence to suggest that cannabinoids are effective for the
treatment of neuropathic pain, muscle spasticity for patients with [multiple
sclerosis], and in controlling nausea for cancer patients’.2
16 While this body of evidence is expanding, it is not yet of adequate
quality for definitive statements to be made about the efficacy
of cannabis in
treating the range of conditions for which it is being used illicitly. A refrain
of the credible scholarly literature
is that further suitably controlled, high
quality studies need to be undertaken in order to evaluate whether the claims,
and aspirations for the efficacy of medicinal cannabis can be
17 Studies that are commonly cited in support of the efficacy of medicinal
cannabis often rely on case reports, make claims arising
from small patient
cohorts, or lack controls and methodological rigour. Others are of limited
utility because they were conducted
on animals or cell lines, not humans. For
the most part, systematic reviews and meta-analyses have offered only very
qualified support
or have identified potential, rather than actual, efficacy in
medicinal cannabis.
18 Comparatively few research trials have been undertaken under close medical
supervision where medicinal cannabis of known constituency
was tested with
double-blind techniques or effective placebo-controls. Few clinical trials have
been conducted using cannabis oil,
tinctures or other herbal preparations.
19 It seems likely that these deficits will be addressed in research
currently underway or soon to commence. When these results become
scientific discussion about the efficacy of medicinal cannabis will be
significantly more sophisticated and informed than
the discussions that can
currently take place.
1 Submission 95. See Appendix B for list of submissions.
2 Submission 38.
Side effects
20 A major reason why some within the medical profession have reservations
of adverse health
effects. Some of these risks are known, and could be serious for some patients.
Other risks, particularly in the
long term, are unknown and this uncertainty
would need to be factored into any decision by a patient or their carer to use
21 The following side effects have been identified, and are well described,
but all are also disputed:
• Smoking cannabis, particularly in combination with tobacco, raises a
risk of respiratory and potentially carcinogenic effects.
• Cannabis use is a risk factor for developing and exacerbating the
symptoms of schizophrenia, and for the development of psychotic
• Cannabis may have an adverse impact on the user’s mood,
particularly if a new user, including by making them anxious,
depressed or
• Although cannabis is not highly addictive or habit-forming, the
potential does exist for a small percentage of users, at least
recreational context, to become dependent upon it to a point where they
experience withdrawal symptoms for a time when they
stop using.
• Heavy cannabis consumption is known to induce tachycardia, and can
increase the risk of heart attack, notably for users with
existing heart disease
or arrhythmias (abnormal heart rhythm).
• Cannabis use during pregnancy has been found to be associated with a
number of undesirable effects.
• Cannabis use is likely to impact adversely upon concentration,
responsiveness to stimuli and psychomotor function.
22 Most studies on the adverse effects of cannabis have focused on
unregulated, illegal cannabis used recreationally, rather than
quality-controlled supply intended for medical use. A systematic review
conducted in 2008 looking at the medical use of cannabinoids
concluded that
short-term use increased the risk of non-serious adverse events compared to a
control group, but not the risk of serious
adverse events. However, the authors
concluded that further research was needed before long-term risks could be
accurately characterised.3
23 The point made by many submissions to the Commission is that the proven
level of adverse effects, even from unmonitored recreational
abuse of herbal
cannabis, is of modest dimensions. Unlike the experience of opiate drug use, no
deaths have been attributed to cannabis
abuse. The Commission is of the view
that, nevertheless, the risks—especially the long-term risks—and the
concerns raised
by the medical profession about them, should be acknowledged.
Any Victorian medicinal cannabis scheme should be designed so as to
use of cannabis only under medical supervision, thereby enabling attentive and
prompt responses to, and management of,
any side effects that are identified to
be emerging from its use.
3 Tongtong Wang et al, ‘Adverse Effects of Medical Cannabinoids: A
Systematic Review’ (2008) 178
Canadian Medical Association
Forms available under a medicinal cannabis scheme
24 As the effects of cannabis depend to some extent on the form in which it
is administered, any Victorian medicinal cannabis scheme
would need to make a
variety of forms available. International experience shows that otherwise
patients will rely on illicit supplies.
The Commission considers that the range
of products should be determined by the scheme regulator, be broad, and be
responsive to
changes in patient needs, research findings and product
development.
25 However, the Commission recommends against patients being permitted to
smoke medicinal cannabis. It is not persuaded by the submission
made on behalf
of the cannabis community of Victoria, which echoed the views of many who
attended public consultations in presenting
reasoned arguments for permitting
smoking as an efficient, effective, practicable and accessible method of THC
26 Cannabis is commonly administered by smoking and is the preferred method
for many users, notably when used for recreational purposes.
It has been said,
however, that fewer than half of the regular users of cannabis in Australia
27 Although the findings are inconsistent, there has been some association
between smoking and lung conditions and cancer risks that
have not been observed
for other modes of administration. There is also the possibility of accidental
ingestion by third parties
through passive smoking.
28 While noting these potential risks, the Commission’s primary concern
is that providing smokable products as a medicine under
a government scheme
would be inconsistent with the public health policy to reduce smoking in the
community. Over the past three decades
governments have passed increasingly more
restrictive laws aimed at protecting public health by prohibiting or
discouraging smoking,
while the not-for-profit sector has run extensive public
health campaigns to the same end. A scheme that enabled people with severe
medical conditions to smoke, for medical reasons, a substance that is illegal
for others to use, would send a confused public health
message and thereby
undermine the achievements of the programs that discourage the general community
from smoking.
29 Another key concern of the Commission is the impact that supplying dried
cannabis under a medicinal cannabis scheme would have
on the risk of diversion.
Although there could be an illicit market for any product produced under the
scheme—particularly
a product with significant THC content—it is
likely that the demand for dried cannabis would be strongest because of its
for recreational use. While probably more expensive, the licit
product would have been produced under controlled conditions, free
contaminants.
30 In addition, the Commission was told that, to continue to enforce the
prohibition on recreational use, law enforcement agencies
would need to be able
to distinguish between licit and illicit cannabis, and this would be extremely
difficult if licit dried cannabis
were made available under the scheme.
4 Submission 95.
Eligibility under a medicinal cannabis scheme
Identifying people in ‘exceptional circumstances’
31 In developing eligibility criteria for access to medicinal cannabis, the
Commission was guided by the policy intention, conveyed
in the terms of
reference, that the scheme should be limited to people in exceptional
circumstances. The following factors were taken
into account:
• the state of the clinical literature in relation to the efficacy or
potential efficacy of medicinal cannabis for the condition
suffered by the
patient, particularly in relation to the potential for cannabis to provide
therapeutic assistance
• the extent to which medicinal cannabis is likely to improve the
patient’s quality of life
• the seriousness of the medical condition, including the
patient’s prognosis and the extent of their disability
• the extent to which the symptoms of the condition interfere with the
patient’s ability to function
• the availability of standard treatments that may assist, how
effective they are and what side effects they cause or may cause
• the state of the clinical literature in relation to the risks or
potential risks posed by medicinal cannabis for the patient.
Criteria based on conditions and symptoms
32 The Commission recommends that a patient’s eligibility to receive
medicinal cannabis should rely on a combination of symptoms
and the condition
which gives rise to the symptoms. The conditions should be ones for which there
is a reasonable measure of research
support in respect of efficacy, or in
respect of which the research is weaker but the circumstances of the category of
patient are
particularly compelling.
33 The Commission has identified a set of conditions and symptoms as the
basis for initially making medicinal cannabis available:
• severe muscle spasms or severe pain resulting from multiple
• severe pain arising from cancer, HIV or AIDS
• severe nausea, severe vomiting or severe wasting resulting from
cancer, HIV or AIDS (or the treatment thereof)
• severe seizures resulting from epileptic conditions where other
treatment options
have not proved effective or have generated side effects which are
intolerable for the patient
• severe chronic pain where, in the view of two specialist medical
practitioners, medicinal cannabis may in all the circumstances
provide superior
pain management by contrast with other options.
34 The basis for these categories and the way they are formulated is the body
of research as to their efficacy, the compassionate
circumstances attaching to
the distressing circumstances of the categories of patients, and the control of
risks and options that
is addressed by the formulations proposed. The proposals
are structured to provide access for a number of different categories of
patients in controlled circumstances that minimise the potential for abuse of
the scheme and optimise the prospect of participation
practitioners.
35 The Commission suggests this list as a basis for further discussion
between the government, the medical community and patients.
This is particularly
important as the research base is constantly changing.
36 The criteria would be set out in regulations, which could be revised from
time to time on the advice of an independent advisory
committee constituted by
the Minister for Health. In addition, the Secretary of the Department of Health
and Human Services, or
a suitably qualified committee, would have the
discretion to permit access, on a case-by-case basis, for patients who do not
the criteria in rare and special cases.
Authorising patients to have access to medicinal cannabis
37 A decision that a patient should be treated with medicinal cannabis is
not a legal decision:
it is a medical decision. The Commission proposes that access to medicinal
cannabis by patients who meet the eligibility criteria
would be authorised by
specialist medical practitioners. However, the patient’s general
practitioner would be responsible for
the patient’s ongoing treatment,
between visits to the specialist, and for monitoring its efficacy and any side
38 The specialist medical practitioner, and subsequently the general
practitioner, would issue an authorisation that is similar to
a prescription.
The use of language relating to prescriptions is avoided because the
circumstances in which medical practitioners
would be facilitating medicinal
cannabis being made available, and monitoring its use, would be different to
some degree from the
circumstances attaching to medication that they prescribe
in the orthodox way.
39 The legal arrangements would be modelled on those that apply to the opioid
replacement therapy program, under which methadone and
other restricted drugs
are made available to patients. Accordingly, the specialist medical practitioner
would need to seek a permit
from the Secretary of the Department of Health and
Human Services before authorising a patient to use medicinal cannabis. The
would be valid for 12 months.
40 In applying for the permit, the specialist medical practitioner would
state that, among other things, the patient’s condition
and associated
symptoms meet the eligibility criteria, it is appropriate in all the
circumstances that the patient be treated with
medicinal cannabis, and the
patient has been informed that its efficacy and side effects have not been
tested by the Therapeutic
Goods Administration.
41 Although the permit requirement and the authorisation process to some
degree constitute an impediment to access, they are necessary
treatment with medicinal cannabis in the community to be effectively monitored.
Importantly, they ensure that a medical
practitioner with the necessary
expertise in the condition or symptom for which the patient would be using
medicinal cannabis is
consulted and is enabled to make the relevant medical
Options for changes to the law
Regulatory objectives
42 Drawing from the terms of reference and comments in submissions, the
Commission has identified objectives that should be relevant
to any law reform
that allows people to use medicinal cannabis in exceptional circumstances. It
referred to these objectives
when reviewing the options for law reform and recommends that any Victorian
medicinal cannabis scheme be designed so as to be compatible
Allow compassionately for exceptional circumstances of medical
If the strict criteria of evidence-based medicine that normally apply to
prescription medications were applied to cannabis, there
would be negligible
scope for medicinal cannabis products to be made available in Victoria today.
Allowing medicinal
cannabis to be used in exceptional circumstances conveys a policy intention,
based on compassion, to depart from the stringency of
the usual rules.
Integrate the use of medicinal cannabis products into the
patient’s medical treatment
Integrating the use of medicinal cannabis into the patient’s medical
regime characterises the reform as a health initiative.
It enables medicinal
cannabis to be integrated as but one of a variety of therapeutic options to meet
a patient’s needs. It
also recognises that a scheme that allows medicinal
cannabis to be used in exceptional circumstances would apply only to patients
with severe illnesses and debilitating symptoms and a substantial medical
Ensure that patients are informed of clinical uncertainty about
the safety and efficacy of medicinal cannabis products they use
Patients who use medicinal cannabis products—or carers who make
decisions on their behalf—must be informed about the risks,
current limits of clinical knowledge about its efficacy and effects, including
those which are long-term.
Ensure that medicinal cannabis products are of reliable quality
and known composition
Any regulation would provide a level of quality assurance that illicit
production cannot guarantee, but the scheme would need to do
more than this. It
should impose standards that provide medical practitioners and their patients
with confidence about the potency
and contents of the products being
administered.
Foster, and be responsive to, clinical research and developments
in technology
Any medicinal cannabis scheme established in Victoria would need to remain
current as scientific knowledge, medical practices and
technology continue to
Preserve the prohibition of unlawful trafficking, cultivation,
supply and use of cannabis
The proposed legislative reform would need to reinforce ongoing prohibitions
on the trafficking, cultivation, possession and use of
cannabis. The reform
would not allow everyone who currently uses cannabis, or wants to use it, to do
so legally.
Provide an equitable and accessible scheme
Any scheme would need to provide the necessary amount of regulation to
achieve its objectives while not becoming so complex, burdensome
or expensive
that it deters those on whom its success depends, and those it is intended to
benefit, from participating.
Identifying the options
43 The Commission examined the current law to identify the options for
reform. Few options could be introduced by Victorian legislation
alone. Almost
all would require the agreement or support of the Commonwealth Government. All
need to be considered in view of Australia’s
international
obligations.
Drugs, Poisons and Controlled Substances Act 1981
(Vic) could
be amended to modify existing prohibitions on the trafficking, cultivation,
possession and use of cannabis, but this would
be only a partial measure.
45 The importation, manufacture and sale of cannabis products for medicinal
purposes is regulated by Commonwealth law. A Victorian
scheme for patients to be
dispensed medicinal cannabis products of known and stable composition and
quality by pharmacists could
be established only in collaboration with the
Commonwealth Government.
46 Commonwealth law and policy on the regulation of cannabis is guided by
Australia’s international obligations under the
Single Convention on
Narcotic Drugs 1961
and related treaties. These instruments require
governments to impose controls on the amount of cannabis produced, the
circumstances
in which it is produced, and the purposes for which it is made
47 As with all international conventions to which Australia is a party, the
obligations imposed by the Single Convention on Narcotic
Drugs are not
incorporated directly into domestic law unless given effect to by statute. Not
all the obligations imposed on Australia
have been incorporated into Australian
law. However, Australia is a party to the Convention, which carries with it
distinct obligations
of significance. Further, if Australia failed to fulfil the
obligations under the Convention to which Australia has agreed, Australia
subject to international criticism and sanction for failing to implement the
Convention’s obligations.
48 Reporting on 11 August 2015 on a Bill to create a Commonwealth medicinal
cannabis scheme, the Senate Legal and Constitutional Affairs
Legislation
Committee recommended that the Bill be amended to ensure that ‘medicinal
cannabis products can be made available
in Australia consistent with
Australia’s international obligations, including under Articles 23 and 28
of the Single Convention
on Narcotic Drugs 1961.’5
49 The Commission therefore considers that a Victorian medicinal cannabis
scheme should be framed in accordance with the specific
requirements and policy
objectives of the Convention.
Review of the options
50 The Commission has identified and formed views on several options for law
reform, as summarised below:
• Importation: Victoria could import cannabis for the purposes of a
medicinal cannabis scheme by special arrangement under Commonwealth
• Exemption from prosecution: eligible patients and their carers could
be authorised to possess small quantities of cannabis
for the patient’s
• ‘Grow your own’: eligible patients and their carers could
be authorised to cultivate cannabis plants for the patient’s
• Regulated not-for-profit production and distribution: not-for-profit
cooperatives could be licensed to cultivate, manufacture
and distribute
medicinal cannabis products among their members, all of whom would need to be
eligible patients and their carers.
• Regulated distribution through dispensaries: medicinal cannabis
products could be distributed through single-purpose dispensaries.
• A government-enforced monopoly: Victoria could authorise or license a
single entity
to cultivate and manufacture cannabis for distribution to patients through
pharmacies.
• Licensed producers: Victoria could issue multiple licences to
cultivators and manufacturers to produce medicinal cannabis
products for
distribution to patients through pharmacies.
51 To create a legally stable scheme, all of the options for producing and
distributing medicinal cannabis in Victoria would be contingent
Commonwealth cooperating in either or both of the following ways:
• removing the production and distribution of medicinal cannabis
products under the
Victorian scheme from the reach of the
Therapeutic Goods Act 1989
• issuing a licence to manufacture cannabis under the
Drugs Act 1967
5 Senate Legal and Constitutional Affairs Legislation Committee, Parliament
of Australia,
Regulator of Medicinal Cannabis Bill 2014
(2015) [5.13].
52 Most of these options would also generate obligations under the Single
on Narcotic Drugs. If Victoria were to regulate the cultivation of cannabis
for medicinal purposes (as opposed to merely decriminalising
its cultivation for
personal use in small amounts), Australia’s international obligations
would require it to license the cultivators
and take physical possession of the
cannabis crops. It would also need to inform the Commonwealth about the amount
of cannabis that
it estimates would be used for medicinal purposes each year, so
that the Commonwealth in turn could report to the International Narcotics
Control Board.
Importation
53 Currently, cannabis can be imported under Commonwealth law and policy only
if approved on a case-by-case basis by the Secretary
of the Commonwealth
Department of Health, exercising powers under the
Therapeutic Goods Act
Customs Act 1901
(Cth). The Law Institute of Victoria proposed that the
Commonwealth provide special access for state governments to import products
the purpose of their medicinal cannabis schemes. This would not require
legislative reform, though, if ongoing, it could be desirable
to have the
security of a statutory avenue of access.
54 The appeal of this option is that it could reduce the cost to Victoria of
administering a medicinal cannabis scheme while providing
access to products
that have been
produced under regulated conditions. However, it does not appear feasible in
the current international environment.
55 The only country that exports medicinal cannabis products is the
Netherlands, and the total amount that the Dutch government permits
exported each year is very low. Moreover, the products are only in the dried
plant form that is supplied domestically and are
able to be smoked. If imported
to Victoria, it would need to be transformed into other forms by a manufacturer
whose activities were
regulated under Commonwealth and Victorian laws.
Exemption from prosecution
56 Patients who have been authorised to be treated with medicinal cannabis
could be made exempt from criminal prosecution for use
or possession of the
amount they need. The
Drugs, Poisons and Controlled Substances Act
amended to create an exception to the offences of possessing or using a drug of
dependence for small amounts of dried cannabis
or cannabis extract where a
person is an authorised medicinal cannabis user.
57 The exception would extend to the patient’s carers, to allow them to
possess the cannabis that the patient may lawfully use.
It would also require an
additional exception to be
made to the offence of introducing a drug of dependence into the body of
another person.
58 This option would protect patients and their carers from the risk of being
prosecuted, and the associated uncertainty and stress.
It may be useful as an
interim measure, pending the establishment of a regulated supply of medicinal
cannabis products under a government
scheme. If it were introduced as an
intermediate step, the Commission considers that
it should apply only to those patients who would be eligible to participate
in the fully operational scheme.
59 However, the Commission does not support this option. It is similar to a
scheme in New South Wales to which there has been a muted
response from
patients, few of whom have participated. It fails to provide access to a safe
and reliable supply of medicinal cannabis
products. Thus, it would not integrate
medicinal cannabis effectively into a health regime: doctors would authorise
patient access
to cannabis, but would not have any mechanism for controlling or
supervising use. The products available to the patient would not
necessarily be
therapeutically appropriate, as they could have unknown or inappropriate THC/CBD
levels and contain unsafe contaminants.
60 Because the cultivation and supply of cannabis would remain unlawful, any
person selling cannabis to an authorised patient or their
carer would still be
committing an offence.
The legislative change would only assist users willing to purchase cannabis
that has been grown and supplied illegally. This in turn
would strengthen the
illicit market.
‘Grow your own’
61 A large number of people who made submissions and attended consultations
argued for a ‘grow your own’ scheme. Eligible
patients could be
licensed by the government to cultivate a designated number of cannabis plants
at home for medicinal purposes
and would be able to nominate carers to assist them. The patients and carers
would be responsible for manufacturing the raw cannabis
into a form appropriate
for the patient to use.
62 Victoria’s Drugs, Poisons and Controlled Substances Act could be
amended to provide that a licensed patient who operates
within the conditions of
the licence would not be engaging in the unauthorised trafficking, cultivation,
possession or use of a drug
of dependence within the meaning of the Act. The
legislation would also need to permit the patient to possess the necessary
substances,
materials and equipment at their residential address for this
63 A grow your own scheme was recommended in 2000 by a New South Wales
Party on the Use of Cannabis for Medical Purposes. More recently, it was
by a Bill that was introduced into the New South Wales Parliament in 2014 and
lapsed during 2015, and a draft Bill that is currently
under consideration by a
committee of the Legislative Assembly of the Australian Capital Territory.
64 This option could provide eligible patients with a readily available and
inexpensive supply of cannabis. They would have control
over their dosage,
frequency of use and form of administration. They would no longer need to rely
on the illicit market for the purchase
of prepared cannabis (provided they were
able and inclined to grow their own) and they would be aware of the conditions
the cannabis is grown and processed.
65 Medical and regulatory experts overwhelmingly rejected this option when
discussed at consultations, as did a significant number
of patients and their
families who want medicinal cannabis to be made available in the same way as
prescription medication. The Commission
shares their concerns. A grow your own
scheme would not provide all eligible patients with access to medicinal cannabis
would exclude those who
do not have the resources, skills and ability to grow their own plants or
have them grown on their behalf. It would not ensure that
the patient’s
cannabis use is integrated with their other medical treatment because their
medical practitioner would not know
of, or be able to monitor, what they were
using or the effects. A patient using home-grown cannabis may not be using a
sufficient quality or consistent composition because of the
significant variability caused by different cannabis strains and growing
conditions, which only sophisticated growing operations are able fully to
66 As noted above, the Commission considers that the products that are made
available under any medicinal cannabis scheme should not
be able to be smoked. A
grow your own scheme would bolster the production of dried plant products, as
this is cheaper and
easier than producing refined products and preferred by many users. There
would also be a substantial diversion risk, as there would
be no distinction
between licit and illicit dried plant products and the limits on production and
distribution would be very difficult
to enforce. This would undermine efforts to
preserve the continuing prohibition of unlawful trafficking, cultivation,
and use. A study of Canada’s scheme in 2012 estimated that 36
per cent of personal cultivation licences were subject to ‘misuse’,
defined as the sale of cannabis grown under such a licence to the illicit
market. It would also generate
the potential for both collateral criminal conduct and a risk of house fires
and toxicity within domestic environments.
67 This option would not ease the regulatory burden and the related costs to
the Victorian Government, compared to the other options,
because an alternative
scheme would still need to be introduced to produce medicinal cannabis products
for patients who are unable—or
do not wish—to be responsible for
producing their own medicine.
Regulated not-for-profit production and distribution
Some submissions advocated the creation of regulated not-for-profit
cooperatives, collectives or clubs which would arrange for the
cultivation and manufacture
of medicinal cannabis products for distribution to their members.
Membership would be confined to authorised patients and their carers.
could engage contractors or rely on its members to grow the plants and
manufacture the products.
Under current law, the Commonwealth would regulate the manufacture and
distribution of therapeutic goods by any such entities. However,
there is some
scope for Victoria to legislate in this area. While the Commonwealth has direct
its power to regulate unincorporated
associations involved in manufacturing and distributing therapeutic goods is
determined by Victorian
legislation. The Commonwealth
Therapeutic Goods Act
applies to them by operation of the
Therapeutic Goods (Victoria) Act 2010
(Vic). To resume jurisdiction over unincorporated associations for the
purposes of this option, Victoria could amend the
Therapeutic Goods (Victoria)
to exclude the operation of the Commonwealth law for the purposes of the
production and distribution of medicinal cannabis by authorised
unincorporated
associations.
The authorised entities would still need to obtain a manufacturing licence
Commonwealth under the Narcotic Drugs Act.
To create the scheme, Victoria could amend the
Drugs, Poisons and
Controlled Substances Act
to provide for licences to be issued either to a
cooperative (to produce medicinal cannabis products for its members), or to a
nominated by the cooperative (to cultivate a certain amount of cannabis,
or produce products, as determined by the cooperative and
approved by the
government).
The licensees would need to comply with detailed rules, which could be a
combination of licence conditions, statutory provisions and
regulations, to
ensure that the products are of good quality and are provided only to authorised
Proponents of this option said that it would reduce the demand for illicit
cannabis and provide hubs for treatment outside the conventional
medical system.
A submission made on behalf of the cannabis community of Victoria put forward a
detailed proposal, based on the British
Columbia Compassion Club, in which the
cooperative would operate a closed system encompassing all steps of the
production and supply
of the product as well as patient care.
The Commission does not consider that this option is suited to Victoria. It
was told on several occasions that patients and their
families would like
medicinal cannabis to be treated as much as possible like conventional
medications. Having medicinal cannabis
cultivated by and for closed communities
of users could reinforce negative perceptions about using it, perpetuate doubts
efficacy, and undermine efforts to encourage communication between
patients and their medical practitioners. It would significantly
exclude the
participation of medical practitioners in monitoring the effectiveness of the
medicinal cannabis and taking suitable
measures to address any risks or side
The Commission also notes that this option would provide little, if any,
opportunity for the government to take possession of the
medicinal cannabis
before it is distributed to patients, as required by the Single Convention on
Narcotic Drugs. This would make
the system legally unstable and could deter the
Commonwealth from agreeing to issue the manufacturing licences on which the
would depend.
Regulated distribution through dispensaries
76 Several submissions suggested that medicinal cannabis products could be
distributed through dispensaries. Dispensaries have been
established in a number
of jurisdictions overseas as outlets for producers of medicinal cannabis
products or in connection with a
clinic that specialises in the use of those
77 This option could provide for the distribution of products by a publicly
funded or commercial entity that has manufactured the
products under licence, as
an alternative
to distribution through pharmacies. Again, as with the previous option, the
government would be unable to meet the obligation under
the Single Convention on
Narcotic Drugs to take possession of the medicinal cannabis before it is
distributed.
78 As the distribution of medicinal cannabis products is regulated under the
Therapeutic Goods Act
, Commonwealth support would be needed. This could take the
form of an exemption under that Act to enable Victoria to regulate the
distribution of medicinal cannabis products by entities that are licensed to do
so under Victorian legislation.
Drugs, Poisons and Controlled Substances Act
could be amended to
provide for a licence to be issued to an entity to distribute medicinal cannabis
products. The amount and content
of the associated rules would depend on the
entity, but probably would be directed to the risk of diversion to the illicit
80 The form and function of medicinal cannabis dispensaries that operate
overseas vary.
The common elements are that they supply only cannabis products and usually
offer the customer a variety of products, information
and effects of each, and advice about which could be most suitable in treating
their condition.
81 The Commission does not consider this option appropriate for a Victorian
medicinal cannabis scheme. Unlike the United States, where
not-for-profit
dispensaries have been established under state medicinal cannabis schemes
because federal government law effectively
prevents the sale of cannabis by
pharmacies, there is no regulatory incentive in Victoria to find an alternative
to existing retail
A government monopoly
82 Under this option, a single entity with the necessary ability and capacity
would cultivate and distribute cannabis and deliver
it to the government, for
distribution through pharmacies. The entity could be a government agency or
government-owned corporation,
a university or research institute, or a privately
owned corporation.
83 It appears that Commonwealth support would be needed for each of these
options, with the possible exception being an agency or
statutory authority that
does not generate revenue. The entity would need to be licensed under the
Narcotic Drugs Act. In addition,
an exemption from regulation under the
Therapeutic Goods Act
would be necessary.
84 The option could be established in either of two ways. The
Drugs, Poisons
and Controlled Substances Act
could be amended to permit a specified
government-funded or -owned entity to cultivate and manufacture cannabis for
medicinal purposes
and exempt it from
of the Act (concerning offences
relating to drugs of dependence). Alternatively, the Act could be amended to
provide for the Secretary
of the Department of Human Services and Health to
issue a licence to cultivate and manufacture cannabis products for delivery to
the government. The government could then grant the licence to a suitable
85 Because only one producer would ever be involved, the scheme would not
involve a substantial regulatory burden. It would create
a simple mechanism that
is substantially compliant with international law and allow for an experienced
entity to start producing
cannabis medicines relatively quickly.
86 The government would have to identify a suitable producer that could
consistently produce enough cannabis of sufficient quality
to satisfy the
requirements of a Victorian medicinal cannabis scheme. The scheme would turn on
the capacity of that single producer
to manage risks and to supply enough
product without subcontracting its functions to other cultivators and
manufacturers. If a suitable
entity could be identified, this option could be an
intermediate step in establishing a scheme that is sustainable in the long term.
However, on balance it is not recommended.
Multiple licensed producers
87 Support was expressed in several submissions for a scheme based on the
current arrangements for the cultivation of alkaloid poppies
and the production
of poppy straw under the
Drugs, Poisons and Controlled Substances Act
model, the government would license multiple private cultivators and
manufacturers to produce cannabis products for supply
through pharmacies.
88 New provisions would be inserted into the Drugs, Poisons and Controlled
Act authorising various dealings that are currently illegal. Commonwealth
support would be needed, exempting the manufacture and production
of medicinal
cannabis from regulation under the
Therapeutic Goods Act
and granting licences
under the Narcotic Drugs Act.
89 This option would allow cultivators and manufacturers to be assessed
against statutory criteria and be subject to other controls
derived from
Victoria’s poppy scheme. The government would be able to exercise the
degree of regulatory control required by
the Single Convention on Narcotic
Drugs. In addition, the scheme would be adaptable to any changes to law or
policy, either in Victoria
or at the Commonwealth level, which could affect the
reach or focus of the scheme. It would not be dependent upon a single source
supply, which can be a logistical vulnerability.
90 This is the Commission’s preferred option and it recommends that it
be adopted as the model for a Victorian medicinal cannabis
Regulation of manufacture and distribution
91 The terms of reference require the Commission to examine the regulation of
medicinal cannabis manufacture and distribution, including
which forms of
cannabis should be permitted for use. The Commission has developed detailed
proposals that are based on the current
arrangements for the cultivation of
alkaloid poppies, the production of poppy straw and the manufacture of
therapeutic goods.
92 New frameworks would be required to regulate activities connected with the
production of medicinal cannabis in Victoria. A new
framework would be required
for cultivation because this activity is currently not allowed. A new framework
would be required for
product manufacture and approval because these activities
are presently regulated by
the Commonwealth. Importantly, though, the scale of the new regulation
required turns on any agreement reached between Victoria and
the Commonwealth,
and the extent to which this results in a transfer of regulatory responsibility
to Victoria.
93 In designing proposals for the regulation of the medicinal cannabis supply
Commission has given priority to:
• integrating legislative changes with existing provisions wherever
• using familiar regulatory tools
• imposing the least regulatory burden necessary to achieve the scheme
• allowing flexibility to the regulator to manage risks
• having regard to the requirements of the Single Convention on
Narcotic Drugs.
Cultivation
94 All cannabis cultivated in Victoria would be cultivated under licence.
Licences to cultivate would be granted by the Secretary
of the Department of
Economic Development, Jobs, Transport and Resources. Recipients could be either
individuals or corporations.
The Department would be responsible for monitoring
and enforcing compliance with the licence conditions and the risk management
95 The licensing scheme would be set out in the Drugs, Poisons and Controlled
Act in similar terms to the provisions allowing for licensing of alkaloid
poppy cultivators.
96 Cultivators would be permitted to sell only to licensed manufacturers, and
would be required to have a contract with a licensed
manufacturer at all
Manufacture
97 Like cultivators, manufacturers of cannabis products would be required to
hold licences issued by the State of Victoria. Licences
to manufacture refined
cannabis products would be granted by the Secretary of the Department of Health
and Human Services. Recipients
could be either individuals or corporations.
98 The arrangements would be modelled on those for the manufacturing of
therapeutic goods under Commonwealth legislation.
Distribution
99 It is proposed that distribution be coordinated by a government agency,
as required by the Single Convention on Narcotic Drugs,
particularly Articles
23 and 28. In order to comply with the Single Convention, licensed manufacturers
would need to deliver all
of the medicinal cannabis products they make to the
Victorian Government, specifically the Secretary of the Department of Health
Human Services.
100 The Secretary would be responsible for the distribution of medicinal
cannabis products to pharmacies. Patients would be dispensed
medicinal products
by a local pharmacy that has opted into the scheme.
101 The rules imposed on pharmacies and pharmacy departments regarding the
distribution of cannabis would be modelled on the program
for opioid replacement
Quality control
102 Only one pharmaceutical-grade cannabis extract (Sativex) has been
approved for sale by the Therapeutic Goods Administration but
it is not marketed
in Australia and therefore, to all practical intents and purposes, is not
available. This means that no medicinal
cannabis products have been marketed or
manufactured to this point in Victoria.
103 A Victorian scheme that requires medicinal cannabis products to be
approved by the Therapeutic Goods Administration would reinforce
the status quo
and not result in any additional approved products being made available to
patients for a significant period
of time. It follows that, if the quality of medicinal cannabis products is to
be ensured, an alternative regulatory structure needs
to be established.
104 The alternative structure must sensibly be one which does not create the
same or similar hurdles to approval as those that apply
to prescription
medicines but does take a cautious approach to ensuring that the products
supplied are of good quality.
105 For the separate character of the Victorian products to be preserved, and
the pre- eminence of conventional approval to be maintained,
it is important
that the character of the products be distinctive. That is, the government
should not endorse these products
as replacements for conventional pharmaceuticals. Therefore, it is the
Commission’s view that medicinal cannabis products should
be presented to
patients as a form of less refined herbal medicine and that this be provided for
by the regulatory structure.
106 The Victorian scheme should ensure that medicinal cannabis products
produced under the scheme are free of unsafe components and
are of known and
stable composition. However, it would not be feasible or desirable for the
scheme to make approval of a particular
medicinal cannabis product contingent on
proof (whether to conventional standards or otherwise) that the product is
effective to
treat a given indication. Clinical trials are costly and
time-consuming to run, and placing similar barriers to product approval
already exist under the Therapeutic Goods Administration would not facilitate
access to medicinal cannabis in any meaningful way.
Controlling risks
107 A Victorian medicinal cannabis scheme could be the first of its kind in
Australia. A drug that would remain illegal for all other
purposes in Victoria
would be made legal, in controlled circumstances, for a limited group of people.
The products would be new and
the size of the patient group is initially
difficult to predict. International experience in introducing medicinal cannabis
indicates that the regulatory scheme could
need to be modified, possibly substantially, within a few years in response
to unpredicted outcomes. For this reason, the Commission
considers it prudent
for the government to take a measured approach to the reforms and draw upon
existing models that work in comparable
108 The Commission has identified a number of risks that are inherent to the
proposal to make medicinal cannabis available to people
in exceptional
circumstances. It has taken them into account when formulating the regulatory
objectives, the recommendations and
the detailed proposals.
Patient safety
109 A risk to patient safety could arise from providing access to products
that have not been required to meet the safety, quality
and efficacy standards
that apply to prescription medicines. The regulatory objectives address this
risk by identifying the need
to ensure that:
• Patients are informed of clinical uncertainty about the safety and
efficacy of medicinal cannabis products they use.
• Medicinal cannabis products are of reliable quality and known
composition.
• The use of medicinal cannabis products is incorporated into the
patient’s medical treatment.
Eligibility criteria
110 There is a risk that the circumstances in which treatment with medicinal
cannabis is permitted are uncertain or controversial.
The Commission’s
recommendation that eligibility be based on specified conditions and symptoms
would make the criteria clear
to patients as well as to medical practitioners.
It is likely that any criteria that confine the coverage of the scheme to people
in exceptional circumstances would be criticised by people who use medicinal
cannabis for non-qualifying conditions. However, the
recommended eligibility criteria are based on the best available evidence of
efficacy, and the Commission has also recommended that
they be subject to
change, on the advice of an expert committee, as more evidence becomes
Commonwealth support
111 The viability of a Victorian medicinal cannabis scheme could be
compromised should the Commonwealth not work with Victoria. The
considers that the preferred option, a comprehensive government licensing
scheme, would comply with the Single Convention
on Narcotic Drugs, and therefore
would be compatible with Commonwealth government policies to support
international measures to inhibit
trade in narcotic drugs. It is also adaptable
should the Commonwealth introduce a national scheme that regulates some elements
Diversion risk
112 A medicinal cannabis scheme could create new opportunities for cannabis
to be supplied and used illegally. The need to enforce
ongoing prohibitions is
reflected in the regulatory objectives and the Commission proposes security
measures at each step of the
supply chain. Law enforcement authorities would be
assisted further by the Commission’s recommendations not to provide
cannabis in smokable form, which is more popular among recreational
Costs to government
113 There is a risk of excessive cost to government in establishing and
operating the scheme.
Although the Commission was not requested to investigate, and has not
investigated, the costs of the options, it appears financially
prudent to build
on existing infrastructure and capabilities. The detailed proposals on
cultivation and manufacturing are drawn from
the cultivation of alkaloid poppies
and the regulation of therapeutic goods; the recommended approach to authorising
the use of medicinal
cannabis by patients follows the procedures for the opioid
therapy replacement program. Using existing institutions and comparable
regulatory methods should substantially reduce the time and expense of
Concerns of the medical profession
114 Medical professional bodies and a number of members of the medical
profession put forward the view, in submissions and at advisory
meetings, that medicinal cannabis products should be made available to patients
only if the products have satisfied the
rigorous requirements of the Therapeutic
Goods Administration. Although the opinions of individual practitioners vary,
concern was
expressed to the Commission about patients being treated with
products that have not been subject to the approval processes that
apply to medicines in Australia. These processes ensure that products are
manufactured to high standards and have been comprehensively
assessed for safety
and therapeutic appropriateness for particular medical conditions. They also
provide to the medical practitioner
extensive information about a
product’s efficacy, its side effects, the recommended dosage, and other
details that enable the
practitioner to make a sound
and defensible professional judgment about whether to recommend the treatment
to their patients. The practitioner can draw on this
information in ensuring
that patients give informed consent.
115 The argument that all medicinal cannabis products should be subject to
approval by the Therapeutic Goods Administration is an
argument for the status
quo. There would be no need for a Victorian medicinal cannabis scheme. However,
as reflected in the regulatory
objectives, it is important that the concerns of
medical practitioners about medicinal cannabis are addressed.
116 For this reason, the Commission has identified means of creating
mechanisms, based on existing practices and procedures, which
respond to the
concern that the medicinal cannabis products made available under the scheme
will not have received Therapeutic Goods
Administration approval. The proposed
eligibility criteria give weight to clinical research; access to medicinal
cannabis by individual
patients requires the authorisation of a specialist
medicinal practitioner who has expertise in the relevant condition; a medical
practitioner specifies the products and dosage; provision is made for the
effects of the treatment to be monitored; and the products
themselves are
prepared under conditions that ensure that they are of consistent quality and
composition.
117 Importantly, too, unlike the position in jurisdictions such as the United
States and Canada, where there remains some amount of
reservation among medical
practitioners about medicinal cannabis, the Victorian scheme would not provide a
grow your own scheme
or involve dispensaries that operate wholly or substantially outside the
health system. Nor would it include smoking of dried cannabis.
Rather, it would
provide for medicinal cannabis to be dispensed by pharmacists in orthodox
therapeutic forms such as oils, tinctures
and vaporisable liquids. It is
proposed that the Secretary of the Department of Health and Human Services
assist medical practitioners
by providing product information about medicinal
cannabis products, as well as training in their application.
118 Thus, what is proposed is that medicinal cannabis be a form of
medication that constitutes one of the available forms of pharmacotherapy
small number of conditions, in ways which substantially enable medical
practitioners to titrate dosage and monitor positive
and negative effects as
they would for Therapeutic Goods
Administration-approved medications. It is thus consistent with standard
medical practice with other medications.
Review of scheme
119 The Commission considers that the scheme should be reviewed after four
years. By that time, the international and national regulatory
environment for
the control of cannabis could have changed, and knowledge about the efficacy of
medicinal cannabis could have moved
far beyond the evidence base on which the
scheme rests. The health and safety risks could be different and the regulatory
120 The review should consider how well the scheme has met its objectives and
evaluate whether it should continue in the same form.
Concluding observations
121 Medicinal cannabis is not a panacea. Research into its efficacy has a
significant way to travel before definitive conclusions
can be drawn about the
extent to which it can contribute to the alleviation of suffering. However, what
can be said is that it has
therapeutic potential. It appears that this potential
is starting to be realised in the lives of people with very serious medical
conditions. It needs to be integrated under medical
supervision into the various options for treatment and management of the care
of people with serious conditions without raising inappropriate
expectations.
122 The opportunity exists for a combined Commonwealth and Victorian
initiative to relieve suffering and to improve the quality of
vulnerable cohort of people within the community.
123 The passage of time and the opportunity for further research, along with
evaluation of the scheme proposed by the Commission,
would allow rigorous review
of the success of this initiative to determine whether the proposed innovation
is worthy of consolidation,
extension or amendment.
Recommendations
Regulatory objectives
1 Law reform to allow people to be treated with medicinal cannabis in
exceptional circumstances should be designed so as to be compatible
following objectives:
(a) Allow compassionately for exceptional circumstances of medical need.
(b) Integrate the use of medicinal cannabis products into the
patient’s medical treatment. (c) Ensure that patients are informed
clinical uncertainty about the safety and efficacy
of medicinal cannabis products they use.
(d) Ensure that medicinal cannabis products are of reliable quality and
known composition.
(e) Foster, and be responsive to, clinical research and developments in
technology. (f) Preserve the prohibition of unlawful trafficking,
cultivation,
supply and use of
(g) Provide an equitable and accessible scheme.
Patient eligibility
2 Eligibility to be treated with medicinal cannabis in exceptional
circumstances should be: (a) determined by the patient’s
medical condition
and symptoms arising from that
condition or its treatment
(b) specified in regulations.
3 Eligibility for any Victorian medicinal cannabis scheme should be based
initially on the following conditions and corresponding
(a) severe muscle spasms or severe pain resulting from multiple sclerosis
(b) severe pain arising from cancer, HIV or AIDS
(c) severe nausea, severe vomiting or severe wasting resulting from cancer,
HIV or AIDS (or the treatment thereof)
(d) severe seizures resulting from epileptic conditions where other
treatment options have not proved effective or have generated
side effects that
are intolerable for the patient
(e) severe chronic pain where, in the view of two specialist medical
practitioners, medicinal cannabis may in all the circumstances
provide pain
management that is superior to what can be provided by other options.
4 The Secretary of the Department of Health and Human Services, or a
committee constituted by the Secretary under delegation, should
be given power
to permit patients on a case-by- case basis to be treated with medicinal
cannabis in exceptional circumstances that
do not otherwise fall within the
eligibility criteria of the scheme.
5 The Minister for Health should constitute an independent medical advisory
committee on medicinal cannabis to provide ongoing advice
and corresponding symptoms on which eligibility to be treated with medicinal
cannabis is based. Such advice
should include reference to:
(a) the responsiveness by patients to medicinal cannabis provided under the
scheme and any side effects experienced by them
(b) the state of the clinical literature in relation to the efficacy or
potential efficacy of medicinal cannabis for particular medical
conditions and
(c) the state of the clinical literature in relation to the risks or
potential risks posed by medical cannabis for patients with
particular medical
(d) the seriousness of the medical conditions, including patients’
prognoses and the extent of the disability caused by their
(e) the extent to which symptoms of the conditions interfere with
patients’ ability to derive enjoyment and fulfilment in their
(f) the extent to which medicinal cannabis can reasonably be anticipated to
improve patients’ quality of life
(g) the availability of standard treatments that may assist, how effective
they are, and what side effects they cause.
6 Any medicinal cannabis scheme in Victoria should be applicable only to
persons who ordinarily reside in Victoria.
Authorisation
7 Specialist medical practitioners should determine which eligible patients
should receive treatment with medicinal cannabis, while
general practitioners
should have principal responsibility for monitoring the efficacy and side
effects of the treatment.
8 A specialist medical practitioner who is registered with the Medical Board
of Australia within a prescribed category for the medical
condition on which
their patient’s eligibility is based should be able to apply to the
Secretary of the Department of Health
and Human Services for a permit to issue
an Authority to Dispense Medicinal Cannabis in respect of that patient. The
application
should state that:
(a) The patient’s condition and associated symptoms meet the
eligibility criteria of the scheme.
(b) It is appropriate in all the circumstances that the patient be treated
with medicinal cannabis.
(c) The patient has been informed and accepts that the medicinal cannabis
product they will receive will not have been tested for
efficacy and side
effects by the Therapeutic Goods Administration, and has been informed of other
treatments which have been so tested,
along with the risks, potential benefits
and side effects, including long-term effects, of each.
(d) The patient has been informed that information about their treatment
will be collected and used for scheme evaluation and research
9 The Secretary of the Department of Health and Human Services should have
the power to issue a permit to a specialist medical practitioner
if satisfied
(a) the specialist medical practitioner is registered as a specialist
with the Medical Board of Australia within a prescribed
category for the medical
condition on which patient eligibility is based
(b) the patient ordinarily resides in Victoria
(c) there is not an unacceptable risk that the patient will abuse the terms
of the permit.
10 A valid permit should entitle the specialist medical practitioner, or a
general practitioner identified on the permit, to issue
an Authority to Dispense
Medicinal Cannabis. An Authority to Dispense Medicinal Cannabis would:
(a) authorise a pharmacy or pharmacy department identified on the permit
to dispense medicinal cannabis in accordance with specified
instructions
(b) enable no more than three months’ supply of the medicinal
cannabis products to be dispensed to the patient or carer
11 The permit issued to a specialist medical practitioner by
the Secretary of the Department of
Health and Human Services should specify:
(a) the duration of the permit, not to exceed 12 months
(b) the name and address of the patient
(c) the name of the general practitioner or clinic with principal
responsibility for monitoring the efficacy and side effects of
the treatment
(d) the pharmacy at which the patient or carer will obtain medicinal
(e) the names of any carers who will collect or administer the medicinal
12 An Authority to Dispense Medicinal Cannabis issued by a specialist
medical practitioner or a general practitioner should specify:
(a) the product and dosage
(b) the name and address of the patient
(c) the pharmacy at which the patient or carer will be dispensed medicinal
(d) the names of any carers who may collect or administer the medicinal
13 New offences should be created, or existing offences expanded, proscribing
dishonest conduct in relation to obtaining a permit
or issuing or obtaining an
Authority to Dispense Medicinal Cannabis.
Drugs, Poisons and Controlled Substances Act 1981
Drugs, Poisons and Controlled Substances Regulations 2006
should be amended to allow patients and carers nominated in a valid Authority to
Dispense Medicinal Cannabis, as appropriate,
to obtain, possess and use the
medicinal cannabis products designated in the Authority.
Drugs, Poisons and Controlled Substances Act 1981
Drugs, Poisons and Controlled Substances Regulations 2006
should be amended to allow medical practitioners, registered nurses and
pharmacists who participate in any Victorian medicinal
cannabis scheme to
obtain, have in their possession, administer, sell and supply medicinal cannabis
products, as appropriate, for
the purposes of the scheme.
16 The Secretary of the Department of Health and Human Services should
provide suitable training and information materials to medical
practitioners,
pharmacists, patients and others with responsibilities under the scheme.
Commonwealth/State cooperation
17 The Victorian Government should seek to work in collaboration with the
Commonwealth
Government in establishing any medicinal cannabis scheme in Victoria.
Recommended option
18 The Victorian Government should create a scheme to regulate the production
of medicinal cannabis by:
(a) licensing private entities to cultivate and manufacture medicinal
cannabis products under regulatory arrangements that are based
on those that
apply to the cultivation of alkaloid poppies, the processing of poppy straw and
the manufacture of therapeutic goods
(b) establishing a process for approving medicinal cannabis products and
ensuring that they are of appropriate quality
(c) providing the Secretary of the Department of Health and Human Services
with the power to administer the scheme and the authority
to take possession of
medicinal cannabis products, account to the Commonwealth for those products, and
arrange their transfer to
pharmacies.
Cultivation
19 Cannabis should be grown for medicinal purposes by cultivators licensed by
the Secretary of the Department of Economic Development,
Jobs, Transport and
20 The licensing and regulation of medicinal cannabis cultivators should be
modelled on Part IVB of the
Drugs, Poisons and Controlled Substances Act 1981
(Vic) as it applies to alkaloid poppy cultivation. Key features of the
scheme should be as follows:
(a) Applicants for a cultivation licence would be subject to a fit and
proper person test and be required to satisfy the Secretary
of their intended
commercial activities and pay a prescribed fee.
(b) The Chief Commissioner of Victoria Police would be able to oppose the
issuing or renewal of a licence to an applicant, in which
case the Secretary
would be unable to issue or renew it.
(c) Licensees would be required to ensure that their employees are of
suitable character. (d) Licensees would be required to prepare
and submit a
risk management plan
addressing safety and diversion risks associated with cultivation and how
be addressed.
(e) Licensees would be required to comply with appropriate quality control
(f) All cannabis grown would be required to be delivered to a licensed
manufacturer or destroyed.
(g) Licensees would be required to have a contract with a licensed
manufacturer at all relevant times.
(h) The Secretary would have the power to suspend or cancel a licence,
including at the request of the Chief Commissioner of Police.
(i) Applications would be able to be made to the Victorian Civil and
Administrative Review Tribunal for review of a decision by the
Secretary to
refuse to issue or renew a licence, or to suspend, cancel or amend it.
21 The Secretary of the Department of Economic Development, Jobs, Transport
and Resources should:
(a) monitor and enforce compliance by licensed cultivators with licence
conditions and risk management plans
(b) be empowered to appoint inspectors for this purpose
(c) be resourced accordingly.
Manufacture
22 Medicinal cannabis products should be made by manufacturers licensed by
the Secretary of the Department of Health and Human Services.
23 Medicinal cannabis products should be made by manufacturers licensed by
the Secretary of the Department of Health and Human Services
under arrangements
modelled on those for licensing manufacturers under the
Therapeutic Goods Act
(Cth) and processors
of poppy straw under the
Drugs, Poisons and Controlled Substances Act 1981
(Vic). Key features of the scheme should be as follows:
(a) Applicants for a manufacturing licence would be subject to a fit and
proper person test, required to satisfy the Secretary of
their intended
commercial activities, and required to pay a prescribed fee.
(b) Applicants for a manufacturing licence should be required to demonstrate
Secretary their capability to comply with quality standards.
(c) The Chief Commissioner of Victoria Police would be able to oppose the
issuing or renewal of a licence to an applicant, in which
case the Secretary
would be unable to issue or renew it.
(d) Licensees would be required to hold a manufacturing licence under the
Drugs Act 1967
(Cth) at all relevant times.
(e) Licensees would be required to ensure that their employees are of
suitable character. (f) Licensees would be required to prepare
and submit a
risk management plan
addressing safety and diversion risks associated with cultivation and how
they will be addressed.
(g) Licensees would be required to comply with appropriate quality control
measures. (h) Licensees would be required to deliver
all medicinal cannabis
products to the
Secretary within four months of the harvest date and destroy any unused
(i) The Secretary would have the power to suspend or cancel a licence,
including at the request of the Chief Commissioner of Police.
(j) Applications would be able to be made to the Victorian Civil and
Administrative Tribunal for review of a decision by the Secretary
to refuse to
issue or renew a licence, or to suspend, cancel or amend it.
24 The Secretary of the Department of Health and Human Services should:
(a) monitor and enforce compliance by licensed manufacturers with licence
conditions and risk management plans
(b) be empowered to appoint inspectors for this purpose
(c) be resourced accordingly.
25 All medicinal cannabis products made by licensed manufacturers should be
purchased by the
Secretary of the Department of Health and Human Services.
26 Medicinal cannabis products purchased by the Secretary of the Department
of Health and Human Services should be dispensed to patients
through pharmacies
and pharmacy departments.
27 Dispensing of medicinal cannabis products to patients should be through
pharmacies and pharmacy departments that elect to participate
in the scheme.
28 Dispensing of cannabis by pharmacies and pharmacy departments should be
modelled on the Victorian program for opioid replacement
therapy and include the
following features:
(a) Patients or carers specified in the Authority to Dispense Medicinal
Cannabis would be able to obtain medicinal cannabis products
only by attending
at the specified pharmacy or pharmacy department.
(b) Pharmacies and pharmacy departments would be able to dispense to
patients or carers only the medicinal cannabis product(s) specified
Authority to Dispense Medicinal Cannabis.
(c) Pharmacies and pharmacy departments would be required to store medicinal
cannabis products pursuant to requirements comparable
to those that apply to the
storage of Schedule 8 and Schedule 9 poisons.
29 The Secretary of the Department of Health and Human Services should
require pharmacists to notify the Secretary about the amount
and type of
products they dispense to patients under an Authority to Dispense Medicinal
30 The Secretary of the Department of Health and Human Services should from
time to time designate a price above which medicinal
products cannot be sold,
incorporating the mark-up able to be charged by pharmacists.
31 Licensed cultivators should be required to comply with appropriate Good
Agricultural and
Collection Practice.
32 Licensed manufacturers should be required to comply with Good
Manufacturing Practice, as reflected in the PIC/S Guide to Good
Manufacturing
Practice for Medicinal Products.
33 The Secretary of the Department of Health and Human Services should have
to determine which medicinal cannabis products may be manufactured under
licence and dispensed in Victoria.
34 The Secretary of the Department of Health and Human Services should
establish and publish a register of medicinal cannabis products
approved for
sale in Victoria. The register should specify, for each product:
(a) its THC and CBD content, as a percentage
(b) its formulation
(c) permitted ingredients
(d) the brand name under which it will be sold
(e) label contents.
35 The Secretary of the Department of Health and Human Services should have
the power to authorise independent testing facilities
in Victoria to test
medicinal cannabis products.
36 All medicinal cannabis products manufactured under a Victorian scheme
should be subject to testing by an authorised testing facility
whether the cannabinoid content correlates with that specified on the label and
to identify the presence of any contaminants.
37 Medicinal cannabis products supplied under any Victorian scheme should:
(a) not include products that can be smoked
(b) include a variety of delivery systems, such as tinctures, oils, capsules,
sprays and vaporisable liquids
(c) provide for variation in cannabinoid content
(d) be kept under review in view of developments in technology and medical
knowledge about the medicinal use of cannabis and specific
cannabinoids.
Research and evaluation
38 Any Victorian medicinal cannabis scheme should foster research by
providing for:
(a) licensed cultivators to supply cannabis to appropriately licensed
manufacturers capable of producing or trialling pharmaceutical-grade
cannabis-derived products
(b) researchers and those holding commercial cultivation licences to obtain
experimental cultivation licences.
39 The Secretary of the Department of Health and Human Services should
have the power to issue medical practitioners with permits
to treat patients
other than those who are eligible under the scheme with medicinal cannabis for
trials and research.
40 The Secretary of the Department of Health and Human Services should
collaborate with the clinical research community in developing
methods and
protocols for collecting and sharing information about the incidence and
outcomes of treatment with medicinal cannabis
products under any Victorian
41 The Secretary of the Department of Health and Human Services should:
(a) retain data collected on permit applications and Authorities to Dispense
Medicinal Cannabis in a way that enables statistical
information about the
operation of the scheme to be compiled and used for evaluation purposes, and for
non-identifying information
to be made available for the purpose of research
into the efficacy of medicinal cannabis
(b) ensure that a privacy impact assessment is conducted when designing the
data collection and management systems in support of the
medicinal cannabis
scheme, to safeguard the information privacy of patients, carers, practitioners,
pharmacists and other participants
in the scheme.
42 The Minister for Health should cause an independent evaluation of the
scheme to take place no later than four years from its date
of commencement and
should be required to report to Parliament on the findings and recommendations
of the evaluation.
Introduction
2 Terms of reference
2 The Commission’s process
3 The Commission’s approach
12 Expectations about implementation
14 Concurrent developments
17 Structure of this report
1. Introduction
Terms of reference
1.1 On 19 December 2014, the Attorney-General, the Hon. Martin Pakula, MP,
asked the Victorian Law Reform Commission, under
section 5(1)(a)
Victorian Law Reform Commission Act 2000
(Vic), to review and report by
31 August 2015 on options for changes to Victorian law to allow people to be
treated with medicinal
cannabis in exceptional circumstances. The terms of
reference appear at page ix.
1.2 The Victorian Government is committed to enabling the lawful use of
cannabis for medicinal purposes in exceptional circumstances.1
The terms of
reference do not invite the Commission’s views on this policy, nor on the
separate question of whether the prohibition
on the cultivation, production,
supply and use of cannabis should be fully lifted. Accordingly, the Commission
makes no comment on
these matters.
The Commission’s process
1.3 The Government appointed Dr Ian Freckelton QC as a Commissioner to lead
the reference, with effect from 27 January 2015 to 31
August 2015.
1.4 The Chair of the Commission exercised his powers under
Victorian Law Reform Commission Act
to constitute a Division to
guide and oversee the conduct of the reference. All members of the Commission
joined him on the Division.
1.5 The terms of reference ask the Commission to appoint expert panels
specifically to examine prescribing practices and the regulation
manufacture and distribution of medicinal cannabis. Committees of experts have
often assisted the Commission in identifying
issues and exploring options for
reform, though they are not involved in
developing or voting on the Commission’s recommendations. They are a
valuable source of advice and the Commission appreciates
the time and expertise
that the members contribute.
1.6 Consequently, two advisory committees were formed for the medicinal
cannabis reference:
• a medical advisory committee, comprising experts in the therapeutic
use of cannabis and current clinical research in the area
• a regulation advisory committee, comprising experts in effective
regulation and the operation of current law and overseas
1 ‘Victorian Government Moves Ahead with Plans to Legalise Medical
Marijuana’,
(online), 19 December 2014 <
http://www.abc.net.au /
1.7 The committees met separately in April 2015, and together in May 2015.
The members are listed at Appendix A.
1.8 The Commission’s usual practice when conducting reviews of this
initial discussions
with stakeholders. In view of the short time line for this reference, the
Commission published an issues paper2
before beginning the consultations. The
issues paper provided background information and asked questions about issues
arising from
the terms of reference.
1.9 The issues paper was published on 17 March 2015. The Commission initially
sought written submissions in response to the questions
by 20 April 2015, to
assist in planning the consultations, but continued to receive them until the
end of July.
1.10 Ninety-nine submissions were received and are listed at Appendix B. The
Commission also received many comments and further information
informally from
interested members of the public.
1.11 Formal consultations, led by the Commission Chair and Dr Freckelton,
were held in Melbourne and eight regional centres in May
and June 2015. In each
location, members of the public were invited to attend an open meeting to
express their views. Private meetings
were also held with individual members of
the public, legal practitioners and health professionals.
1.12 Over the course of the reference, the Commission consulted many other
people in Victoria and overseas, including government officials
involved in
implementing medicinal cannabis programs. The consultations are listed at
Appendix C.
1.13 The Commission records its appreciation for the substantial contribution
made to its work by everyone who put forward their ideas
and insights.
The Commission’s approach
Scope of the reference
1.14 The Victorian Government has made a public commitment to introduce
legislation that will enable cannabis to be used for medicinal
purposes in
exceptional circumstances. Announcing the reference to the Commission, the
Premier said: ‘We’ll get the advice
not on if we should do it, but
how we should do it’.3 The government aims to present a bill to
Parliament by the end of 2015.4
1.15 The terms of reference convey a policy intention that people will be
allowed to be treated with medicinal cannabis only in exceptional
circumstances,
and that cannabis will be legalised only for that purpose. Growing, supplying,
possessing and using cannabis for other
purposes will remain illegal.
1.16 Arguments against this policy were made in some submissions and during
consultations, but the Commission did not enter the debate.
The scope of the
review is determined by the terms of reference and the Commission has confined
its investigations, comments and
recommendations accordingly.
2 Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
3 ‘Victorian Government Moves Ahead with Plans to Legalise Medical
Marijuana’,
(online), 19 December 2014 <
http://www.abc.net.au /
4 Vanessa Desloires, ‘Premier Daniel Andrews Hope to Have Bill on
Legalising Medical Marijuana Before Parliament Before End
(Online), 19 December 2014
http://www.theage.com.au /victoria /
Focus of inquiry
1.17 The Commission discerned two fundamental lines of inquiry from the terms
of reference:
• What should the ‘exceptional circumstances’ be?
• How can the law be amended to enable people who are allowed to be
treated with medicinal cannabis to obtain it, while preventing
unauthorised
Exceptional circumstances
1.18 The question of who should be eligible to be treated with medicinal
cannabis under a scheme that permits it in ‘exceptional
circumstances’ is a health issue. The starting point for the Commission in
pursuing this aspect of the reference was to consider
the results of clinical
research into the efficacy of cannabis in treating different medical conditions
and symptoms, as well as
the evidence for risks and side effects.5
1.19 The Commission also took account of the growing amount of material from
other sources suggesting that cannabis can be as effective
as, and the side
effects less problematic
than, opiate forms of analgesia and other pharmaceutical products. This
includes less rigorous scientific research, substantial anecdotal
testimonials, and surveys. The reliability of the claims varies, as does their
evidentiary value for the purpose of developing
eligibility criteria for a
Victorian medicinal cannabis scheme.
1.20 There have been marked improvements in the quality of life of some
severely ill Victorians after being treated with cannabis,
with noticeably
better results than prescription medicines had been able to achieve. The
Commission met a number of these patients
and their families, and many others in Victoria and interstate provided
written submissions about their experiences. Their experiences
compelling examples of the limits of prescription medicines in treating their
conditions and of a groundswell of support
for exploration of an alternative
therapeutic option such as medicinal cannabis.
1.21 The Commission’s conclusions are discussed in Chapter 3 of this
Law reform options
1.22 In addressing the question of how the law could enable eligible patients
to be treated with medicinal cannabis, the Commission
determined whether the
responsibility
to regulate each step of the supply chain falls within Victoria’s
It then explored
the scope for Victoria to introduce reforms either with or without the
assistance of the Commonwealth.
1.23 This analysis was set out in the issues paper and the Commission sought
submissions on how the supply and distribution of medicinal
cannabis in Victoria
should be regulated. The views of the regulation advisory committee were sought,
and the Commission also looked
to the approaches taken in other countries.
1.24 A number of options emerged from the consultations and submissions. They
are discussed in Chapter 5 of this report.
Regulatory objectives
1.25 The Commission’s recommendations about options for legislative
change—as well as the Government’s decisions
make and how to implement them— need to be guided by clear expectations
to achieve.
1.26 For this reason, the Commission identified objectives that would be
relevant to any law reform that allows people to use medicinal
cannabis in
exceptional circumstances, and invited comments on them. They have been derived
from the policy conveyed in the terms
of reference.
5 A comprehensive overview of the current state of clinical research was
included in the issues paper and has not been replicated
in this report. See
Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
6 Victorian Law Reform Commission,
Medicinal Cannabis: Issues
(2015) Ch 4.
Allow compassionately for exceptional circumstances of medical need
1.27 If the strict criteria of evidence-based medicine that normally apply to
prescription medications were applied to cannabis products,
there would be
little scope for cannabis products to be prescribed in Victoria today.7 The
medical profession is divided on the issue,
but many practitioners consider it
premature to change the law before more clinical evidence is available.8
1.28 Allowing medicinal cannabis to be used in exceptional circumstances
conveys an intention to depart from the rules that normally
apply under the
Commonwealth Therapeutic Goods Administration (TGA) scheme. It suggests that, in
some cases, medicinal cannabis
products should be able to be used even if their quality, safety and efficacy
have not been verified to the same exacting standards
as apply to prescription
medications.
1.29 The basis for such a policy is compassion. There are numerous examples
of cannabis being used in Australia and other countries
by people for whom
prescription medicines have been ineffective or have caused debilitating and
serious side effects. The particularly
compelling cases are those where there is
such a marked improvement in the patient’s quality of life following
treatment with
medicinal cannabis—succeeding where prescription
medications have failed—that the benefits are seen to outweigh the risks
of unwanted side effects, including those which could emerge in the longer
1.30 Aaron Johnson, whose daughter suffers from Dravet syndrome,9 a rare
form of epilepsy, described the conundrum facing the families
of severely ill
Too many parents like myself are in desperate circumstances, law abiding
citizens with a[n] unconscionable choice to make, break the
law or watch your
child suffer or possibly die, wondering why a government with the power to make
change has failed them.10
1.31 AMA Victoria expressed concerns about terminology or concepts such as
‘compassionate’
or ‘exceptional’ circumstances, as they are ‘vague,
subjective terms and are likely to lead to lack of clarity in
practice’.11
1.32 The Commission agrees that compassion should not be the criterion for
determining whether a person is eligible to use medicinal
cannabis under a
Victorian scheme. For the purposes of framing amendments to the law, the term
provides insufficient guidance for
a decision maker when determining if a
patient is eligible, and would create uncertainty for the patient about their
legal entitlements.
The regulatory objective underscores the desirability of
taking a compassionate approach when identifying what the eligibility criteria
Integrate the use of medicinal cannabis products into the patient’s
medical treatment
1.33 Integrating the use of medicinal cannabis into the patient’s
medical regime is a necessary objective of a medicinal cannabis
characterises the reform as a health initiative. It also recognises that a
scheme that allows medicinal cannabis to be
used in exceptional circumstances
would apply to patients with severe illnesses and debilitating symptoms
and a substantial medical history. A patient in such circumstances is highly
likely to be under the care of a medical practitioner.
1.34 Those calling for reform commonly assume that any treatment with
medicinal cannabis would be under the care of a medical practitioner,
same way as conventional treatment.12
7 Michael Vagg, ‘Is the Medical Marijuana Debate Even Worth
The Conversation
(16 February 2015)
http://theconversation.com
8 Advisory committee (Meeting 1); Submissions 27, 38, 40, 42, 47, 48;
Consultation 16.
9 Also known as severe myoclonic epilepsy of infancy, a rare and
catastrophic form of intractable epilepsy that begins in infancy.
10 Submission 33. See Appendix B for list of submissions.
11 Submission 38.
12 Submissions 2, 8, 42, 53, 56, 67; Consultation 13. See Appendix C for list
of consultations.
1.35 AMA Victoria agrees that medical practitioners should have a
‘gatekeeper’ role that involves advising patients about
advantages, disadvantages and risks of treatment, but asserts that they are not
currently equipped to do so:
AMA Victoria reiterates that medical practitioners are only able to conduct
this crucial educational role as part of good medical
practice, once conclusive
clinical trials are conducted on the efficacy and side effects of medicinal
cannabis.13
1.36 Individual medical practitioners expressed divergent views. The
Commission was told that doctors would not prescribe medicinal
cannabis because
there is insufficient evidence
of its efficacy, no guidelines about its use, and no approved product
available for sale in Australia.14 However, the view was also
put that it would
be better to supervise patients in using measured amounts of products of known
quality and composition than have
them experiment with illegal products without
medical supervision. Concern was expressed that patients are declining
conventional
therapies because of the claims being made about cannabis.15
1.37 Some submissions argued that medical supervision is unnecessary and
unlikely to be forthcoming. Amanda Newell, for example,
said in her submission
I personally don’t feel a GP is necessary. Colorado have a good thing
going, Australia should take some advice from them. Otherwise,
sell it over the
counter at the chemist, similar to Codeine (that’s a far more dangerous
and addictive drug than Cannabis though).16
1.38 Matthew Pallett identified a need for guidance but said that this should
come from outside the medical profession:
Nobody has ever died from using cannabis or whole plant cannabis extracts
which have been around for a couple of centuries, even from
uncontrolled illicit
street supply. This indicates a need for use under medical supervision to be
totally unnecessary
but guidance for administration for inexperienced users by those experienced
in the practices, would make reasonable sense in order
to avoid unwanted side
effects that can occur with incorrect strain choice.17
1.39 Other submissions called for a broad range and variety of health and
allied health practitioners to advise and monitor patients
medicinal cannabis.18
1.40 The question of who should be able to authorise medicinal cannabis
treatment is
discussed in Chapter 3. However, the objective of integrating the use of
cannabis with the patient’s program of medical treatment
extends beyond
the ‘gatekeeper’ role. While no one may have died from cannabis,
many have died from conditions that cannabis
is being used to treat. A decision
to use medicinal cannabis should not isolate the patient from broader medical
care or undermine
their other medical treatment. Rather, it should be integrated
into broad medical management of the therapeutic needs of the patient.
13 Submission 38.
14 Advisory committee (Meeting 3); Consultations 8, 16.
15 Advisory committee (Meeting 1).
16 Submission 16.
17 Submission 59.
18 Submissions 1, 10, 84, 91, 95; Consultation 3.
Ensure that patients are informed of clinical uncertainty about the safety
and efficacy of medicinal cannabis products they use
1.41 Patients with access to licit medicinal cannabis products that have not
been approved by the TGA could wrongly assume that their
quality, safety and
efficacy have been tested
to the same standards as prescription medicines. If they have read
information on the internet promoting the many therapeutic benefits
to cannabis use, they may have a false impression about the probative value of
some of the claims.
1.42 Accordingly, the scheme would need to ensure that patients who use
medicinal cannabis—or carers who make decisions on their
behalf—know
and effects, including its long-term
1.43 The Law Institute of Victoria pointed out that, as part of their duty of
care, medical practitioners must provide their patients
with information that
will enable them to give their informed consent to medical treatment. This
includes information about all material
risks. A medical practitioner who fails
to do so is exposed to civil liability for the outcome, even if the treatment
was not negligent:
With the example of a medicinal cannabis product that is not regulated under
the Commonwealth TGA, medical practitioners would arguably
need to provide an
appropriate disclaimer as to the limited therapeutic research and the limited
evidence of efficacy. The patient
would need to assume the risk. This is more
complicated in the situation of minors and people who lack capacity to give
consent and their ability to assume that risk.
As the efficacy of the medicinal cannabis (without an established therapeutic
product in an appropriate registered form) is still
unclear (on a clinically
trialed basis), this may cast doubt that express consent from a decision maker
was adequately informed.19
1.44 Some medical practitioners have questioned how they could ensure that a
patient gives informed consent to use medicinal cannabis
when they themselves
are unclear about the possible consequences of the decision.20 The Royal
Australasian Society of Physicians
has noted that the potential risks and
benefits will be very different from one patient group to the next.21 The
Commission expects
that concerns of this nature could be addressed
to some extent by training and guidelines that could be offered under a
medicinal cannabis scheme. In addition, clinical trials that
are underway or
proposed in Australia and internationally will continue to enrich knowledge
1.45 It is nevertheless clear that any scheme introduced in Victoria would
need to accommodate the uncertainties surrounding a decision
to use a medicinal
cannabis product that has not been tested to the standards required by the TGA
for prescription medicines. Patients
would need to be informed (preferably
verbally and in writing in language they are likely to understand) that aspects
of the treatment
such as the dosage, the best form of administration, immediate
and long-term side effects and interaction with other medications
have not been
established authoritatively by clinical trials, and would need to take
responsibility for the decision to proceed with
the treatment in view of the
information with which they are provided.
1.46 The scheme would also need to support the development of expertise among
medical practitioners in the use of cannabis for medicinal
purposes, and to
ensure that only those with appropriate training would assess whether it should
be made available to their patients.
19 Submission 63.
20 Submission 38; Advisory committee (Meeting 3).
21 Submission 52.
Ensure that medicinal cannabis products are of reliable quality and known
composition
1.47 There are many reasons why products provided under a Victorian medicinal
cannabis scheme would need to be of reliable quality
and known composition:
• It is essential to patient safety.
• It would enable a doctor to titrate dosage and monitor dose-response
• It would provide a superior product to what is available
• It would enable useful data to be collected on the efficacy and side
effects when treating particular conditions and symptoms.
1.48 Any regulation would provide a level of quality assurance that illicit
production cannot guarantee, but the scheme would need
to impose standards that
provide medical practitioners and their patients with certainty about the
potency and contents of the products
being administered.
1.49 A number of submissions pointed out the need to ensure that the products
to which patients are given access are of reliable and
verifiable composition.22
Many members of the public who told the Commission that they wish to be able to
use cannabis legally said
that their main concern is to have access to products
of a consistently good quality. As Shirley Humphris argued in her submission:
‘We need a supply that is clean and grown under controlled conditions
(street cannabis can be heavily laced with pesticide)’.23
1.50 Possible approaches to regulating the quality of products are discussed
in Chapter 7.
Foster, and be responsive to, clinical research and developments in
1.51 Any medicinal cannabis scheme established in Victoria would need to
remain effective over time as scientific knowledge, medical
practices and
technology continue to evolve. Greater understanding about the therapeutic
properties of cannabis could have an impact
on the range of products made
available in Victoria, the conditions under which they are provided, and the
size and focus of the
scheme. Accordingly, the scheme would need to keep pace
with, and be responsive to, clinical research and developments in the medicinal
cannabis industry.
1.52 Measures that would enable a Victorian medicinal cannabis scheme
to be responsive to developments in clinical knowledge,
and subject to ongoing
monitoring and review, are discussed in Chapter 8.
Preserve the prohibition of unlawful trafficking, cultivation, supply and use
of cannabis
1.53 The proposed legislative reform would need to reinforce ongoing
prohibitions on the cultivation, supply and use of cannabis.
The reform would
not allow everyone who currently uses, or wants to use, cannabis to do so
legally. It follows that the illicit market
would continue to exist.
1.54 Depending on the features of the scheme that is established, it could
create new opportunities for cannabis to be supplied and
used illegally. For
example, medicinal cannabis supplied under the scheme could be diverted to
unauthorised users by:
• authorised patients who pass on some of their supply to others
• medical practitioners who enable access by patients who do not meet
the eligibility criteria
• theft of cannabis seeds or plants under cultivation
22 Submissions 22, 25, 35, 57, 60, 61, 69, 71.
23 Submission 49.
• theft of medicinal cannabis products from distributors or
1.55 Opinions vary on the impact that a Victorian medicinal cannabis scheme
could have on the illicit market. Concerns that legitimising
the use of cannabis
for medicinal purposes
‘normalises’ recreational use among young people have not been
supported by recent research findings.24 However, international
experience has
shown significant diversion
of cannabis produced in ‘grow your own’ schemes to the illegal
market where adequate controls are not in place.25
1.56 The Law Institute of Victoria indicated that the risk of diversion is
affected by the balance of supply and demand and this should
be borne in mind
when establishing the scheme.26
The Victorian Alcohol and Drug Association suggested that cannabis is so
widely available and affordable illegally that legal products
would have little
street value.27 Dr Andrew Katelaris pointed out there is no risk of CBD-dominant
cannabis products being diverted
for recreational use because CBD has no
psychotropic effect.28
1.57 In addressing the risk of diversion, law enforcement authorities would
need to be able to determine whether a person in possession
of medicinal
cannabis is authorised under the scheme and to distinguish between products that
have been made available under the
scheme and diverted to the illegal market and
products that have been produced illegally. In addition, security measures
appropriate
to the assessment of the risk would need to
be put in place at every step of the supply chain. Many submissions commented
on the security risks and suggested how they could be
managed.29 The Commission
has taken such risks into account in developing its recommendations.
Provide an equitable and accessible scheme
1.58 This objective has been developed in response to comments that the
Commission received on the issues paper, notably from the
advisory committees.30
It recognises the need for the reform to create a scheme that provides the
necessary amount of regulation
to achieve its objectives while not becoming so
complex, burdensome or expensive that
it deters those on whom its success depends, and those it is intended to
benefit, from participating.
1.59 A concern frequently raised with the Commission is the importance of
making the medicinal cannabis products that are sold under
a Victorian scheme
affordable for patients, particularly as many could be on low incomes because of
disabilities stemming from their
conditions.31
1.60 Otherwise, as a submission made on behalf of cannabis users and
advocates pointed out, patients could resort to using less expensive
Patients’ access to cannabis under any regulated scheme is vital to its
success. If patients are unable to practically access
cannabis, they will not
embrace the system and return to buying their medicine from the illicit
24 Deborah S Hasin et al, ‘Medical Marijuana Laws and Adolescent
Marijuana Use in the USA from 1991 to 2014: Results from Annual,
Cross-sectional Surveys’ (2015) 2
The Lancet Psychiatry
25 Submissions 37, 61, 74. Gerald Caplan, ‘Medical Marijuana: A Study
of Unintended Consequences’ (2012) 43
McGeorge Law Review
Delsys Research Group,
Cost-Benefit Analysis of Regulatory Changes for
Access to Marihuana for Medical Purposes, Final Report
(2012). Yu- Wei Luke
Chu, ‘The Effects of Medical Marijuana Laws on Illegal Marijuana
Use’ (2014) 38
Journal of Health Economics
26 Submission 63.
27 Submission 46.
28 Submission 30.
29 Submissions 21, 23, 26, 29, 40, 42, 44, 58.
30 Advisory committee (Meetings 1 and 2).
31 Advisory committee (Meetings 1 and 2); Consultations 2, 4, 5, 6, 8, 23,
32 Submission 95.
1.61 This has been the experience overseas. This has been an important issue
in the various iterations of the Canadian medicinal cannabis
scheme.33 In
Italy, eligible patients were permitted in 2013 to access imported medicinal
cannabis from the Netherlands. However,
the imported cannabis was priced at ten
times the cost of products purchased on the
illicit market, at €38 per gram, or €1,000 per month for a
typical patient. As a result, only a ‘few dozen’
Italian patients
signed up for the program.34 Italy now produces its own medicinal cannabis.
1.62 In a number of jurisdictions, retail prices for medicinal cannabis are
set by the government because of its involvement in the
market. In the
Netherlands, the Office of Medicinal Cannabis sells all the medicinal cannabis
provided under the scheme. It sets
the prices based on the net costs it incurs
in purchasing, analysing, packaging and distributing the cannabis.35 The scheme
is revenue-neutral.36
1.63 Some states in the United States impose price controls by regulation
rather than by government involvement in the distribution
process. In Vermont,
for instance, dispensaries are required to have ‘a sliding-scale fee
system that takes into account a
registered patient’s ability to
pay’.37 In New York, the government will set the ‘per dose
at which medicinal cannabis may be sold.38 Prices are also controlled
indirectly by the common requirement that distributors operate
not-for-profit basis.
1.64 A view put forward in several submissions was that
patients should be able to grow
their own cannabis, to keep the costs affordable.39 This would be only a
partial solution, because not all patients have the ability,
inclination or
resources to grow their own. They would be reliant on products that have been
manufactured under regulation and sold
for a higher price.
1.65 A number of factors other than the purchase price of the products would
be likely to affect the accessibility of the scheme for
patients. Patients may
be unable or unwilling to participate if:
• The authorisation process is expensive, difficult or protracted.
• No local medical practitioners will supervise the treatment.
• There are extensive delays in meeting demand for the products.
• The monitoring and review obligations impose an unreasonable
1.66 The obligations imposed by the scheme on other participants should also
not be too onerous. Over-regulation of the cultivation
and processing of
cannabis, excessive licence fees, or duplication of regulation by Victoria and
the Commonwealth would increase
costs and act as a disincentive to potential
licensees. If the qualifications or reporting requirements under the scheme are
time-consuming, medical practitioners may choose not to be involved, or
they may charge a higher fee to patients to recover their
costs. Similarly, if the rules concerning distribution depart too much from
existing practice and require new procedures and systems
to be established,
pharmacies may be reluctant to participate as well. Considerations such as these
at any point of the process could
affect the viability of the scheme.
1.67 The more efficient the design of any Victorian medicinal cannabis
scheme, the lower would be the costs at each step of the supply
chain. In turn,
the extent to which the government may need to subsidise the purchase price of
the products would be reduced. The
Commission has been mindful of this
consideration in evaluating the law reform options in this report.
33 Submission 95. See also Ian Freckelton, ‘Medicinal Cannabis Law
Reform: Lessons from Canadian Litigation’ (2015) 22
Journal of Law
34 Steve Scherer, ‘To Grow Cheap Marijuana, Italy Calls in the
(online), 12 October 2014
http://www.reuters.com
35 Consultation 28.
37 18 Vt Stat Ann § 4474e (b)(2).
38 NY Public Health Law § 3366-D.
39 Submissions 6, 23, 53, 95.
Recommendation
Law reform to allow people to be treated with medicinal cannabis
in exceptional circumstances should be designed so as to be compatible
following objectives:
(a) Allow compassionately for exceptional circumstances of medical need.
(b) Integrate the use of medicinal cannabis products into
medical treatment.
(c) Ensure that patients are informed of clinical uncertainty about the
safety and efficacy of medicinal cannabis products they use.
(d) Ensure that medicinal cannabis products are of reliable quality and
known composition.
(e) Foster, and be responsive to, clinical research and developments in
technology.
(f) Preserve the prohibition of unlawful trafficking, cultivation, supply
and use of cannabis.
(g) Provide an equitable and accessible scheme.
1.68 The introduction of a scheme to allow Victorians to be treated with
medicinal cannabis in exceptional circumstances would generate
risks that need
to be taken into account in considering the law reform options. The option
preferred by the Commission has been developed
with a view not only to the
regulatory objectives but to the management of these risks.
1.69 There are hierarchies of risk at every level of any regulatory scheme.
The Commission focused on those which are inherent to
the proposed reform:
• Patient safety is compromised when using products that do not meet
the safety, quality and efficacy standards that apply to
prescription medicines
under the national regime.
• There is uncertainty or controversy about the circumstances in which
access to cannabis is permitted.
• Medicinal cannabis products are diverted to unauthorised users.
• There are excessive costs to government in establishing and operating
a scheme outside the national framework for regulating
therapeutic goods.
• Victoria does not secure the necessary support from the Commonwealth
in establishing and operating an effective scheme.
1.70 The Commission discusses these risks throughout the report. Although
they are relevant considerations in introducing the proposed
reform, it is
important to acknowledge that numerous other factors will inform the many
decisions required in drafting legislative
amendments and establishing and
operating a medicinal cannabis scheme.
Expectations about implementation
1.71 The Commission’s approach to identifying and assessing the options
for reform is underpinned by a number of expectations
medicinal scheme that may be established in Victoria. The discussion about the
options in this report assumes
that each would have these features.
A regulator
1.72 Responsibility for establishing and administering the scheme would
reside within the portfolio of the Minister for Health. The
Commission is aware
that preparatory work is already underway within the Department of Health and
Human Services, driven by a newly
established medicinal cannabis taskforce,
pending the completion of this reference.
1.73 Depending on the features of the scheme that is adopted, the Commission
expects that the Secretary of the Department of Health
and Human Services would
be responsible for functions such as:
• establishing and maintaining records in relation to eligible patients
and carers, and participating medical practitioners
and pharmacists
• granting permits to medical practitioners
• creating and enforcing quality assurance standards
• controlling the manufacture and distribution of medicinal cannabis
• providing data to the Commonwealth in order to meet international
reporting obligations
• preparing guidelines and educational material for the public, medical
practitioners and pharmacists.
1.74 The Secretary’s lawful functions may need to be amended
accordingly40 and other government agencies may also need to be
involved in
regulating aspects of the scheme.41
In any event, the functions would be within the remit of existing government
agencies and there are no compelling reasons to create
an independent statutory
authority for this purpose.42
1.75 To the extent that there is a need for the Victorian Government to enter
into contracts or own property, these powers could be
exercised by an existing
body corporate
known as the ‘Secretary to the Department of Health and Human
Services’.43 This body corporate and its predecessors have
a long history
of contracting and owning property for discharging various health-related
functions.44
1.76 The Commission also expects that, while the new regulatory powers would
be formally reposed in the Secretary, in practice they
would be exercised by, or
on the advice of, a business unit within the Department of Health and Human
Services. In this report,
the Commission refers to this unit as the
‘Office of Medicinal Cannabis’.
40 The Secretary’s functions are set out in the
Public Health and
Wellbeing Act 2008
and can be expanded by regulation:
Alternatively, new provisions could be added to the Act.
41 The Commission expects that the Secretary of the Department of Economic
Development, Jobs, Transport and Resources would regulate
any cultivation of
cannabis for medicinal purposes by licensed entities: see Chapter 6.
42 Victorian Public Sector Commission,
Legal Form and Governance
Arrangements for Public Entities: Guidelines
(May 2013) [3.2].
43 Under the
Public Health and Wellbeing Act 2008
‘Secretary to the Department of Health’ is established as a body
corporate, which is capable of owning property
and doing all other acts which
may be done by body corporate. By force of the current Administrative
Arrangements Order (No 219)
2014, the ‘Secretary to the Department of
Health’ is to be read as the ‘Secretary to the Department of Health
Human Services’: Victoria,
Government Gazette
, No S 460, 24
December 2014, Table 2, Item 22.
44 See Victoria,
Parliamentary Debates
, Legislative
Assembly, 10 March 2010, 748 (Daniel Andrews, Minister for Health).
An advisory body
1.77 The Commission has recommended above that one of the regulatory
objectives of any medicinal cannabis scheme in Victoria should
be to foster, and
be responsive to, clinical research and advancements in technology. It was
suggested to the Commission that the
Government establish and use a panel of
experts to guide it on the state of the science and how this should inform its
decision making.45
1.78 The Commission concurs with the thrust of these submissions. An Expert
Advisory Committee on Medicinal Cannabis was established
by the Department of
Health and Human Services in 2014 and could form the basis of such an advisory
body under a medicinal cannabis
1.79 Professor David Penington recommended the formation of a panel of
patient advisors
who are ‘knowledgeable about alternative products and methods of
administration.’46 The Commission agrees that the Department
of Health and
Human Services should consult with patients and their carers about the
operation of the scheme. However, while the
panel proposed by Professor
Penington could be useful, and community consultation
is important, there may be better means of communicating with this disparate
and widespread group of people.
Interim measures
1.80 There could be a considerable period of time between a decision being
made by the Government about the type of scheme to introduce
and the supply of
medicinal cannabis products under the scheme. The duration would depend on how
much of the supply chain is regulated
by the scheme. In the meantime, it is
reasonable to expect that the patients for whom the scheme is designed would
continue to use,
or could seek to use, illicit medicinal cannabis products.
1.81 Accordingly, the Commission acknowledges that the Government may
consider introducing interim measures in anticipation of the
scheme coming into
operation. These could be introduced under interim legislation that is repealed
upon the full scheme coming into
effect. Such measures could include, for
example, the establishment of a registration scheme for patients for whom
specific services
and authorisations could
be created. The Commission makes no recommendations about any such measures
as it would be beyond the scope of the terms of reference.
However, the
following observations are made for the Government’s information.
1.82 In considering which interim measures, if any, to introduce, it would be
prudent to be guided by the regulatory objectives that
the full scheme is
intended to achieve. An interim measure should not permit activities which again
would be prohibited under the
scheme; if it did, the final scheme would be
undermined by the interim scheme that preceded it.
1.83 The immediate priorities identified by patients and their families who
spoke with the Commission about their current illicit
use of cannabis for
medicinal purposes, and who would be eligible to participate in the scheme if
the recommended eligibility criteria
were applied, are to be protected from
prosecution and be able to find out the composition of the products they
1.84 A number of submissions, and comments made during consultations, called
for an amnesty for patients and their suppliers.48 However,
‘amnesty’ would need to take
the form of an authorisation to conduct activities that are otherwise
prohibited under the
Drugs, Poisons and Controlled Substances Act 1981
45 Submission 60 proposes that an expert committee be used to review
proposals to conduct clinical trials; Submission 61 suggests
establishing an
‘indication committee’ to establish eligibility criteria, and an
‘exemption committee’ to
consider special cases of eligibility.
46 Submission 24.
47 Consultations 2, 4, 6, 13.
48 Submissions 35, 43, 64, 71, 89, 95; Consultations 2, 5, 6, 9, 24,
1.85 Interim measures could authorise specific classes of people to possess
or administer cannabis for medicinal purposes, including
for example:
• patients and carers who have been registered for the purposes of the
interim measures
• medical practitioners and nurses involved in their care
• employees of testing facilities for the purpose of implementing any
interim measures allowing for medicinal products to be
Concurrent developments
Rescheduling of cannabidiol
1.86 On 1 June 2015, the cannabinoid cannabidiol (CBD) was rescheduled to
Schedule 4 of the
Standard for the Uniform Scheduling of Medicines and
.49 This means that a medicine containing cannabidiol and two per
cent or less of other cannabinoids may be made available by prescription
throughout Australia, as long as it has first been approved by the TGA.50
Clinical trials
1.87 A number of clinical trials of medicinal cannabis are underway or
planned in Australia.
1.88 New South Wales, Queensland and Victoria are sponsoring three trials to
explore the efficacy of cannabis and/or cannabis-derived
products. Led by New
South Wales, the first trial is of children with severe, drug-resistant
epilepsy. It will involve up to 200
participants, from mid-2016. The Victorian
Government aims for at least a quarter to be from Victoria. The results of the
expected in two to five years.51
1.89 The other two trials are for adults. One will focus on relieving
the pain symptoms of adults with terminal illness. The
other will be for adults
with chemotherapy-induced nausea and vomiting, where standard treatment is
ineffective.
1.90 Following a donation of $33.7 million for medicinal cannabinoid
research, the University of Sydney recently announced that it
will conduct a
multi-year program to build on existing expertise to ultimately produce
cannabinoid-based medicines. A priority will
to understand the potential for CBD and other cannabinoids to treat
paediatric epilepsy.52
The University of Sydney is also involved in the government-sponsored
Regulator of Medicinal Cannabis Bill 2014
1.91 In November 2014, the
Regulator of Medicinal Cannabis Bill 2014
was introduced to the Senate as a Private Member’s Bill.53 The Bill
establishes the Regulator of Medicinal Cannabis,
an agency that would:
• approve medicinal cannabis products for inclusion in a register of
regulated cannabis products54
• make, and monitor compliance with, rules for licensing the
production, use, experimental use and import and export of medicinal
cannabis.55
49 Therapeutic Goods Administration (Advisory Committee on Medicines
Scheduling),
Final Decisions and Reasons for Decisions by Delegates of the
Secretary to the Department of Health
(19 March 2015) 56 – 60.
50 Approval of medicines by the Therapeutic Goods Administration, the
operation of the
Standard for the Uniform Scheduling of Medicines and Poisons
and the consequences of rescheduling CBD are discussed further in Chapter
51 Premier of Victoria, ‘Victoria to Participate in Medicinal Cannabis
Trials’ (Media Release, 19 April 2015) <
http://www.premier.vic.gov.au /
victoria-to-participate-in-medicinal-cannabis-trials>.
52 The University of Sydney, ‘Lambert Donation Puts Australia at
Forefront of Medicinal Cannabinoid Research’ (Media
Release, 12 June
http://sydney.edu.au /news /
53 Commonwealth,
Parliamentary Debates,
Senate, 27 November 2014, 9506
(Richard Di Natale). See rule 6.6.1.
Regulator of Medicinal Cannabis Bill 2014
55 Ibid cl 12.
1.92 The proposed office of Regulator is designed to satisfy the requirements
of the Single Convention on Narcotic Drugs regarding
government supervision of
licensed cannabis cultivation.56 The source of constitutional authority for the
Bill is said to be the
treaty implementation aspect of the external affairs
power.57 The scheme would apply only in those states and territories that opt
1.93 On 12 February 2015, the Senate referred the Bill to the Senate
Legal and Constitutional Affairs Legislation Committee
for report by 21 April
2015. On 11 August 2015 the report was tabled, supporting ‘in principle,
the access to products derived
from cannabis for
use in relation to particular medical conditions where the use of those
products has been proven to be safe and effective.’
The committee
recommended amendments to the Bill
to address issues in relation to its interaction with the existing
Commonwealth regulatory framework for medicinal products, including
Therapeutic Goods Act 1989
Narcotic Drugs Act 1967
(Cth) and relevant
customs legislation. It also recommended amendments to the Bill to ensure
compliance with Australia’s international
obligations, including under
articles 23 and 28 of the Single Convention on Narcotic Drugs 1961.59
1.94 The Commission is aware of active discussion at the political level, and
among government agencies, about the possible introduction
of Commonwealth
legislation. Although Commonwealth legislation could modify the design of a
Victorian scheme, the discussion in this
report would remain relevant.
Draft Drugs of Dependence (Cannabis Use for Medical Purposes)
Bill 2014 (ACT)
1.95 The Standing Committee on Health, Ageing, Community and Social Services
of the Australian Capital Territory Legislative Assembly
is also considering
proposed medicinal cannabis legislation—the Drugs of Dependence (Cannabis
Use for Medical Purposes) Amendment
Bill 2014 (ACT). On behalf of the ACT Greens
party, the Minister for Justice60 presented an exposure draft of the Bill and a
paper to the Legislative Assembly in August 2014. The exposure draft
and paper were referred to the committee.61
1.96 The purpose of the draft Bill is to set up a licensing system for
patients to possess and grow their own cannabis for medicinal
purposes if
approved by the Chief Health Officer.62
Patients would be able to make one of three types of application:
• Category 1 application: for the mitigation of symptom(s) of a
terminal illness63
• Category 2 application: for the mitigation of one or more listed
symptoms associated with a listed condition, set out in a
table (such as severe
pain associated with cancer)64
• Category 3 application: for the mitigation of a symptom of any other
medical condition or its treatment.65
1.97 The application would have to be supported by a statement from a doctor,
with increasingly stringent requirements according to
the category of
application.66 In all cases, the applicant would need to have tried or
considered conventional treatment first.67
Once approved, a patient would be permitted to possess cannabis. An approval
would essentially amount to a licence to possess and
use cannabis.68
56 Explanatory Memorandum,
Regulator of Medicinal Cannabis Bill 2014
Single Convention on Narcotic Drugs 1961
is discussed in
57 Explanatory Memorandum,
Regulator of Medicinal Cannabis Bill 2014
Regulator of Medicinal Cannabis Bill 2014
59 Senate Legal and Constitutional Affairs Legislation Committee, Parliament
of Australia,
Regulator of Medicinal Cannabis Bill 2014
60 Shane Rattenbury MLA.
61 Australian Capital Territory,
Parliamentary Debates,
Legislative
Assembly, 7 August 2014, 2154 (Shane Rattenbury).
62 Drugs of Dependence (Cannabis Use for Medical Purposes) Amendment Bill
2014 (ACT) cl 14.
63 Ibid cl 7(3).
64 Ibid cl 7(4).
65 Ibid cl 7(5).
66 Ibid cl 8–9.
67 Ibid cl 8 (2) – (3).
68 Ibid cl 14.
1.98 The patient would also be permitted to seek a licence to cultivate
cannabis either personally or on their behalf by a nominated
carer. It would be
valid for a limited time (no longer than a year) and would stipulate maximum
possession amounts.69 In applying
for a cultivation licence, the applicant would have to establish that they
have appropriate security measures in place,70 and only
one patient would be
able to be associated with any given cultivation site.71 The scheme would be
reviewed after five years by a
multi- stakeholder committee.72
1.99 At the time of writing, the committee was due to report by the last
sitting day of August
2015.73 The outcome could also be affected by any decision by the
Commonwealth to legislate in this area.
Tasmanian parliamentary inquiry
1.100 On 20 November 2014, Government Administration Committee
‘A’ of the Tasmanian Legislative Council released an interim
on the use of natural botanical medicinal cannabis flower and extracted
cannabinoids for medicinal purposes. The interim report
noted that many
Tasmanians were already using cannabis medicinally and that the law did not
provide protections for these users or
those who supply them.
1.101 While acknowledging that more research was needed, the Committee
recommended immediate legislative change, on compassionate
grounds, to protect
users of medicinal cannabis from criminal charges associated with possession and
administration. It also recommended
that the Tasmanian Government:
• develop a legislative framework to enable medicinal cannabis to be
used under medical supervision, including the preparation,
cultivation and
supply of medicinal cannabis
• facilitate clinical research
• adopt a cooperative approach with other jurisdictions regarding
legalisation of the prescription, administration, possession
and cultivation of
cannabis for medicinal use
• engage with companies with appropriate expertise and capacity to
progress the cultivation, extraction and processing of cannabinoids
existing and/or future regulatory framework.74
1.102 The Tasmanian Government responded to the interim report by expressing
its support for clinical trials and the potential use
of medicinal cannabis in
Tasmania, subject to a proper evidence-based approach, strong regulatory
framework and appropriate approvals
from national regulators.75 However, it
rejected the Committee’s recommendation to legislate immediately to
protect individuals
who are using medicinal cannabis from criminal charges. The
Police Commissioner had said that Tasmania Police would not criminally
terminally ill users of cannabis or people who had contributed to the
The Committee presented its final report to the Legislative Council on 21
April 2015.77 It said that continuing the inquiry in light
of the introduction
Regulator of Medicinal Cannabis Bill 2014
to the Senate and the New South
Wales Government’s commitment to clinical trials may be duplicative and
unnecessary. The interim
report stands as the substance of the final
69 Ibid cl 16 –22.
70 Ibid cl 18 (3)(d).
71 Ibid cl 18 (3)(e).
72 Ibid cl 25.
73 Standing Committee on Health, Ageing, Community and Social Services, ACT
Legislative Assembly (2015)
http://www.parliament.act.gov
74 Legislative Council Government Administration Committee ‘A’,
Parliament of Tasmania,
Interim Report on Legalised Medicinal
75 Michael Ferguson, ‘Interim Report on Medicinal Cannabis’
(Media Release, 20 November 2014) <
http://www.premier.tas.gov.au
/releases /
interim_report_on_medicinal_cannabis>.
77 Legislative Council Government Administration Committee ‘A’,
Parliament of Tasmania,
Final Report on Legalised Medicinal Cannabis
Norfolk Island licence to cultivate and export cannabis
1.103 In April 2015, the responsible minister announced that AusCann Group
Holdings Pty Ltd had lodged an application for a licence
to ‘import,
export, plant, cultivate, tend or harvest and sell’ cannabis, for the
purpose of establishing a medicinal
cannabis industry on Norfolk Island.79
Norfolk Island legislation permits the Minister to grant such a licence under
conditions as the Minister thinks appropriate’80 and the
Administrator has the discretion to cancel it at any time.81
1.104 In May 2015, it was reported that the licence had been granted. The
AusCann Managing director revealed that the company aimed
to produce high
quality medicinal-grade cannabis for export to importers that were licensed in
accordance with the Single Convention
on Narcotic Drugs.82 It had an initial
order from Canada for one tonne and aimed to provide ten tonnes in the future.
crop was to be planted in November
2015, to be harvested in May or June 2016.83
1.105 Since then, the legal and governance framework for Norfolk Island has
changed. The form of self-government that was established
Island Act 1979
(Cth) has been abolished.84 The Legislative Assembly and
Executive Council will be replaced from
1 July 2016 by a regional council that will provide local and municipal
services. State-
level services will be provided by the New South Wales Government, and the
law of New South Wales will apply. In the meantime an advisory
council has been
established as an interim body and the statutory office of Administrator will
1.106 Norfolk Island laws will stay in place until they are specifically
replaced by New South
Wales law.85
Structure of this report
1.107 Any approach to determining the exceptional circumstances in which a
person could lawfully use cannabis for medicinal purposes
should be grounded in
an understanding of its therapeutic benefits, efficacy, risks and dangers.
Chapter 2 contains an overview of
what cannabis is, how it is used, and what is
currently known and claimed about its therapeutic properties.
1.108 The Commission’s conclusions and recommendations about the
eligibility criteria for
a scheme that allows for people to be treated with medicinal cannabis in
exceptional circumstances are explained in Chapter 3. Discussion
then turns to
who could authorise an individual patient’s access to medicinal cannabis
and the possible regulatory mechanisms
1.109 The legislation that controls access to cannabis is discussed in
Chapter 4. The
Drugs, Poisons and Controlled Substances Act 1981
Therapeutic Goods (Victoria) Act 2010
(Vic) and associated
regulations constitute Victoria’s contribution to national legislative
frameworks that control narcotic
drugs and ensure the quality, safety and
efficacy of therapeutic goods.
79 Robin Adams, Minister for Cultural Heritage and Community Services,
‘A Medicinal Cannabis Industry for Norfolk Island’
24 April 2015).
Dangerous Drugs Act 1927
Dangerous Drugs Act 1927
(NI) s 13. The Administrator exercised
this power to cancel a licence issued under s 7A to Tasman Health Cannabinoids
(NI) Pty Ltd
(Tascann) in 2014 after identifying a need for the social, economic
and environmental impacts to be properly assessed and for the
community to be
adequately consulted. He also expressed doubt that the licence adequately
addressed international obligations regarding
the cultivation and trade of
illicit drugs and noted that it had been issued without consulting the relevant
federal authorities:
Gary Hardgrave, Administrator, Australian Territory of
Norfolk Island, ‘Tasman Health Cannabis Licence Cancelled’
Daun’taun (Government News from Kingston), 14 August 2014)
http://norfolkonlinenews.com
82 ‘Firm to export medical cannabis’,
20 May 2015 <http //
www.skynews.com.au /news
/national /
83 3AW, ‘Medical Marijuana Grown on Norfolk Island’, 20 May 2015
http://www.3aw.com.au
Norfolk Island Legislation Amendment Act 2015
85 Department of Infrastructure and Regional Development, Australian
Government,
Fact Sheet: Answers to Your Questions from the
Information Sessions
(May 2015) <
http://regional.gov.au
/territories /norfolk_island /fact-sheets /
Norfolk-Island-reforms-answers-from-info-
sessions.aspx>.
1.110 Chapter 5 sets out the options for reform. The range of proposals put
to the Commission is discussed. Some are not feasible
because they are legally
unstable or otherwise undesirable when considered in view of the regulatory
objectives. An option that is
feasible and most likely to achieve the regulatory
objectives is identified and recommended. It is adopted as a model in the
chapters. Chapter 6 contains details of how medicinal cannabis
products could be manufactured, supplied and distributed in Victoria
recommended option.
1.111 Under the recommended option for the supply of medicinal cannabis
products the Victorian Government would regulate the quality
and type of
products available. Ways in which this could be done are discussed in Chapter
1.112 Any medicinal cannabis scheme introduced in Victoria could be the first
of its kind in Australia, and would be implemented at
a time when information
purposes are changing rapidly.
Chapter 8 discusses possible measures for ensuring that the operation of the
scheme contributes to research and is subject to ongoing
monitoring and
1.113 Chapter 9 concludes the report.
cannabis for medicinal purposes
20 Introduction
20 What is medicinal cannabis?
23 Use of medicinal cannabis
30 Research support for efficacy
2. The use of cannabis for medicinal purposes
Introduction
2.1 This chapter provides an account of the Commission’s view
of what constitutes medicinal cannabis, a discussion of
the way cannabis is
currently used medicinally in Victoria, and a record of information provided to
the Commission about the effects
of cannabis used for medicinal purposes. It
also reviews the research base for:
• the efficacy of cannabis in alleviating the symptoms of particular
• the adverse effects that cannabis may have for patients when provided
to them for medicinal purposes.
What is medicinal cannabis?
Scope of review
2.2 The Commission has been asked to review and report on options for changes
to the law to allow people to be treated with ‘medicinal
in exceptional circumstances. For the purposes of its review the Commission must
therefore adopt a position on what
is meant by ‘medicinal
2.3 ‘Cannabis’ refers to the flowering tops of plants in the
.1 Generally, the species used for medicinal and
recreational purposes are Cannabis sativa and Cannabis indica,2 with
plants also available.3 While the whole of the plant
contains varying levels of between 80 and 100 cannabinoids, they are found
the highest concentrations in the flowering tops, meaning this part of the plant
is most relevant for those wishing to use cannabis
for medicinal purposes.4
2.4 The efficacy of cannabis for particular medical conditions is affected by
the types and amounts of cannabinoids in the product.
Products can contain high
or low levels of delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD),5 in
various combinations
with the other cannabinoids. Some forms are psychoactive, principally because
of their concentration of THC.6
1 In addition to being the commonly understood meaning of the term, this is
also the meaning adopted in the
Single Convention on Narcotic
art 1(1)(b).
2 A third species,
Cannabis ruderalis
, also exists, but the Commission
was not told that it is used medicinally. See Karl W Hillig, ‘Genetic
Evidence for Speciation
in Cannabis (Cannabaceae)’ (2005) 52
Resources and Crop Evolution
161. See generally Michael Backes,
Cannabis Pharmacy
(Black Dog & Leventhal, 2014); Submission 95.
3 Recent literature has disputed whether the
Cannabis sativa
, exists: A Hazekamp and J T Fischedick,
‘Cannabis—From Cultivar to Chemovar’ (2011) 4
Drug Testing
and Analysis
4 Some medicinal users assert that the leaves of the plant also have
therapeutic value.
5 Such as the ‘Charlotte’s Web’ strain, which was developed
by cross-breeding a strain of cannabis with industrial
hemp to achieve a low-THC
strain used in treating the epilepsy of Charlotte Figi: Epilepsy Foundation of
Frequently Asked Questions
http://www.epilepsycolorado.org
6 The level of psychoactivity depends chiefly on the THC content. Products
which contain predominantly CBD or unconverted THCA are
minimally psychoactive.
2.5 Cannabis is used for recreational purposes for its euphoriant effect,
among other things, but also for medicinal purposes to cure
or remedy symptoms
of medical conditions.
2.6 ‘Medicinal’ means ‘relating to, having the properties
of, a medicine; curative; remedial’.7
Thus, cannabis should be regarded as ‘medicinal cannabis’ when
it is used for a medicinal objective—to achieve
a curative or remedial
effect.8 In this respect, medicinal purposes are to be equated with
‘therapeutic’ purposes.9
This is to be contrasted with its use for
recreational purposes.
2.7 In consideration of the options for changes to the
Drugs, Poisons and
Controlled Substances Act 1981
(Vic), the Commission comprehends cannabis to
be used medicinally when it is both:
• taken by a person for the medicinal purpose of attempting to cure or
remedy a medical condition,10 and
• taken in a manner that enables the purported curative or remedial
effect to be appropriately supervised and verified by a
qualified medical
professional.
2.8 Advances in the understanding of cannabis over the past half-century have
enabled the development of synthetic pharmaceuticals
that mimic the effects of
cannabinoids on the body. For the purposes of this report, though, the
Commission does not treat
these products as falling within the meaning of ‘medicinal
cannabis’. On the other hand, products that are extracted from
cannabis plant and used for medicinal purposes are regarded as falling within
the meaning of ‘medicinal cannabis’.
Characteristics of medicinal cannabis
2.9 The Drug Policy Modelling Program at the University of New South
Wales observed in its submission that cannabis products
used medicinally can be
categorised according to how their production is regulated:
• pharmaceutical-grade cannabis products, approved by conventional
regulators such
as the Therapeutic Goods Administration (TGA) and including the nabiximols
and synthetic cannabinoids
• controlled and standardised herbal cannabis, such as the products
made in the Netherlands by Bedrocan BV, which have standardised
cannabinoids and have been tested to be free of harmful adulterants
• unregulated illegal herbal cannabis, which is anything bought from
the black market and generally has unknown concentrations
of cannabinoids and
potentially harmful contaminants.11
Macquarie Dictionary
(6th ed, 2013).
8 See Jonathan P Caulkins et al,
Marijuana Legislation: What Everyone
Needs to Know
(Oxford University Press, 2012) 14.
9 See the etymological origin from the Greek of ‘therapeutic’,
namely ‘healing’ and the definition ‘relating
to the treating
or curing of disease, curative’:
Macquarie Dictionary
2013). Thus, in the
Therapeutic Goods Act 1989
‘therapeutic use’ is defined as, among other things,
‘preventing, diagnosing, curing or alleviating a disease,
ailment, defect
or injury in persons’.
10 Often described as seeking a ‘therapeutic effect’, that being
a drug’s pharmacological effect on the body that
translates into a
clinical benefit for the patient: see David Warrell, Timothy M Cox and John D
Firth (eds),
Oxford Textbook of Medicine
(Oxford University Press,
2003) 1013.
11 Submission 21.
2.10 Cannabis can also be differentiated by the form in which it is supplied.
The categories of product made available for medicinal
purposes in other
• the dried flowering tops of the cannabis plant, taken through being
smoked, vaporised or infused in tea
• cannabis resin, collected and compressed from the flowering tops
• infused cannabis products, such as alcohol-based tinctures, edible
oils infused with cannabis and products made from these,
and suppositories
• extracts of cannabis, containing concentrated extracts of
cannabinoids, taken orally, topically or by vaporisation
• raw, undried cannabis leaves, consumed as a food.
2.11 Some submissions provided to the Commission distinguished between the
Cannabis sativa
Cannabis indica
for different
purposes. Both forms contain a number of compounds that have the potential for
medical application.
2.12 Views differ regarding what makes medicinal cannabis effective. Most
submissions highlighted the therapeutic use of THC and CBD,
and a number of
people stressed the significance of the endocannabinoid system and the role of
the Type 1 and 2 cannabis receptors.12
CBD is known to moderate the effects of
THC and is being researched for its potential to treat epilepsy, schizophrenia
psychotic disorders, type II diabetes, inflammatory bowel disease,
gliomas and drug dependency, among other conditions.13
2.13 THC and CBD are not the only compounds of interest in the cannabis
plant. Besides
THC, researchers at the University of Sydney have identified what they refer
‘big 10’ non-psychoactive and non-addictive cannabinoids that
show the most promising therapeutic potential. They are:
• cannabidiol (CBD) and its acid form (CBDA)
• cannabidivarin (CBDV)
• the acid form of THC (THCA)
• tetrahydrocannabivarin (THCV) and its acid form (THCVA)
• cannabigerol (CBG) and its acid form (CBGA)
• cannabinol (CBN)
• cannabichromene (CBC).14
2.14 Research as to the effects of these cannabinoids remains at an early
phase, but the compounds have possible medical application
in the treatment of
epilepsy, pain, psychosis, cancer, diabetes, inflammation, anxiety and a host of
other conditions.15
2.15 Besides cannabinoids, up to 300 other compounds found in the cannabis
plant are asserted to contribute to its overall therapeutic
effect. These
include terpenes and flavonoids, which are not unique to the cannabis plant but
contribute to each strain’s chemical
‘fingerprint’.16 Some
with whom the Commission consulted emphasised the
‘entourage effect’, said to arise from the ‘whole’
cannabis plant which results in an overall beneficial effect
beyond what could
be obtained from each cannabinoid on its own.17
12 Submissions 13, 29, 30, 35, 59, 69, 90, 97. See Appendix B for list of
submissions.
13 Government of WA Department of Health and Government of Victoria
Department of Health,
Application to Amend the Poisons Standard
(Substance: Cannabidiol)
, 6 October 2014,
http://www.health.vic.gov.au /dpcs /medicinal-cannabis.htm
14 David Allsop et al, Submission No 52 to Senate Legal and Constitutional
Affairs Legislation Committee, Parliament of Australia,
Inquiry into the
Regulator of Medicinal Cannabis Bill 2014
16 A Hazekamp and J T Fischedick, ‘Cannabis—From Cultivar to
Chemovar’ (2011) 4
Drug Testing and Analysis
17 Submissions 59, 95. See Ethan Russo, ‘Taming THC: Potential Cannabis
Synergy and Phytocannabinoid-Terpenoid Entourage Effects’
British Journal of Pharmacology
Use of medicinal cannabis
2.16 It is apparent from the submissions received and consultations conducted
by the Commission that cannabis is currently being used
illegally by a wide
range of Victorians to attempt to alleviate a broad array of health conditions.
Others have informed the Commission
that they would use it but are deterred by
its current unlawful status.
2.17 As outlined in the issues paper, cannabis has a long history of
medicinal use. It was introduced into Western medicine in the
19th century, at
which time medicines were much less refined than contemporary pharmaceuticals.
By the early 1900s, botanical extracts
of cannabis were still in use, but the
product was ‘difficult to store, its extracts were variable in potency,
and the effects
of oral ingestion were not constant’.18 At the same time,
its recreational use increased, and by the mid-20th century its
medicinal use
had all but disappeared.19
2.18 The Commission heard compelling stories from users of medicinal cannabis
regarding the dramatic changes they had experienced
after starting treatment
with medicinal cannabis. Many spoke of the ways in which cannabis had enabled
them to stop using pharmaceutical
drugs with serious side effects, or to
‘get their lives back’. Others without experience of medicinal
cannabis told the
Commission about the desperation they felt
in experiencing, or watching a loved one experience, the pain and suffering
of a chronic illness, and expressed sincere hope that
cannabis might be
effective for them.
Personal accounts of conditions where cannabis has provided relief
2.19 The following paragraphs summarise some of the personal accounts as to
the efficacy of medicinal cannabis, as conveyed in submissions
consultations with members of the public.
Multiple sclerosis
2.20 Pain and muscle spasms associated with multiple sclerosis were reported
as having been effectively treated through the use of
medicinal cannabis. KF
informed the Commission that she was diagnosed with multiple sclerosis in 2011
‘after many years in
limbo’. Her main symptoms were pins and
needles, electric shocks, nerve pain in her feet and legs that made it very
for her to walk, severe throat spasms, loss of sensation in
the right side of her face, cognitive issues and extreme fatigue. She also
suffered from alopecia areata for 10 years. She told the
Commission that she
started taking cannabis oil made according to the ‘Rick Simpson
protocol’20 in 2012. The result
I no longer lose my hair, I no longer get the pins and needles or the
electric shocks, I have recovered some of the feeling in my
face but not all.
If I take a small amount of cannabis oil every other day, I am able to do
activities that include walking, without
extreme pain. My MS has also not
progressed.21
2.21 The Commission heard from a number of people with children suffering
from rare and severe forms of epilepsy. Many told of the
dramatic reduction in
symptoms their children had experienced following treatment with cannabis
18 I Tomida, R G Pertwee and A Azuara-Blanco, ‘Cannabinoids and
Glaucoma’ (2004) 88
British Journal of Ophthalmology
20 That is, by using a volatile solvent (usually naphtha or petroleum ether)
to prepare a concentrated extract of cannabis: Luigi
Arno Hazekamp, ‘Cannabis Oil: Chemical Evaluation of an
Upcoming Cannabis-Based Medicine’ (2013) 7
Cannabinoids
21 Submission 96.
2.22 The parents of Cooper Wallace told the Commission in person and in a
written submission about the major symptom relief that he
received from
administration of cannabis oil. They acknowledged that it was not a cure for
him but asserted that ‘it gives
a quality of life for him, and our entire
family’.22 Prior to using cannabis oil his condition had been
deteriorating. After
using cannabis oil for some time they have found that
Cooper’s previously extensive fitting has become very limited and he
able to eat and
drink instead of relying on tube-feeding. His conventional medications have
been reduced and in some cases stopped.
We recently ran out of cbd oil, within days he was in hospital. One day alone
he had over 900 seizures. On oil he has only 2–3
seizures. A dramatic
2.23 A similar account was given to the Commission by the parents of Tara
O’Connell, who is treated with an ultra-low dose treatment
using THC and
THC Acid.24 In 2012, Tara was suffering around 200 seizures per day and had been
resuscitated eight times. She used
a wheelchair, was not toilet-trained and had
limited capacity to speak. Her medications had caused drug-induced anorexia. She
not expected to live for more than 24 months.25
The Commission was told that, upon the administration of cannabis to Tara,
her seizures stopped and the respite from the seizures
has extended for over 24
months.26 She no longer requires the use of a wheelchair and can attend school
part-time. She has also ceased
using all pharmacy drugs.27
2.24 Michelle Whitelaw informed the Commission of a similar response obtained
by her son, Jai, who was experiencing in the order of
500 seizures a day. She
told the Commission that his incidence of seizures had fallen to three over the
previous five months:
His pupils are no longer fixed nor dilated. He is eating/drinking without
choking, attending school, able to write, speech is improving,
walk steady, kick
a ball and ride his bike, socialise, dress and toilet himself. All of these are
FIRSTS. His personality is bubbly
and he is so incredibly alive and well. Jai
has not experienced any negative side effects. 28
2.25 The Commission also received submissions on behalf of adults suffering
from intractable epilepsy. Lyn Cleaver wrote about her
adult son, Jeremy, who
suffers from epilepsy.
In 2014, he experienced a drug-induced psychosis after one of his medications
was increased on the advice of a neurologist. Subsequent
adjustments to his
dosages were
of no effect, and the family decided to try medicinal cannabis. Ms Cleaver
described the results as follows:
Almost immediately we saw improvements, his sleep patterns, behaviours and
seizures were all much more tolerable! We knew then that
we must find a way to
source cannabis medicines to give him the best possible chance at a fulfilling
life. ... Jeremy has been at
the end of the line for available treatment for his
seizures for years. We
have been forced to wait for the next anti convulsant to be available on the
market. ALL of the anti convulsants he has trialled have
failed to control his
seizures, ALL of them have caused unwanted side effects—some of them very
serious. Cannabis is the first
medicine we have been able to offer him that is
both safe and effective.29
22 Submission 50.
24 Submission 29.
25 Submission 51; Consultation 18. See also Cheri O’Connell, Submission
109 to Senate Legal and Constitutional Affairs Legislation
Committee, Parliament of Australia,
Inquiry into the
Regulator of
Medicinal Cannabis Bill 2014
26 See also Submission 29.
27 Cheri O’Connell, Submission 109 to Senate Legal and Constitutional
Affairs Legislation Committee, Parliament of Australia,
Inquiry into
Regulator of Medicinal Cannabis Bill 2014
28 Submission 71.
29 Submission 81.
Relief from the symptoms of cancer
2.26 The Commission was informed by a number of people about the advantages
in terms of pain relief and comfort obtained by patients
with terminal cancer
when they took one form or another of medicinal cannabis. Some provided powerful
accounts of the help that they
and their loved ones had received from different
forms of cannabis during the later stages of their experience of terminal
particularly cancer.
2.27 Robert Wisbey spoke movingly at a public consultation in Geelong30 about
the experience of his son, Mason, who passed away from
bowel cancer in April
2015. He told the Commission that when Mason received cannabis oil he was
‘able to sleep, he was able
to eat’.31 Mason had previously been
unable to eat significantly for an extended period of time. In addition,
according to
his father, while cannabis did not remove Mason’s pain, it
rendered it manageable and significantly increased Mason’s
quality of life
during the later period of his life.
2.28 In a subsequent written submission, Mr Wisbey described the unrelenting
pain and discomfort from which Mason suffered until he
began to take cannabis
As a human being Mason deserved BETTER he deserved to have a life without
pain without suffering without the constant side effects
caused by his
medication and treatment, this was finally found in Cannabis Oil as much as I
doubted its effect I could NOT refute
what I was seeing before my eyes, my son
was able to sleep, he was able to eat, an appetite that had left his body many
months before
returned with a vengeance he was not pain free but it was
manageable at a level far far lower than what Doctors were able to give.32
2.29 This account has many features in common with the experience of Dan
Haslam in Tamworth, New South Wales who also experienced
significant relief from
the symptoms of bowel cancer from administration of cannabis oil.33
2.30 The Australian Lawful Use of Cannabis Alliance relayed the story of
another parent treating his child with cannabis oil:
The recent tragic experience of one of our members, Mr Adam Koessler, is a
example of this... He is currently facing criminal charges and family court
proceedings for administering cannabis oil to his daughter
who has terminal
cancer and is undergoing a long process of chemotherapy.34
2.31 A woman who attended the public consultation in Wodonga said that her
husband’s palliative care nurse had suggested cannabis
for relief of
cancer pain before he passed away. She said she was surprised at this, but that
it did provide very good pain relief.35
2.32 Many who communicated with the Commission lamented the effects of opiate
medications which had adversely affected the mental
state of cancer sufferers
and had caused a variety of side effects including chronic and distressing
constipation. However, they
asserted that cannabis did not have such effects and
was either as effective as, or more effective than, prescribed opiate
medications.
30 Submission 64.
33 See James Robertson, ‘Dan Haslam, Who Changed Mike Baird’s
Views on Medicinal Cannabis, Dies of Cancer’,
Sydney Morning
25 February 2015.
34 Submission 35.
35 Consultation 6. See Appendix C for list of consultations.
Chronic pain
2.33 Many accounts were given to the Commission of respite from chronic pain
after using medicinal cannabis.36
2.34 Matthew Corda has an acquired brain injury and many associated problems,
and uses cannabis to treat pain and depression. He stated:
I have tried nearly everything to no real solution to pain etc relief, but
found cannabis a magic thing, kills the pain for longer,
and am functioning
adult. ... All [treatments] have been trialled and failed, or as in my case the
strong pain [medications] gives
the feeling of a zombie and difficult to
function. ... [T]he benefits far outweigh what is wrote or discussed by people
with no experience
or used cannabis.37
2.35 Danielle Rose-de Montignie used cannabis to treat her chronic pain
caused by cancer
from which she suffered 28 years ago. She also suffers from lymphoedema,
which causes pain and swelling. She explained that she has
successfully treated
herself with cannabis, with her general practitioner’s knowledge, and
believes that she has avoided becoming
an opiate user as a result.
2.36 Matthew Pallett described using cannabis medicinally for many years,
referring to it as
‘the only substance I have ever found to give relief from debilitating,
neuropathic pain caused by spinal injury that occurred
at 12 years of
2.37 A large number of the people who attended the public consultations had
used medicinal cannabis for chronic pain. At the Mildura
public consultation,
the Commission heard
from a woman who suffered chronic pain from prolapsed discs and arthritis.
Having taken morphine for 16 years to deal with the pain,
she was unable to
function and slept for up to 22 hours per day. She was unable to work a
full-time job and could not attend university.
She had contemplated suicide.
After taking cannabis, she found that she can remain awake during the day.39
2.38 Another person at the Mildura consultation described herself as
suffering chronic pain
due to car accidents that was so bad that she would ‘vomit’ from
nausea. Her weight had dropped to 38kg and she was told
she was at risk of death
from organ failure. She had been prescribed morphine for over 15 years for the
pain. After using cannabis,
she found that her nausea disappeared and she was
able to eat and eventually return to work.40
Failure or harms of other treatments
2.39 As is apparent from the accounts described above, many of those who have
resorted to medicinal cannabis have done so after the
available treatments have
failed or had unacceptable consequences.
2.40 Lindsay Milton started using cannabis after a spinal injury 25 years ago
and subsequent surgery which left him in intense pain.
He said that the
medication he had been prescribed was ineffective, and he was taking extra
medication to counteract the side effects
of the pain killers:
2 days into using Cannabis I knew things could only get better if what was
happening with pain relief continued and it did. I started
sleeping better, was
getting 5 times the pain relief pharmaceuticals were giving me and I got my
appetite back all with no side effects
whatsoever. 41
36 Not all who had tried using cannabis for chronic pain had found it
4) told the
Commission that it had not been useful for this purpose.
37 Submission 5.
38 Submission 59. Mr Pallett also states that cannabis ‘helps to
modulate the “intensity” associated with my particular
39 Consultation 5.
41 Submission 92.
2.41 After another bad accident, which led to several operations and months
in hospital being treated with pethidine for pain, he
suffered withdrawal
symptoms when he returned home. He was then given morphine, in increasing
amounts as the pain continued to affect
When the family saw me [dying] on the bed taking 700mg a day of morphine and
[diazepam] thrown in to help the morphine with pain family
and friends had saw
enough. I went from a fit 6’ 4” 100 kilo man to a 160 kilo blob and
I was slowly [dying], nothing
surer, I was waiting on it. I had absolutely no
recollection of anything that
was going on around me and never spoke about anything anyone could
understand. Then family and friends teamed up to firstly get me
off the morphine
which they did by reintroducing Cannabis back into my life for pain and slowly
they kept lowering the
morphine dose. It took 12 months to be free of it but my use in Cannabis was
now part of my pain control and it works perfectly. 42
2.42 The Australian Lawful Use of Cannabis Alliance told the Commission about
one woman who had turned to cannabis after exhausting
conventional
treatments:
The story of one of our members, Ms. Debra Lynch, perfectly encapsulates this
tragic saga being played out in our communities. Debra
suffers from an incurable
illness called Raynaud’s Phenomenon with Limited Scleroderma and
Gastrointestinal Involvement.
She is allergic to every available conventional pharmaceutical treatment
option. The only therapeutic treatment she can tolerate
is a course of
medical-grade cannabis oil. Like many of our members, and the members of the
Medical Cannabis Users Association of
Australia, she is daily faced with the
unconscionable choice of unlawfully accessing the only available treatment for
her condition
and its symptoms.43
2.43 Some people informed the Commission that they take cannabis in addition
to pharmaceutical preparations. Natalie Vassallo, for
instance, said that she
has a variety
of conditions and is taking a range of medicines to treat them, but finds
cannabis more helpful to her than most of her prescription
medications:
When I cannot get hold of any Cannabis, my symptoms get worse. I suffer with
pain in my neck, shoulders, arms, hands, lower back &
knees. I suffer panic
attacks that prevent me from leaving the house most of the time. It is
debilitating to feel like this.44
Pathways to access
2.44 The Commission heard from many individuals who obtain cannabis from
people who specialise in cultivating and refining cannabis
for medicinal
purposes. Indeed, several producers attended the Commission’s
consultations and made written submissions.45
They showed a detailed knowledge
of the cannabis plant, its varieties and refined versions, and expressed strong
views about its
potential medicinal applications.
2.45 People who presently access cannabis for medicinal purpose apparently
receive significant advice and guidance from the suppliers
of cannabis products,
including instructions
on strains, dosage and indications. The cost of obtaining medicinal cannabis
through these illegal channels varies but was described
as significant by some
who spoke to the Commission.
42 Submission 92.
43 Submission 35.
44 Submission 80.
45 Consultations 1, 5, 7.
2.46 Clearly, for a sufficiently interested person, it is easy to find
information regarding medicinal cannabis and its potential
uses, particularly on
the Internet. Many submissions referred the Commission to resources on the
Internet. Some people described
how they learnt online about the possible
benefits of cannabis for their condition or that of a loved one. Several of them
to seek out cannabis products through online stores and social media.
Despite the illegal nature of all cannabis products in Australia,
patients in
Australia do not need to rely solely on local networks. They are able to access
information or even the product itself
from other jurisdictions where cannabis
has been legalised for medicinal and/or recreational purposes.
Interest in medicinal cannabis
2.47 In addition to the accounts received on behalf of people already
obtaining relief from cannabis, the Commission heard from a
number who are
interested in using it to treat a variety of conditions, having been
unsuccessful with or disillusioned by conventional
treatments.
2.48 Aaron Johnson and Kelli Russell told the Commission about their
two-year-old daughter, Harper, who has Dravet Syndrome and suffers
life-threatening seizures as a result. After reading on the Internet about the
use of medicinal cannabis for seizures, they started
investigating cannabis oil
as a treatment for epilepsy. They read about the benefits and concluded that
‘we need to give Australians
numerous avenues to access cannabis based
medicine legally’.46
2.49 This account reflects a common theme among submissions: that the patient
or their carers do not wish to try cannabis until it
is made legal. A mother who
attended the Shepparton public consultation, for example, stated that her son
suffers from a rare form
of epilepsy. She and her partner are desperate for
relief, but they need to be able to act legally because they cannot afford to
lose their jobs.47
2.50 Joylene Donovan told the Commission about her 11-year-old daughter, Ava,
who also suffers from Dravet Syndrome. She described
severe side effects of
anticonvulsant medications, and how attempts to wean her daughter off them have
only led to increasing seizures
and hospital admissions:
I would give anything to be able to have the opportunity to trial Medical
Cannabis for Ava given the success we are seeing world wide
for many children
with the same condition as Ava. I see it as another option, another treatment
and potentially a life changer for
her. For some it will work, for others it
won’t and like any medication therapy it is definitely a trial and error
to the many combinations available. I understand the concern of long
term effects but the reality is that what we are currently
using to treat our
children we don’t even know if there is a long term, as we have
already seen our beautiful children disappear in front of our eyes using
pharmaceutical drugs, which are all addictive or toxic with
long term use... Our
pharmaceutical treatments may stop seizures but doses are often so high that our
children become zombies and
cause side effects that no parent should ever have
to witness their child going through.48
46 Submission 33.
47 Consultation 7.
48 Submission 78.
2.51 Other examples of carers interested in being able to legally access
medicinal cannabis for their loved ones were Diane and Max
Lock who spoke of the
plight of their granddaughter, Madison, who has epilepsy:
Madison has been on many epilepsy drugs in the past few years, all of which
have very nasty side effects, including aggression, pains
in her head, psychotic
episodes. This is devastating to see, and does not stop the seizures, nothing
seems to work. Everything we
have researched on medicinal cannabis seems
favourable and not destructive like the prescribed medications the neurologist
Grand Daughter on. I know they are trying to help, but so far none of
the prescription medications have worked.49
2.52 Similar sentiments were expressed by Shirley Humphris about her
granddaughter, Cambrie, who has intractable epilepsy. Cambrie
has been trialled
with ‘over 12 antiepileptics all with frightening side effects and some
with unknown long-term risks for
children’. 50
2.53 People with adult epilepsy also expressed interest in trying medicinal
cannabis. Derek Spence told the Commission about his wife,
Elyse, who suffers
from intractable epilepsy. He stated she ‘has tried every drug available
and they’re all crap and
don’t work plus have numerous side
effects.’51 Jan Hartwich told the Commission about her 55-year-old
daughter, Karyn,
who has suffered from epilepsy since birth. Ms Hartwich said
that her daughter is on a number of drugs, which do not fully control
symptoms and have
numerous side effects, such as blurred vision, anxiety and depression. They
also cause her to sleep for more than 18 hours each day.
Ms Hartwich advised
that Karyn’s neurologist believed cannabis could be of assistance to her
but ‘because [of] its illegal
status we are unable to use it’.52
2.54 A couple who attended the public consultation in Shepparton told the
Commission about their adult son who suffers from epilepsy.
He has seizures all
day, and is severely incontinent. His condition has ‘taken away the lives
of three people’—his
and his parents—and has the potential to
break up families. If cannabis could reduce or eliminate his symptoms, they
they might be able to get their lives back.53
2.55 Mark Eastick, who experiences pain and muscle spasms as a result of a
spinal cord injury, told the Commission he wished to try
medicinal cannabis for
his symptoms.54
2.56 Another person told the Commission about his wife, who ‘has been
in constant pain for over 15 years’, which has been
categorised as
fibromyalgia, and more recently as a type of pain believed to be nerve-based.
He stated that she has received various
forms of medical help, including pain
medication, pain counselling and physiotherapy, but ‘nothing seems
to be working’, leaving her confined to a wheelchair. She considered
using morphine but her apparent drug sensitivities have
left few options as
regards medication. Although desperate for some relief, the person’s wife
has not yet tried cannabis:
The use of cannabis may or may not work, but given media reports that it has
worked in unusual cases, it is [her] desire to at least
test it to see if it can
make a difference. Her current medical condition is now pushing us to look at
what may be considered extreme
approaches which may entail a measure of risk but
we often wonder if it will be much worse than current efforts and associated
Given that all known conventional help has been exhausted with little
relief from symptoms, an opportunity should be given anyone
seeking help without
undue hindrance to at least test the efficiency or otherwise when all other
options are not proving effective.55
49 Submission 67.
50 Submission 49.
51 Submission 62.
52 Submission 66.
53 Consultation 7.
54 Submission 72.
55 Submission 65.
2.57 The Commission also received a submission from a person suffering from a
number of medical conditions, including a rare condition
known as Idiopathic CD4
Lymphocytopenia, otherwise known as ‘non-HIV AIDS’—a form of
AIDS which is not caused by
HIV. The person described a grave illness, which has
left them largely bedridden and causes
a range of debilitating symptoms, including ‘chronic unrelenting’
pain. They cannot tolerate a number of medications,
and experimental treatments
have been suggested which would come at a high cost and require overseas travel.
After researching cannabis
online, the person has formed the view that
‘medicinal cannabis is the only realistic and comparatively safe treatment
available’. Notwithstanding this, the person has elected not to
access cannabis because it is unlawful:
I have been tormented by thoughts of unlawful activity, experiencing feelings
of great despair and loss that I have found myself in
a position of having to
choose between everything that I have believed in and stood for (the law) and
trying to save my own life.
The unlawful status surrounding cannabis, does not
only affect me, it also affects those I live with. If prosecuted, my partner
stand to lose his current professional licence.56
Research support for efficacy
Breadth and variety of data
2.58 The Commission’s issues paper posed the question: ‘For what
conditions is there sufficient knowledge of the therapeutic
benefits, dangers,
risks and side effects of cannabis to
justify allowing sufferers to use it lawfully in Victoria?’
2.59 In response, the Commission received submissions that, together,
asserted that a wide variety of conditions can be cured or assisted
by medicinal
cannabis and thus should be viewed as ‘exceptional circumstances’
for the purpose of determining who should
have access to medicinal cannabis
under a Victorian scheme. These included asthma/ breathing disorders,57
HIV/AIDS,58 Ebola,59
cancer,60 nausea from cancer,61 Crohn’s
disease/gastrointestinal disorders/colitis,62 diabetes,63 epilepsy,64
glaucoma,65
C,66 migraines/headaches,67 muscle spasms and pain due to multiple
sclerosis,68 pain,69 fibromyalgia,70 arthritis,71 inflammation,72
pain,73 menopause,74 stress and anxiety,75 insomnia/sleep disorders,76
bipolar disorder,77 depression,78 psychotic
illnesses,79 attention deficit
hyperactivity disorder (ADHD),80 Tourette syndrome,81 nymphomania,82
post-traumatic stress disorder,83
Alzheimer’s disease and dementia,84
Parkinson’s disease,85
56 Submission 43.
57 Consultation 5; Submissions 1, 3, 80, 95.
58 Consultations 2, 4, 9; Submissions 1, 13, 24, 39, 45, 56, 72, 91.
59 Submission 22.
60 Consultations 1, 2, 4, 5 6; Submissions 1, 2, 3, 11, 12, 13, 19, 29, 30,
35, 39, 49, 56, 59, 68, 72, 74, 83, 85, 95, 97.
61 Consultation 4; Submissions 1, 7, 12, 24, 32, 38, 45, 57, 60, 70, 91;
advisory committee (Meeting 1).
62 Submissions 1, 10, 13, 30, 35, 45, 91, 95, 97.
63 Submissions 11, 22, 35, 56, 60, 91, 95.
64 Consultations 1, 6, 7, 8, 9, 12, 13,16; Submissions 1, 2, 3, 6, 11, 12,
24, 29, 30, 33, 35, 50, 51, 56, 60, 66, 67, 70, 71, 72,
74, 78, 81, 82, 90,
65 Consultation 6, 7; Submissions 1, 13, 35, 45, 95.
66 Submissions 1, 45, 95.
67 Consultation 6; Submissions 1, 11, 13, 95.
68 Consultations 1, 12, 18; Submissions 1, 13, 19, 24, 32, 35, 39, 45, 52,
56, 59, 72, 91, 95, 96; advisory committee (Meeting 1).
69 Consultations 1, 4, 5, 6, 7, 8; Submissions 1, 2, 5, 7, 10, 12, 13, 18,
19, 29, 37, 39, 45, 55, 59, 60, 61, 70, 71, 74, 80, 91,
70 Consultations 1, 5, 6; Submissions 12, 56, 59, 65, 80, 86, 88, 91, 95,
71 Consultations 5, 8; Submissions 1, 10, 11, 28, 35, 45, 49, 53, 70, 74, 89,
72 Submissions 35, 45, 53, 55, 59, 95, 97.
73 Submissions 19, 95.
74 Submission 95.
75 Consultation 4; Submissions 10, 13, 28, 35, 70, 80, 95.
76 Submissions 19, 60, 95.
77 Submissions 3, 11, 19.
78 Consultations 4, 9; Submissions 5, 11, 13, 19, 35, 60, 80, 87, 93, 95.
79 Submissions 3, 11, 19, 32, 95.
80 Consultation 9, Submissions 3, 18, 74, 95, 97.
81 Consultation 6, Submissions 1, 45, 60, 95, 97.
82 Submission 19.
83 Consultations 6, 12; Submissions 3, 10, 12, 13, 30, 35, 45, 80, 89, 93,
84 Submissions 1, 35, 49, 60, 91, 95.
85 Consultation 2; Submissions 13, 19, 49, 95.
autism and Asperger’s disorder,86 thyroid disorders,87 ageing,88 back
pain, scoliosis, neck pain and spinal cord injury,89
cardiovascular health and
blood pressure,90 eating disorders,91 haemorrhoids,92 heavy metal
toxicity,93 phlebitis and venous
ulcerations,94 skin conditions, dermatitis and
psoriasis,95 scars, ulcers, warts and moles,96 weight management,97 wounds,
corns, acne, furuncles and nail fungus.98
2.60 The supporting evidence for each of these claims varies in quality and
quantity. Certainly the volume of information is vast.
Matthew Pallett pointed
out in his submission that:
The current literature base available in the recognised medical libraries and
medical journals of the world amounts to over 30,000
peer reviewed studies and
journal articles on Cannabis.99
2.61 In determining what the eligibility criteria should be for a scheme that
allows people to be treated with medicinal cannabis
in exceptional
circumstances, and when making clinical decisions about a patient’s
treatment, not all evidence is of equivalent
2.62 A threshold consideration when making these types of decisions regarding
medicinal cannabis is the clinical evidence for its
efficacy in treating
particular conditions and symptoms. The associated risks must also be taken into
2.63 Partly as a result of the broadly stated, often divergent, claims made
regarding medicinal cannabis, it is important that, prior
to introducing any
kind of medicinal cannabis scheme, the available evidence is evaluated to
determine which claims can be substantiated,
to what degree. The conventional means of doing so is by reference to
evidence-based medicine.
Evidence-based medicine and the quality of evidence
2.64 Evidence-based medicine is an approach to the practice of medicine that
has been described as the ‘conscientious, explicit,
and judicious use of
current best practice in making decisions about the care of individual
patients.’100 It aims to improve
decision making by medical practitioners
critically appraises
the available clinical evidence.
2.65 A cornerstone of evidence-based medicine is the hierarchical system of
classifying evidence, often referred to as ‘levels
of evidence’.
This approach is used by the National Health and Medical Research Council
(NHMRC). Medical practitioners
are encouraged
to find the highest level of evidence to answer clinical questions, including
whether they should prescribe or encourage access to
particular forms of
medication.101
2.66 As Justice Perry observed in
Australian Competition and Consumer
Commission v
Consumer Plus! Australia Pty Ltd
The standard taxonomy of levels of evidence for intervention studies based on
NHMRC guidelines and starting with the highest quality of evidence, is as
Level I: evidence obtained from a systematic review of Level II studies;
86 Submissions 22, 29, 35, 59, 71, 95, 97.
87 Submission 95.
88 Submission 69.
89 Submissions 18, 28, 30, 72, 80, 92, 93, 95.
90 Submissions 53, 95.
91 Submissions 11, 19, 95.
92 Submission 95.
95 Consultation 4; Submissions 35, 95.
96 Submission 95.
97 Submissions 45, 56, 95.
98 Submission 95.
99 Submission 59.
100 David L Sackett et al, ‘Evidence-Based Medicine: What It Is and
What It Isn’t’
British Medical Journal
101 See Patricia B Burns, Rod J Rohrich and Kevin C Chung, ‘The Levels
of Evidence and their Role in Evidence-Based Medicine’
Plastic and Reconstructive Surgery
Level II: evidence obtained from at least one properly designed randomised
controlled trial of appropriate size;
Level III-1: evidence obtained from well-designed pseudo-randomised
controlled trials; Level III-2: evidence from comparative studies
systematic reviews of such
studies) with concurrent controls being a non-randomised experimental trial,
study, an interrupted time series or matched case-controlled study;
Level III-3: evidence from a comparative study without concurrent controls,
a historical control study, two or more single arm studies (i.e. case series
from two studies), or a well-designed interrupted time
series trial without a
parallel control group from more than one centre or research group or from case
reports; and
Level IV: evidence obtained from a case series, either post-test or
pre-test/post-test outcomes. 102
2.67 The evidence-based medicine hierarchy ranks clinical evidence according
to the authoritativeness of the results. At the top of
the hierarchy (at Level
I) are systematic reviews and meta-analyses. These studies draw conclusions in a
systematic way, based on
high-level published studies in the literature.
2.68 Next are randomised, double-blind, placebo-controlled studies (Level
II). These studies are particularly valuable because they
are designed to be
unbiased, and to have the lowest
risk of errors.
2.69 Further down the hierarchy are ‘cohort studies’ and then
‘case control’ studies (Level III), considered
to be less valuable
because fewer controls are placed on the conduct of the research, making it more
difficult for conclusions to
be drawn from the findings.103
2.70 Case series (Level IV) and case examples follow. They are at the lowest
level of the hierarchy and do not normally form the basis
of decision making
2.71 The evidence cited in support of the medicinal properties of
cannabis ranges across a number of these categories. In the
next section, an
overview is given of the status of current knowledge about the efficacy of
cannabis for conditions regarding which
particular claims have been made to the
Commission.104 The overview emphasises
outcomes at the highest level of clinical evidence: systematic reviews and
meta-analyses.
The quality of cannabis research
2.72 A substantial body of evidence now exists in relation to the efficacy of
certain forms of cannabis for particular medical conditions.
AMA Victoria, for
instance, acknowledges that there is ‘some evidence to suggest that
cannabinoids are effective for the treatment
of neuropathic pain, muscle
spasticity for patients with MS, and in controlling nausea for cancer
patients.’105
[2014] FCA 1412
, [67]. See also House of Commons Science and Technology
Committee, United Kingdom Parliament,
Evidence Check 2: Homeopathy
45) Fourth Report of Session 2009–10 (2010).
103 For example, participants are not randomly selected for exposure and are
not blinded to exposure. In addition, these types of
trials are ordinarily
retrospective, meaning that participants are recruited only after exposure has
104 In this report the term ‘efficacy’ is used to denote the
actual effect of the administration of medicinal cannabis,
by contrast with
‘effectiveness’ which may also be the product of a ‘placebo
effect’. See House of Commons Science and Technology
Committee, United
Kingdom Parliament,
Evidence Check 2: Homeopathy
(HC 45) Fourth Report
of Session 2009–10 (2010).
105 Submission 38.
2.73 However, while this body of evidence exists—and, indeed, is
rapidly expanding—it is of inadequate quality for definitive
statements to
be made about the therapeutic efficacy
of cannabis for many conditions. This causes consternation in many quarters
of medicine about claims of the legitimacy or advisability
of prescribing
medicinal cannabis. The Senate Legal and Constitutional Affairs Legislation
Committee observed that: ‘there
remain significant gaps in our scientific
understanding’ and that ‘it is important that
medicinal cannabis is used to treat identified medical conditions where it
has been proven to be safe and effective.’106
2.74 In an editorial in the Journal of the American Medical Association
published in June 2015, for instance, D’Souza and Ranganathan
argued that
for most conditions that have been regarded as appropriate for medicinal
approval has relied on low-quality scientific evidence, anecdotal reports,
individual testimonials, legislative initiatives, and public
opinion. ... For
most of the conditions that qualify for medical marijuana use, the evidence
fails to meet [Food and Drug Administration]
standards.107
2.75 In May 2015 the College of Physicians and Surgeons of British Columbia
prefaced its position on medicinal cannabis with the observation
‘Few reliable published studies are available on the medical benefits of
marijuana’. However, it accepted that:
there are sometimes circumstances in medical practice where exceptions to
strong relative contraindications may be appropriate. When
physicians utilize a
therapeutic agent despite strong relative contraindications, the standard of
care mandates detailed documentation
of their rationale.108
2.76 The Royal Australasian College of Physicians also expressed concern
the majority of the trials that have taken place on this issue have been
small and weak and have not been tested against standards
of care. Randomised
controlled trials are required to establish the efficacy and benefits of
treating particular conditions with
medicinal cannabis and evidence of any harm
that may arise as side effects.109
2.77 A refrain of the credible scholarly literature is that further suitably
controlled, high quality studies need to be undertaken
to evaluate whether the
claims, anecdotes and aspirations for the efficacy of medicinal cannabis can be
justified. An example in
this regard is the extensive review of the literature
published in 2015 by Belendiuk, Baldini and Bonn-Miller who lament ‘the
dearth of rigorous research on the effects of marijuana for the most common
conditions for which it is currently recommended’.
110 They observed
It is paramount that well-designed [randomised controlled trials] with larger
sample sizes be conducted to determine the actual medical
benefits and adverse
effects of marijuana for each of the [conditions for which claims of efficacy
have been made].111
2.78 It can be difficult to reconcile belief in medicinal cannabis with the
strength of the clinical evidence. Views of the evidence
for the efficacy of
medicinal cannabis vary, and perceptions based on faith, hope and experience
with cannabis, on the one hand,
can depart substantially from views based on the
assessment of the clinical trials.112 A possible exception is in respect of
106 Senate Legal and Constitutional Affairs Legislation Committee, Parliament
of Australia,
Regulator of Medicinal Cannabis Bill 2014
(2015) [5.2] ,
107 Deepak Cyril D’Souza and Mohini Ranganathan, ‘Medical
Marijuana: Is the Cart Before the Horse?’ (2015) 313
Journal of the
Medical Association
108 College of Physicians and Surgeons of British Columbia,
‘Professional Standards and Guidelines: Marijuana for Medical
109 Submission 52.
110 Katherine A Belendiuk, Lisa L Baldini and Marcel O Bonn-Miller,
‘Narrative Review of the Safety and Efficacy of Marijuana
Treatment of Commonly State-Approved Medical and Psychiatric Disorders’
(2015) 10 (10)
Addiction Science and Clinical Practice
111 Ibid 6.
112 See Submission 40.
2.79 To this must be added that there are obstacles to the accumulation of
high-quality cannabis research which do not exist for other
drugs. For example,
conducting research with cannabis or cannabinoids tends to attract much more
onerous regulatory complexity than
for other drugs. To adapt the conclusion of
an American writer describing this difficulty, ‘[t]his creates a vicious
marijuana is [a schedule 9 drug] and has no currently accepted medical
use in treatment because there is no data on its safety
and efficacy there is no data because marijuana is [schedule 9] and clinical
testing is restricted.’113
2.80 Further, whole-plant forms of cannabis generally do not have a
‘sponsor’ with a financial interest in funding clinical
possibly resulting in fewer or smaller studies.
Determining efficacy
2.81 The Commission’s issues paper reviewed the state of the clinical
literature as of early 2015 regarding a number of the
conditions asserted to be
responsive to the administration
of medicinal cannabis as a therapeutic agent. The following section isolates
particular conditions that were identified in submissions
and have also been the
subject of recent systematic reviews, meta-analyses and other significant
evaluations.
Multiple sclerosis
2.82 The results of a meta-analysis by Whiting et al published in the
Journal of the American
Medical Association
in June 2015 indicate that there is
‘moderate-quality evidence
to suggest that cannabinoids may be beneficial for the treatment of
spasticity due to [multiple sclerosis]’.114 The authors
identified 11
placebo-controlled trials meeting the selection criteria, and concluded
Studies generally suggested that cannabinoids were associated with
improvements in spasticity, but this failed to reach statistical
significance in
most studies.115
2.83 Results of trials on the efficacy of cannabis to treat multiple
sclerosis are complicated somewhat because there are a number
of ways to measure
spasticity. Some of these rely on objective measures of spasticity, while others
rely on subjective measures,116
with subjective measures sometimes said to be
more informative but complicating the
interpretation of trial results.117 Often research findings depend upon
patient self-reports.
2.84 On 26 November 2012 the TGA registered Sativex oromucosal spray118 to
treat the symptoms of patients with moderate to severe
spasticity due to
multiple sclerosis, and included it in Schedule 8 of the
Standard for the
Uniform Scheduling of Medicines and Poisons
.119 However, Sativex was denied
listing on the Pharmaceutical Benefits Scheme, which would have enabled it to be
sold at a subsidised
2.85 Sativex was not listed on the Pharmaceutical Benefits Scheme because the
Pharmaceutical
Benefits Advisory Committee considered that there was insufficient evidence
of its efficacy and its relative effectiveness compared
to standard care. In
summary it found:
• There is insufficient evidence to establish comparative effectiveness
113 Joseph Gregorio, ‘Physicians, Medical Marijuana and the Law’
Virtual Mentor
114 Penny F Whiting et al, ‘Cannabinoids for Medical Use: A Systematic
Review and Meta-Analysis’ (2015) 313
Journal of the American
Association
2456, 2467.
115 Ibid 2463. The MUSEC (Multiple Sclerosis and Extract of Cannabis) trial,
which was a double-blind, placebo-controlled study, found
that a 12-week
treatment with an oral cannabis extract was associated with a statistically
significant improvement in patient-reported
muscle stiffness, muscle spasms,
body pain and sleep compared to placebo in patients with stable MS: JP Zajicek
et al, ‘Multiple
Sclerosis and Extract of Cannabis: Results of the MUSEC
Trial’ (2012) 83
Journal of Neurology, Neurosurgery and Psychiatry
116 Advisory committee (Meeting 1).
117 In reconsidering the initial decision to refuse approval of the
registration of Sativex, the Minister for Health’s delegate
noted that the
subjective tool used in assessing Sativex ‘is a valid and reliable tool
for the measurement of spasticity and
better corresponds to the patients’
daily experience of spasticity than the objective measures currently in
use.’ However,
the delegate accepted that the subjective tool has ‘a
large subjective element that could be affected by mood, fatigue, pain,
and the possible unblinding of the subject, raising the possibility of
substantial confounding’: Therapeutic Goods
Administration,
Public Assessment Report for Nabiximols
(27 September 2013) 198.
118 A whole-plant botanical extract of cannabis, administered as a mouth
spray, containing THC and CBD in approximately equal proportions.
119 Department of Health, Australian Government,
Medicinal Cannabis
(27 May 2015) <
http://www.health.gov.au
/internet /main /publishing.
nsf/Content />.
compared with standard care alone in patients who are intolerant to
anti-spasticity medication.
• There is no evidence of efficacy and safety provided in comparison
with high dose baclofen alone, or in combination with dantrolene
or diazepam as
the second-line therapy.
• The nominated comparator was not appropriate (the second-line therapy
of oral baclofen dose escalation alone or in combination
with dantrolene or
diazepam should have been included at least as a secondary comparator).
• Although the results of the key trial showed an improvement in the
average rating of spasticity, the design of the trial meant
that it was
difficult to extrapolate this benefit to patients likely to be treated in the
Pharmaceutical Benefits Scheme population.
• The clinical relevance of the benefit was not adequately
substantiated; the claim for superior efficacy over standard care
inadequately supported; and nabiximols appeared to be inferior over standard
care in terms of comparative safety.120
2.86 Although not conclusive, there is a reasonable level of research support
for the effectiveness of cannabis in relieving pain
and spasticity for those
suffering multiple sclerosis.
2.87 The state of epilepsy research at the time of writing is characterised
by uncertainty and change with respect to the efficacy
of medicinal cannabis.
The research collected to
date has delivered results of limited significance. At the same time,
considerable research energy is being committed to the further
cannabinoids as a treatment for refractory epilepsy, particularly in juvenile
2.88 In 2013, Canada Health issued this guidance for medical practitioners:
‘Increasing evidence points to a role for the endocannabinoid
the modulation of neuronal tone and excitability and possibly in
epilepsy.’121 However, this does not mean that
the evidence is yet clear.
In 2014, the authors of an article in a medical journal on epilepsy argued that:
‘Until data from
well designed clinical trials are available and reliable,
and standardised CBD products that are produced using good manufacturing
practices are available, caution must be exercised in any consideration of using
CBD for the treatment of epilepsy.’122 Also
in 2014, the American Society
of Neurology expressed the view that the use of oral cannabinoids is of unknown
efficacy in epilepsy
and that there was not sufficient evidence to prescribe CBD
or to recommend self-treatment with medicinal cannabis.123
2.89 A Cochrane Review124 published in 2014 on ‘Cannabinoids for
Epilepsy’125 reviewed research literature to assess
the efficacy and
safety of cannabinoids when used as a single therapy or add-on treatment for
people with epilepsy. It was very reserved
in its findings. It found that
‘no reliable conclusions’ could yet be drawn regarding the efficacy
of cannabinoids as
a treatment for epilepsy. It identified only four studies
from 1978 to
1990 that met the selection criteria of randomised controlled trials. All
used CBD as the treatment agent. It observed that patient
numbers in the studies
were small (48 patients in total) and that there had been varying reports of
reduction in seizure frequency
and/ or seizure freedom. The review’s
authors also expressed the view that, as the studies ran
120 The Pharmaceutical Benefits Scheme, ‘Nabiximols, oral spray, 10 mL
(90 actuations of 100 microlitres) Sativex’, July
121 Hanan Abramovici,
Information for Health Care Professionals: Cannabis
(Marihuana, Marijuana) and the Cannabinoids
(Health Canada, 2013)
122 Timothy E Welty, Adrienne Luebke and Barry E Gidal, ‘Cannabidiol:
Promise and Pitfalls’ (2014) 14
Epilepsy Currents
123 See Gary W Mathern, Laurie Beninig and Astrid Nehlig, ‘Fewer
Specialists Support Using Medical Marijuana and CBS in Treating
Patients Compared with Other Medical professionals and Patients: Results of
Epilepsia’s Survey’ (2014) 56
Epilepsia 1
124 Cochrane Reviews are systematic reviews of primary research in human
health care and health policy, and are internationally recognised
as the highest
standard in evidence-based health care. They investigate the effects of
interventions for prevention, treatment and
rehabilitation. They also assess the
accuracy of a diagnostic test for a given condition in a specific patient group
and setting.
They are published online in the Cochrane Library, and supported by
the National Health and Medical Research Council of Australia.
125 Gloss, David and Barbara Vickrey, ‘Cannabinoids for Epilepsy:
Review’ (2014) 3
Cochrane Database of Systematic Reviews
http://www.thecochranelibrary.com
for short periods of time (four weeks to 18 months) the safety of long-term
cannabidiol treatment could not be reliably assessed.
2.90 In addition, a systematic review of the efficacy and safety of medical
marijuana in treating selected neurological disorders,
including epilepsy, was
published by the American Academy of Neurology in 2014. It concluded that oral
cannabinoids are of unknown
efficacy in epilepsy, that the risks and benefits of
medical marijuana should be weighed carefully, and that the comparative
effectiveness
of medical marijuana as against other therapies for epilepsy are
unknown.126
2.91 The position of Epilepsy Australia in relation to the efficacy of
medicinal cannabis is also reserved:
There have been several reports in the media of dramatically positive
responses to derivatives of cannabis, medical marijuana in children
with severe
forms of epilepsy that have not responded to available therapies. While these
reports give reason for hope,
we must be mindful that these are anecdotal reports only. However such
reports have brought attention to the potential for cannabis
to provide a new
anti-epileptic therapy and help us understand how epilepsy occurs.127
2.92 However, there is optimism that research currently underway will deliver
positive results, supportive of the efficacy of cannabis
for treating severe
forms of epilepsy.128 Researchers from the United States presented results at
the 2015 Annual Meeting of the
American Academy of Neurology from an open-label
trial on the treatment of children and young adults suffering from
drug-resistant
forms of epilepsy129 with purified CBD (Epidiolex). The trial
recruited 213 participants, of whom 123 were included in efficacy
calculations.
The data showed a median reduction in seizure frequency of 46 per cent by the
twelfth week. Patients with Dravet Syndrome
had a reduction in seizure frequency
of 51 per cent by week 12, while those with Lennox-Gastaut Syndrome experienced
a median reduction
52 per cent. The researchers concluded that:
CBD showed reductions in seizure frequency across multiple drug-resistant
epilepsy syndromes and seizure types and was generally well
tolerated in this
open-label cohort. Controlled trials are indicated to characterize efficacy and
2.93 Two Phase III trials using Epidiolex to treat Lennox-Gastaut Syndrome
have also commenced, with data expected to become available
in early 2016.131
The Commission notes that a particular component of the trials to be conducted
in New South Wales, with the participation
of Victoria and Queensland, is
intended to be in respect of the efficacy
of medicinal cannabis for paediatric epilepsy.
2.94 Therefore, there is emerging research support for the effectiveness of
cannabis in relieving the symptoms of epilepsy, especially
for those with
juvenile syndromes.
126 B S Koppel et al, ‘Systematic Review: Efficacy and Safety of
Medical Marijuana in Selected Neurological Disorders: Report
Subcommittee of the American Academy of Neurology’ (2014) 82
127 Epilepsy Australia,
Medical Marijuana in the Treatment of Epilepsy
(30 October 2014)
http://www.epilepsyaustralia.net /Advocacy/ Position_Statements / Medical_Marijuana_in_the_treatment_of_epilepsy.aspx
128 Anup Patel has commented that: ‘Further robust research using
strong scientific methodology is desperately needed to formally
evaluate the
role of medicinal cannabis products in children suffering neurological
disorders.’ Anup Patel, ‘Medical
Marijuana in Pediatric Neurological
Disorders’ (2015)
Journal of Child Neurology
(published online
before print) <jcn.sagepub.com>.
129 Including Dravet Syndrome, Lennox-Gastaut Syndrome and ten other
conditions.
130 American Academy of Neurology, ‘Epidiolex (Cannabidiol) in
Treatment Resistant Epilepsy’ (Abstract of presentation
Academy of Neurology 67th Annual Meeting, Washington DC, 22 April 2015).
131 GW Pharmaceuticals, ‘GW Pharmaceuticals Initiates Phase 3 Pivotal
Study of Epidiolex (CBD) in Lennox-Gastaut Syndrome’
(Press Release,
11 May 2015)
http://www.gwpharm.com
Pharmaceuticals, ‘GW Pharmaceuticals Initiates Second Phase 3 Pivotal
Study of Epidiolex
(CBD) in Lennox-Gastaut Syndrome’, (Press
Release, 11 June 2015)
http://www.gwpharm.com
Chronic pain
2.95 Assessment of the experience of pain is complex. It incorporates
complicated overlaps between the physical and the psychological.
The concept of
exclusively ‘physical pain’ is no longer accepted in light of our
understanding of the neurophysiology
and psychology of pain as it has evolved
over the past 80 years. The contemporary understanding of pain is now embodied
in the definition
adopted by the International Association for the Study of
Pain is always subjective. Each individual learns the application of the
word through experiences related to injury in early life.
Biologists recognize
that those stimuli which cause pain are liable to damage tissue. Accordingly,
pain is that experience we associate
with actual or potential tissue damage. It
is unquestionably a sensation in a part or
parts of the body, but it is also always unpleasant and therefore also an
emotional experience.132
2.96 Importantly, according to the Association’s definition,
Many people report pain in the absence of tissue damage or any likely
pathophysiological cause; usually this happens for psychological
reasons. There
is usually no way to distinguish their experience from that due to tissue damage
if we take the subjective report.
If they regard their experience as pain, and
if they report it in the same ways as pain caused by tissue damage, it should be
as pain.133
2.97 The fact that pain is both physical and psychological results in its
intensity being difficult to measure and its impact upon
different patients in
terms of both subjective suffering and functionality being highly variable. As a
result, a significant element
of the contemporary therapeutic response to pain
is that its management is more than just pharmacological; it incorporates
and multidisciplinary forms of intervention, tailored to the needs of
the individual patient and an assessment of what is most efficacious
individual patient.134
2.98 In evaluating the potential contribution of medicinal cannabis to
alleviating the experience of patients’ pain, it is fundamental
acknowledge that it should only form part of an overall strategy for pain
management—it is not the complete answer. Thus
it should be integrated,
and regulated as necessary, within a broad-based approach to the suffering
caused by the experience of pain.
2.99 It is also important to distinguish between the potential effect of the
THC component of cannabis in inducing euphoria and any
effect it may have in
relieving or alleviating pain.135
2.100 A systematic review and meta-analysis of cannabis treatment for chronic
pain was published in 2009.136 It reviewed 18 trials
and concluded that the
evidence suggested that cannabis treatment was moderately efficacious for
treatment of chronic pain but observed
that its beneficial effects may be
partially (or completely) offset by potentially serious harms. It concluded that
more evidence
from larger, well-designed trials was needed to clarify the true
balance of benefits to harms.137
132 International Association for the Study of Pain, Task Force on Taxonomy,
Classification of Chronic Pain
(2nd ed, 1994), 210 reproduced at
http://www.iasp-pain.org
134 See, eg, Kevin T Galloway et al, ‘War on Pain: Multimodal and
Multidisciplinary Therapy for Pain Management’ (2011)
135 Professor David Penington has argued that ‘[i]f a person in the
late stages of painful cancer seeks the euphoria of THC,
why should they not
have it?’: David Penington, ‘Medicinal Cannabis: Time for Clear
Thinking’ (2015) 202
Medical Journal of Australia
136 Eva Martin-Sanchez et al, ‘Systematic Review and Meta-Analysis of
Cannabis Treatment for Chronic Pain’ (2009) 10
Pain Medicine
137 In 2015 Eric Baron noted some research literature supporting the role of
medicinal cannabis in alleviating symptoms of headaches
but concluded that:
‘Despite the limited evidence and research suggesting a role for cannabis
and cannabinoids in some headache
disorders randomised clinical trials are
lacking and necessary for confirmation and further evaluation’: E P Baron,
‘Comprehensive
Review of Medicinal Marijuana, Cannabinoids and Therapeutic
Implications in Medicine and Headache: What a Strange Trip It’s
...’ (June 2015) 55
2.101 A more recent systematic review and meta-analysis, published in June
2015 and including
79 trials with 6,462 participants, concluded that there is evidence of
moderate quality to support the use of cannabinoids for the
treatment of chronic
2.102 In May 2015 Mark Ware, the Executive Director, Canadian Consortium for
the Investigation of Cannabinoids and Director of Clinical
Research at the Alan
Edwards Pain Management Unit, McGill University Health Center, argued to the
American Pain Society Annual Scientific
Meeting that:
much of what we know about medical marijuana is anecdotal, so the challenge
is to recognize that patients who say they get pain
relief by self medicating
with marijuana may be right, and move forward in conducting more scientific
studies to better understand
its analgesic benefits and overall safety.139
2.103 A 2011 systematic review of randomised controlled trials examining
cannabinoids in
the treatment of chronic non-cancer pain reported that 15 of the 18 trials
that met the inclusion criteria demonstrated a significant
analgesic effect of
cannabinoids as compared with placebos and several reported significant
improvements in sleep. No serious adverse
effects were reported. This led the
authors to conclude that there was evidence that cannabinoids were safe and
modestly effective
in neuropathic pain (nerve pain) with preliminary evidence of
efficacy in fibromyalgia and rheumatoid arthritis. It called for further
studies of longer duration examining specific cannabinoids in homogeneous
populations.140
2.104 As discussed in the issues paper,141 a number of studies have suggested
that medicinal cannabis, variably taken by vaporiser,142
oromucosal spray143
or smoking,144 may be efficacious for neuropathic and non-cancer pain. A
Canadian review of the literature
in 2014 recommended that smoked cannabis be prescribed by doctors only for
severe neuropathic pain syndromes that have not responded
to adequate trials for
pharmaceutical cannabinoids and other analgesics.145
2.105 The current status of the research indicates moderate, albeit emerging,
support for the proposition that chronic non-cancer
pain, incuding neuropathic
pain, can be alleviated to some degree by medicinal cannabis. However, the
Commission notes that medicinal
cannabis generally has the potential only to be
part of an overall and preferably multimodal strategy for medical management of
patient’s chronic pain.
Palliative control of pain
2.106 There are many assertions that cannabis oil and other forms of cannabis
are able to assist in reducing the severity of pain
experienced by persons dying
of terminal illnesses, in particular cancer and HIV/AIDS.146 There is some
research evidence which
supports the capacity of medicinal cannabis
(specifically cannabis with a significant THC content) to provide relief in
these circumstances.
138 Penny F Whiting et al, ‘Cannabinoids for Medical Use: A Systematic
Review and Meta-Analysis’ (2015) 313
Journal of the American
Association
139 Mark Ware, ‘Strong Evidence Still Lacking on Medical Marijuana for
Pain’ (15 May 2015)
Science Daily
http://www.sciencedaily.com
140 Mary E Lynch and Fiona Campbell, ‘Cannabinoids for Treatment of
Chronic Non-Cancer Pain: A Systematic Review of Randomised
Trials’ (2011)
British Journal of Clinical Pharmacology
141 Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [3.23] – [3.27].
142 See Barth Wilsey et al, ‘Low-Dose Vaporized Cannabis Significantly
Improves Neuropathic Pain’ (2012) 14
The Journal of Pain
143 See Turo J Nurmikko et al, ‘Sativex Successfully Treats Neuropathic
Pain Characterised by Allodynia: A Randomised, Double-Blind
Placebo- Controlled
Clinical Trial’ (2007) 133
144 See Mark A Ware et al, ‘Smoked Cannabis for Chronic Neuropathic
Pain: A Randomized Controlled Trial’ (2010) 182
Association Journal
145 Meldon Kahan et al, ‘Prescribing Smoked Cannabis for Chronic
Noncancer Pain: Preliminary Recommendations’ (December
Canadian Family Physician
146 See, eg,
Dan’s Story
http://www.dansstory.com.au
Cancer National Alliance,
Two Sides of Medical Marijuana: Anne’s
(1 July 2010)
http://www.ovariancancer.org
Francene Norton and Patrick Williams, ‘Support for Cairns Man Charged with
Medical-Grade Cannabis Oil to Cancer Patient Daughter’,
16 January 2015
http://www.abc.net.au
2.107 There is evidence that cannabis (particularly smoked cannabis) is an
effective treatment for pain caused by HIV-associated sensory
neuropathy. A
systematic review of treatments for the condition published in 2010 located two
randomised controlled trials showing
superior results for pain relief from
cannabis as compared to the placebo.147
2.108 In relation to cancer, there is limited high-quality research
literature on the subject. The position of the American Cancer
Society remains
that it supports the need for more scientific research on cannabinoids for
cancer patients, and recognises the need
for better and more effective therapies
that can overcome the often debilitating side effects of cancer and its
treatment.148
2.109 In 2013 Health Canada also observed a need for more research:
establishing the effectiveness of cannabis as a viable treatment option in a
palliative care context requires a careful assessment
of its effects in a wide
range of conditions; such evidence is not yet abundant and further research is
2.110 A 2014 review called for caution:
the effectiveness of cannabinoids for the treatment of chronic cancer pain
remains unclear, although any benefit is likely to be modest.
The available
evidence indicates
a risk of potentially serious adverse effects, including alterations in
perception, motor function, and cognitive function.150
2.111 Research is ongoing. Sativex is currently undergoing trials for the
treatment of cancer pain in the United States, but results
to date have been
equivocal.151 In 2015, medicinal cannabis will be administered in Chile to 200
patients with cancer to assess
its analgesic effects.152 For the present, what
can be said is that there is some evidence of the capacity of medicinal cannabis
to alleviate the symptoms of patients with high levels of pain and discomfort
from cancer and HIV/AIDS.
Relief from nausea and vomiting
2.112 The evidence indicates that medicinal cannabis in a variety of forms
can assist in relieving nausea and vomiting and in enhancing
appetite.153 This
has the potential to be of particular utility for chemotherapy-induced nausea
and vomiting (CINV) and for persons
with wasting (cachexia) caused by HIV/AIDS.
For instance, a 2008 meta-analysis found that a synthetic cannabinoid was
superior to
a number of other options for reducing nausea. A variety of studies
summarised by Kramer in 2015 have identified efficacy in both
respects.154
2.113 However, as Cancer Council Victoria pointed out in its submission, the
research support is not unequivocal:
a systematic review that considered cancer patient perceptions of the
effectiveness
of synthetic cannabinoids and natural cannabinoid extract products in
comparison to traditional anti-emetic treatments showed that
patients perceive
these products as only slightly more effective than traditional anti-emetics;
however, they also preferred cannabinoid
use to alleviate the side effects of
future chemotherapy.155
147 Tudor J C Phillips et al, ‘Pharmacological Treatment of Painful
HIV-Associated Sensory Neuropathy: A Systematic Review and
Meta-Analysis of
Randomised Controlled Trials’ (2010) 5(12)
148 American Cancer Society, ‘Marijuana and Cancer’:
http://www.cancer.org /treatment
149 Hanan Abramovici,
Information for Health Care Professionals: Cannabis
(Marihuana, Marijuana) and the Cannabinoids
(Health Canada, 2013)
150 Michael Farrell, Rachelle Buchbinder and Wayne Hall, ‘Should
Doctors Prescribe Cannabinoids’ (2014) 348
British Medical Journal
151 GW Pharmaceuticals,
Cancer Pain
http://www.gwpharm.com
. Recently reported
results from Phase III trials found no statistically significant difference in
effect between Sativex and
placebo: Ben Hirschler, ‘GW Pharma’s
Cannabis Drug Fails in Cancer Pain Study, Shares Fall’,
January 2015,
http://www.reuters.com
152 Jack Simpson, ‘Chile Harvests First Marijuana Plants in Project to
The Independent
http://www.independent.co.uk
153 See eg Martin R Tramèr et al, ‘Cannabinoids for Control of
Chemotherapy Induced Nausea and Vomiting: Quantitative
Systematic Review’
British Medical Journal
154 Joan Kramer, ‘Medical Marijuana for Cancer’ (2015) 65 CA:
A Cancer Journal for Clinicians
155 Submission 57.
2.114 Therefore, there is a modest level of research support for the capacity
of medicinal cannabis to reduce nausea and vomiting
caused by chemotherapy and
to reduce the wasting caused by HIV/AIDS.
Spinal cord injury
2.115 There is some research evidence to suggest that medicinal cannabis can
assist with the symptoms associated with spinal cord
injury, particularly pain
and spasticity. Double-blind, placebo-controlled trials156 ‘suggested
modest improvements in pain,
spasticity, muscle spasms and sleep quality in
patients with spinal cord injury’.157
2.116 Although there is some evidence to support the contention that
medicinal cannabis can alleviate some symptoms associated
with spinal cord
injury, at this stage the research on the issue is at a comparatively early
Post-Traumatic Stress Disorder
2.117 In a 2015 review of 46 articles in relation to treatment of
Post-Traumatic Stress Disorder (PTSD) with medicinal cannabis, Yarnell
that it has been suggested on a significant number of occasions that those with
less perceived ability to withstand emotional
distress were more likely to
attempt to ‘self-soothe’ with cannabis in response to distressing
emotions related to trauma.158
2.118 Additionally, those with PTSD-related symptoms have been asserted to be
more likely to use cannabis with the explicit purpose
of coping.159 It has been
suggested too that patients with more severe PTSD symptoms may have an even
stronger motivation to use
cannabis. The literature establishes that the fact
that a person is diagnosed with PTSD significantly increases his or her chance
of using cannabis at some point in life.160
2.119 Yarnell’s conclusion was not positive:
To date, there is no large-scale, randomized, controlled study investigating
efficacy of marijuana and PTSD symptomatology; however,
the literature that
exists suggests that it may have an effect on decreasing PTSD symptoms, and the
neurobiological and animal studies
seem to suggest potential underlying
mechanisms consistent with these findings. However, PTSD may also be related to
problematic,
pathological use of cannabis. Additionally, the overall literature
may be limited by publication bias, and the lack of standardized,
large-scale
controlled trials at this time makes any final conclusions on the efficacy
uncertain. As the number of people seeking
medical marijuana as well as those
self-medicating for PTSD continues to rise, there is a clear need for more
research trials and
monitoring of the long-term effects of using cannabis for
the treatment of PTSD
and other medical conditions.161
2.120 As yet it is premature to conclude that research has established that
medicinal cannabis can alleviate the symptoms of PTSD.
156 See, eg, Derick T Wade, ‘A Preliminary Controlled Study to
Determine Whether Whole-Plant Cannabis Extracts Can Improve Intractable
Neurogenic Symptoms’ (2003) 17
Clinical Rehabilitation
157 Health Canada, Information for Health Care Professionals: Cannabis
(Marihuana, Marijuana) and the Cannabinoids (2013) 43
http://www. hc-sc.gc.ca /dhp-mps /alt_formats /pdf/marihuana /med /infoprof-eng.pdf
158 Stephanie Yarnell, ‘Marijuana for Posttraumatic Stress Disorder: A
Review of the Current Literature’ (2015) 17(3)
Primary Care Companion
for CNS Disorders
. See also C M Potter et al, ‘Posttraumatic Stress
Disorder and Cannabis Use in a Nationally Representative Sample’
Journal of Anxiety Disorders
159 See M O Bonn-Miller et al, “Posttraumatic Stress Symptom Severity
Predicts Marijuana Use Coping Motives Among Traumatic
Event- Exposed Marijuana
Users’ (2007) 20
Journal of Traumatic Stress
160 See J R Cougle et al, ‘Posttraumatic Stress Disorder and Cannabis
Use in a Nationally Representative Sample’ (2011)
Psychologically
Addictive Behaviors
161 Stephanie Yarnell, ‘Marijuana for Posttraumatic Stress Disorder: A
Review of the Current Literature’ (2015) 17(3)
Primary Care
for CNS Disorders
Schizophrenia
2.121 In 2014 a Cochrane Review reviewed the correlation between cannabis and
schizophrenia, including the potential for medicinal
cannabis to be used for
treatment of psychotic illnesses such as schizophrenia. The study identified
eight previously conducted
randomised trials, involving 530 participants, which met the rigorous
selection criteria of the Cochrane Collaboration. It particularly
had regard to
the contention that CBD has an antipsychotic effect and compared whether CBD was
more effective as a treatment than
the antipsychotic, amisulpride. It found the
evidence ‘insufficient’ for such an assertion.162
2.122 As yet it is premature to conclude on the basis of research that
medicinal cannabis can inhibit the experience of the symptoms
of schizophrenia.
However, as noted below, there is concerning evidence that it can be
detrimental for some persons who have a
vulnerability to develop psychotic
illnesses such as schizophrenia.
Anti-cancer properties
2.123 A number of people who made submissions or attended consultations
asserted that cannabis has the capacity to reduce tumour size
across a number of
cancer types.163 The
‘antitumorogenic’ properties of cannabinoids have been known for
some time, with animal studies conducted as early as
the 1970s.164
2.124 Since that time, a ‘vast range of cancer cell and tumour
models’ have been used to evaluate the anti-tumour properties
cannabinoids, and increased quantities of endocannabinoid receptors have been
detected in various cancer cell lines, supporting
the empirical findings. While
these studies have shown cannabinoids in some cases reduce tumour cell growth,
in others they have
caused it to increase.165
2.125 The authors of a 2013 review article concluded that:
It is a distinct possibility that the cannabinoids may have a place in the
future treatment of cancer. Several reports have shown
that the synthetic
cannabinoids in particular
have the potential to show sufficient specificity and efficacy to be
precursors to clinical treatments. However, at this point in
time, the results
from studies are lacking sufficient depth of understanding to allow this
transition to occur. The contradictory
nature of reports around the efficacy of
compounds highlights our lack of detailed understanding of mechanisms of action.
The resolution
of the conflicting evidence around cannabinoid action will
continue to be a research priority in the near future, and it is expected
developing a more robust understanding of the mechanisms of action underlying
cannabinoid action will facilitate the acceptance
of cannabinoid use in a
clinical setting.166
2.126 Significant human studies on the cancer-fighting properties of cannabis
are yet to occur.
However, a number of clinical trials are on the horizon for specific cancer
Cancer Council Victoria submitted that the available evidence does not
support the use of cannabis as a treatment for cancer.168
The National Cancer
Institute in the United
States supports this position.169 The Clinical Oncology Society of Australia
and the Cancer
Council Australia stated their view clearly in a recent joint submission:
162 B C McLoughlin et al, ‘Cannabis and Schizophrenia: Review’
Cochrane Database of Systematic Reviews
http://www.thecochranelibrary.com
See also B C McLoughlin et al, ‘Cannabis and Schizophrenia’ (2015)
Schizophrenia Bulletin
163 Consultations 1, 2, 4, 5, 6; Submissions 1, 2, 3, 11, 12, 13, 19, 29, 30,
35, 39, 40, 49, 56, 57, 59, 60, 64, 68, 72, 74, 83,
85, 95, 97.
164 A E Munson et al, ‘Antineoplastic Activity of Cannabinoids’
Journal of the National Cancer Institute
597. The study, which
looked at the effect of cannabinoids on a mouse model of lung adenocarcinoma,
found that cannabinol (CBN) and
8-THC inhibited tumour growth, while CBD and
9-THC had no effect.
165 Belinda J Cridge and Rhonda J Rosengren, ‘Critical Appraisal of the
Potential Use of Cannabinoids in Cancer Management’
Management and Research
166 Ibid 301, 310.
167 For example, an international phase I trial looking at the treatment of
glioblastoma multiforme brain tumour using Sativex and
temozolomide (an oral
chemotherapy drug) is shortly to commence: Cancer Research UK
Looking at Sativex with Temozolomide for Glioblastoma Multiforme Brain Tumour
(29 May 2015)
http://www.cancerresearchuk.org
Researchers in Israel propose to undertake a trial looking at the use of pure
CBD as a treatment, but the trial is yet to start
recruiting participants:
ClinicalTrials.Gov,
A Study: Pure CBD as a Single-Agent for Solid Tumor
(NCT02255292)
(1 October 2014)
http://www.clinicaltrials.gov
168 Submission 57.
169 National Cancer Institute,
Cannabis and Cannabinoids
(6 November
http://www.cancer.gov
There is no current evidence that cannabinoids are effective at inhibiting
tumour growth or treat or cure cancer in humans. In addition,
there is no
current evidence that cannabis or cannabinoids reduce risk or prevent cancer
occurrence or promote good health.170
2.127 On this evidence it is premature at yet to conclude that research has
established that medicinal cannabis is able to reduce
or curtail the
progression of cancer.
Other conditions
2.128 The Commission received evidence that a number of other conditions can
be assisted by the use of medicinal cannabis. For reasons
of space it is not
possible to set out in detail the most recent clinical research findings
regarding each of these conditions. However,
a few important conditions merit
specific note and these are discussed briefly below.
Tourette syndrome
2.129 The 2015 meta-analysis by Whiting et al concluded that there was
‘low-quality evidence’ (two small, placebo-controlled
demonstrating the efficacy of cannabinoids
for Tourette syndrome.171 An earlier Cochrane Review considering these same
studies concluded that there was currently insufficient
evidence to support the
use of cannabinoids in treating Tourette syndrome.172
2.130 There is a large incidence of patients using cannabis to treat the
symptoms of arthritis. As at June 2013, 65 per cent of Canadian
authorised to receive cannabis reported
‘severe arthritis’ as their diagnosis.173 Many forms of
arthritis are due to inflammation, and cannabinoids have potential
anti-inflammatory properties, particularly those which act on the CB2
receptor.174 However, there is scant research support for the
efficacy of
cannabinoids for pain caused by rheumatoid arthritis, with a 2014 review
concluding that: ‘In light of other available
treatment options for the
management of arthritis
pain, lack of sound evidence for effect, and potential for harm, herbal
cannabis cannot be recommended for arthritis pain management
time.’175 Preliminary studies using Sativex found a small but significant
analgesic effect in patients with rheumatoid
arthritis,176 but it does not
appear that follow-up studies were conducted. A clinical trial that reviewed the
efficacy of vaporised
herbal cannabis for painful osteoarthritis of the
knee (a non-rheumatoid form) has been approved to take place in Canada and is
currently recruiting patients.177
170 Cancer Council Australia and Clinical Oncology Society of Australia,
Submission 37 to the Senate Legal and Constitutional Affairs
Legislation
Committee, Parliament of Australia,
Inquiry into the
Regulator of
Medicinal Cannabis Bill 2014
171 The studies, which included a total of 36 participants,
suggested that THC capsules may be associated with a significant
improvement in
tic severity associated with Tourette syndrome: Penny F Whiting et al,
‘Cannabinoids for Medical Use: A Systematic
Meta-Analysis’
Journal of the American Medical Association
172 Adrienne Curtis, Carl E Clarke and Hugh E Rickards, ‘Cannabinoids
for Tourette’s Syndrome’ (2009) 4
Cochrane Database of
173 Mary-Ann Fitzcharles et al, ‘The Dilemma of Medical Marijuana Use
by Rheumatology Patients’ (2014) 66
Arthritis Care and Research
174 Slava Rom and Yuri Persidsky, ‘Cannabinoid Receptor 2: Potential
Role in Immunomodulation and Neuroinflammation’ (2013)
Neuroimmune Pharmacology
175 Mary-Ann Fitzcharles et al, ‘The Dilemma of Medical Marijuana Use
by Rheumatology Patients’ (2014) 66
Arthritis Care and Research
176 D R Blake, ‘Preliminary Assessment of the Efficacy, Tolerability
and Safety of a Cannabis-based Medicine (Sativex) in the
Treatment of Pain
Caused by Rheumatoid Arthritis’ (2006) 45
Rheumatology
177 The trial is titled ‘Cannabinoid Profile Investigation of
Vapourized Cannabis in Patients with Osteoarthritis of the Knee’
sponsored by
Prairie Plant Systems Inc, a Canadian licensed producer of cannabis (trial
identifier NCT0232477). See <
http://clinicaltrials.gov/ct2/show/
NCT02324777>.
Motor-neurone disease (also known as amyotrophic lateral sclerosis)
2.131 Cannabis has been suggested as a potentially useful treatment for
motor-neurone disease because it possesses many properties
with potential
relevance to the disease (such as analgesia, muscle relaxation, saliva reduction
and sleep induction).178 Animal studies
have shown that cannabinoids could delay progression of the disease.179 A
recent review concluded that ‘Based on the currently
available scientific
data, it is reasonable to think that cannabis might significantly slow the
progression of amyotrophic lateral
sclerosis (ALS), potentially extending life
expectancy and substantially reducing the overall burden of the disease. ...
trials with cannabis are the next logical step.’180
2.132 The progression of glaucoma has been shown to be slowed by the lowering
of intraocular pressure. Many glaucoma drugs cause side
effects which patients
find unacceptable.
THC is believed to reduce intraocular pressure, and a possible mechanism has
been identified.181 Other studies have shown promising
results using
cannabinoids.182 However, it appears that the effects of cannabis on
intraocular pressure are of short duration,183
by contrast with other
therapeutic options, and not sustained over time.184 There are also other
medications that address intraocular
pressure. Use of cannabis for glaucoma has
been dismissed due to the adverse effects associated with smoking cannabis,185
quantities required to be consumed and because other available therapies
provide ‘round- the-clock’ reductions in intraocular
without the psychoactive effects.186 However, researchers have shown some
interest in topical and oral cannabinoid preparations,
composed of isolated
cannabinoids or synthetic agonists.187 According to a 2004 review article,
cannabinoids have the ‘potential
of becoming a useful treatment for
glaucoma’, as they seem to have neuroprotective properties and effectively
reduce intraocular
pressure, but noted that difficulties associated with side
effects and administration methods
needed to be overcome.188 It therefore appears that the most promising
avenue of inquiry for glaucoma treatment is pharmaceutical
preparations. The
position of the American Glaucoma Society is that while medicinal cannabis can
lower intraocular pressure, its
short duration of action (3–4 hours), its
side effects and the lack of evidence that its use alters the course of glaucoma
preclude its being recommended.189
178 Gregory T Carter and Bill S Rosen, ‘Marijuana in the Management of
Amyotrophic Lateral Sclerosis’ (2001) 18
American Journal of Hospice
and Palliative Care
179 C Raman et al, ‘Amyotrophic Lateral Sclerosis: Delayed Disease
Progression in Mice by Treatment with a Cannabinoid’
Other Motor Neuron Disorders
180 G T Carter et al, ‘Cannabis and Amyotrophic Lateral Sclerosis:
Hypothetical and Practical Applications, and a Call for Clinical
American Journal of Hospice and Palliative Care
181 Anna Porcella et al, ‘The Human Eye Expresses High Levels of CB1
Cannabinoid Receptor mRNA and Protein’ (2001) 12
European Journal
Neuroscience
182 A randomised, double-blind, placebo-controlled, four-way crossover study
conducted in 2006 with six participants found that a
low dose of
9-THC administered sublingually was associated with significantly lower
intraocular pressure than placebo, with mild side effects.
CBD was not found to
have beneficial effects: I Tomida et al, ‘Effect of Sublingual
Application of Cannabinoids on Intraocular
Pressure: A Pilot Study’ (2006)
Journal of Glaucoma
183 Keith Green, ‘Marijuana Smoking vs Cannabinoids for Glaucoma
Therapy’ (1998) 116
Archives of Opthalmology
184 A J Flach, ‘Delta-9-tetrahydrocannabinol (THC) in the Treatment of
End-stage Open-angle Glaucoma’ (2002) 100
Transactions of the
American Opthalmological Society
185 See, eg, Keith Green, ‘Marijuana Smoking vs Cannabinoids for
Glaucoma Therapy’ (1998) 116
Archives of Opthalmology
186 Keith Green, ‘Marijuana Smoking vs Cannabinoids for Glaucoma
Therapy’ (1998) 116
Archives of Opthalmology
1433. The author
refers to treatments such as once- or twice-a-day eye drops (blockers such as
timolol maleate, or the prostaglandin
agonist latanoprost).
188 I Tomida, R G Pertwee and A Azuara-Blanco, ‘Cannabinoids and
Glaucoma’ (2004) 88
British Journal of Opthalmology
189 American Glaucoma Society,
Position Statement on Marijuana and the
Treatment of Glaucoma
(10 August 2009)
http://www. americanglaucomasociety.net
Parkinson’s disease
2.133 The issues paper noted Parkinson’s disease as a condition for
which cannabis may provide relief, by reference to a
number of clinical
trials.190 However, a systematic review published in 2014 concluded that oral
cannabis extract is ‘probably
ineffective for treating levodopa- induced
dyskinesias in patients with Parkinson disease’.191
Inflammatory bowel disease
2.134 Some studies192 have been conducted on the use of cannabis for
inflammatory bowel disease. One placebo-controlled trial, conducted
on sufferers
of Crohn’s disease in 2013, found that a short course of smoked THC-rich
dried cannabis produced ‘significant
clinical, steroid-free benefits to 10
out of 11 patients in the treatment group, with some able to be weaned from
steroid dependency.
There were no significant side effects’.193
The author of a recent review concluded that: ‘During the forthcoming
years, the plant might be widely used in the treatment
of [inflammatory bowel
disease] patients. ... It
is, however, necessary to accurately confirm the safety and effectiveness of
the plant by performing large clinical studies.’194
Sleep disorders
2.135 Whiting et al concluded that there was ‘low-quality
evidence’ to support the use of cannabinoids in the treatment
disorders. The authors located two studies, one considering sleep apnoea and the
other insomnia. The first trial, which
was identified as having a high risk of
bias, found that nabilone had a greater effect than a placebo. The second trial
that nabilone had a greater effect than placebo, but that it was less
effective than amitriptyline in terms of sleep restfulness.195
Anxiety and depression
2.136 Whiting et al found no research support for the use of cannabis as a
treatment for depression. It did consider studies targeted
at other conditions
but where effects on depression were measured found that cannabinoids were no
better than placebo.196 In relation
to anxiety, the authors located one
‘small parallel-group’ trial that found CBD to have a greater effect
than placebo
on generalised social anxiety disorder, but considered that this
trial was ‘at high risk of bias’. This trial was described
authors as ‘very low quality’ evidence.197
Issues for policy-makers
2.137 As summarised above, the evidence base for the clinical efficacy of
medicinal cannabis remains of at best moderate quality for
most conditions in
respect of which claims of efficacy are made. There are several reasons for
this. Many of the studies which are
commonly cited in support of its efficacy
are low in the evidentiary ‘hierarchy’ because they:
• rely on case reports
• make claims arising from small patient cohorts
• lack controls and methodological rigour.
190 Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [3.55] – [3.59].
191 Barbara Koppel et al, ‘Systematic Review: Efficacy and Safety of
Medical Marijuana in Selected Neurologic Disorders’
192 See T Naftali et al ‘Treatment of Crohn’s Disease with
Cannabis: an Observational Study’ (2011) 13
Israel Medical Association
455; S Lal et al, ‘Cannabis Use Among Patients with Inflammatory Bowel
Disease’ (2011) 23
European Journal of Gastroenterological and
193 T Naftali et al, ‘Cannabis Induces a Clinical Response in Patients
with Crohn’s Disease: A Prospective Placebo-Controlled
Study’ (2013)
Clinical Gastroenterological and Hepatology
1276. The primary end
point (induction of remission) was, however, statistically not achieved.
194 Aikaterini Triantafyllidi et al, ‘Herbal and Plant Therapy in
Patients with Inflammatory Bowel Disease’ (2015) 28
Gastroenterology
195 Penny F Whiting et al, ‘Cannabinoids for Medical Use: A Systematic
Review and Meta-Analysis’ (2015) 313
Journal of the American
Association
2456, 2464.
196 Ibid 2463. These studies used dronabinol and nabiximols.
197 Ibid 2463– 4.
2.138 As of 2015 few systematic reviews or meta-analyses strongly support the
efficacy of medicinal cannabis.
2.139 Some studies which might otherwise be regarded as promising are of
limited utility because they were conducted on animals or
cell lines, not
humans. For the most part, systematic reviews and meta-analyses have been
discouraging or have identified potential
rather than actual efficacy in
medicinal cannabis.
2.140 There is also a great level of variability in the type of medicinal
cannabis used in the reported studies. Many studies are
based on smoked cannabis
leaf rather than medicinal cannabis products of known constituency—in
terms of THC and CBD content—and
known amounts of consumption. THC, CBD,
THCA, and the entourage effect are claimed to be explanations for reported
efficacy. However,
there has been little correlation of successful outcomes with
particular aspects, strains or constituents of the cannabis
plant. This presents a difficulty when assessing the available evidence in
relation to its prospective utility for Victorians in exceptional
circumstances.
Most of the anecdotal information communicated to the Commission arises from use
of cannabis grown
in a variety of unregulated circumstances and containing unknown and/or
variable constituents.
2.141 Comparatively few research trials have been undertaken under close
medical supervision, using medicinal cannabis of known constituency,
instance using cannabis oil of identified strength, with double-blind techniques
or with effective placebo-controls. Some trials
using pharmaceutical medicinal
cannabis products (such as Sativex and Epidiolex198) have been undertaken.
However, for many conditions,
the results of these trials have been equivocal at
2.142 The submission by the Drug Policy Modelling Program observed that most
trials have been conducted with one or another of the pharmaceutical-grade
cannabis products, rather than with herbal cannabis:
To date, cannabinoids other than CBD and THC have not been isolated into
pharmaceutical preparations, and thus the synergistic effect
has only been
observed when herbal cannabis or its compounded extracts are used
medically.199
2.143 Put another way, little research has been done as yet in respect of the
use of products such as cannabis oil or tinctures. AMA
Victoria has also
observed that most research conducted on cannabis has used pharmaceutical
preparations, rather than ‘crude
cannabis’.200
2.144 In principle, on the basis of anecdote and some trials, there is reason
for optimism in relation to the efficacy of medicinal
cannabis. The orthodox
research-derived position is that medicinal cannabis shows promise201 but it is
too soon to state definitively
that it is therapeutically efficacious for any
medical condition. It seems likely that these deficits will be addressed in
or future research. When these results become available, scientific
discussion about the efficacy of medicinal cannabis will be significantly
informed than it is now.
198 Reference to synthetic cannabinoids such as Marinol is not made in this
context because of the view that they are significantly
different from cannabis
medications manufactured from plant extracts.
199 Submission 21.
200 Submission 38.
201 Notably Harold Kalant and Amy Porath-Waller have observed that: ‘It
appears unlikely that cannabis will realize the full
therapeutic potential
implied by the endocannabinoid systems. ... Research is currently underway to
develop a new generation of safe
and effective cannabinoid medications that
avoid the adverse effects associated with smoked cannabis. ...In summary,
research supports
the medical use of cannabis to relieve nausea, vomiting and
chronic pain, but the research is still emerging in its application to
conditions’: Harold Kalant and Amy J Porath-Waller, ‘Medical Use of
Cannabis and Cannabinoids’ (2014)
Canadian Centre on Substance Abuse
Clearing the
Smoke on Cannabis Report Series
(No 5, 2014)
http://www.ccsa.ca
Evidence of side effects
2.145 A major reason for concern about the creation of a medicinal cannabis
scheme is the identification of the risk of adverse health
2.146 All medicines come with some risk of adverse side effects or toxicity.
What is of interest is whether the medicine’s benefits
outweigh its risks.
A medicine can be very risky—for example, because it is very
toxic—and still be justified because
it is necessary to treat a serious
condition. What is of concern, particularly to medical practitioners, is that
the risks of cannabis
are inadequately known and so no assessment can be made of
its benefit
to a patient on balance. In particular, while there is reasonable knowledge
of the risks posed by recreational use of cannabis, there
are very few studies
as yet on the side effects of medicinal cannabis, including non-smokable forms.
This is especially so in respect
of medium-term and long-term risks for different categories of patients with
different vulnerabilities.
2.147 For instance, AMA Victoria has contended that ‘the potency and
safety of crude cannabis is unknown, variable and unregulated’.
addition, it has argued that the negative side effects produced by cannabis
should not be disregarded ‘merely because of
a patient’s age or
health status, such as approaching the end of life.’ It has also raised
the issue of
‘psychological side effects including psychosis-like symptoms in some
patients’.202
2.148 Another expression of concern was from the Faculty of Pain Medicine of
the Australian and New Zealand College of Anaesthetists,
which said it was
‘very concerned about the adverse event profile in cannabis users,
especially in young people, including
impaired respiratory function, psychotic
symptoms and disorders, and cognitive impairment’.203
2.149 However, the point made by many submissions to the Commission is that
the proven level of adverse effects, even from unmonitored
recreational abuse of
herbal cannabis, is of relatively well known and modest dimensions.204 Unlike
in respect of opiate drugs,
no deaths have been attributed to cannabis overdose
or abuse.205
2.150 Most studies on the adverse effects of cannabis have focussed on
unregulated, illegal cannabis used recreationally, rather than
quality-controlled supply intended for medical use, and may be of limited
application to identifying the risks of the latter.206
are important limitations on the extent to which it is legitimate to
extrapolate from risks relating to recreational use of cannabis
to risks arising
from medicinal cannabis, in particular when use of medicinal cannabis is
suitably supervised by a medical practitioner.
2.151 A systematic review conducted in 2008 looking at the medical use of
cannabinoids, as distinct from the recreational use of cannabis,
concluded that
short-term use of cannabinoids increased the risk of non-serious adverse events
compared to a control group, but not
the risk of serious adverse events.
However, the authors concluded that further research was needed before long-term
risks could
be accurately characterised.207
202 Submission 38.
203 Faculty of Pain Medicine, Australian and New Zealand College of
Anaesthetists, ‘Statement on “Medicinal Cannabis”
Reference to its Use in the Management of Patients with Chronic Non-Cancer
Pain’ (2015).
204 Submissions 16, 19, 22, 29, 30, 59, 95.
205 Submission 95; see also Mark A Ware and Vivianne L Tawfik, ‘Safety
Issues Concerning the Medical Use of Cannabis and Cannabinoids’
Pain Research & Management
206 Laurence Mather et al, ‘(Re) introducing Medicinal Cannabis’
Medical Journal of Australia
759. See also Laurence Mather,
Alex Wodak and William Notcutt, ‘Re: Should Doctors Prescribe
Cannabinoids’, response to
article in the
British Medical Journal
/content /348 /bmj.g2737/rr/701867>.
207 Tongtong Wang et al, ‘Adverse Effects of Medical Cannabinoids: A
Systematic Review’ (2008) 178
Canadian Medical Association
1669. See also Louisa Degenhardt and Wayne D Hall, ‘The Adverse Effects
of Cannabinoids: Implications for Use of Medical Marijuana’
Canadian Medical Association Journal
2.152 As the submission made on behalf of the cannabis community of Victoria
acknowledged:
‘Cannabis ... is not “harmless”’.208 Cannabis use
carries a range of known side effects which, while well
described, are of
disputed magnitude. The most important of these are summarised below.
Respiratory effects
2.153 If cannabis is smoked, particularly in combination with tobacco, a
range of potentially carcinogenic effects may arise, as well
as ones which are
adverse for respiratory function.209
Psychotic effects
2.154 There is a small and relatively unresearched incidence of recreational
users who have experienced psychoses in the context of
cannabis use. This has
been manifested in the commission of some violent crimes.210 Cannabis use is a
risk factor for developing
schizophrenia211 and for the development of
psychotic symptoms in young people.
2.155 While cannabis use is associated with precipitating and exacerbating
schizophrenia, it is not clear whether the correlation
is causative or due to a
tendency for the affected group to use cannabis.212 Some submissions have
argued that the presence of
CBD in cannabis may counteract the psychotogenic
properties of THC. As a result, a percentage of the cannabis psychoses which
been identified may well be attributable to very high THC- content
cannabis, known as ‘skunk’, and used by some recreational
2.156 The relevance of this phenomenon to a scheme which is properly
clinically monitored
by medical practitioners, where the amount of THC ingested by the patient is
known, is very limited. In addition, it is likely that
some categories of
patients, such as those with epilepsy, will receive medicinal cannabis with very
low or no THC content. This removes
the risk of THC-induced psychosis for these
Mood effects
2.157 A further concern identified has been the potential for cannabis to
impact adversely upon users’ moods, including by making
them anxious,
depressed or paranoid. However, while often seen among new users, these effects
are uncommon in regular users and tend
to disappear after a few months of
abstinence.214 Again, this is a phenomenon that has been identified for a small
percentage of
recreational users but there is little information on the issue in
respect of individuals who receive cannabis for medicinal purposes.
Impairment of learning ability, memory and motivation
2.158 Adults who use marijuana chronically have demonstrated poorer
performance on tests of learning and memory, attention, visuospatial
processing speed, and executive functions. However, some studies have found no
performance deterioration among heavy cannabis
users. A meta-analysis examined
11 studies that met strict inclusion criteria, and ascribed impaired learning
and memory to chronic
recreational cannabis consumption,
208 Submission 95.
209 Mark A Ware and Vivianne L Tawfik, ‘Safety Issues Concerning the
Medical Use of Cannabis and Cannabinoids’ (2005)
Pain Research and
210 See, eg,
[1999] VSCA 208
[24] (Phillips CJ).
211 Stanley Zammit et al observed in 2012 that: ‘Despite the inevitable
uncertainty inherent when relying upon observational
studies rather than
[randomised controlled trials] , we believe there is a strong body of evidence
from epidemiological studies that
use of cannabis increases the risk of
developing psychotic disorders, supported by findings in other research
fields’: Stanley
Zammit et al, ‘Does Cannabis Use Cause
Schizophrenia? The Epidemiological Evidence’ in David Castle, Robin M
Deepak Cyril D’Souza (eds),
Marijuana and Madness
(Cambridge University Press, 2nd ed, 2012), 181.
212 Mark A Ware and Vivianne L Tawfik, ‘Safety Issues Concerning the
Medical Use of Cannabis and Cannabinoids’ (2005)
Pain Research &
213 Submission 24; Consultation 1.
214 Mark A Ware and Vivianne L Tawfik, ‘Safety Issues Concerning the
Medical Use of Cannabis and Cannabinoids’ (2005)
and Management
31A, 32A–33A.
but determined that other cognitive domains remained unaffected.215
Particular issues arise in this context in respect of children,
whose brains are
developing. Care would need to attend the monitoring of children by medical
practitioners in this regard.
2.159 An issue that has arisen in respect of recreational users of cannabis
and that may be relevant in relation to long-term users
of medicinal cannabis
is the potential for them to become physically or psychologically dependent on
it. In general, cannabis is
not a highly addictive or habit-forming drug216 but
the potential does exist for a small percentage of users, at least in the
recreational
context, to become dependent on it to a point where they experience
withdrawal symptoms for a time when they stop using. Symptoms
may include
craving for cannabis, decreased appetite, sleep difficulty and weight loss, as
well as aggression, irritability, restlessness
and strange dreams.217 The
American Psychiatric Association identified the diagnosis of ‘cannabis
withdrawal’ in its
2013 edition of the
Diagnostic and Statistical
Manual of Mental Disorders
(DSM-5).218 However, it has been suggested that
its severity is similar to withdrawing from smoking tobacco.219
Cardiac effects
2.160 Cannabis consumption is known to induce tachycardia, and can
increase the risk of myocardial infarction (heart attack).
However, these
effects tend to be problematic only in conjunction with other cardiac risk
factors, such as existing heart disease
or arrhythmias.220
Pregnancy complications
2.161 Cannabis use during pregnancy has been found to be associated with a
number of undesirable effects, but these findings are disputed.221
Impairment of concentration and psychomotor response:
2.162 The evidence is compelling that using cannabis retards concentration
and response to stimuli.222 Critical tracking tests,
reaction times, divided
attention tasks, lane position variability and speeding have all shown
cannabis-induced impairment in the
driving context.223 Psychomotor performance
generally is impaired by cannabis.224 It is also common for subjects not to
their level of impairment.225 Impairment is exacerbated when combined
with the consumption of alcohol.226 This has important ramifications
for those driving under the influence of medicinal cannabis and for safety in
the workplace.227
215 I Grant et al, ‘Non-acute (Residual) Neurocognitive Effects of
Cannabis Use: A Meta-Analytic Study’ (2003) 9
Journal of the
International
Neuropsychological Society
216 See Wayne Hall, ‘What Has Research Over the Past Two Decades
Revealed About the Adverse Health Effects of Recreational Cannabis
217 See David Castle, Robin M Murray and Deepak Cyril D’Souza,
Marijuana and Madness,
(Cambridge University Press, 2nd ed, 2012) 10.
218 American Psychiatric Association,
Diagnostic and Statistical Manual of
Mental Disorders
(American Psychiatric Association, 2013) 514–515.
219 National Cannabis Prevention and Information Centre,
(1 November 2011) <https://ncpic.org.au>.
220 Mark A Ware and Vivianne L Tawfik, ‘Safety Issues Concerning the
Medical Use of Cannabis and Cannabinoids’ (2005)
Pain Research &
221 Ibid 34A.
222 See, eg, R Andrew Sewell, James Poling and Mehmet Soluoglu, ‘The
Effect of Cannabis Compared with Alcohol on Driving’
(2009) 18 (3)
American Journal of Addiction
223 R L Hartman and M A Huestis, ‘Cannabis Effects on Driving
Skills’ (2013) 59
Clinical Chemistry
478; M G Lenne et al,
‘The Effects of Cannabis and Alcohol on Simulated Arterial Driving:
Influences of Driving Experience and
Task Demand’ (2010) 42
Analysis and Prevention
224 See Paul Armentano, ‘Cannabis and Psychomotor Performance: A
Rational Review of the Evidence and Implications for Public
Drug Testing and Analysis
52; Stephen Maisto, Mark Galizio and
Gerard Connors,
Drug Use and Abuse
(Cengage Learning, 2014), 280.
225 See A Menetrey et al, ‘Assessment of Driving Capability Through the
Use of Clinical and Psychomotor Tests in Relation to
Blood Cannabinoids Levels
Following Oral Administration of 20mg Dronabinol or of a Cannabis Decoction Made
with 20 or 60mg Delta9-THC’
Journal of Analytical Toxicology
226 See eg LA Downey et al, ‘The Effects of Cannabis and Alcohol in
Simulated Driving: Influences of Dose and Experience’
Accident Analysis and Prevention
879; R Andrew Sewell, James Poling and
Mehmet Soluoglu, ‘The Effect of Cannabis Compared with Alcohol on
Driving’ (2009)
American Journal of Addiction
227 See Jennan A Phillips, Michael G Holland and Debra D Baldwin,
‘Marijuana in the Workplace: Guidance for Occupational Health
Professionals and Employers: Joint Guidance Statement of the American
Association of Occupational Health Nurses and the American
College of Occupational and Environmental Medicine’ (2015) 57
Journal of Environmental Medicine
Guidance by College of Physicians and Surgeons of British Columbia
2.163 This combination of factors led the College of Physicians and Surgeons
of British Columbia to conclude in May 2015 that dried
cannabis is generally not
appropriate for patients
• are under the age of 25
• have a personal history or strong family history of psychosis
• have a current or past cannabis use disorder
• have an active substance use disorder
• have cardiovascular disease (angina, peripheral vascular disease,
cerebrovascular disease, arrhythmia) or respiratory disease
• are pregnant, planning to become pregnant or are breastfeeding.
2.164 In order to address such identified risks and ‘the paucity of
evidence to support the use of marijuana for medical purposes’,
required physicians to adopt the following measures:
Document that conventional therapies for the condition for which the
authorization of marijuana for medical purposes was provided
have been attempted
to assist the patient in the management of his/her medical condition and have
not successfully helped the patient.
Assess the patient for addiction and/or risk of addiction. For the latter,
use a validated addiction risk tool and retain a copy in
the patient record.
Discuss with the patient the risks of using marijuana and record in the
patient’s medical record that a discussion occurred.
Review the patient’s PharmaNet information prior to issuing an
authorization for marijuana for medical purposes and in any reassessment
patients receiving marijuana for medical purposes.
Retain a copy of the document provided for the authorization of marijuana for
medical purposes in the patient’s medical record.
Include processes to identify any misuse/abuse/diversion by the patient in
any reassessment of patients receiving marijuana for medical
Not sell or dispense marijuana for medical purposes to any patient.
Not complete a document for the authorization of marijuana for medical
purposes for a patient unless
- the physician has a longitudinal treating relationship with the patient,
- the physician is in direct communication with another physician or nurse
practitioner who has a longitudinal treating relationship
with the patient and
both are in well- documented agreement with the issuance of a document for the
authorization of marijuana for
medical purposes. 228
228 College of Physicians and Surgeons of British Columbia,
Professional
Standards and Guidelines: Marijuana for Medical Purposes
2015). See also Hanan Abramovici,
Information for Health Care
Professionals: Cannabis (Marihuana, Marijuana) and the Cannabinoids
(Health Canada, 2013).
Managing risk
2.165 It is important that any medicinal cannabis scheme acknowledges the
reality of a diverse range of actual and potential side
effects for patients.
For the most part, such risks were recognised by submissions made to the
Commission.
2.166 However, such side effects generally arise from cannabis with a
significant THC content and thus do not arise or are significantly
less relevant
in the context of cannabis that has a high CBD content.
2.167 Many potential side effects can be minimised by avoiding uncertain and
excessive levels of consumption arising from self-administration
and also by
establishing a scheme that does not include smoked forms of cannabis.
2.168 Most prescribed medications have side effects for which appropriate
warnings are given to patients by their medical practitioners
(as well as by
pharmacists) so that the consent that patients (or those responsible for them)
provide is properly informed. In addition,
a fundamental responsibility of
medical practitioners is to review the condition of patients for whom they
prescribe in order to
identify not only the correct level of medication to
address patients’ symptoms but also the onset of any side effects, so
these can be addressed. Medicinal cannabis is no different from other
medications in this regard, save that for the most part
the side effects arising
from the use of medicinal cannabis are unlikely to be life-threatening provided
that suitable steps to avoid
misuse are taken by medical practitioners.
Access to medicinal
cannabis in
‘exceptional circumstances’
52 Introduction
53 Exceptional circumstances
55 Eligibility criteria
75 Authorisation of treatment
3. Access to medicinal cannabis in
‘exceptional circumstances’
Introduction
3.1 Law reform to allow people to be treated with medicinal cannabis in
exceptional circumstances needs to establish a way of distinguishing
eligible and who is not. This chapter explores the concept of exceptional
circumstances and how to convey it in legislation
in the form of eligibility
criteria. The criteria would be applicable to treatment with medicinal cannabis
under any of the law reform
options discussed in this report.1
3.2 The conclusion reached is that the criteria should be based on two
• evidence of the efficacy of cannabis in treating a medical
• the extent to which it is likely to improve the patient’s
quality of life.
3.3 Compassion demands that individual suffering be taken into account, but
clinical efficacy be ignored. With this perspective as a guide, a number of
conditions and associated symptoms are identified and
a set of criteria
3.4 Because a decision to use medicinal cannabis is a medical one,
participation in the scheme should not be determined by statutory
alone. For the treatment to be truly ‘medical’ in nature, the supply
and administration of medicinal cannabis
must take place under medical
supervision. The reasons for this are twofold. First, treatment with medicinal
cannabis must be rational—that
is, it must be made available only where
there is a reasonable prospect that it will provide a benefit to the patient.
Second, the
use of medicinal cannabis must be appropriately supervised so that
its use does not harm the patient or interfere with other treatments
It needs to be integrated into the healthcare holistically provided to the
3.5 At the same time, the requirements of medical supervision must not
present an insurmountable barrier to patients who could be
assisted by the use
of medicinal cannabis; nor should it be intolerable to patients wishing a
reasonable measure of autonomy in the
treatment they receive or unacceptable to
the medical practitioners asked to act as ‘gatekeepers’ to the
scheme. The
regulatory framework should put the eligibility criteria into
operation by allowing access by patients who meet the criteria,
preventing access by those who do not, and addressing the risks of dishonest
and criminal conduct by those who seek to divert medicinal
cannabis products to
people who are ineligible to participate in the scheme. Similar regulatory
challenges are encountered in administering
the opioid replacement therapy
program. This chapter sets out a system for regulating access to medicinal
cannabis that is based
on that scheme.
1 See Chapter 5.
Exceptional circumstances
The idea of ‘exceptionality’
3.6 ‘Exceptional circumstances’ conveys the notion of a limited
group of individuals whose experience differs substantially
from the norm. The
term suggests that there must be something identifiably, objectively different
and unusual about the circumstances
in which medicinal use of cannabis is
authorised that make them exceptional.
3.7 The task for the Commission is to demarcate these cases from those that
‘exceptional’.2 They are not more worthy than other
cases—rather, they are just far enough outside the usual experience
justify an exception being made.
3.8 The term ‘exceptional circumstances’ is found in a number of
areas of Victorian law.3 It
is frequently intended to convey a situation which is highly unusual, such
that departure from the ordinary rules can be justified.4
Indeed, it conveys a
situation where the exercise of discretion is compelled by considerations that
are outside normal experience.5
‘exceptional circumstances’ is in some cases defined,6 courts and
legislators have generally been reluctant to confine
the application of the term
to a rigid set of scenarios, reflecting the need for flexibility in compelling
circumstances.7
3.9 This approach reflects the function of ‘exceptional
circumstances’ in the context of the Commission’s review:
distinguish those cases in which a departure from the ordinary rules can be
3.10 The ordinary rules are that cannabis is a prohibited substance unless
provided in a form that has been approved by the conventional
processes for
regulating therapeutic goods.8
The Attorney-General’s terms of reference imply that an alternative
regulatory approach is to be considered where circumstances
require that an
exception be made. The alternative approach being contemplated for such
circumstances is to take certain products
of the conventional, evidence-driven approval and treatment framework.
3.11 The challenge is to identify those matters that justify
exceptionality.
2 A number of submissions opposed this exercise altogether. Heather Marie
Gladman, Australian HEMP Party summarised the views of a
number of people who
communicated with the Commission: ‘It should be available to everyone who
needs it ... All cannabis use
is medical’: Submission 10. Others called
for cannabis to be legalised for all purposes. The Australian Lawful Use of
asked why, in view of its potential protective and preventative benefits,
only the sick should have access to cannabis: Submission
Commission notes these objections but is confined to examine only those
matters raised by the terms of reference.
3 As Hedigan J said in
Kent v Wilson
[2000] VSC 98
, [20]: ‘The
courts have frequently been obliged to consider the meaning of the phrase
“exceptional circumstances”
in a variety of contexts, perhaps most
commonly in connexion with the granting of bail in murder cases and the taking
out of time.’
Charter of Human Rights and Responsibilities Act 2006
(regarding when an human rights override declaration will be made);
Youth and Families Act 2005
(regarding when a child can be
prosecuted otherwise than on summons);
Serious Sex Offenders (Detention and
Supervision) Act 2009
(Vic) s 183 (regarding when a court can authorise
publication of information regarding
an application for a sex offender’s continued detention or
supervision);
Sentencing Act 1991
(regarding when
a community correction order, fines work order or community work permit can be
suspended by the Secretary to the
Department of Justice);
Road Safety Act
(Vic) ss 51(12) and (12A) (regarding where a judge can cancel an
immediate driver’s licence suspension imposed on a person
found drink
5 Redlich JA said that for something to amount to ‘exceptional
circumstances’, it must be ‘clearly unusual or quite
distinctly out of the ordinary’. He said it is not enough to find
something which ‘falls within the range
of normally anticipated
consequences, behaviours
or exigencies’:
R v Ioannou
[2007] VSCA 277
(2007) 17 VR 563
, 568. But,
depending on the context, something does not have to be ‘beyond reasonable
expectation or contemplation’ in
order to be exceptional. Lord Bingham of
Cornhill CJ understood the phrase in a similar way: ‘We must construe
“exceptional”
as an ordinary, familiar English adjective and not as
a term of art. It describes a circumstance which is such as to form an
which is out of the ordinary course, or unusual, or special, or
uncommon. To be exceptional a circumstance need not be unique, or
unprecedented,
or very rare; but it cannot be one that is regularly, or routinely, or normally
encountered’:
[2000] 1 QB
Road Safety Act 1986
Kent v Wilson
[2000] VSC 98
, Hedigan J stated at [22]:
‘Courts have been both slow and cautious about essaying definitions of
phrases of this kind, leaving
the content of the meaning to be filled by the ad
hoc examination of the individual cases. Each case must be judged on its own
and it would be wrong and undesirable to attempt to define in the
abstract what are the relevant factors’.
8 That is, only where a particular form is moved to a different schedule of
the SUSMP and approved for inclusion on the Australian
Register of
Therapeutic Goods: see Chapter 4.
Compassion as a basis for action
3.12 In the Commission’s view, the common factor that justifies a
different approach for a small group of patients is compassion9
empathy and an authentic desire to address another person’s suffering.10
This is reflected in the recommended
regulatory objective which refers to
‘allowing compassionately for exceptional circumstances of medical
3.13 Many submissions received by the Commission urge it to achieve a balance
the stern demands of conventional approval processes and the large number of
reports and studies that have identified positive effects
or potential from
medicinal cannabis for patients with a variety of conditions. Some arguments
were mounted from principle—
identifying limitations of the research or
medical practice—and others were generated by experience of the
therapeutic assistance
provided by medicinal cannabis. As discussed in Chapter
2, many people with a variety of painful and life-threatening conditions
informed the Commission of assistance that they had derived from forms of
medicinal cannabis that they had procured illegally.
3.14 Indeed, throughout the Commission’s consultations it was evident
that a tension exists between those who advocate a rigid
adherence to provision
of medication only on the basis of research of the kind demanded for
conventional medicines, with no exception
being made for medicinal cannabis, and
those whose approach is more liberal— influenced or even determined by
anecdotal and
experiential accounts of therapeutic efficacy, as well as by
compassion. The Commission has received submissions at either end of
continuum and at many different points along it.
3.15 For cannabis to be included among the medicinal options available in
Victoria, a compromise needs to be found between the extreme
positions in order
to cater to the present-day suffering of patients that is not being adequately
alleviated by conventional forms
of relief. It is evident that a tipping-point
has been reached within the community which requires such a compromise to be
3.16 Laurence Mather and his co-authors argued in 2013 that compassion
commands us to act, in spite of incomplete research:
A civilised and compassionate country that supports evidence-based medicine
policy should acknowledge that medicinal cannabis is acceptably effective
and safe, and probably also cost-effective, especially
when the costs of
resource use and improvement to the lives and functionality of patients and
carers are considered. There is certainly
more to learn about medicinal
cannabis, but we know more than enough to act now.12
3.17 The exercise of compassion to mitigate the harshness of a wholly
evidence-based approach has been urged or drawn upon regularly
in respect of
medicinal cannabis. For instance, this was the hallmark of the approach of a
report in 2013 by a committee of the New
South Wales Parliament which emphasised
the promise of medicinal cannabis in treating a number of painful conditions
that do not
respond to existing treatment, and advocated a ‘compassionate
approach’.13 In 2014, the Public Health Association of
Australia similarly
identified a ‘need for a compassionate regime whereby seriously and
terminally ill individuals who have
been appropriately authorised may possess
and use cannabis without penalty’.14
9 Etymologically, suffering with another. See generally Michelle Brenner,
Conversations on Compassion
(Create Space, 2015).
10 See Emma Seppala, ‘The Compassionate Mind’ (2013) 26 (5)
Association for Psychological Science Observer
www.psychologicalscience.org
11 See Chapter 1.
12 Laurence Mather et al, ‘(Re) introducing Medicinal Cannabis’
Medical Journal of Australia
13 General Purpose Standing Committee No 4, Legislative Council of the
Parliament of New South Wales, The Use of Cannabis for Medical
Purposes (2013).
14 Public Health Association of Australia,
Position Statement: Medicinal
Cannabis in Australia
http://www.phaa.net.au /documents
item /365>.
3.18 The medicinal cannabis community also draws on the concept of
compassion,15 and clubs that have been established in Australia
internationally to supply medicinal cannabis call themselves ‘compassion
3.19 In its submission to the Commission, in which it listed arguments for
the legalisation of medicinal cannabis, the Macedon Ranges
Group of Christian
Business Men Australia gave primacy to compassion:
Compassion for children who suffer from frequent and highly debilitating
seizures and also for cancer sufferers who are in constant,
severe pain where
the only known effective treatment has been presently illegal medicinal
cannabis. Compassion is also warranted
in regard to the agonising dilemma of
parents of affected children as they must currently break the law or watch
their children
suffer and deteriorate mentally and physically.16
3.20 The Commission endorses this approach. It is not an approach that
renders irrelevant the state of research knowledge about the
efficacy, safety
and risks attaching to medicinal cannabis. However, it does mean that the strong
feelings and hopes of patients,
the potential of medicinal cannabis, and the
proliferation of accounts about the apparent efficacy of medicinal cannabis for
conditions should be taken into account in construing when it should be
made available in ‘exceptional circumstances’.
3.21 The Commission’s incorporation of compassion as a relevant
consideration for making medicinal cannabis available to some
patients should
not be mistaken for a suggestion that ‘compassion’ should explicitly
be made the basis for eligibility
under a Victorian medicinal cannabis scheme;
this would fail to take account of other relevant considerations. As observed by
Victoria, ‘terminology or concepts such as
‘compassionate’ or ‘exceptional’ circumstances ...
are vague, subjective terms and are likely to lead to a
lack of clarity in
medical practice.’17 Rather, the exercise of compassion has influenced the
Commission’s identification
of certain exceptional circumstances for the
present in which access to medicinal cannabis should be allowed. It is not a
for access, but informs how that threshold should be determined.
Eligibility criteria
Factors informing eligibility criteria
3.22 Determining when a patient should be eligible for medicinal cannabis
under any Victorian scheme is not a mechanical or purely
scientific exercise; it
is an approach that should respond humanely and empathically to the experience
of pain and suffering which
not being effectively remediated by conventional forms of relief (such as
opiates, anti- spasticity, anti-emetic or anti-epileptic
drugs). At the same
time, it should not disregard the evidence regarding the potential utility of
cannabis as a medicinal agent.
It follows that the eligibility criteria must
take account of the experience of particular conditions, and whether there is a
potential for medicinal cannabis to assist, while also placing
particular emphasis on patients’ (subjective) experience of
suffering and
their desire for another therapeutic option.
3.23 Thus, the Commission has had regard to several factors in developing
eligibility criteria for access to medicinal cannabis:
• the state of the clinical literature in relation to the efficacy or
potential efficacy of medicinal cannabis for particular
medical conditions and
symptoms, particularly in relation to the likelihood that cannabis will
15 The theme of the 2014 conference of the Medical Cannabis Users Association
in Tamworth was ‘United in Compassion’
http://www.unitedincompassion.com.au
16 Submission 34. Christian Business Men Australia also provided the
Commission with a copy of a petition they prepared, for presentation
Parliament, calling for a ‘Compassionate Use of Medical Cannabis
Act’. See Appendix B for list of submissions.
17 Submission 38. The Commission’s medical advisory committee concurred
with this view.
• the seriousness of the medical conditions, including patients’
prognoses and the extent of the disability caused by
their conditions
• the extent to which the symptoms of the conditions interfere with
patients’ ability to derive enjoyment and fulfilment
in their lives
• the extent to which cannabis can reasonably be anticipated to improve
quality of life
• the availability of standard treatments that may assist, how
effective they are, and what side effects they cause or may cause
• the state of the clinical literature in relation to the risks or
potential risks posed by medicinal cannabis for patients
with particular medical
conditions.
3.24 While there must be evidence supporting the likely efficacy of cannabis
for a particular medical condition, such evidence should
not be the sole
criterion applied. Compassion demands that the extent of suffering should be
taken into account, and compared with
the relief the patient might receive. The
level of evidence required (regarding efficacy and side effects) should respond
severity of the patient’s suffering and the availability of
alternatives.
Methods of determining eligibility
3.25 Although a wide range of eligibility criteria are used for medicinal
cannabis schemes in other countries, three main approaches
identified:
• case-by-case decisions by a medical practitioner, who decides at
their discretion whether a patient is eligible to be treated
with medicinal
• case-by-case decisions by a panel or a government official, which
decides whether a patient is eligible by referring to a
general statutory
• a categorical test.
Decision by medical practitioner
3.26 A number of submissions to the Commission put the view that eligibility
should be determined by the patient’s medical practitioner,
unfettered discretion.18 The practitioner’s assessment would focus upon
the condition and symptoms of the patient,
but the decision about eligibility
would be made by the practitioner independently, free of constraints imposed by
statutory eligibility
3.27 This is the approach taken in the Netherlands. While the Office of
Medicinal Cannabis suggests some conditions where there
is strong evidence
cannabis can assist, medical practitioners are free to prescribe cannabis for
any indication.19 Toby Stewart called
for this approach to be adopted in
The law cannot and must not displace the judgement of doctors. If it does,
doctors will become clerks who look up laws and dole out
drugs for a profit.
They will no longer have any ethical duty, no[r] any interest in the complex
issues of suffering, dignity and
death. It is not for the law to decide who uses
what drug. It is for the law to decide which drugs doctors may prescribe to
suffering, and which they may not.
This issue for reform here is the treatment of a drug by the law. The issue
is not the wholesale revision of medical professional
competence, and the
replacement of doctors by merry statute. We must let doctors continue to
prescribe those drugs which are lawful,
as they deem fit in their professional
capacity. People will not accept a law that displaces doctors. It will be a
farce, and a disgrace,
to propose such a law.20
18 Submissions 7, 23, 55, 84. Submission 97 also supported retaining
discretion for medical practitioners.
19 Consultation 28.
20 Submission 23.
3.28 Notwithstanding such concerns, the Commission does not consider that the
task of determining whether a particular patient is
eligible should be a task
entirely for the medical practitioner. The Commission’s medical advisory
committee strongly opposed
scheme where the determination was entirely left to medical practitioners.
The committee stated that this would give medical practitioners
latitude and inadequate guidance to decide who should have access,21 with the
risk of highly variable decision making.
The conventional regulatory structure
in Australia, the Therapeutic Goods Administration (TGA), limits the
circumstances in which
approved medicines can be prescribed, and
practitioners’ professional obligations allow them to go outside these
restrictions
only in limited circumstances.
3.29 Furthermore, while all decisions about a patient’s treatment,
including treatment with medicinal cannabis, should be made
on a case-by-case
basis, this approach does not provide a basis for determining which
patient’s circumstances are exceptional.
It provides no objective standard
against which to assess who should have access to medicinal cannabis when it is
to be available
only in exceptional circumstances.
Decision by a panel or government official
3.30 Another means of implementing a case-by-case determination would be for
a government official or panel of doctors to determine,
on application, whether
a patient is eligible to be treated with medicinal cannabis, according to some
very general statutory test
of eligibility relating to the individual’s
circumstances. It was suggested at a public consultation that people other than
doctors could be involved in the decision.22
3.31 The Commission is unaware of a medicinal cannabis scheme that relies on
this approach, but expects that it could work in a similar
fashion to the
Special Access Scheme, under which the Secretary of the Commonwealth Department
of Health has the discretion to allow
unapproved medicines to be imported for,
or supplied to, a patient on a case-by- case basis.23 A similar approach is
taken in countries
like Germany to manage requests to import medicinal cannabis
products.24
3.32 In the Commission’s view, this approach is not desirable as a
systematic means of controlling access in Victoria. It
would create
administrative costs for the Victorian Government and uncertainty within the
medical profession about who is eligible.
It could also generate administrative
appeals and applications for judicial review of decisions not to approve
access.25 Importantly,
the time taken to process applications for access would
delay the treatment of gravely ill (possibly terminally ill) people with
products that might assist them.26
Categorical test
3.33 An alternative approach is for categories of patients who are eligible
to receive medicinal cannabis under the scheme to be
set out in legislation.
This would give clarity to medical practitioners and the public. It would also
reduce the pressure placed
on medical practitioners to provide access to
medicinal cannabis to treat minor conditions, where patients’
symptomatology
is not significant, or in other circumstances that clearly are
not exceptional.27 For this reason, the Commission’s medical
committee expressed strong support for eligibility criteria which specifically
identify the medical circumstances that qualify
a person for access.
3.34 There are some drawbacks to adopting a categorical approach. JB, for
instance, expressed
21 Advisory committee (Meeting 1).
22 Consultation 3. See Appendix C for list of consultations.
23 See Therapeutic Goods Administration,
Access to Unapproved Therapeutic
Goods via the Special Access Scheme
(November 2009).
24 Federal Institute for Drugs and Medical Devices (Germany),
http://www.bfarm.de
Marco Evers and
Höflinger, ‘Legal Highs: Welcome to the Cannabis Revolution’
Australian Financial Review
(originally
Der Spiegel
25 Decisions to refuse applications under the Special Access Scheme can be
appealed internally or to the Administrative Appeals Tribunal:
Therapeutic Goods Act 1989
26 A case-by-case assessment by a government official could, however, be a
means of dealing with rare and unusual conditions.
27 Concern about the pressure that could be placed on doctors was expressed
by the advisory committee (Meeting 1) and at Consultation
concern about not taking account of the patient’s individual
circumstances:
Deciding who should be allowed access to medicinal cannabis should be on a
patient by patient basis. All cases treated on their merits
and not an umbrella
decision affecting all people with the same condition.28
3.35 The Drug Policy Modelling Program cautioned against the possibility of
creating a division between those deemed to be ‘deserving’
against ‘undeserving’.29 Another contributor argued that list-based
tests are ‘generally exclusionary rather
than inclusionary’ and
‘contrary to the notions of a compassionate scheme. They are limited in
their ability
to alleviate suffering and exclude many people in need.’30 It was also
suggested that a categorical approach would limit the
ability of the scheme to
keep pace with scientific developments.31
3.36 Comments made in a confidential submission argued that many patient
groups other than those which receive media attention could
benefit from access
to medicinal cannabis. It was said that using a test based on categories risks
making the assessment of ‘exceptional
circumstances’ more one of
politics than clinical judgment.32
3.37 Notwithstanding these reasoned objections, the Commission considers that
a test which establishes eligibility for categories
of patients would be far
more workable than one that requires an independent decision to be made for each
individual patient by a
doctor, panel or government official. A common theme of
comments made at advisory committee meetings and during consultations was
medical practitioners need clarity and certainty regarding when medicinal
cannabis can be used. A categorical approach is the
best way of achieving
3.38 Employing a categorical test does not mean that the patient’s
individual circumstances are not taken into account. As discussed
later in this
chapter, the Commission considers that patients who meet the eligibility
criteria would be treated with medicinal cannabis
only after assessment by a
medical practitioner. It is also acknowledged that patients with rare
conditions may be marginalised
by tests based on categories and that, as the
clinical evidence base for the efficacy of medicinal cannabis changes, so too
the categories. Ways in which residual flexibility for patients with rare
conditions could be incorporated into the scheme, and for
the scheme to be
responsive to developments in clinical knowledge, are also discussed later in
this chapter.
3.39 A categorical test of eligibility could be based on:
• medical conditions
• symptoms and conditions.
3.40 These are discussed in turn below.
28 Submission 11.
29 Submission 21.
30 Submission 43.
31 Submission 43, 97.
32 Submission 32.
Condition-based test
3.41 Some submissions argued that eligibility should be based on whether the
patient suffers from a particular medical condition.33
For instance, Cancer
Action Victoria argued that there should be access to medicinal cannabis for
patients with a listed medical
condition for which there is clinical knowledge
3.42 Some United States jurisdictions rely in whole or in part on lists of
conditions to establish
a patient’s eligibility for medicinal cannabis.35 For example, access
to medicinal cannabis is available in Connecticut to
patients with a
‘debilitating medical condition’, which includes
‘cancer, glaucoma, positive status for human immunodeficiency virus or
acquired immune deficiency syndrome, Parkinson’s
disease, multiple
sclerosis, damage to the nervous tissue of the spinal cord with objective
neurological indication of intractable
spasticity, epilepsy, cachexia, wasting
syndrome, Crohn’s disease, posttraumatic stress disorder’ or other
approved by the government.36
3.43 There are difficulties with a condition-based test. As cannabis
alleviates specific symptoms and does not treat the underlying
disease, it
could be inappropriate to base eligibility on
a person’s condition alone. As Scott Hulley pointed out: ‘A
condition with no symptoms is just a title/name’.37
3.44 In particular, a definition that relies on a person’s condition
alone would suggest a homogeneity of symptoms for each
of the specified
conditions which does not in fact exist. For example, not all multiple sclerosis
patients suffer from intractable
spasticity; likewise, not all HIV/AIDS patients
experience wasting;38 and a percentage of patients who have chemotherapy do not
experience serious nausea and vomiting. Similarly, not all patients with
epilepsy have fits which cannot be adequately controlled
by means other than
medicinal cannabis.
3.45 This is important because, for instance, a patient with a recent
diagnosis of multiple sclerosis may as yet be asymptomatic,
such that it would
be inappropriate for them to be prescribed medicinal cannabis to deal with
spasticity and pain that they do not
yet experience. In this regard, the Royal
Australasian College of Physicians observed that:
Not all epilepsy variants are drug-resistant ... In many cases of apparent
drug-resistance, the epilepsy diagnosis is incorrect after
further assessment or
the medication chosen in the first two instances is inappropriate. ...
Furthermore, many patients regarded
as drug- resistant may be appropriate
candidates for potentially curative epilepsy surgery.39
3.46 The Commission agrees with these concerns and considers that an
eligibility test that required only that a person have a specified
would capture individuals for whom medicinal cannabis would provide no medical
benefit. It does not sufficiently satisfy
the requirement for
exceptionality.
Symptom-based test
3.47 Alternatively, a test for eligibility could be based on symptoms alone.
In order to
be eligible, a patient would need to have a designated level of symptoms,
with no requirement that they be tied to a particular condition.
In Maryland,
for example, medicinal cannabis may be made available to patients who have a
‘chronic or debilitating disease’
that results in admission to
palliative or hospice care or that produces ‘cachexia, anorexia or wasting
syndrome, severe pain,
severe nausea, seizures or severe or persistent muscle
33 Submissions 24, 37, 72, 74.
34 Submission 54.
35 Illinois relies on a condition-based test: 410 Ill Comp Stat 130 /10 (h).
In addition, the jurisdictions listed at n 44 below have
listed conditions as
part of their eligibility test.
36 Conn Gen Stat § 21a-408 (2).
37 Submission 22.
38 Consultation 1.
39 Submission 52.
40 Md Code Ann § 13-3307(c). The statute also allows for symptoms to be
produced by the treatment of a condition, eg chemotherapy.
3.48 The Royal Australasian College of Physicians opposed a test based on
symptoms alone:
A symptoms list alone is not appropriate to determine a person’s
eligibility because symptoms can be common across multiple
conditions. ... For
example, not all seizures are epileptic, some seizures are symptomatic of other
remediable conditions such as
alcohol abuse or electrolyte imbalance, therefore
a thorough evaluation of the patient, condition and treatment options are
... The situation for multiple sclerosis is similar.41
3.49 In the Commission’s view, a definition which relies on symptoms
alone would be undesirable. The mere existence of a symptom
or symptoms, even if
required to be
‘severe’, does not provide enough detail to determine whether
medicinal cannabis would be of assistance. Further, it would
not effectively
ensure that medicinal cannabis was restricted only to patients in
‘exceptional circumstances’, as the
symptoms for which medicinal
cannabis has been found to assist include some that are commonly experienced by
people without chronic
illnesses (such as nausea). A qualification based on
symptoms alone would not convey whether a patient’s state was serious
3.50 For these reasons, a symptom-based test would afford doctors a
substantial amount of latitude in authorising access to cannabis
such that the
scheme could become almost indistinguishable from one where eligibility is
determined solely at their discretion. Criteria
such as ‘severe
pain’ or ‘severe nausea’ (wording used in other
conjunction with a condition-based
test) would require practitioners to engage in a subjective assessment while not
conveying much
UTT BioPharmaceuticals argued that this could lead to
‘exploitation and abuse of the system’.42
Test based on conditions and symptoms
3.51 The third option is to adopt a test that makes eligibility contingent on
the patient’s condition and the symptoms from
which they suffer. Such a
test could be structured in either of two ways:
• disjunctively, using separate lists of symptoms and conditions
• conjunctively, where eligibility is based on the patient having a
combination of symptoms and conditions.
3.52 A significant number of American states use disjunctive eligibility
criteria: that is, they contain both stand-alone symptoms
and stand-alone
conditions.43 For example, the Nevada statute defines a ‘chronic or
debilitating medical condition’
as ‘acquired immune deficiency
syndrome, cancer, or glaucoma’ or as ‘a medical condition or
treatment for
a medical condition that produces, for a specific patient, one or more of the
following: cachexia, persistent muscle spasms, including,
without limitation,
spasms caused by multiple sclerosis, seizures, including, without limitation,
seizures caused by epilepsy, severe
nausea, or severe pain’.44 Patients
under such a test can qualify for medicinal cannabis by having a specified
condition or
a specified symptom. The Commission’s view is that such a
model incorporates the weakness of both types of test—it is
overly broad
in the same way as the condition- and symptom-based tests are.
3.53 The conjunctive option is the one preferred by the Commission. That test
would require a patient to show that they have a particular
symptom or symptoms
and that they are afflicted by a given condition. For example, while severe
nausea would not be enough on its
own, it could make a patient eligible if it
was the result of cancer or its treatment.
41 Submission 52.
42 Submission 60.
43 Alaska (Alaska Stat § 17.37.070 (4)); Arizona (Ariz Rev Stat Ann
§ 36-2801), Colorado (
Constitution
Article XVIII); Delaware
Del Code Ann § 4902A); Hawaii (Haw Rev Stat § 329-121); Maine (22
Me Rev Stat § 2422); Michigan (Mich Comp Laws §
333.26423); Montana
(Mont Code Ann § 50-46-302(2)); Nevada (Nev Rev Stat § 453A.050); New
Mexico (although no symptoms
are listed in the statute they have been added by
rulemaking: NM Stat § 26-2B-3); Oregon (Or Rev Stat § 475.302(3));
Rhode Island (RI Gen Laws § 21-
28.6-3); Vermont (18 Vt Stat Ann § 4472)
44 Nev Rev Stat § 453A.050.
A test of this kind was previously used in Canada,45 has been proposed in
the Australian Capital Territory46 and is employed in
some United States
committee.48
3.54 In the Commission’s view, a test which combines the requirements
of a condition-based test and a symptom-based one addresses
the shortcomings of
each test. It ensures that the patient’s condition is serious and
long-lasting, and that the symptoms experienced
are of a sort likely to be
relieved by medicinal cannabis.
3.55 An exception to this conclusion exists for chronic pain. As explained
elsewhere in this report, chronic pain is difficult for
clinicians to manage and
can be caused by a variety of underlying disorders, if a cause can be identified
at all. The management
of pain varies for different individuals, and the success
of a particular treatment will depend on individual circumstances besides
underlying condition. For these reasons, the discipline of pain medicine has
shifted towards the management of pain, rather than
the diagnosis of its
cause.49 Given this landscape, should chronic pain be among the conditions for
which medicinal cannabis is made
available, it would not be possible or
appropriate for the sufferer to also show they were affected by a particular
condition or
conditions. Chronic pain is considered in more detail below.
3.56 In addition, as set out below, particular considerations apply where
medicinal cannabis, with its unresolved side-effect profile,
is given to
children. Thus, an additional requirement is proposed in respect of the
provision of medicinal cannabis for epilepsy
conditions,
where many of the patients will be under-age.
Recommendation
Eligibility to be treated with medicinal cannabis in exceptional
circumstances should be:
(a) determined by the patient’s medical condition and symptoms
arising from that condition or its treatment
(b) specified in regulations.
Proposed conditions and symptoms
3.57 The Commission considers that, in determining the eligibility criteria,
the conditions and symptoms selected should only be those
for which there is a
reasonable measure of research support in respect of efficacy or for which the
research is weaker but the
circumstances of the patient are particularly compelling. Conditions and
their symptoms which meet these criteria are:
• severe muscle spasms or severe pain resulting from multiple
• severe pain arising from cancer, HIV or AIDS
Marihuana Medical Access Regulations
, SOR /2001-227 sch 1.
46 Exposure Draft of Drugs of Dependence (Cannabis Use for Medical Purposes)
Amendment Bill 2014 (ACT) cl 7(4).
47 In Massachusetts (listed eligible conditions must be
‘debilitating’ with debilitating defined by regulations to mean
‘causing weakness, cachexia, wasting syndrome, intractable pain, or
nausea, or impairing strength or ability, and progressing
to such an extent that
one or more of a patient’s major life activities is substantially
limited’: 2012 Mass Acts Ch
369, § 1(C) and 105 Mass Code Regs §
725.004); New Hampshire (NH Rev Stat Ann § 126-X:1(IX)); New York (NY
Health Law § 3360 (7)(a)). In some states, this type of test is only
employed for some patients, while others can qualify solely
on the basis of
their condition: see Minnesota (where a cancer sufferer or
terminally ill patient will only qualify if experiencing severe or chronic
pain, nausea /severe vomiting, or cachexia /severe wasting:
§ 152.22(14)(1) and (9)); New Jersey (where cancer and HIV/AIDS suffers
must be experiencing severe or chronic pain, severe nausea
or vomiting, cachexia
or wasting syndrome resulting from the disease or its treatment: NJ Stat Ann
§ C:24:6I-3).
48 Advisory committee (Meetings 1 and 3).
49 Australian and New Zealand College of Anaesthetists Faculty of Pain
Medicine, ‘Statement on Patients’ Rights to Pain
Management and
Associated Responsibilities’ (Position Statement No 45, 2010)
http://www.fpm.anzca.edu.au
• severe nausea, severe vomiting or severe wasting resulting from
cancer, HIV or AIDS (or the treatment thereof)
• severe seizures resulting from epileptic conditions where other
treatment options have not proved effective or have generated
side effects that
are intolerable for the patient
• severe chronic pain where, in the view of two specialist medical
practitioners, medicinal cannabis may in all the circumstances
provide pain
management that is superior to what can be provided by other options.
3.58 The Commission does not assert that this set of conditions and symptoms
is objectively the only formulation available and suggests
this list as a basis
for further discussion between the government and the medical community. This is
particularly important as the
research base is rapidly changing and will
continue to do so for some time.
Multiple sclerosis
3.59 There is a reasonable level of research support for the efficacy of
medicinal cannabis products, most particularly Sativex, in
the treatment of pain
and spasticity relating to multiple sclerosis. There are also strong
circumstantial reasons for allowing patients
to be treated with medicinal
cannabis under the scheme for this purpose.
3.60 The incidence and impact of the spasticity in multiple sclerosis were
described in a submission from MS Australia and MS Research
Muscle spasticity is a significant problem for many people living with
[multiple sclerosis], affecting over 80% during the course
of the disease and
negatively impacting mobility and personal independence. Spasticity can cause
pain, sleep disturbance and reduced
mobility. These symptoms can significantly
limit a person’s quality of life as they have
less energy, ability to complete everyday tasks and social activity. It can
also lead to
an increased reliance on carers and the health system if symptoms progress to
a stage where mobility is significantly hampered or
hospitalisation is
required.50
3.61 MS Australia and MS Research Australia observed that, to date,
medications to treat spasticity for people with multiple sclerosis
always been effective and can have
‘intolerable side effects’.51 The joint submission stated that
this position was guided by a scientific evidence-based
approach and advocated
for a regulatory framework that would facilitate further clinical trials
‘to determine the components,
dosage and frequency of cannabis-based
products and their effectiveness in managing a range of symptoms for people
living with chronic
conditions like MS.’52
3.62 The Royal Australasian College of Physicians told the Commission that:
‘Muscle spasticity is a significant problem for
many people living with
multiple sclerosis and therapeutic options are currently limited’. It
stated that many multiple sclerosis
specialists believe
there is sufficient scientific evidence to develop guidelines to trial the
medical prescription of cannabinoid products (Sativex)
for the treatment of
spasticity in some patients with multiple sclerosis.
3.63 Sativex has been approved for multiple sclerosis-associated spasticity
in Canada, New Zealand, the United Kingdom, Austria, the
Czech Republic,
Denmark, Germany, Sweden, Israel, Italy and Spain. In Australia, it was
registered in 2012 by the TGA as a treatment
for symptom improvement in patients with moderate to severe spasticity due to
multiple sclerosis who have not responded adequately
to other anti-spasticity
medication and who demonstrate clinically significant improvement in
spasticity-related symptoms during
an initial trial of therapy.53
50 Submission 25.
51 These can include fatigue, dryness of the mouth, dizziness, nausea,
sleepiness, cognitive impairment, liver toxicity and addiction:
Therapeutic
Goods Administration,
Australian Public Assessment Report for Nabiximols
(27 September 2013) 194.
52 Submission 25.
53 Pharmaceutical Benefits Advisory Committee,
Public Summary Document:
(July 2013) <
http://www.pbs.gov.au /info
listing /elements /pbac-meetings /psd /2013-07/nabiximols>.
3.64 The Commission’s medical advisory committee informed the
Commission that there is consensus that cannabis can be effective
at treating
spasticity where other treatments have failed. Not all patients experience
spasticity, and for many patients conventional
treatments (including
pharmaceuticals and physiotherapy) can effectively control these symptoms.
Members told the Commission that
the symptoms of multiple sclerosis change over
time, including the nature of the patient’s spasticity, and accordingly
response to cannabis would need to be carefully monitored by the treating
3.65 There is also some evidence that medicinal cannabis can help relieve
pain associated with multiple sclerosis. Sativex has conditional
approval in
Canada as an adjunctive treatment for neuropathic pain in multiple sclerosis.
This approval is said to reflect the ‘promising
nature of the clinical
evidence which must be confirmed with further studies’.55 The Faculty of
Pain Medicine of the Australian
and New Zealand College of Anaesthetists
conceded that a possible exception to its adverse position on the use of
medicinal cannabis
would be for the treatment of pain in multiple
sclerosis.56
3.66 The authors of a 2014 review on cannabinoids were guarded in their
findings on both spasticity and pain. They concluded that:
... the effectiveness of cannabinoids for the treatment of muscle spasticity
or neuropathic pain in multiple sclerosis is unclear
and any benefit is likely
to be modest, while mild to moderate adverse events are common and long term
safety has not been established.57
3.67 Some advisory committee members argued that, as Sativex is already
approved for use in treating multiple sclerosis, there
would be no advantage in
making an alternative form of medicinal cannabis available.58
3.68 Although Sativex is licensed for use in Australia, it is not sold in
this country and, if it were, the cost would not be subsidised
Pharmaceutical Benefits Scheme. Therefore, practically speaking, Sativex is
available for very few patients, due to the
high out-of-pocket cost and
bureaucratic complexity associated with obtaining it.
3.69 On balance, the Commission’s view is that there are sound reasons
to include multiple sclerosis patients suffering severe
symptoms in a medicinal
cannabis scheme. They
are alone among the patient groups under consideration in that they have
access to a cannabis-based drug that has been approved for
use in their
condition, but accessing this medicine is presently highly problematic. In
addition, the evidence supporting the utility
of cannabis for multiple sclerosis
is among the strongest of all the groups considered here. Refusing this group
access would be
an unacceptable outcome, particularly given the limited
treatment options otherwise available and the impact of spasticity on
patients.59
54 This observation was echoed in the TGA’s initial assessment of
Nabiximols, where the examiner stated ‘a 4 week trial
seems likely to
identify most eventual responders. Clinicians would only be justified in
proceeding to long-term treatment if there
was a clear improvement in
spasticity’: Therapeutic Goods Administration,
Australian Public
Assessment Report for Nabiximols
(27 September 2013) 108.
55 Health Canada, Approval of Sativex with Conditions: Fact Sheet (13 April
http://www.hc-sc.gc.ca
56 Faculty of Pain Medicine, Australian and New Zealand College of
Anaesthetics
Statement on “Medicinal Cannabis” with
Reference to its Use in the Management of Patients with Chronic Non-Cancer
Pain’ (2015).
57 Michael Farrell, Rachelle Buchbinder and Wayne Hall. ‘Should Doctors
Prescribe Cannabinoids’ (2014) 348
British Medical Journal
58 Advisory committee (Meeting 1).
59 In deciding to overturn the initial decision to refuse TGA approval to
Nabiximols, the delegate of the minister used similar reasoning
to conclude that
Nabiximols should be allowed to be registered, notwithstanding disputes over its
efficacy: ‘in view of the
limited therapeutic options for treatment of
spasticity in the proposed treatment population and the capacity to sufficiently
the potential risks from Sativex ... the Delegate of the Minister
considers this response rate provides sufficient evidence of efficacy
the registration of
Sativex.’ Therapeutic Goods Administration,
Australian Public
Assessment Report for Nabiximols
(27 September 2013).
Control of pain for cancer and HIV/AIDS patients
3.70 Many submissions called for cannabis to be made available to alleviate
pain associated with cancer and HIV/AIDS.60 Cancer Action
Victoria argued that
cancer should be incorporated on the list of medical conditions for which
medicinal cannabis can be provided
to patients.61
3.71 Between 30 and 50 per cent of cancer patients experience pain, while 70
to 90 per cent of patients with advanced cancer suffer
from pain.62 However, the
causes are complex and the mechanisms differ from those that cause inflammatory
or neuropathic pain. Opioids,
including morphine and oxycodone, are currently
the primary therapy used
to relieve pain in cancer patients, but have many undesirable side effects,
including constipation, sedation, respiratory depression
and tolerance
formation.63
3.72 Cancer Council Victoria observed in its submission that a clinical trial
is underway in Australia to determine the efficacy
of administrating Sativex to
relieve persistent chronic pain in patients with advanced cancer who have not
responded to conventional
medicines.64 It also conducted a survey of Cancer
Council Victoria Clinical Network members, to gain insight into their attitudes
and experiences regarding the current use of medicinal cannabis in cancer care
and the proposed medicinal cannabis scheme. The members
who responded said that
pain management was the most common reason
for patients using cannabis medicinally, followed by nausea, vomiting and
weight loss management associated with their cancer treatment:
Although there is a level of skepticism about the effectiveness of medicinal
cannabis, due to the current gaps in clinical evidence,
many think that it
should be an accepted part
of standard medical care in the treatment of cancer-related symptoms. Some
clinicians would be reluctant to prescribe medicinal cannabis,
even if a scheme
is introduced. Again, this is due in part to evidence gaps not only with regard
to its effectiveness, but with respect
to required dosing and administration
routes. There was strong support for medicinal cannabis to be available to
cancer patients
only ‘when conventional treatments have been tried and
3.73 The Commission was told by the medical advisory committee that although
cannabis would be used relatively rarely in pain management
for terminally ill
patients, it could be helpful for a small subset of such patients. It would be
unlikely to be used as a first-
or second-line treatment. Cannabis was said to
be less effective than drugs administered through new ‘intrathecal’
system (where analgesic drugs are administered through the spinal cord
3.74 As discussed in Chapter 2, there is limited research evidence that
addresses the utility of cannabis to treat pain specifically
caused by cancer.
The Commission does not comment on whether the research conducted on chronic
pain has application to pain caused
by cancer. The Commission notes that Sativex
has conditional approval in Canada as an adjunctive treatment for moderate to
pain in patients with advanced cancer. This approval is said to reflect
the ‘promising nature of the clinical evidence which
must be confirmed
with further studies’.67
60 Submissions 12, 24, 45, 60, 64, 70, 83. Consultations 2, 4.
61 Submission 54.
62 Submission 57.
63 L J Kehl, ‘A Cannabinoid Agonist Differentially Attenuates Deep
Tissue Hyperalgesia in Animal Models of Cancer and Inflammatory
Pain’ (2003) 103
64 Submission 57.
65 Submission 99.
66 Advisory committee (Meeting 1).
67 Health Canada,
Authorization with Conditions of Sativex
(1 August 2007)
http://www.hc-sc.gc.ca
3.75 The research evidence is stronger regarding HIV/AIDS. Approximately 40
per cent of people living with HIV and being treated with
antiretroviral
medications experience the painful condition ‘HIV-associated sensory
neuropathy’.68 There are few treatments
available which are proven to relieve pain caused by this condition. Cannabis
is among the few treatments which have been proven through
randomised controlled
3.76 There are other considerations that are strongly supportive of the
provision of medicinal cannabis to people experiencing pain
associated with
cancer or HIV/AIDS. These conditions have the potential to diminish a
person’s quality of life in a profound
way, as conveyed by the submissions
received by the Commission,70 and cannabis may provide
a treatment option that offers relief from pain at a time when patients are
in need of comfort. In addition, as these conditions are
recommended below as
legitimising access
to cannabis for the treatment of nausea, vomiting and wasting, there seems
little utility in preventing access to it for pain relief
as well. Accordingly,
the Commission’s view is that cannabis in medicinal forms should be
available to patients suffering from
cancer or HIV/ AIDS and experiencing
severe pain.
Relief from nausea, vomiting and wasting
3.77 Nausea and vomiting are common and distressing problems for cancer
Approximately 50 per cent of patients with cancer experience nausea or
vomiting, either as a result of the cancer itself or its treatment.
symptoms have been summarised as follows:
Nausea and vomiting are common problems in cancer patients throughout the
trajectory of their illness. Whether these patients are
receiving high-dose
cisplatin 1 [a chemotherapy drug] with the best available antiemetic therapy or
are experiencing the advanced
stages of cancer, approximately one half will
experience nausea or vomiting, or both. The causes of these distressing symptoms
diverse, and they include medication, radiation therapy, and the effect of
the cancer itself. ... Although therapy that aims
to correct the underlying cause is rational, for many patients, such an
approach is not possible.71
3.78 Both cancer and HIV/AIDS patients can experience wasting as a result of
their disease.
Depending on the type of cancer, 30 to 80 per cent of cancer patients
experience weight loss, which can be as a result of the condition
treatment.72 Severe wasting, known
as cachexia, ‘adversely affects the patients’ ability to fight
against infection and withstand treatment by chemotherapy
and radiotherapy. As
a result of all these negative effects, the body begins to waste away.’73
This is counter-therapeutic
in every sense.
3.79 In its submission to the Commission, Cancer Council Victoria supported
making medicinal cannabis available for nausea and vomiting
where other
treatments have failed, and observed there is evidence supporting its
efficacy.74 Similarly the joint submission by
the National Cancer Council and
the Clinical Oncology Society of Australia to the Senate Legal and
Constitutional Affairs Committee’s
inquiry into the
Regulator of Medicinal
Cannabis Bill
asserted there is evidence that medicinal cannabis could be useful
for this purpose,
and commented that: ‘Managing illness induced by chemotherapy,
especially in patients with advanced cancer who have responded
conventional relief options, is a significant problem for cancer patients and
their doctors.’75
68 Tudor J C Phillips et al, ‘Pharmacological Treatment of Painful
HIV-Associated Sensory Neuropathy: A Systematic Review and
Meta-Analysis of
Randomised Controlled Trials’ (2010) 5(12)
70 See, eg, Submission 64.
71 David Warr, ‘Chemotherapy- and Cancer-Related Nausea and
Vomiting’ (2008) 15
Current Oncology
72 Submission 57; Raghu Dhanapal, T R Saraswathi and Rajkumar N Govind,
‘Cancer Cachexia’ (2011) 15
Journal of Oral and
Maxillofacial
73 Raghu Dhanapal, T R Saraswathi and Rajkumar N Govind, ‘Cancer
Cachexia’ (2011) 15
Journal of Oral and Maxillofacial Pathology
74 Submission 57.
75 Cancer Council Australia and Clinical Oncology Society of Australia,
Submission 37 to the Senate Legal and Constitutional Affairs
Legislation
Committee, Parliament of Australia,
Inquiry into the
Regulator of
Medicinal Cannabis Bill 2014
3.80 In these circumstances, given the evidence for the effectiveness of
medicinal cannabis in enhancing appetite and reducing nausea
and wasting, the
Commission is satisfied that
in appropriate circumstances medicinal cannabis has a therapeutic role to
play for this category of patient.
3.81 The present state of research on the efficacy of cannabinoids
(particularly cannabidiol) as a treatment for epilepsy does not
yet allow firm
conclusions to be drawn. The existing research lacks authoritativeness, and
rigorous studies are only now starting
to get underway, including in Australia, but there is emerging support for
the efficacy of cannabis in relieving the symptoms of
epilepsy, especially for
those with juvenile syndromes.
3.82 The reality pointed out to the Commission in its consultative processes
is that significant numbers of parents faced with epilepsy
syndromes such as
Dravet, Lennox-Gastaut
and genetic forms of epilepsy such as CDKL5 are turning to cannabis in an
attempt to address life-endangering seizures in their children,
which can be
hundreds daily and which may not be responsive to orthodox epilepsy medications.
The Commission heard moving accounts
from parents of children with such
syndromes who maintained that various forms of medicinal cannabis had extremely
positive effects
on the experience of symptoms by their children.
3.83 While the clinical research on this application of cannabis does not
itself provide a compelling basis for action, the other
considerations
affecting this patient group are overwhelming. The feature which sets this
group apart from other conditions where
research is lacking is the scale of the
transformations anecdotally observed for epileptic patients treated with
medicinal cannabis.
It is true that the results seen by families have not been
rigorously assessed, but anecdotally there are numerous children for whom
medicinal cannabis has provided astonishing relief.
3.84 However, because both the risks associated with medicinal
cannabis—particularly for children—and the benefits of
remain uncertain, at this stage treatment should be limited to only the most
gravely ill sufferers of epilepsy, where other
treatments have failed to bring
the patient’s symptoms under control or have caused intolerable side
effects. Thus, in respect
of this category of patients, in part because of the
unknown consequences of administration of medicinal cannabis over what may be
extended period of time to children with developing brains, the Commission is of
the view that
it is proper to require that other forms of treatment have been attempted and
found ineffective before medicinal cannabis is used.
Chronic non-cancer pain
3.85 In 2015 the Faculty of Pain Medicine of the Australian and New Zealand
College of Anaesthetists issued a formal position in relation
to the use of
cannabinoids for patients with chronic non-cancer pain, concluding that:
With the possible exception of pain and spasticity in multiple sclerosis,
there is little evidence for the effectiveness of cannabinoids
non-cancer pain situations, whether or not the pain attracts the descriptor
‘neuropathic’.76
3.86 This statement does not apply to patients who are in palliative
3.87 A number of questions arise about:
• the capacity of medical practitioners to identify categories of
patients within the chronic pain cohort effectively
76 Faculty of Pain Medicine, Australian and New Zealand College of
Anaesthetists, ‘Statement on “Medicinal Cannabis”
Reference to its Use in the Management of Patients with Chronic Non-Cancer
Pain’ (2015).
• the role of patient-self-report of symptoms among sufferers of
chronic pain
• the distinctions between patients who seek medicinal cannabis for a
combination
of psychotropic effects and pain relief, as against those for who seek it
solely for its analgesic qualities
• whether the consequences of long-term provision of such medication
are overall therapeutically advantageous.
3.88 In addition, it is apparent that modest numbers of United States and
Canadian medical practitioners have been prepared to authorise/prescribe
medicinal cannabis to patients with chronic pain,78 this in turn creating
difficult pressures for practitioners and potentially distorting
effects on the
doctor–patient relationship.79 These matters need to be explored further
by carefully constructed studies.
3.89 The Commission considers that, while there are likely to be advantages
for some patients who experience chronic pain from a variety
of conditions in
being treated with medicinal cannabis, as against opiate analgesia,80 further
analysis needs to be undertaken
before medicinal cannabis is made available as
a first line or even an alternative form of treatment for patients who suffer or
claim to suffer chronic symptoms of pain.
3.90 For this reason, the Commission does not propose that chronic pain be a
qualifying condition or symptom on its own, and instead
considers that
additional conditions should be imposed in respect of it. Nor should particular
underlying conditions be specified
in the eligibility criteria.81
3.91 This stance will be controversial but it is a considered position on the
part of the Commission. While it is conceded that a
number of studies have
demonstrated therapeutic potential for medicinal cannabis for neuropathic pain,
this therapeutic option remains
contested within the medical profession.
3.92 Allowing patients suffering from chronic pain to be treated with
medicinal cannabis gives rise to other issues not raised by
the other conditions
• As the ‘chronic’ pain is a long-term phenomenon, there is
the potential for any treatment option to be sustained.
This raises the issue of
risk in a way that is more problematic in light of the limited clinical and
research knowledge than is the
case when the measure is relatively short-term,
such as in treating symptoms of a terminal illness, or in circumstances of acute
clinical need, such as in treating wasting or refractory epileptic
conditions.
• There is the potential for such conditions to be asserted by patients
without medical practitioners being able effectively
to evaluate the clinical
accuracy of what is
asserted. The blurring between asserted medical use of cannabis and
recreational use, as arguably has occurred in jurisdictions such
California,82 should be avoided.
• There is the potential for medical practitioners to be placed under
uncomfortable pressures to authorise medicinal cannabis
in such situations based
upon patients’ unverifiable self-reports of chronic pain. There is a
serious risk that a problematic
number of medical practitioners could decide not
to participate in the scheme. This could undermine its viability.
78 See, eg: Elin Kondrad and Alfred Reid, ‘Colorado Family
Physicians’ Attitudes Toward Medical Marijuana’ (2013)
of the American
Board of Family Medicine
79 Samuel Fair noted that: ‘A formidable concern is that undue
pressure will be placed on doctors to use the treatment experimentally,
patient does not receive a desired response from more conventional treatment.
... The concern is that such pressure may pose
a risk to the doctor/patient
relationship’: Submission 40.
80 As discussed in the issues paper, among the benefits is a reduced
incidence of opioid overdose deaths: Marcus A Bachhuber et al,
Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States,
1999–2010’ (2014) 174
JAMA Internal Medicine
1668; Victorian
Law Reform Commission,
Medicinal Cannabis: Issues Paper
81 The Commission heard, for example, about fibromyalgia, complex regional
pain syndrome and other conditions: Consultations 1, 7.
82 See J Michael Bostwick, ‘Blurred Boundaries: The Therapeutics and
Politics of Medical Marijuana’ (2012) 87
Mayo Clinic Proceedings
3.93 Thus the Commission is of the view that, if medicinal cannabis is to be
provided to alleviate chronic pain, it is appropriate
that two specialists
should be required to arrive at the determination. While this is an extra burden
for a patient who may be desirous
of being treated with medicinal cannabis, the
Commission has determined that for the present this is a reasonable requirement
• the risk of abuse
• the fact that such pharmacotherapy may be long-term, with the ensuing
• the fact that there are a variety of non-pharmacological options for
the management of pain.
3.94 The Commission has concluded, on advice from the medical advisory
committee, that the patient’s chronic pain should not
refractory in the sense of its having failed to respond to other forms of
analgesia. Rather, the decision in respect of
the advisability of medicinal
cannabis as against (or in conjunction with) other treatment options should be
that of the specialists
who are consulted.
3.95 The specialists’ evaluation of the patient’s suitability for
treatment with medicinal cannabis would include the
likelihood that the patient
would respond beneficially, and also whether it is the best form of treatment
for the patient’s
pain. This would be likely to take into account whether
other measures have already been employed but found unsatisfactory—
variety of reasons. It is common for there to be a variety of approaches to
managing pain, and for pharmacotherapy to be only
one of several components in
the attempt to manage a patient’s symptoms. It is the Commission’s
view that medicinal cannabis
should only be made available to patients with
chronic pain (not caused by cancer, HIV/AIDS
or multiple sclerosis) where two specialists conclude that it may in all the
circumstances provide superior pain management by contrast
Other conditions
3.96 As described in Chapter 2, there is a range of other conditions where
claims of efficacy are made or preliminary research exists.
However, there is
not yet a strong evidence base for the efficacy of medicinal cannabis. In
particular, there is insufficient research
at this stage to support allowing
patients with any of the following conditions routine83 access to medicinal
• spinal cord injury
• post-traumatic stress disorder
• schizophrenia
• treatment of cancer (as opposed to its symptoms)
• Tourette syndrome
• inflammatory disorders
• motor-neurone disease (also known as amyotrophic lateral
• Parkinson’s disease
• inflammatory bowel disease (including Crohn’s disease)
• hepatitis C
• sleep disorders
• anxiety and depression.
83 Some patients in these categories may be able to access
medicinal cannabis by reason of their experience of chronic pain.
3.97 In each of these cases, there is research which is promising, and future
studies may produce evidence sufficient to support provision
of medicinal
cannabis to these patients. However, at present, the Commission considers the
government should be cautious about enabling
cannabis to be dispensed to these
categories of patients.
3.98 While the Commission has adopted an approach which is not rigidly
controlled by the outcomes of blinded, placebo-controlled trials,
there is still
a need to ensure that cannabis is supplied to patients on a rational
basis84—that is, where there is a base
level of evidence suggesting that
cannabis is likely to assist. In the case of the conditions listed above, for
some there has been
almost no controlled evidence collected and, for others, no
human studies of any rigour have been performed. To allow access to cannabis
the basis of such limited evidence would lack a reasonable evidence base and
would be speculative.
3.99 It is acknowledged thatthere is a degree of arbitrariness in selecting
particular conditions as against others. Those selected
by the Commission are in
response to clinical scenarios of particular need and distress identified by
written submissions and by
persons whom the Commission has met during its
consultative processes. In addition, each has been selected on the basis of
evidence supporting the efficacy of cannabis, although the evidence is
not at the highest level.. As discussed later in this chapter,
the scheme should
allow for the conditions that are included to be kept under review, and also
provide for case-by-case exceptions.85
Recommendations
3.100 In light of the above discussion, the Commission considers that, at the
outset of a Victorian medicinal cannabis scheme, patients
who have certain
designated conditions and are experiencing serious symptoms from those
conditions should be eligible to be treated
with medicinal cannabis. Whether an
individual patient should receive such treatment would be determined under
procedures that are
discussed later in this chapter.
Recommendation
Eligibility for any Victorian medicinal cannabis scheme should be
based initially on the following conditions and corresponding symptoms:
(a) severe muscle spasms or severe pain resulting from multiple
(b) severe pain arising from cancer, HIV or AIDS
(c) severe nausea, severe vomiting or severe wasting resulting from cancer,
HIV or AIDS (or the treatment thereof)
(d) severe seizures resulting from epileptic conditions where other
treatment options have not proved effective or have generated
side effects that
are intolerable for the patient
(e) severe chronic pain where, in the view of two specialist medical
practitioners, medicinal cannabis may in all the circumstances
provide pain
management that is superior to what can be provided by other options.
84 In part because of international law requirements: see [4.10].
85 Discussed at [3.121] – [3.129].
Other considerations
‘Severe’ symptoms
3.101 The qualifying adjective ‘severe’ is employed in these
recommendations to require a high level of experience of
the relevant symptoms
of a designated category of condition.86
This approach is adopted to communicate clearly that medicinal cannabis,
like other medications such as opioid analgesics, should
only be used when
therapeutically necessary (namely to address a set of symptoms), rather than as
a prophylactic or as a continuing
therapeutic option if symptoms do not require
Medicinal cannabis as a ‘last resort’?
3.102 Some submissions called for medicinal cannabis to be used as a
‘last resort’—that is, after other conventional
have failed.87 A small majority of clinicians surveyed by Cancer Council
Victoria considered that eligibility should be
defined by whether conventional
treatments had been tried and failed.88 Other submissions opposed making
medicinal cannabis a last
resort.89 Some said it should be a matter of personal
choice,90 and that if it works patients should not be required to exhaust
other options before they can use it.91
3.103 Professor David Penington noted that ‘failed’ is not a
neatly defined term, and queried whether a treatment like
morphine, which might
be partially effective but cause a distressing addiction, would be considered to
have ‘failed’.92
Similarly, others drew attention to the many who
suffer from side effects or allergies, and queried whether this would be a
of the treatment.93 Along similar lines, Mullaways Medical
Cannabis Pty Ltd asked, ‘how many years of failed conventional treatments,
with all their side
effects and cost, must a person with exceptional circumstances endure before
they have a right to cannabis treatment?’94
3.104 The Royal Australasian College of Physicians opposed making resistance
to treatment a requirement of eligibility:
It is not appropriate that all reasonable conventional treatments have failed
before a person is eligible to use medicinal cannabis;
this is not a requirement
for antiepileptic drug trials or for potentially curative epilepsy
3.105 The Australian Nursing and Midwifery Federation—Victorian
Branch told the Commission that it opposed restricting medicinal
cannabis to
those people for whom other treatments had failed. It stated:
We are concerned that being required to meet this threshold may cause
unnecessary delay in patients receiving effective treatment
and result in
prolonged and avoidable suffering. Additionally, it is unclear who would
determine the length of time that would be
required to decide that conventional
treatments have failed and what criteria would be used to assess them as having
failed. Alleviation
of pain and the effective relief of adverse effects of
treatment and symptoms of medical conditions should be provided in a timely
and not obstructed by a requirement to exhaust other treatment options.96
86 See the spectrum of terms discussed in
Humphries v Poljak
[1992] VicRp 58
, 134: ‘slight’, ‘mild’, ‘moderate’,
‘significant’, ‘marked’, ‘serious’,
87 Submissions 1, 5, 20, 31, 42, 49, 48, 50, 61; Consultation 8.
88 Submission 99.
89 Submissions 12, 22, 29, 54 and 75, Consultation 1.
90 Submissions 18, 35, 18, 74.
91 Submission 12; Consultation 26.
92 Submission 24.
93 Submissions 2, 43.
94 Submission 29.
95 Submission 52.
96 Submission 74.
3.106 The Commission acknowledges that, given the unproven, novel character
of medicinal cannabis, it would be more appropriately
used after proven,
conventional treatments have been trialled. It would be very rare, for instance,
for it to be an analgesic of
first resort,
and even rarer for it to be a therapeutic option on its own for the relief of
chronic pain. In respect of other conditions, too, it
is to be expected that
other therapeutic options would first be tried for a patient.
3.107 However, the Commission does not recommend a rigid or statutory
prerequisite of intractability or refractoriness of the condition
to other forms
of medication or medical intervention. The weighing of management options and
combinations of treatment should be
a matter for decision between a patient and
their medical practitioner, as would ordinarily be the case. In addition, the
is concerned not to raise the bar too high for patients to be able
to gain access to medicinal cannabis. This is justified by the
fact that the
known risks of medicinal cannabis are only moderate and, for the most part,
should be able to be addressed by attentive
monitoring and responsiveness by the
patient’s treating doctor.
3.108 There are two partial exceptions to this. For the reasons set out
above, the Commission considers that medicinal cannabis should
only be able to
be authorised for the treatment of epilepsy where other treatment options have
not proved effective or have generated
side effects that are intolerable for the
patient. In respect of chronic pain, there should
be a requirement that specialists conclude that medicinal cannabis may in all
the circumstances provide pain management that is superior
to what can be
provided by other options.
Terminal illnesses
3.109 The Commission considered whether to provide a standalone category
for the terminally ill to qualify for medicinal cannabis.
The Royal Australasian
College of Physicians stated in its submission:
In the case of terminally ill patients, the use of medicinal cannabis (if the
patient wishes
to trial its use) most likely holds limited potential for damage and can
always be ceased if there is no useful response. The [Royal
Australasian College
of Physicians] acknowledges there are many anecdotes where the use of
cannabinoids have greatly benefited terminal
patients without the associated
side effects that opioid use cause.97
3.110 In some jurisdictions in the United States (such as the District of
Columbia, Maryland, Montana, New Jersey and New Mexico)
a patient can become
eligible for medicinal cannabis solely because their condition is terminal or
they are receiving palliative
Such a test has also been mooted in the Australian Capital Territory99 and
previously existed in Canada.100 Incorporating such a test
into a Victorian
scheme would mean that the terminally ill could qualify for medicinal cannabis
whether or not they were otherwise
eligible by virtue of their condition and
97 Submission 52.
98 DC Code § 7-1671.01; Md Code §§ 13-3307(c) & 13-3301;
Mont Code Ann § 50-46-302(2); NJ Stat § 24:6I-3
& 24:6I-5; NM
99 Exposure Draft of Drugs of Dependence (Cannabis Use for Medical Purposes)
Amendment Bill 2014 (ACT) cl 7.
Medical Marihuana Access Regulations
(Can) (SOR 2001/227) s 1(1)
(definition of ‘category 1 symptom’).
3.111 The Commission’s advisory committees and people who attended a
consultation in Shepparton opposed this approach as unnecessary.101
Participants felt that the terminally ill would largely be captured by the
proposed condition- and symptom-based criteria
in any event, and that it would be counterproductive to provide medicinal
cannabis to patients if it was unlikely to assist them.102
AMA Victoria observed
that disregarding potential risks and side effects ‘solely based on the
patients’ end of life status,
diminishes the value of the lives of the
terminally ill.’103
3.112 The Commission agrees that separate eligibility criteria for patients
who suffer from terminal conditions would be undesirable.
As for all other
patients, there should be
some prospect that cannabis can assist the patient’s specific symptoms,
which is ensured by the condition- and symptom-based
test recommended above. Any
alteration in the assessment of risk to respond to the position of a terminally
ill person (for example,
a diminished regard to long-term risks) would be taken into account in the
medical practitioner’s clinical judgment.
The need for caution
3.113 There are significant pragmatic advantages to taking a gradual,
step-by-step approach to the introduction of medicinal cannabis
in Victoria,
given the current limited reliable research base for its introduction as a
lawful therapeutic option. The limitations
in the current research literature
are discussed in Chapter 2.
3.114 Most importantly, such an approach would allow for prompt intervention
those whose suffering is particularly severe. It also recognises that what is
proposed is a significant social change—the removal
of a drug from
illegal status and its absorption in certain circumstances into the orthodox
pharmacopoeia.
3.115 It would also allow a change in culture to start in respect of the
recognition and use of medicinal cannabis as a therapeutic
option, starting
with a limited number of conditions. This is the approach most likely to
engender confidence among medical practitioners,
an issue which experience in
of a medicinal cannabis
scheme.104 It keeps to a minimum the range of
circumstances in which there is encroachment upon the paradigm of evidence-based
and thus preserves the standard of medicine based on high-level
evidence in the form of double-blind, placebo-controlled trials as
the principal
determinant for the provision of treatment by contemporary medicine.
3.116 It would also allow for Victoria’s medicinal cannabis scheme to
take advantage of
fast-evolving global research into the efficacy and risks of medicinal
cannabis, prior to extending it to a broader set of conditions.
3.117 More generally, it would allow for review of the medicinal cannabis
scheme (recommended below after four years) to assess its
success in all
respects, including in relation to its effectiveness in alleviating suffering
for the conditions initially designated.
3.118 Inevitably, this means that some people who want to obtain lawful
access to medicinal cannabis will not be able to do so, at
least for a time,
but, on balance, the Commission considers that this is the best option to make
the proposed scheme viable and to
command community and professional confidence
from the start.
3.119 In addition, it allows for development of the scheme in a way that
protects against actual or potential abuses. The Commission
has noted the
profile of medicinal cannabis patients in jurisdictions where people who claim
to suffer chronic pain can obtain access
to medicinal cannabis. The statistical
profiles of users suggest that these schemes may be
101 Advisory committee (Meeting 3), Consultation 26.
102 Consultation 26.
103 Submission 38.
104 See generally Ian Freckelton, ‘Medicinal Cannabis Law Reform:
Lessons from Canadian Litigation’ (2015) 22
Journal of Law and
serving more than the patient cohort with the greatest degree of
suffering.105 It is clear that a disproportionate number of consumers
medical cannabis in the United States seek the medication for relief of chronic
pain, as well as for relaxation, in respect of
which other options have not
proved palatable or effective. This is not necessarily clinically inappropriate
but it does create a
real potential for abuse of a scheme and for medical
practitioners to be placed under difficult pressures to enable access to
cannabis when their ability to evaluate need objectively is
3.120 The opportunity exists for Victoria to introduce a scheme which
minimises the potential for abuse that could bring it into disrepute
and imperil
its viability by making medical practitioners reluctant to authorise access to
medicinal cannabis. This opportunity should
be realised by a conservative
introduction of conditions and criteria enabling patient access to medicinal
Incorporating flexibility
Allowing for exceptional cases
3.121 The Commission was told, both in written submissions and at its
consultations, of patients with rare conditions who believe
they have received
therapeutic benefit from medicinal cannabis or think they might do so.106 A
number of submissions supported the
a mechanism for allowing people who would not otherwise be eligible to be
treated with medicinal cannabis under the scheme to be treated
with medicinal
cannabis.107 However, there was limited support for such a provision in the
Commission’s medical advisory committee.108
3.122 Some submissions said that this should only occur in the context of a
clinical trial.109
Others supported a provision under which access by people in exceptional
cases could occur if a second practitioner endorsed the use.110
3.123 The Commission is satisfied that it would be humane and reasonable to
provide for a mechanism for a person outside the designated
categories to
request access to medicinal cannabis in exceptional circumstances. Applications
would need to be supported by a specialist
medical practitioner.
105 In Rhode Island, for instance, a 2015 review identified that the most
common reason for receiving medicinal cannabis was chronic
pain management: N
Zaller et al, ‘Profiles of Medicinal Cannabis Patients Attending
Compassion Centers in Rhode Island’
Journal of Psychoactive
18. This study is consistent with a study of 1,655 patients seen in
medical marijuana specialty practices in California, where Proposition
permitted cannabis for cancer, anorexia, AIDS, chronic pain, spasticity,
glaucoma, arthritis, migraine or ‘any other
illness for which marijuana
provides relief’ since 1996. 73% of applicants seeking a recommendation
were male and half of the
applicants were under 35. 82.6% of applicants reported
using medical marijuana for pain relief, 70.6% for improved sleep, and 55.6%
relaxation. Physicians’ diagnoses were consistent with high levels of
diagnosis of low back pain, muscle spasm, arthritis
and lumbar degenerative disc
disease in applicants for medicinal cannabis entitlement: Helen Nurnberg, Beau
Kilmer, Rosalie Licardo
and James Burgdorf, ‘An Analysis of Applicants
Presenting to a Medical Marijuana Specialty Practice in California’ (2011)
Journal of Drug Policy Analysis
1. Similarly, the 2014 annual report
filed under the
Arizona Medical Marijuana Act
found that approximately
70% of those who received medical marijuana authorisations were male and
‘severe and chronic pain’
was either the sole debilitating condition
among the debilitating conditions (19.2%) reported by those who were
authorised, while conditions such as those with cancer (2.7%)
and seizures
(1.0%) did not figure prominently: Arizona Department of Health Services,
Arizona Medical Marijuana Act (AMMA) End of Year Report
http://www.azdhs.gov
. In Colorado, where
patients have been able to receive medical marijuana since 2000, 93.1% of
patients report the qualifying
condition ‘severe pain’. The next
most common conditions were muscle spasms (17.5%) and severe nausea (10.8%),
by cancer (3.6%) and seizures (2.3%): Colorado Department of Public
Health & Environment,
Medical Marijuana Registry Program Statistics
(30 June 2015) <https://
www.colorado.gov
106 Submissions 43, 68.
107 Submissions 3, 4, 6, 11, 13, 18, 24, 29, 32, 45, 48, 61, 63.
108 Advisory committee (Meeting 1).
109 Submissions 7, 52.
110 Submissions 7, 20, 32, 48.
3.124 These matters could be considered by a committee, comprising medical
experts who could advise on the appropriateness of cannabis
for the particular
condition. Such decision making would be analogous to the decisions made by the
TGA in the context of the Special
Access Scheme.111 The committee would
undertake a similar inquiry to that undertaken by a Drug and Therapeutics
Committee in determining
whether to approve use of an unapproved drug,112 but
determine whether to permit use by particular patients on a case-by-case
Recommendation
The Secretary of the Department of Health and Human Services, or a
committee constituted by the Secretary under delegation, should
be given power
to permit patients on a case-by-case basis to be treated with medicinal cannabis
in exceptional circumstances that
do not otherwise fall within the eligibility
criteria of the scheme.
Flexibility for ongoing determination of eligibility
3.125 Ongoing clinical trials and research are likely to change the
evidentiary landscape significantly with respect to both the efficacy
of medicinal cannabis. Within even five years there will be much better
knowledge that could affect the evolution of the
kind of medicinal cannabis
scheme that is being recommended by the Commission.
3.126 It follows that a fundamental attribute of the proposed scheme should
be flexibility to adapt to such developments in clinical
knowledge. In
particular, should evidence emerge regarding the conditions for which medicinal
cannabis is likely to be effective,
the eligibility criteria may need to be
amended by the addition or removal of conditions or symptoms. This would mean
amending the
regulations that set out the criteria.
3.127 The Commission considers that an advisory body should be constituted to
advise the Minister for Health about the operation of
the scheme and, in
particular, the ongoing suitability and effect of the eligibility criteria,
including whether they need to be
amended. It should have independence from the
Minister for Health. This is important to maintain the confidence of the public
the medical profession by demonstrating that decisions which affect the
scope and features of the scheme are informed by health practitioners
with professional expertise in the efficacy of medicinal cannabis.
3.128 An advisory committee could be established in either of two ways:
• As a consultative council, by executive order of the minister using
existing powers.113
No new legislation would be required. Under this option, the matters and
functions of the council would be determined by the minister
and specified in an
• As a statutory body, akin to the advisory committees that advise the
Secretary of the Commonwealth Department of Health on
the scheduling of
medicines and chemicals. The Secretary is obliged to have regard to any
recommendations or advice of these advisory
committees when exercising relevant
scheduling powers.114 Regulations set out how the committees are constituted and
how meetings
are to be conducted..115
111 A scheme under which applications may be made to import or supply an
unapproved therapeutic good. See Therapeutic Goods
Administration,
Access to Unapproved Therapeutic Goods via the Special
Access Scheme
112 See New South Wales Health,
Role of Drug and Therapeutics Committee in
the Evaluation and Approval of Medicines for Use in Public
(Policy Directive No PD2008_037).
113 Contained in
Public Health and Wellbeing Act 2008
Therapeutic Goods Act 1989
Therapeutic Goods Regulations 1990
Divs 3A and 3B.
3.129 The initiative to amend the eligibility criteria of the scheme, through
regulation, should rest with the Minister for Health
on the advice of the
advisory body.
Recommendation
The Minister for Health should constitute an independent medical
advisory committee on medicinal cannabis to provide ongoing advice
conditions and corresponding symptoms on which eligibility to be treated with
medicinal cannabis is based. Such advice
should include reference to:
(a) the responsiveness by patients to medicinal cannabis provided under
the scheme and any side effects experienced by them
(b) the state of the clinical literature in relation to the efficacy or
potential efficacy of medicinal cannabis for particular medical
conditions and
(c) the state of the clinical literature in relation to the risks or
potential risks posed by medicinal cannabis for patients with
particular medical
(d) the seriousness of the medical conditions, including patients’
prognoses and the extent of the disability caused by their
(e) the extent to which symptoms of the conditions interfere with
ability to derive enjoyment and fulfilment in their lives
(f) the extent to which medicinal cannabis can reasonably be anticipated to
improve patients’ quality of life
(g) the availability of standard treatments that may assist, how effective
they are, and what side effects they cause.
Authorisation of treatment
Overview of proposed procedure
3.130 A decision that an individual patient is treated with medicinal
cannabis is a medical one.
While the recommended eligibility criteria would establish at law who may
participate in the scheme, the question of whether medicinal
cannabis is an
appropriate form of treatment for each eligible patient needs to be determined
by a medical practitioner. Further,
in line with the recommended regulatory
objectives, the use of medicinal cannabis should be under medical
supervision.
3.131 Thus, the regulatory framework for any Victorian medicinal cannabis
scheme needs to enable medical practitioners to authorise
the medicinal cannabis
products to be dispensed to those of their patients who meet the eligibility
criteria and for whom it is appropriate
in all the circumstances that they
receive this form of treatment.
3.132 It was proposed to the Commission that the opioid replacement therapy
program and procedures for providing access to Schedule
8 medicines provide
useful models on which to base the regulatory framework for dispensing medicinal
cannabis.116 These mechanisms
are an established means of allowing certain
categories of patients to have access to strictly controlled medicines.
116 Advisory committee (Meeting 2); Submission 8; Consultations 2,
3.133 There is merit in building on existing practices while accommodating
the different objectives and risks in providing access
to medicinal cannabis.
The remainder of this chapter sets out a procedure for authorising the supply of
medicinal cannabis to patients,
under medical supervision. In summary, it
comprises the following features:
• A medical practitioner who specialises in the medical condition on
which their patient’s eligibility is based applies
to the Department of
Health and Human Services for a permit to issue an Authority to Dispense
Medicinal Cannabis.
• The application for the permit conveys the specialist medical
practitioner’s opinion that the patient is eligible to
participate in the
scheme and it is appropriate in all the circumstances that they be treated with
medicinal cannabis. It would also
certify that the patient has been informed
that the product has not been approved by the TGA, the approved alternatives,
risks, potential benefits and side effects.
• On obtaining the permit, the specialist medical practitioner issues
an Authority to Dispense Medicinal Cannabis which, like
a prescription,
authorises a pharmacist to dispense the medicinal cannabis. The pharmacist is
identified on the permit and on the
Authority to Dispense.
Residence requirement
3.134 The Commission considers that only patients ordinarily resident in
Victoria should be able to obtain medicinal cannabis under
any Victorian
scheme.117 If residents of other states or territories were eligible to access
medicinal cannabis, they would be exposed
to prosecution under their local laws
if they took it back to their home jurisdiction, and the Victorian community
would bear the
additional costs of supporting a much larger patient
population.118 The Law Institute of Victoria highlighted this as an issue:
Access to the regulated scheme in Victoria should be restricted to permanent
Victorian residents and the drug may only be used when
within Victorian borders.
This would prevent issues with medical ‘tourism’ and the conflict
with criminal sanctions in
other jurisdictions.119
3.135 Because the Victorian scheme would be departing from the national
therapeutic goods framework, it would not be lawful to possess
cannabis products sold in Victoria in other states and territories of Australia
unless reciprocal laws were passed. In
addition, pharmacies outside Victoria
would be unable to supply the product specified.120
3.136 It would be undesirable for non-residents to travel to Victoria, obtain
medicinal cannabis, then return to a part of Australia
where the product is
unlawful and cannot be purchased as they would therefore be unlikely to receive
medical supervision. In some
circumstances they would be liable to be prosecuted
for use and possession of the drug. For similar reasons, patients who are
to obtain medicinal cannabis in Victoria should be warned not to take
the product interstate or overseas.
Recommendation
Any medicinal cannabis scheme in Victoria should be applicable
only to persons who ordinarily reside in Victoria.
Firearms Act 1996
Relationships Act 2008
Legal Aid Act 1978
(5). The Department of
Health and Human
Services would determine what supporting evidence for a person’s
residency should be required.
118 The Royal Australasian College of Physicians made this observation in
Submission 52.
119 Submission 63.
120 Submission 52.
Which practitioners?
3.137 Registered health practitioners in Australia have diverse areas of
expertise, ranging across the many facets of healthcare.121
Several categories
of health practitioners have the capacity to prescribe medicines,122 and many
have a range of sub-specialities.123
3.138 In the issues paper, the Commission sought feedback on who should have
the authority to assess whether a patient is an appropriate
candidate to be
treated with medicinal cannabis.124
Health practitioners other than medical practitioners
3.139 Several submissions endorsed the involvement of registered health
practitioners other than medical practitioners.125 The Cannabis
Policy Project
recommended that a broad range of practitioners be considered, arguing that the
inclusion of nurse practitioners in
the Canadian scheme ‘speaks to a
continuing problem of accessibility to the program whilst doctors are the only
gatekeepers’.126
3.140 Cannabis Science Australia Ltd suggested that non-medically trained
practitioners could effectively authorise treatment, under
supervision.127
Other submissions endorsed including health practitioners with prescribing
entitlements.128
3.141 Some submissions called for naturopaths to be involved.129 Naturopaths
are not legally registered health professionals in Victoria130
and have no
prescribing entitlements. In this regard, Victoria Police submitted that:
It would be inappropriate for practitioners, such as alternative therapists
who are not authorised to prescribe scheduled medicines,
to be authorised to
prescribe medicinal cannabis.131
3.142 The majority of submissions and other comments made to the Commission
on this issue recommended that only medical practitioners,
or a subset thereof,
be able to authorise treatment with medicinal cannabis.132 It was submitted
that involving other types of health
practitioners would be too broad.133 In
endorsing this approach, Cheryl Wright stated:
It should not be made difficult or impossible for patients to access medical
cannabis, but it also needs to be monitored by practitioners
who know what
they’re doing.134
3.143 The Commission agrees. Only registered medical practitioners should be
able to authorise access to medicinal cannabis. Given
that eligibility would be
confined to people with severe conditions and symptoms, the ability to authorise
should be confined to
medical practitioners.135
121 Including Chinese medicine practitioners, dentists, medical
practitioners, nurses, occupational therapists, optometrists, osteopaths,
pharmacists, physiotherapists, podiatrists and psychologists: see
Practitioner Regulation National Law
, s 4 (definition of ‘health
profession’).
122 Namely, medical practitioners, nurse practitioners, dentists,
optometrists and certain podiatrists:
Drugs, Poisons and Controlled
Regulations 2006
(Vic) rr 8, 9, 10, 11 and 11A.
123 For example, medical practitioners can be registered as general
practitioners or specialists: Medical Board of Australia,
Registration
(25 August 2014)
http://www.medicalboard.gov.au
Nurses can seek endorsements on their registration enabling them to perform a
greater range of functions: Nursing and Midwifery
Board of Australia,
Registration & Endorsement
(31 July 2015)
http://www. nursingmidwiferyboard.gov.au
124 Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [7.53] – [7.57].
125 Submissions 4, 11, 14, 16, 37.
126 Submission 37.
127 Submission 69.
128 Submissions 47, 48, 75. For example, nurse practitioners
in Victoria are able to prescribe certain medicines (not
including any substance
listed in Schedules 8 or 9):
Drugs, Poisons and Controlled Substances Act
s 13(1)(ba)
and Minister for Health, ‘Approval under
Section 14A
’ in Victoria,
Victoria Government Gazette
, No G 39, 25
September 2014.
129 Submission 4, Consultation 4, 7.
130 Naturopaths are generally registered with a private professional
association (for example, the Australian Naturopathic Practitioners
Association
Inc) but are not subject to any government registration: Better Health Channel,
Naturopathy
(January 2015)
http://www. betterhealth.vic.gov.au /bhcv2/bhcarticles.nsf/pages / Naturopathy?open
131 Submission 44.
132 Advisory committee (Meetings 1, 3); Submissions 1, 2, 3, 5, 6, 7, 18, 19,
20, 23, 24, 28, 29, 31, 32, 38, 39, 42, 44, 45, 49,
52, 54, 60, 61,
64, 67, 72, 74.
133 Submission 23.
134 Submission 2.
135 Nurses and nurse practitioners should, however, be authorised to possess
and administer medicinal cannabis products when authorised
a medical practitioner.
Which medical practitioners?
3.144 The Commission heard from many sources that only specialist medical
practitioners136 should be able to authorise access to medicinal
cannabis.137
Others opposed confining authorisation powers to specialists.138 The debate
primarily came down to a question of access
against control and expertise.
3.145 The question of access raises issues such as cost, waiting times and
the need to travel to a metropolitan centre. Few specialists
routinely travel to
regional centres, meaning that significant time and expense can be associated
with arranging to see one.139 Jeni
Martin submitted that confining authorisation
powers to specialists would ‘impact heavily on invalid pensioners and
in rural and remote areas’.140
3.146 On the other hand, it was observed that ‘telemedicine’ has
made it easier for people in the regions to access specialists.141
Medical Cannabis Pty Ltd stated that, even though specialists are seen
infrequently, most people in exceptional circumstances
‘have a team of
doctors overseeing their treatment’.142
3.147 Some on the Commission’s medical advisory committee raised
concern about the pressure that could be placed on general
practitioners by
their patients.143 Equally, it was submitted that permitting only specialists
to authorise would create a bottleneck,
leading to long waiting lists.144
3.148 The need for expertise in treating the patient’s condition
suggests that it should be specialists who can authorise access.
Australasian College of Physicians recommended that only specialist medical
practitioners in relation to the condition
that cannabis is intended to treat145
should be able to authorise access. For example, paediatric neurologists would
authorise for
paediatric epilepsy, while adult neurologists would authorise for
multiple sclerosis:
This restriction is proposed because... there is a long list of proposed
conditions for which medicinal cannabis has been suggested.
This would avoid a
sudden influx of prescriptions that may be otherwise inappropriate and prior to
other treatment options being
3.149 Professor David Penington, on the other hand, drew attention to
palliative care, where services are increasingly being offered
at the primary
care level, with more patients seeking to die at home. In these circumstances,
he submitted, it would be appropriate
for general practitioners to be able to
authorise access.146
Commission’s conclusion
3.150 The Commission considers that access to cannabis should be able to be
authorised only by specialist medical practitioners.147
It acknowledges that
this significantly limits access, particularly in regional areas, but considers
that this compromise is necessary
to ensure expertise, especially in the early
phases of the scheme.
136 Namely, medical practitioners registered under the
Health Practitioner Regulation National Law
in a specialty approved by
the Australian Health Workforce Ministerial Council under s 13 that Law: see
Health Practitioner Regulation National Law
, s 4 (definitions of
‘specialist’ and ‘recognised specialty’). A current list
of the approved specialties
is available on the Medical Board of Australia
http://www.medicalboard.gov.au
137 Advisory committee (Meeting 1); Submissions 31, 32, 42, 60.
138 Submission 7.
139 Consultations 23, 24.
140 Submission 7. Submission 49 agreed with this concern as it relates to
remote patients.
141 Consultation 8.
142 Submission 29.
143 Advisory committee (Meeting 1).
144 Advisory committee (Meeting 1).
145 Analogously to high-cost cancer drugs, which may only be
prescribed by oncologists. Commonwealth Department of
Human Services, Education
Guide—Efficient Funding of Chemotherapy, 11 March 2015
http://www.humanservices.gov.au
146 Submission 24.
Poisons Regulations 1965
(WA) rr 38C–38P. These
provisions state that, in Western Australia, certain named substances (eg
thalidomide)
shall not be prescribed except by certain specialists (eg a physician or a
dermatologist). Substances like these are restricted using
‘warrant’ system in Victoria:
Poisons and Controlled Substances Regulations 2006
(Vic) pt 2 div 9
3.151 The experience of other jurisdictions has shown the dangers of making
the power to authorise too wide. In Arizona, the ‘vast
majority’ of
patient certifications have come from naturopaths, even though there are ten
times as many medical doctors in
the state. Arizona’s Director of Health
Services reportedly said that ‘not all naturopaths are writing
certifications, but a handful of them are clearly in the certification
business’.148 In Colorado as at 2012, more than two
per cent of the
state’s population had received a medicinal cannabis recommendation and 49
per cent of medicinal cannabis recommendations
had been issued by only 15
medical practitioners.149
3.152 One of the recommended regulatory objectives of any Victorian medicinal
cannabis scheme is to ‘integrate the use of medicinal
cannabis products
into the patient’s medical treatment’,150 which requires that the
use is under medical supervision.
At the outset of the scheme, it is important
that focus is directed to developing and sharing knowledge about the effects of
with medicinal cannabis for patients with the medical conditions
covered by the scheme. As specialists are better placed to review
evidence and
conduct research in their area of speciality, it would be more appropriate to
place this responsibility with them. The
Commission also notes concerns about
the extent to which authorisation decisions could be influenced by the
ideological views of
the practitioner, and this would be easier to identify and
contain where a smaller number of practitioners are involved.
Which specialists?
3.153 Some medicinal cannabis schemes in other jurisdictions require a
practitioner who authorises access to have a pre-existing relationship
patient. AMA Victoria opposed this approach, noting that ‘it is becoming
increasingly uncommon for a person to have
a long-standing physician-patient
relationship with a specific medical practitioner’.151
3.154 Another submission, from an individual, also opposed requiring a
pre-existing relationship:
I currently must wait anywhere between 2–3 months to access my treating
specialists. If an established relationship with such
a physician is required
(as is required in some overseas jurisdictions) before access is granted to a
patient, it could realistically
take patients like myself, 12 months or more,
before they were able to have access to medicinal cannabis. 152
3.155 The Commission agrees and does not propose that the authorising
specialist be required to have an existing relationship
with the patient,
although it notes that in many instances the authorising specialist will be the
patient’s treating specialist
practitioner.
148 Owen Dyer, ‘The Growth of Medical Marijuana’ (2013)
British Medical Journal
149 Elin Kondrad and Alfred Reid, ‘Colorado Family Physicians’
Attitudes Toward Medical Marijuana’ (2013) 26
Journal of the American
Family Medicine
150 See [1.33] – [1.40].
151 Submission 38.
152 Submission 43.
3.156 The precise categories of specialists would require consultation
between government and medical professionals. However,
the Commission notes that
the following categories may be appropriate:
Specialist categories
Specialist medical oncologists Specialist radiation oncologists Specialist
palliative medicine physicians Specialist haematology
physicians Specialist
paediatric haematologists
Specialist paediatric medical oncologists
Specialist gynaecologists
Specialist infectious diseases physicians
Specialist pain medicine physicians
Multiple sclerosis
Specialist neurologists
Specialist paediatric neurologists
Specialist rehabilitation physicians
Specialist neurologists
Specialist paediatric neurologists
Specialist pain medicine physicians
Involving general practitioners
3.157 Monitoring a patient’s use of medicinal cannabis is essential to
ensure that their treatment is safe and medically appropriate,
and in particular
that dosages are correct and that adverse effects (including, potentially, the
development of dependence or the
experience of side effects) are monitored and
suitably addressed. In the Commission’s view, return visits to a medical
practitioner
should be required at regular intervals—say, three
monthly—to ensure continuing monitoring and care.
3.158 The Commission has noted that permitting only specialists to authorise
treatment with medicinal cannabis would limit the accessibility
of the scheme.
The access considerations raised earlier apply to an even greater degree for
this aspect of the scheme, such that
making the specialist responsible for
monitoring would compound the accessibility issues further. Therefore, the
Commission considers
that this supervisory role should be the principal
responsibility of general practitioners; of course, it would generally be shared
with the treating specialist practitioner.
3.159 To address this, some of those consulted by the Commission proposed
that treatment
with medicinal cannabis could be authorised at first by a specialist and then
be supervised by a general practitioner.153 The general
practitioner would
supervise the patient’s use
and response, but would be unable to authorise access. It was suggested that
general practitioners would not need cannabis training,
and that they could
obtain sufficient guidance from the authorising specialist.154
3.160 The Commission endorses this approach as one which strikes an
appropriate balance between access and expertise. It is suggested
that a person
could be authorised by their specialist for a set period (say, 12 months), with
continuing access contingent on their
returning at set intervals (say, every
three months) to a nominated general practitioner. The implementation of this
aspect of the
scheme should be careful to avoid a situation
in which practitioners mechanically continue treatment without considering
the patient’s response.
3.161 At the conclusion of the period of authorisation, it would be standard
(and necessary) practice for the general practitioner
to report back to the
authorising specialist regarding patient outcomes, adverse effects, dosage
control and similar. The Commission
considers that this need not be the subject
of a specific recommendation.
3.162 General practitioners who are to be involved in the monitoring of a
patient’s use of medicinal cannabis would need to
obtain satisfactory
knowledge with respect to medicinal cannabis, as they would with respect to any
new drug which they prescribe
or whose effects they need to monitor.
Recommendation
Specialist medical practitioners should determine which eligible
patients should receive treatment with medicinal cannabis, while
practitioners should have principal responsibility for monitoring the efficacy
and side effects of the treatment.
Practitioner’s role
Authorisation models
3.163 A number of models for the type of authorisation system Victoria should
adopt were proposed to the Commission and identified
in the systems that exist
overseas. The two most common models about which submissions were received were
the certification and prescription
3.164 Under a ‘certification’ model,155 a medical practitioner
has no role other than to certify that a patient has at
least one of the
eligible conditions and/or symptoms. No product
or dose is specified by the practitioner and, accordingly, patients may
purchase whatever they wish, subject to any statutory purchase
Importantly, the certification decision does not require the practitioner to
make an assessment of whether cannabis would
be appropriate for the particular
patient, including by considering the benefits and risks for them; rather, their
role is merely
to confirm the patient’s diagnosis.
153 Advisory committee (Meeting 1); Submission 20.
154 Advisory committee (Meeting 1).
155 This is the model used in all United States jurisdictions where retail
sales of medicinal cannabis are permitted, primarily because
practitioners there are forbidden to prescribe cannabis, but permitted by their
constitutional right to free speech to ‘recommend’
cannabis to
patients: Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [6.103]. The previous Canadian model also used
such a system:
Marihuana Medical Access Regulations
SOR /2001-227, s 6
3.165 A ‘prescription’ model,156 by contrast, involves a medical
practitioner prescribing a particular form of cannabis,
as they would for any
other medicine. The practitioner specifies the product, dosage and frequency of
administration, in the form
of a ‘written direction... to a pharmacist for
preparing and dispensing a drug’.157 Practitioners are required to make
an assessment of whether cannabis would be beneficial for the patient, having
regard to its risks and benefits, and can decline to
prescribe if they feel
medicinal cannabis would be inappropriate.
3.166 The chief differences between these approaches are the depth of
assessment of the patient’s circumstances made by the
practitioner, and whether the practitioner is asked to specify the product the
patient should receive.
3.167 Many submissions suggested there would be difficulties implementing the
‘prescription’ model without an approved
product standardised in the
usual way.158 One member of the Commission’s medical advisory committee
stated that, on the basis
of the evidence currently available, they would not
prescribe it.159 The Royal Australasian College of Physicians made this point
It is unacceptable for a doctor to be asked to authorise a patient’s
use of or prescribe a substance of unknown composition
and uncertain clinical
effects.160
3.168 Professor David Penington also thought that adopting the prescription
model presented difficulties:
Use of a herbal product without the usual rigorous trials with testing of
outcomes, dose and side effects would be unlikely to be
acceptable to medical
practitioners for
‘prescription’.161
3.169 A number of other submissions advanced a certification model as their
preferred option.162 That is, they proposed that the
practitioner’s role
be limited to confirming
the patient’s diagnosis, and not extend any further.163 The Royal
Australasian College of
Physicians was among those seeking a ‘certification’ model:
In the absence of a reliable supply of cannabis products of known and
certified composition, the doctor’s responsibilities must
be confined to
certification of a person’s eligibility ... and the monitoring of drug
interactions and adverse effects.164
3.170 Consistently with his reservations regarding prescriptions, Professor
Penington also suggested that certification would be a
more appropriate role for
medical practitioners:
Fears over medico-legal hazards in prescribing a herbal remedy can be
overcome if effective regulation of the products is established,
and the role of
the medical practitioner is that of certifying, with the patient’s
agreement, the nature of the patient’s
clinical condition, in relation to
those uses approved by legislation. The legislation could require this as a
condition to register
as a medicinal cannabis user. The relationship between
doctor and patient would not be disturbed with the doctor free to give advice
any stage.165
3.171 Shirley Humphris echoed these views:
A doctor maybe would not exactly prescribe cannabis in the usual way (doctors
may fear potential litigation for ‘prescribing’
an untested product
with unknown dosage) but rather certify the illness or symptoms. It would then
be legal to have the discussion
156 This is the model used in the Netherlands: Victorian Law Reform
Commission,
Medicinal Cannabis: Issues Paper
(2015) [6.101].
Oxford Concise Medical Dictionary
(9th ed, 2015) 612 (definition
of ‘prescription’).
158 Submissions 24, 49.
159 Advisory committee (Meeting 3).
160 Submission 52.
161 Submission 24.
162 Submissions 10, 24, 29, 30, 35, 37, 72.
163 Heather Marie Gladman stated in Submission 10, for example, that the
practitioner’s role should be limited to ‘[t]he
ability to sign a
form saying this person can use medicinal cannabis. That’s it.’
164 Submission 52.
165 Submission 24.
with the doctor re risks and benefits without fear of being informed on.
Importantly the doctor would be able to run tests to monitor
the effect cannabis
may be having on existing meds (it is known ... the concentration of some
epilepsy meds are affected by cannabis).166
3.172 A number of other submissions advocated for the prescription model,
supporting the maintenance of discretion for medical practitioners.167
Martin stated, ‘[w]e need to trust that our medical professionals are
generally conservative & unlikely to prescribe
or recommend medicinal
cannabis without adequate reasons.’168
The preferred authorisation model
3.173 The system of authorisation should be acceptable to the medical
profession. The effective participation of medical practitioners
is a key to the
success of any medicinal cannabis scheme.169 The fact that medical
practitioners were not comfortable with their
as gate-keepers in Canada has led to a number of the problems in
consolidating the operation of the scheme in that country.170
3.174 The Commission acknowledges that there are significant difficulties
associated with asking medical practitioners to ‘prescribe’
medicinal cannabis. If Victoria were to make available medicinal cannabis
products that are quality-controlled and standardised for
cannabinoid content,
they would not be in the nature of medicines ‘approved’ by the
TGA171 and thus medical practitioners
would not have the usual level of
information
to decide whether prescription was warranted and what product and dose should
be prescribed.
3.175 Prescription-type models have given rise to objections from the medical
profession in other jurisdictions. In opposing the shift
‘certification’ model to an ‘authorisation’ model, the
College of Family Physicians of Canada stated:
In our view, Health Canada places physicians in an unfair, untenable and to a
certain extent unethical position by requiring them
to prescribe cannabis in
order for patients
to obtain it legally. If the patient suffers a cannabis-related harm,
physicians can be held liable, just as they are with other prescribed
medications. Physicians cannot be expected to prescribe a drug without the
safeguards in place as for other medications—solid
evidence supporting the
effectiveness and safety of the medication, and a clear set of indications,
dosing guidelines and precautions.172
3.176 The ‘certification’ model has a range of drawbacks,
however. In merely certifying
a patient’s diagnosis, the medical practitioner does not consider
whether there are any particular features of the patient (such
as history of
drug dependency, poor cardiovascular health or a strong family history of
psychosis) which might make cannabis inappropriate
for them. It also ordinarily
does not involve the practitioner in the selection of an appropriate formulation
or strength, leaving
the patient to determine this for themselves.173 This is
problematic for patients, with some of those currently using cannabis telling
the Commission they did not believe patients should be left to work out the best
product on their own.174
166 Submission 49.
167 Submissions 2, 23. Many called for the doctor’s role to be the same
as for any other medicine: Submissions 9, 18, 28, 45.
168 Submission 7.
169 Submission 57.
170 See Ian Freckelton, ‘Medicinal Cannabis Law Reform: Lessons from
Canadian Litigation’ (2015) 22
Journal of Law and Medicine
171 See [4.64] – [4.65] and Chapter 7.
172 The College of Family Physicians of Canada, ‘The College of Family
Physicians of Canada Statement on Health Canada’s
Proposed Changes to
Medical Marijuana Regulations’ (Position Statement, February 2013).
173 Under the system of licensed producers in Canada, medical practitioners
do not specify the type of cannabis to be used on a patient’s
‘medical document’. In addition, licensed producers are
prohibited by Health Canada from recommending strains to patients
as the best
for treating a particular condition. As a result, a set of cannabis
‘consultants’ have started operations
in Canada, in part to give
patients advice on strain selection and administration methods, in a context
where the strains a patient
can obtain are virtually unlimited: Consultation
174 Consultation 13.
3.177 The Commission considers that, notwithstanding the discomfort of many
members of the medical profession with the ‘prescription’
scheme which does not involve the medical practitioner in a consideration of the
risks and benefits for the particular patient
would be an intolerable policy
outcome. Patients should not be left to determine, on
their own, whether medicinal cannabis is appropriate for them, and what form
of it they should obtain.
3.178 In the Commission’s view, a patient’s treating medical
practitioner should be required to consider, for the patient
before them,
whether cannabis would be an appropriate treatment, having regard to the
considerations that would usually inform their
clinical decision making. This
reinforces the notion, expressed above, that a medicinal cannabis scheme should
be centred on treatment
by a medical practitioner. It is also consistent with
the requirement under international law that drugs such as cannabis be used
‘rational’ way.175
3.179 Consequently, the Commission considers that, when deciding whether to
authorise a patient to access medicinal cannabis, a medical
practitioner should
be required to make the same assessment as would be made for prescription
medicines.176 This would include a
consideration of:
• the likely benefits for the patient,
• the patient’s risk factors and the significance of those risks
for the particular patient
• the availability of other treatments the patient has not yet
• whether there is a likelihood of abuse.
3.180 In addition, the medical practitioner should select the product and
dosage the patient will receive. While the products
would not be approved by the
TGA, a Victorian scheme could limit and standardise the range of products
available, giving practitioners
confidence, as
in the Netherlands, in the products they prescribe.177 In the
Commission’s view, such an approach is essential to fulfilling
regulatory objective of integrating medicinal cannabis into the patient’s
medical treatment.
3.181 It is inevitable that some practitioners would hesitate at the outset
to make decisions under this model in the absence of an
approved product.
However, analogous decisions are often made by medical practitioners in the
context of off-label prescribing; by
extension, they can be made in the context
of medicinal cannabis. As the scheme evolves, and more information about dosage
is assembled and made available through continuing medical education
programs, medical practitioners’ knowledge and experience
will grow. This
is reflected in the Canadian experience. At the start of the Canadian medicinal
cannabis program, the number of practitioners
signing authorisations was very
small, while today significant numbers are involved in the scheme.178
Practitioners are also reportedly
growing in their acceptance of the scheme,
with professional networks and training programs becoming more
established.179
Similarity to off-label and unlicensed prescribing
3.182 Medicinal cannabis products supplied under a Victorian scheme may have
not been approved by the TGA, and this would place medical
practitioners in the
difficult position of dealing with substances for which dosages and reactions
are not clearly quantified
by virtue of research conducted methodically under controlled circumstances
human subjects with a variety of different conditions. However, models for
this type of prescribing can be found in ‘off-label’
‘unlicensed’ prescribing.
175 See [4.10].
176 That is, whether a ‘therapeutic need’ exists for the
medication:
Drugs, Poisons and Controlled Substances Regulations 2006
(Vic) reg 8.
177 Consultation 28.
178 Ian Freckelton, ‘Medicinal Cannabis Law Reform: Lessons from
Canadian Litigation’ (2015) 22
Journal of Law and Medicine
179 Consultation 20.
3.183 Off-label prescribing involves the provision of approved drugs in
situations180 for which they are not approved.181 Unlicensed
prescribing, on
the other hand, involves the provision of drugs not approved for any indication.
Off-label prescribing is widespread,
particularly in areas such as paediatrics,
oncology, psychiatry and palliative care.182
3.184 Joe Collier explains the ‘clinical and ethical dilemmas’
associated with off-label and unlicensed prescriptions:
The licensing arrangements ensure a rigorous assessment of each medicine,
using volumes of data ... on the efficacy and safety of
the product when used
for a given indication. Tight controls are set on the quality of the product,
and when it is given according
to the recommendations in the [product
information] the authority calculates that it is more likely to improve patient
than do harm. ... When a medicine is prescribed outside of these
arrangements, this support is absent and treatment tends to be based
assumptions and extrapolations.183
3.185 Guidelines issued by the Council of Therapeutics Advisory Groups in
2013 state that off-label prescribing should ordinarily
only be considered where
all other options, including medicines approved by the TGA, are unavailable,
exhausted, not tolerated or
unsuitable.184 They instruct practitioners that, if
there is high-quality evidence to support a proposed use, off-label use is
appropriate but if only lesser quality evidence exists and the
potential benefits appear greater than the potential harms, use should
confined to exceptional cases or be allowed conditionally, subject to review.
If there is no evidence at all, use should be confined
to a clinical
3.186 In this regard, the Royal Australasian College of Physicians drew a
link between unapproved but standardised cannabis products
and clinical
If a reliable and legal supply of a purified form of medicinal cannabis is
established in Victoria, but an absence of trial data
concerning efficacy,
safety and dosing information persists, the doctor’s role in prescribing
medicinal cannabis should be
as per the conduct of a clinical trial.186
3.187 The essential difference between a decision to prescribe a medicine
off-label and the decision to prescribe in an approved way
practitioner must exercise greater judgment about whether a use is appropriate
for the patient when prescribing off-label.
In the case of unapproved medicines
sought to be accessed through the Special Access
Scheme, a similar judgment is required, but the ultimate decision maker is
the TGA. These decisions are much more guided and constrained
where a medicine
is prescribed within the scope of its approval, where the risks and benefits
have been assessed in advance by the
180 This could include prescribing an unapproved dose, for an unapproved
indication, outside the approved age range or via an unapproved
route: Council
of Australian Therapeutics Advisory Groups,
Rethinking Medicines
Decision-Making in Public Hospitals: Guiding Principles for the Quality Use of
Off-Label Medicines
(November 2013) 4.
181 Off-label prescribing is not prohibited under Commonwealth or Victorian
law, but a sponsor is not permitted to promote the use
of a drug in an
unapproved way: Council of Australian Therapeutics Advisory Groups
Rethinking Medicines Decision-Making in Public Hospitals: Guiding Principles for
the Quality Use of Off-Label Medicines
(November 2013) 6.
182 Council of Australian Therapeutics Advisory Groups,
Medicines Decision-Making in Public Hospitals: Guiding Principles for
Quality Use of Off-Label Medicines
(November 2013) 6.
183 Joe Collier, ‘Paediatric Prescribing: Using Unlicensed Drugs and
Medicines Outside Their Licensed Indications’ (1999)
British Journal
Clinical Pharmacology
184 Council of Australian Therapeutics Advisory Groups,
Medicines Decision-Making in Public Hospitals: Guiding Principles for
Quality Use of Off-Label Medicines
(November 2013) 10.
185 Ibid 9.
186 Submission 52.
Children and vulnerable patients
3.188 By adopting usual practices for the authorisation of medicines, there
would be no need
to adopt special rules for the eligibility of children and other vulnerable
patients—medical practitioners would apply the same
considerations as they
would for other types of medicines. As the Royal Australasian College of
Physicians submitted, for such patients,
provided the practitioner ensures there
is a medical need for the prescription and it is
in the patient’s best interests, the same considerations should apply
as for any other treatment.187
Acknowledging difference
3.189 In acknowledgement of the fact that medicinal cannabis remains of a
fundamentally different nature to other medications ordinarily
supplied on
prescription—in particular, that the products made available under a
Victorian scheme would not have received TGA
approval—the Commission
considers that a different name should be used for the document that authorises
medicinal cannabis
to be dispensed to a patient. It suggests that it be referred
to as an ‘Authority to Dispense’.
Patient education and monitoring
3.190 There are a number of reasons why that the use of medicinal cannabis by
patients should be closely supervised by a medical practitioner.
• Potential psychiatric and other harms associated with cannabis,
including the development of dependence or psychosis, should
be monitored by an
independent expert.
• Cannabis has the potential to interact with other medications.188
• Dose-response effect should be reviewed regularly to ensure that the
form of administration, type of medicinal cannabis and
quantity of active
constituents can be titrated and adjusted to achieve optimally beneficial
• Patients should be encouraged not to cease other necessary
medications.
• Cannabis should be used as only one part of treatment provided by
medical practitioners to patients for serious conditions
from which they
3.191 Submissions called for medical practitioners to play a role in
educating and assisting patients. JB, for instance, stated that
practitioners
provide educational material to a patient outlining the benefits, advantages,
disadvantages, side effects (if any), dosages, follow
up appointments to
ascertain the benefits and progress of the patient after commencing medicinal
cannabis189
3.192 The Commission agrees with these comments and emphasises that
monitoring by a medical practitioner of the authorised use of
cannabis for
medicinal purposes is essential, whichever model of authorisation is
187 Submission 52. The Royal Australian College of Physicians also observed
that, for children, consent to be treated with medicinal
cannabis would be a
matter of parental responsibility, as set out in
Re: Sean and Russell
(Special Medical Procedures)
[2010] FamCA 948
, subject to whether the minor
is capable of understanding the medical treatment proposed and of providing
informed consent on their
own behalf:
Gillick v West Norfolk Area Health
[1985] UKHL 7
[1986] AC 112.
188 For example, there is research to suggest that cannabis may interact with
Atazanavir, an antiretroviral drug commonly used in
the treatment of HIV: Q Ma
et al, ‘Tobacco and Marijuana Use Significantly Decrease Atazanavir (ATV)
Trough Concentrations
in HIV-Infected Individuals’, paper presented to the
49th Interscience Conference on Antimicrobial Agents and Chemotherapy,
Francisco, 15 September 2009, cited
in ACON and others, Submission to NSW Legislative Council
Inquiry into the
Use of Cannabis for Medical Purposes
(February 2013).
189 Submission 11.
Legal procedures
3.193 The above passages considered the substantive obligations which should
be imposed on medical practitioners in connection with
authorising use of
medicinal cannabis. This section will consider how those obligations should be
reflected in law.
Permit requirement
3.194 In the Commission’s view, the legal arrangements for patient
authorisation should be modelled on the permit requirement
for prescription of
opioid replacement therapy.190
A specialist medical practitioner who wishes to authorise medicinal cannabis
to be dispensed should first seek a permit from the Secretary
of the Department
of Health and Human Services. A permit would have to be sought in all
3.195 The Secretary of the Department of Health and Human Services should
have discretion
to decline to issue a permit where the patient is identified as having
diverted their supply of medicinal cannabis to an unauthorised
deceived their medical practitioner concerning their eligibility. As medicinal
cannabis would be supplied under the scheme
to gravely ill people, this would not be appropriate as a general rule, but a
discretionary power to refuse may be appropriate in
particular cases.192 The
Secretary should also have discretion to refuse in other scenarios, such as
where false or misleading information
has been supplied in seeking a permit193 or where another practitioner has
already been issued a permit in respect of that patient.
3.196 Because each permit application would be associated with a particular
patient and a particular medical practitioner, the system
would allow the
Department to supervise patients and authorising practitioners. There would need
to be a means for pharmacists dispensing
medicinal cannabis to confirm that a
permit has been granted for a patient. For consistency with other permits,
appeal rights should
be created for persons affected by permit refusal.194
3.197 Regulations would control the content of the permit application form,
thereby enabling the Secretary to collect data regarding
the use of medicinal
cannabis.195 The permit itself would contain specified information,
• the duration of the permit, not to exceed 12 months
• the name and address of the patient
• the name of the general practitioner or clinic with principal
responsibility for monitoring the efficacy and side effects
of the treatment
• the pharmacy at which the patient or carer will obtain medicinal
• the names of any carers who will collect or administer the medicinal
3.198 Following the issue of a permit to the specialist medical practitioner,
an ‘Authority to Dispense’ could be issued
in accordance with the
permit. This document would perform the same function as a prescription, in that
it would authorise a pharmacist
at the nominated pharmacy to dispense a stated
product and amount of medicinal cannabis to the patient or their nominated
Drugs, Poisons and Controlled Substances Act 1981
The scheme for opioid replacement therapy is technically a subset of the
Schedule 8 permit scheme.
191 As for opioid replacement therapy. While opioid replacement drugs are
Schedule 8 poisons, for which permits are only required
circumstances, they are always required if the patient is drug dependent, which
opioid replacement therapy patients always
Drugs, Poisons and
Controlled Substances Act 1981
192 By way of comparison, pharmacotherapy (eg methadone) can continue to
access opioid replacement drugs even if they have diverted
their medication to
third parties.
Medical Marihuana Access Regulations
(Can) (SOR 2001/227) s
194 If a permit to prescribe is refused by the Secretary under the existing
scheme for permits to prescribe Schedule 8 or Schedule
9 drugs, any person who
feels aggrieved by such a decision may appeal the decision to the
Magistrates’ Court within six months:
Drugs, Poisons and Controlled
Substances Act 1981
Drugs, Poisons and Controlled Substances Regulations 2006
r 19 and sch 2 Form DP2A.
3.199 After the initial Authority to Dispense is made by the specialist,
Authorities to Dispense would generally be given by the patient’s
practitioner. This means that patients would need to consult their general
practitioner periodically in order to continue
the treatment, so that the
general practitioner can monitor relevant symptoms. For this reason it is
important for the general practitioner
to be able to amend the product or
3.200 It should be noted that, under the opioid replacement therapy permit
schemes, many aspects of prescribing and approval practices
are set out in
departmental policies.196 This approach could be replicated for medicinal
cannabis, so that the requirement for the
applicant to be a specialist, refusal
of permits, prescribing practices and so on can be governed more flexibly than
if these matters
were specified in legislation.
Recommendations
A specialist medical practitioner who is registered with the
Medical Board of Australia within a prescribed category for the medical
condition on which their patient’s eligibility is based should be able to
apply to the Secretary of the Department of Health
and Human Services for a
permit to issue an Authority
to Dispense Medicinal Cannabis in respect of that patient. The application
should state that:
(a) The patient’s condition and associated symptoms meet the
eligibility criteria of the scheme.
(b) It is appropriate in all the circumstances that the patient be treated
with medicinal cannabis.
(c) The patient has been informed and accepts that the medicinal cannabis
product they will receive will not have been tested for
efficacy and side
effects by the Therapeutic Goods Administration, and has been informed of other
treatments which have been so tested,
along with the risks, potential benefits
and side effects, including long-term effects, of each.
(d) The patient has been informed that information about their treatment
will be collected and used for scheme evaluation and research
The Secretary of the Department of Health and Human Services
should have the power to issue a permit to a specialist medical practitioner
satisfied that:
(a) The specialist medical practitioner is registered as a specialist with
the Medical Board of Australia within a prescribed category
for the medical
condition on which patient eligibility is based.
(b) The patient ordinarily resides in Victoria.
(c) There is not an unacceptable risk that the patient will abuse the terms
of the permit.
196 For example, under the opioid replacement therapy program: Department of
Policy for Maintenance Pharmacotherapy for Opioid
Permit delegation
3.201 As noted above, while the initial power to authorise a patient to be
treated with medicinal cannabis should rest with a specialist
practitioner, supervision of the patient
ought to be the role of approved general practitioners. The permit system
could also be used to implement this. Under the existing
permit system for
Schedule 8 opioid replacement therapy drugs, medical practitioners can delegate
to another practitioner at the
same practice, who can prescribe to existing
patients during times when they
are absent. A similar approach could be taken for medicinal cannabis. While
the permit would be sought by the authorising specialist
medical practitioner,
that practitioner could delegate to a general practitioner or clinic named on
the permit to continue treatment
with medicinal cannabis.
3.202 Authorities to Dispense medicinal cannabis would only authorise a set
number of months’ worth of medicinal cannabis to
be dispensed. In order to
continue receiving medicinal cannabis, a patient would need to return regularly
to their general practitioner
a further Authority to Dispense. The general practitioner should have the
select the product to be dispensed, and should not be constrained to select
the product originally identified by the specialist. As
with prescriptions, the
Authority to Dispense would specify how much could be purchased and how
Informed consent
3.203 The likelihood that medicinal cannabis provided under a Victorian
scheme would not have been approved in a conventional fashion
(namely by the
TGA) raises some risks of an uncertain level for patients. There is a need for
medical practitioners to ensure that,
in light of this uncertainty, they pay
particular attention to obtaining properly informed consent from the patient
prior to authorising
the dispensing of medicinal cannabis.
3.204 The TGA’s ‘authorised prescriber’ scheme, which
allows medical practitioners to seek approval to supply individual
patients with
unapproved goods (such as those which are used in a clinical trial or have been
withdrawn from the Australian market)
recommends that patients be specifically
informed of the following matters before giving consent to treatment:
• that the product is not approved (that is, registered or listed) in
• the possible benefits of treatment and any risks and side effects
that are known
• the possibility of unknown risks and late side effects
• any alternative treatments using approved products which are
available.197
3.205 The Commission considers that a similar set of matters should be
required to be part of the discussion between practitioner
and patient in
obtaining informed consent to treatment with medicinal cannabis. Importantly,
this means that the patient assumes
the risks associated with using a drug that
is unapproved, but only in circumstances where they have been supplied with a
level of information that they are able to do so in an informed way.
The Department of Health and Human Services may wish to consider
developing a
standard patient consent form, similar to that used in clinical trials.198
Liability and indemnity
3.206 Medical practitioners involved in a Victorian medicinal cannabis scheme
may be concerned that, in authorising unapproved medicinal
cannabis products,
they could be liable civilly or professionally for consequences flowing from
that decision, particularly where
the available information regarding the
efficacy and side effects of medicinal cannabis is comparatively limited. A
medical practitioner
may face legal consequences if they fail to inform a
patient of a risk which they knew would be significant to the patient.
Rogers v Whitaker
, the High Court held that a medical
practitioner has a duty to warn a patient of any ‘material’ risks
inherent in a proposed
treatment. A risk would be ‘material’ if, in
the circumstances of the particular case, a reasonable person in the
position would be likely to attach significance to it if warned
of its existence, or if the medical practitioner is or should reasonably
aware that the particular patient, if warned of the risk, would be likely to
attach significance to it.199 However, liability
in negligence will only be
established if it can be proven that, had they been informed of the particular
risk, the patient would
not have proceeded to obtain the treatment.200
197 Therapeutic Goods Administration,
Access to Unapproved Therapeutic
Goods: Authorised Prescribers
(October 2004) 12.
198 See the various patient information and consent forms available at
Department of Health,
Clinical Trial Research: How to Make an HREC
Application
(24 June 2015)
http://www.health.vic.gov.au /clinicaltrials /application-instructions.htm
[1992] HCA 58
(1992) 175 CLR 479
, 490 (Mason CJ, Brennan, Dawson, Toohey and McHugh
Rosenberg v Percival
[2001] HCA 18
(2001) 205 CLR 434
, 443 (McHugh J). The test
in Australia is a subjective test of causation; that is, it relies on what
specific patient would have done, not a hypothetical reasonable
3.208 This analysis can become more complicated where a treatment is
experimental, or little is known about its risks and efficacy.
A practitioner
would be obliged to give a patient
a balanced overview of the evidence regarding such matters and, where little
is known, to indicate this.201 Medical practitioners
also have a duty to stay
informed regarding developments in the literature where experimental treatments
are involved.202 Ultimately
though, the decision whether to consent to
treatment, once properly advised, resides with the patient.203
3.209 In addition to civil liability, failure to obtain informed consent can
give rise to breaches of a medical practitioner’s
professional
obligations.204 This requirement is, at heart, about ensuring that the
treatment undertaken by the patient is entirely
voluntary.205 National
guidelines state that a patient’s informed consent must be obtained before
treatment is administered,
and specify the matters that must be brought to a
patient’s attention.206
3.210 In Canada, medical practitioners are required to make an individualised
assessment of whether cannabis would be appropriate
for the specific patient
(although this assessment falls short of a prescription207). The Canadian
Medical Protective Association,
which is the main insurer of the Canadian
medical profession, advises that practitioners:
should not feel obligated to complete the medical document for medical
marijuana if they are unfamiliar with its treatment or use,
or if they feel it
is medically inappropriate for a patient. Physicians who choose to complete a
medical document should rely on
sound medical judgment and comply with their
College’s relevant guideline or policy.’208
3.211 Notably, too, practitioners have the advantage of a comprehensive
document issued by
Health Canada.209
3.212 The Commission was told by advisory committee members that providers of
medical indemnity insurance in Australia may refuse
to provide cover for medical
practitioners’ activities in connection with approving access to medicinal
cannabis, or may impose
an increased premium if such cover is desired.210 This
would be an unfortunate response, if it occurred.
3.213 The Commission notes that, although medicinal cannabis products would
be in the nature of unapproved drugs, existing indemnity
insurance policies do
not automatically exclude such drugs from the scope of their coverage, and
frequently include cover for practitioners
taking part in clinical trials.
Chiropractic Board of Australia v Hooper
[2013] VCAT 878
[309] – [314].
South Eastern Sydney Area Health Service v King
[2006] NSWCA
203 See, eg,
Rosenberg v Percival
[2001] HCA 18
(2001) 205 CLR 434.
Medical Board of Australia v Laska
[2011] VCAT 1888
(finding that
failure to obtain informed consent to a medical procedure amounted to
professional misconduct for the purposes of the
Health Professions
Registration Act 2005
Charter of Human Rights and Responsibilities Act 2006
(c), which establishes that every person has a right not to be subjected to
medical treatment without his or her full, free and informed
206 Medical Board of Australia,
Good Medical Practice: A Code of Conduct
for Doctors in Australia
(March 2014) [3.5].
207 According to the Canadian Medical Protective Association, ‘the
medical document issued by physicians is distinct from a
prescription.
Prescriptions are required to access drugs approved for use and regulated by
Health Canada. Health Canada does not currently approve
nor regulate medicinal
marijuana. Therefore, the medical document provided by physicians to allow
patients to access medical marijuana
can only be considered to be analogous to a
prescription in limited ways’: Canadian Medical Protective Association,
Medical Marijuana: New Regulations, New College Guidance for Canadian Doctors
(July 2015)
http://www.cmpa-acpm.ca
208 Canadian Medical Protective Association,
Medical Marijuana: New
Regulations, New College Guidance for Canadian Doctors
(July 2015)
http://www.cmpa-acpm.ca
209 Health Canada, Information for Health Care Professionals: Cannabis
(Marihuana, Marijuana) and the Cannabinoids (2013)
http://www.hc-sc.gc.ca /dhp-mps /alt_formats /pdf/marihuana /med /infoprof-eng.pdf
210 Advisory committee (Meeting 3).
3.214 In other contexts, medical practitioners are afforded immunity under
certain statutory schemes, primarily when conducting drug
and forensic tests
(provided they act properly or in good faith).211 The Commission notes that it
would be open to the Victorian
Government to provide medical practitioners (both
the original specialist and the supervising general practitioner) with an
or immunity in respect of their decisions on medicinal cannabis.
Patients’ rights and obligations
3.215 Patients for whom an Authority to Dispense has been issued should have
certain rights under the scheme. They would be authorised
to possess and use
medicinal cannabis products obtained from a pharmacy in accordance with the
Authority to Dispense.
3.216 It would remain illegal for non-authorised persons to possess medicinal
cannabis, and a patient who supplied medicinal cannabis
to anyone other than an
authorised professional or their nominated carer would engage in trafficking,
giving rise to an offence under
Drugs, Poisons and Controlled Substances Act 1981
Likewise, a carer who supplied cannabis to an unauthorised person would also
engage in trafficking for the purposes of
the legislation.
3.217 The legislation should also ensure that relevant offences in the Drugs,
Poisons and
Controlled Substances Act 1981 are expanded to capture the following
• fraudulently obtaining or granting an Authority to Dispense213
• representations that a product is a lawfully produced medicinal
cannabis product despite it not having been manufactured under
the scheme214
• allowing an ineligible patient to access medicinal cannabis.
3.218 Appendix D sets out in detail other conduct which the legislation
should ensure is captured by new or existing offences.
Recommendation
New offences should be created, or existing offences expanded,
proscribing dishonest conduct in relation to obtaining a permit or
obtaining an Authority to Dispense Medicinal Cannabis.
Consequential changes
3.219 The impact of medicinal cannabis on driving would need to be
considered. It is an offence to be in control of a vehicle while
influence of a drug of dependence or with any concentration of THC in blood or
saliva.215 The evidence strongly suggests
THC impairs a person’s ability to drive.216 While some jurisdictions
overseas have set the
211 Various legislation provides that ‘no action lies’ against a
medical practitioner who administers a forensic test:
(in respect of anything ‘properly and necessarily done’),
Public Health and Wellbeing Act 2008
(practitioner must
‘in good faith and with reasonable care’),
Road Safety Act
(in respect of anything done in accordance with the
subject’s consent).
212 Section 71AC.
Drugs, Poisons and Controlled Substances Act 1981
which applies to fraudulently obtaining a prescription.
214 This may be covered under consumer protection laws.
Road Safety Act 1986
(1)(a), (ba), (bb),
(definitions of ‘prescribed illicit drug’ and ‘prescribed
concentration of drugs’). While the legislation
in fact prohibits driving
with more than a ‘prescribed concentration’ of THC in blood or
saliva, that concentration is
set at zero.
216 Submission 44; Rebecca Hartman and Marilyn Huestis, ‘Cannabis
Effects on Driving Skills’ (2013) 59
Clinical Chemistry
Michael Lenné, Tom Triggs and Michael Regan, ‘Cannabis and Road
Safety: A Review of Recent Epidemiological Driver
Impairment, and Drug Screening
Literature’ (Monash University Accident Research Centre Report No 231,
2004); Olaf Drummer et
al, ‘The Involvement of Drugs in Drivers of
Motor Vehicles Killed in Australian Road Traffic Crashes’ (2003) 943
Accident Analysis and Prevention
1; National Cannabis Prevention and
Information Centre,
Driving Under the Influence of Cannabis: A
Brief Review of the Literature
http://www.ncpic.org.au
prescribed concentration of THC above zero,217 the Commission does not
recommend that this occur in Victoria. Accordingly, there would
be a need to
warn patients upon receipt of medicinal cannabis that their use of any
THC-containing products could make them unable
to drive.218 Similar warnings
should be included regarding the dangers of operating heavy machinery, aircraft,
vessels and so on.219
3.220 The Commission heard from people who have been adversely affected by
workplace drug-testing following the use of cannabis, or
feared they would
be.220 Some overseas jurisdictions have introduced laws to protect lawful
medicinal cannabis users from workplace
discrimination as a result of their use
of cannabis.221 The Commission notes that Victorian anti-discrimination laws
do not presently
explicitly prevent discrimination on the basis of medical
treatment.222 Action taken as a result of workplace testing is
primarily a private matter between an employer and employee, and employees
would be protected from unreasonable actions by unfair
dismissal laws,223 so
the Commission does not recommend any changes to the law in this regard.
Other participants
3.221 It would not be sufficient to authorise patients alone to possess and
use medicinal cannabis. Many patients, including children
and the physically
infirm, may be unable to travel to collect medicinal cannabis or to administer
it to themselves, and would rely
on others to do it for them. The scheme would
need to ensure that it does not criminalise the actions of such people by
recognise their role and cater properly to it.
3.222 The legislation should therefore authorise nominated carers224 to
possess medicinal cannabis, in the form and up to the amount
the patient could
possess themselves.225
Carers would also need to be authorised to administer the medicinal cannabis
to the patient.226 The carer would not be authorised
to use the medicinal
cannabis themselves.227
The scheme should have a mechanism through which professionals, such as
in-home carers and workers at palliative care facilities or
nursing homes can
also act as carers.
Recommendation
Drugs, Poisons and Controlled Substances Act 1981
(Vic), and the
Drugs, Poisons and Controlled Substances Regulations 2006
(Vic) should be amended to allow patients and carers nominated in a valid
Authority to Dispense Medicinal Cannabis, as appropriate,
to obtain, possess
and use the medicinal cannabis products designated in the Authority.
217 Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [6.110]. Washington state, where cannabis has been legalised for
recreational use, allows drivers to have up to 5 nanograms
of THC per millilitre
of blood: Washington Department of Licensing,
Washington Driver Guide
http://www.dol.wa.gov
218 As THC remains in a person’s system for a significant time after
consumption, patients may need to abstain from driving
for longer than if they
had consumed alcohol.
Road Safety Act 1986
(Vic) offers a defence to
people who are charged with the offence of driving a motor vehicle while
impaired by a drug under
(1)(ba) if the drug they were impaired by was
consumed in accordance with a medical practitioner’s advice, and they did
and could not reasonably have known that the drug would impair their
(3B). This defence would not, therefore, apply to a person
consuming medicinal cannabis that was appropriately labelled, and in any
does not apply to the offence of driving with more than the prescribed
concentration of THC in saliva.
Marine (Drug, Alcohol and Pollution Control) Act 1988
(1)(ba) and (bb);
Civil Aviation Act 1988
Rail Safety
Operations) Act 2006
(Vic) pt 6 div 3. Drug tests
conducted pursuant to a court order may also be affected: Consultation 24.
220 Consultations 1, 7.
221 Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [6.109].
222 While the
Equal Opportunity Act 2010
(Vic) prohibits
discrimination on the basis of disability, disability is not defined by
reference to loss or impairment of bodily
functions, rather than by reference to
the treatment of any such disorder:
(1) (definition of
‘disability’).
223 See Jim Nolan, ‘Employee Privacy in the Electronic Workplace
Drug Testing, Out of Hours Conduct and References’ (2000) 7
Law & Policy Reporter
224 Nominated on the authority: see [3.197]. A definition of
‘carer’ can be found in the
Carers Recognition Act 2012
225 This could be achieved by an amendment to the
Poisons and Controlled Substances Regulations 2006
(Vic) r 5, which, among
other things, authorises persons who have the care of or are assisting in the
care of a patient authorised
to possess a scheduled poison to do so themselves:
226 This would otherwise be an offence under the
Drugs, Poisons and
Controlled Substances Act 1981
If the patient is a child, the
offence of supplying a drug of dependence to a child may also apply:
227 This could be achieved by an amendment to the
Drugs, Poisons and
Controlled Substances Regulations 2006
(Vic) r 45, which states that a
person must not administer or use a Schedule 4, 8 or 9 poison except in the
treatment of the person for whom it was prescribed.
3.223 The legislation would also need to ensure that registered medical
practitioners, pharmacists, nurses and nurse practitioners
were authorised to
possess, supply and/or administer medicinal cannabis products.228 This would be
unnecessary if medicinal cannabis
products were treated as Schedule 9 Poisons
under the legislation. However, as explained below, a new category of substance
need to be created for medicinal cannabis products, meaning that
cannabis-specific authorisation provisions would be required.
Recommendation
Drugs, Poisons and Controlled Substances Act 1981
(Vic), and the
Drugs, Poisons and Controlled Substances Regulations 2006
(Vic) should be amended to allow medical practitioners, registered nurses
and pharmacists who participate in any Victorian medicinal
cannabis scheme to
obtain, have in
their possession, administer, sell and supply medicinal cannabis products,
as appropriate, for the purposes of the scheme.
A new category of poison
3.224 Because ‘Schedule 9 poison’ is defined in the Drugs,
Poisons and Controlled Substances
Act by reference to the
Standard for the Uniform Scheduling of Poisons
(SUSMP),229 the existing rules regarding Schedule 9 poisons would continue
to apply to cannabis and cannabis products under a Victorian
scheme unless
cannabis is moved to another Schedule in the SUSMP. This could cause practical
difficulties regarding the storage and
dispensing of cannabis.
3.225 This problem is best solved by removing authorised cannabis products
from the definition of a ‘Schedule 9 Poison’
for the purposes of the
Drugs and Controlled Substances Act
and the Regulations. Instead, a new class of poison would be introduced into
‘medicinal cannabis’. Cannabis products created under the scheme
would be treated as ‘medicinal cannabis’
when used lawfully, and as
a drug of dependence when used unlawfully. ‘Medicinal cannabis’
would then be used throughout
the Act and the Regulations to authorise certain
persons to deal in medicinal cannabis. The Commission has identified the
changes in Appendix D.
Implementation issues
Practitioner training
3.226 Medical practitioners would need education and resources on the
evidence supporting the use of cannabis, its pharmacology,
adverse effects and
so on. Knowledge of these matters is limited among medical practitioners at
present due to the limited trial
data available and a lack of experience with
cannabis. Comments were made in several submissions and at consultations about
for suitable training to be made available to medical practitioners.230
Cancer Council Victoria stated that ‘[a]ny change to
legislation should
coincide with educational support to health professionals’.231 A
respondent to Cancer Council Victoria’s
clinician survey stated:
Drugs, Poisons and Controlled Substances Act 1981
and (bb) and
Drugs, Poisons and Controlled Substances
Regulations
(Vic) r 5(2). It is not necessary to specifically authorise
medical practitioners and pharmacists as s 13(1)(a) already authorises
to possess, use, sell and supply drugs of dependence ‘in the lawful
practice of [their] profession’, which would include
medicinal cannabis
Drugs, Poisons and Controlled Substances Act 1981
(definition of ‘Schedule 9 Poison’).
230 Submissions 12, 35, 50, 69, 74; Consultation 1; advisory committee
(Meeting 1).
231 Submission 57.
Although my knowledge is increasing, I do not feel I have an adequate
understanding of the clinical use of cannabis or its derivatives.
think that until I have some degree
of clinical experience I can identify suitable patients.232
3.227 Many in the cannabis community argued that medical practitioners have
little understanding of concepts such as the endocannabinoid
system.233 Matthew
Pallett’s views were typical of those received by the Commission on this
As there are no registered medical professionals within Australia with
training in the application of cannabinoid medicines or the
endocannabinoid
system no meaningful
‘medical oversight’ is possible in Australia at present. ... the
endocannabinoid system is NOT taught in medical or nursing
schools at Australia
and doctors therefore have little to no knowledge of this system.234
Should training be mandatory?
3.228 One means of ensuring that only appropriately trained practitioners are
able to participate in the scheme would be to restrict
the participation of
practitioners to those who have completed relevant training. This approach is
adopted in some United States
3.229 Dr David Bearman identified a training requirement as a way to
‘marginalize those physicians who might wish to practice
minimalist medicine in making recommendations and/or writing prescriptions for
the medicinal use of cannabis’. He
suggested that:
You can do this by requiring any physician who makes twenty-five (25) or more
cannabis prescriptions a year to be certified. Such
certification could include
having attended a certain amount of category I CME say twenty hours, passing a
test and practicing an
acceptable standard of medicine.236
3.230 The Australian Lawful Use of Cannabis Alliance proposed a register of
qualified practitioners:
Victoria should establish a register of healthcare practitioners who intend
to provide medical cannabis treatments. Entry on this
Register should have, as a
pre-requisite, the annual completion of a continuing professional education
program specifically related
to cannabis medicine and/or cannabis medical
treatment options.237
3.231 Such an approach is also used in the context of opioid replacement
therapy.238 Medical practitioners generally may only prescribe
replacement therapy drugs, such as methadone, if they have been appropriately
trained and are presently approved by the Department
of Health and Human
Services.239 The approval system aims to ensure that prescribing practitioners
are familiar with the principles
of opioid replacement therapy
and prescribing policies.240 A similar scheme could be adopted in order to
oversee medical practitioners involved in authorising access
to medicinal
232 Submission 99.
233 Submissions 12, 45
234 Submission 59.
235 Such as Maryland, Massachusetts, New Jersey and New York: Victorian Law
Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [6.99].
236 Submission 97.
237 Submission 35.
238 Opioid replacement therapy includes the provision of methadone and other
drugs for the treatment of dependence on heroin or pharmaceutical
239 Department of Health,
Policy for Maintenance Pharmacotherapy for
Opioid Dependence
(2013) 13-14. Practitioners can prescribe combined
buprenorphine /naloxone for up to five patients without being approved, but
is required for all other types of pharmacotherapy.
240 Department of Health,
Policy for Maintenance Pharmacotherapy for
Opioid Dependence
(2013) 6, 13-14. The Department may withdraw
approval for practitioners who do not comply with the requirements of the
prescribing policy.
3.232 The approval system is also used in the context of opioid replacement
therapy to manage the number of patients per doctor. That
is, a medical
practitioner’s approval sets a maximum for the number of concurrent
treatment permits the practitioner may hold.
The maximum can be increased at the
practitioner’s request. This system could similarly be used in a medicinal
cannabis scheme
to limit the pressure on doctors by placing a cap on the number
of patients permitted to be treated with medicinal cannabis under
their care at
any given time.
3.233 It is important that the Department encourage medical practitioners to
access appropriate training on medicinal cannabis, and
it may be constructive
for the Department itself to provide information and training in respect of such
matters, as in Canada. However,
requiring practitioners to be approved by the
Department, and making the completion
of training a condition of approval, would be excessive and would unduly
number of practitioners able to authorise treatment with medicinal cannabis.
The number of specialists registered in the specialisations
that are relevant to
the conditions that determine eligibility is relatively small, and imposing an
approval requirement may restrict
this further. If this requirement were imposed
on the supervising general practitioners
as well, patients could be unable to continue treatment with their regular
general practitioner, potentially disrupting their existing
medical care.
3.234 Further, the risks attached to opioid replacement therapy that the
approval system is designed to control would be largely absent
from a medicinal
cannabis scheme. One key imperative behind the use of approvals in the opioid
replacement therapy scheme is the
desire to prevent ‘doctor
shopping’ by enabling departmental supervision of prescribing patterns.
This risk would be
significantly reduced in the proposed medicinal cannabis
scheme, as only certain specialists would be permitted to authorise access.
the risks associated with overuse of cannabis are not of the same scale as
for opioid replacement drugs: a fatal overdose of methadone
and like products
can occur if a patient takes only a few times the daily dose, while a fatal
overdose from the use of cannabis has
not been recorded. For these reasons, the
Commission does not consider that the medical practitioners involved in the
scheme should
be limited to those who have been approved by the Department on
the basis of having completed mandatory training.
3.235 The Commission agrees that specialists involved in the medicinal
cannabis scheme should be encouraged to undertake training
on the medicinal use
of cannabis prior to becoming involved in the authorisation decision. However,
undertaking training should be
Provision of training
3.236 The Commission considers that the Department of Health and Human
Services should have a role in addressing the need for practitioners
education and support. Examples of how this could be done include:
• offering training courses
• preparing guidelines to assist medical practitioners to determine
when treatment with medicinal cannabis is appropriate
• making available detailed information on products, their formulation
and pharmacology.
3.237 In Canada, Health Canada co-ordinated the collation and publication of
clinical data on the efficacy and side effects of cannabis,
disseminated to the profession to guide and inform them on appropriate uses,
dosing and monitoring.241 This comprehensive
document covers all aspects of
cannabis use, and sets out the clinical evidence and pharmacology with extensive
reference to research.
241 Health Canada,
Information for Health Care Professionals:
Cannabis (Marihuana, Marijuana) and the Cannabinoids
(February 2013).
3.238 The Commission understands, however, that, while detailed, the document
is not seen as particularly useful as a practical guide.
In part to remedy this,
at least one guidance document has been produced that, in addition to setting
out the clinical evidence,
sets out consequential recommendations, giving
clearer guidance to practitioners about when treatment with medicinal cannabis
appropriate.242
3.239 The Department of Health and Human Services would also need to play an
active role
in communicating product information to practitioners. Because the Secretary
would be the sole supplier of medicinal cannabis products,243
the Department
should be regarded as responsible for conveying information about product
content and administration. The
Department would also need to collate any reports of adverse events relating
to particular products and find ways of conveying this
information to
practitioners.
Recommendation
The Secretary of the Department of Health and Human Services
should provide suitable training and information materials to medical
practitioners, pharmacists, patients and others with responsibilities under the
Role of professional associations
3.240 In Canada the professional associations and Canadian regulations do not
direct practitioners on how the decisions should be
made in relation to
authorisation of use of medicinal cannabis, but guidance has been issued by the
Canadian Medical Association
and provincial colleges.244 The Canadian Medical
Association advises practitioners they should not feel obligated to authorise
cannabis for a patient if they feel it is medically inappropriate.245
It also recommends to practitioners that, among other things:
• they consider authorising cannabis only after conventional therapies
have proven ineffective, until there is compelling evidence
of its efficacy and
safety for specific indications
• they assess the patient’s medical history, conduct a physical
examination and assess for the risk of addiction and diversion,
using available
clinical support tools and tests
• they reassess the patient on a regular basis to establish the
effectiveness of the medicinal cannabis in treating the medical
condition for
which it was authorised, as well as to assess possible addiction and diversion,
and support maintenance, adjustment
or discontinuation of treatment.246
242 The College of Family Physicians of Canada,
Authorizing Dried Cannabis
for Chronic Pain or Anxiety: Preliminary Guidance
243 See [6.68] – [6.72].
244 Canadian Medical Association,
CMA Statement Authorizing Marijuana for
Medical Purposes (Update 2015)
(2015); Canadian Medical Protective
Association,
Medical Marijuana: New Regulation, New College Guidelines for
Canadian Doctors
(document number W14-005-E, July 2015) <https://
www.cmpa-acpm.ca
245 Canadian Medical Protective Association,
Medical Marijuana: New
Regulation, New College Guidelines for Canadian Doctors
number W14-005-E, July 2015) <https://
www.cmpa-acpm.ca
246 Canadian Medical Association,
CMA Statement Authorizing Marijuana for
Medical Purposes (Update 2015)
3.241 In addition, the College of Family Physicians of Canada recently issued
Preliminary Guidance: Authorizing Dried Cannabis for Chronic Pain or
, a detailed document that advises practitioners on:
• what is known about the potential harms and benefits of cannabis use
in various populations and for treating different conditions,
with a focus on
pain and anxiety
• regulations and suggested best practices to follow before authorising
and continuing a patient’s access to cannabis
• tools to use when screening patients for misuse or addiction risk
• information about the strains available from licensed producers
• calculations for dosing.247
3.242 Among other guidance, the College sets out a number of categories of
patient for whom it considers dried cannabis is ‘not
appropriate’,
including those who are under the age of
25; have a personal history or a strong family history of psychosis; have a
cannabis use disorder or a substance use disorder; have
cardiovascular disease;
have respiratory disease; or are pregnant or breastfeeding.248
3.243 The Commission notes these developments and observes that professional
colleges would have an important role to play in guiding
and informing decision
making by Victorian medical practitioners.249
Data collection, monitoring and evaluation
3.244 Through use of a permit system, a Victorian scheme could facilitate the
collection of data regarding the use of medicinal cannabis.
The system could
also incorporate reporting requirements, whereby medical practitioners supply
information to the Department on results
achieved with medicinal cannabis. The
data collected by medical practitioners and passed on to the Department would
need to be the
minimum required and not be unduly burdensome.
3.245 In determining the data to be collected under the scheme, consideration
should be given to how it could usefully assist in evaluating
whether the scheme
is meeting its regulatory objectives and in contributing to research data about
the use of cannabis for medicinal
3.246 The collection of data regarding patient health and treatment raises
Proposed data collection methods should be subject to a privacy impact
assessment before implementation, and have appropriate safeguards
built in, in
consultation with the Commissioner for Privacy and Data Protection and the
Health Services Commissioner.
Is a register of patients necessary?
3.247 Many submissions touched upon the idea of creating a
‘register’ of patients who have been authorised to access medicinal
cannabis in Victoria.250 Registration would be a prerequisite for patients being
treated with medicinal cannabis under the scheme.
3.248 Victoria Police suggested that a central registry of patients could be
useful as a means of monitoring the scheme:
In the interests of conducting a fully informed trial of medicinal cannabis,
Victoria Police recommends that consideration be given
to maintaining a register
of prescribers and patients in relation to medicinal cannabis. The purpose of
the register would be to
track and record the number and types of prescriptions
made, and the conditions/symptoms for which cannabis is prescribed.251
247 College of Family Physicians of Canada,
Preliminary Guidance:
Authorizing Dried Cannabis for Chronic Pain or Anxiety
(September 2014)
248 College of Family Physicians of Canada,
Preliminary Guidance:
Authorizing Dried Cannabis for Chronic Pain or Anxiety
(September 2014)
249 This was broadly endorsed by the advisory committee (Meeting 1).
250 Submissions 29, 44, 60, 64, 70.
251 Submission 44.
3.249 The data collection benefits of registration were also remarked on by
Mullaways Medical
Cannabis Pty Ltd:
A Medical Cannabis Card would... record the amount of Cannabis/Cannabinoid
medicine prescribed and the outcomes of the treatment.
This will allow a big
data analysis of the results which medical professionals can use to achieve the
best outcome for the patient.252
3.250 The Commission considers it likely that the Department of Health and
Human Services would create, or be able to generate, records
of patients who
participate in the scheme. This has parallels in respect of dependence-forming
drugs (such as opiates) supplied
to drug-dependent persons.253 The process of issuing a permit on the
application of a specialist medical practitioner for each patient
would generate
a significant amount of data, which would be supplemented by records of
medicinal cannabis products that are dispensed
pursuant to those permits. It
should be noted that the Office would be bound by the privacy and access
provisions in the
Health Records Act 2001
3.251 While some overseas jurisdictions do not maintain records of medicinal
cannabis patients,255 the Commission considers that this
should be an integral
component of the Victorian scheme. Without it, the government would have no way
of monitoring the conditions
for which cannabis is being authorised, no way of
supervising the medical
practitioners involved in authorising access. This would severely compromise
the integrity of the scheme, its ability to support research,
and the capacity
to review the scheme after a suitable period of time. It would also create the
potential for abuse of the scheme.
3.252 However, the Commission does not consider it necessary to require
patients to register with the Department or to be issued with
identification
cards, as occurs in some other countries that have medicinal cannabis
schemes.256 It is not required for access to
other controlled therapeutic goods
and there are no features of the proposed medicinal cannabis scheme that would
make it necessary
for government or helpful for the patient.
252 Submission 29.
Drugs, Poisons and Controlled Substances Act 1981
Health Records Act 2001
(Vic) provides that the
legislation applies to the public sector.
255 In the Netherlands, medical practitioners may prescribe cannabis to
patients, who collect it from a pharmacy like any other prescription
There is no central registry of patients. In Canada, patients who possess a
medical document signed by an appropriate
health practitioner are entitled to
register with a ‘licensed producer’, who deals with them directly
and does not supply
their details to the government.
256 This is necessary, for instance, where persons are permitted to have
dried cannabis in their possession for medicinal purposes
- they require
to be able to prove straightforwardly to police enforcing the general law
precluding cannabis use and possession that they are ‘entitled’
use and possess the permitted amount.
Current regulation
of cannabis
102 Introduction
102 Restriction of supply as a narcotic drug
107 Control of quality, safety and efficacy as a therapeutic good
114 Implications for a Victorian medicinal cannabis scheme
117 Conclusion
4. Current regulation of cannabis
Introduction
4.1 Two national frameworks of Commonwealth, state and territory legislation
regulate access to cannabis in Australia. One restricts
the cultivation,
manufacture, supply and use of narcotic drugs in accordance with international
obligations to act against drug abuse.
The other ensures that therapeutic goods
sold in Australia meet suitable standards of safety, quality and efficacy. Both
Commonwealth, state and territory legislation and are intended to
protect public health and welfare.
4.2 Victorian legislation has an important role to play in establishing and
maintaining these frameworks. Currently, the supply and
use in Victoria of
cannabis for medicinal purposes is prohibited, unless it has been approved or
specially exempted under Commonwealth
4.3 The options for changing the law in Victoria are influenced by the
operation of the national frameworks. Conversely, the national
frameworks could
be affected by any Victorian reform. The frameworks are described in this
chapter, and the options are discussed
in Chapter 5.
Restriction of supply as a narcotic drug
4.4 Any law reform within Victoria to make cannabis available as a medicine
must take account of the national framework that implements
Australia’s
international obligations to control narcotic drugs.1 Some of these obligations
are incorporated into Australian
Narcotics Drugs Act 1967
(Cth). They are also implemented
indirectly through other legislative instruments, principally in Victoria by the
Drugs, Poisons and Controlled Substances Act 1981
Single Convention on Narcotic Drugs 1961
4.5 Australia is a signatory to three international conventions concerning
the control of narcotic drugs. The most significant for
a Victorian medicinal
cannabis scheme is the
Single Convention on Narcotic Drugs 1961
purpose of the Single Convention on Narcotic Drugs is to foster international
efforts against the abuse of narcotic drugs.
1 Cannabis is classified internationally as a narcotic drug.
2 Opened for signature 30 March
1961, 520 UNTS 204
(entered into force 13
December 1964); the other relevant conventions are the
Convention on
Psychotropic Substances
, 1019 UNTS 175
(entered into force 16 August
1976), and the
Convention Against Illicit Traffic in Narcotic Drugs and
Psychotropic Substances
, 1582 UNTS 165
(entered into force 11 November
4.6 The Single Convention on Narcotic Drugs is administered by two
Commission on Narcotic Drugs of the Economic and Social
Council of the United Nations
may make decisions about which substances are
encompassed by the Single Convention on Narcotic Drugs and the controls that
them. It may also make recommendations for implementing the aims and
provisions of the Single Convention on Narcotic Drugs.3
International Narcotics Control Board
comprises 11 members
elected by the Economic and Social Council of the United Nations. It imposes
quotas on the production of narcotic
drugs in each country, based on estimates
provided to it, and monitors compliance both with these quotas and with the
of the Single Convention on Narcotic Drugs. It can call upon a
government that has not complied to adopt remedial measures.4
General obligations and control measures
4.7 Among other things, signatories to the Single Convention on Narcotic
Drugs have a general obligation to take necessary legislative
and administrative
measures to:
limit exclusively to medical and scientific purposes the production,
manufacture, export, import, distribution of, trade in, use and
possession of
4.8 The Single Convention on Narcotic Drugs categorises the drugs to which it
applies into four schedules and sets out control measures
that apply generally
to them, depending upon their category. Some additional measures are specific to
particular drugs. Cannabis,6
cannabis resin,7 the cannabis plant,8 and cannabis
leaves9 are the subject of controls under the Convention.
4.9 The general control measures apply to cannabis, cannabis resin, and
extracts and tinctures of cannabis.10 Cannabis and cannabis
resin are also
singled out for ‘special measures of control’11 on the grounds that
they are particularly liable to be
abused and produce ill- effects, and that
this is not offset by having substantial therapeutic advantages compared to
have not been singled out.12
Use of cannabis for medical and scientific purposes
4.10 The international community views only the ‘rational’ uses
of cannabis for medical and scientific purposes as legitimate
under the Single
Convention on Narcotic Drugs.13 A controlled substance is used
‘rationally’ when it is prescribed and
administered by a
professional in response to a patient’s clinical need, in a way that is
efficacious for treating the patient’s
condition, at an adequate dosage at
proper intervals.14 The need to ensure treatment is ‘rational’ is
underpinned by
Article 30 of the Convention.15
Single Convention on Narcotic Drugs 1961
4 Ibid arts 9–14.
5 Ibid art 4 (c). A ‘drug’ is ‘any of the substances in
Schedules I and II [of the Single Convention] , whether
synthetic’.
6 Defined in art 1(1)(b) of the Single Convention on Narcotic Drugs as
‘the flowering or fruiting tops of the cannabis plant
(excluding the seeds
and leaves when not accompanied by the tops) from which the resin has not been
extracted, by whatever name they
may be designated’.
7 Defined in art 1(1)(d) of the Single Convention on Narcotic Drugs as
‘the separated resin, whether crude or purified, obtained
cannabis plant’.
8 Defined in art 1(1)(c) of the Single Convention on Narcotic Drugs as
‘any plant of the genus Cannabis’.
9 Cannabis leaves are undefined by the Single Convention on Narcotic
10 This being the consequence of inclusion in Schedule I of the Single
Convention on Narcotic Drugs: see art 2(1).
11 This being a consequence of inclusion in Schedule IV of the Single
Convention on Narcotic Drugs: see art 2(5)(a).
12 Single Convention on Narcotic Drugs art 3.5.
13 United Nations Office of Drugs and Crime,
Drug Policy Provisions from
the International Drug Control Conventions
(2014) 3; World Health
Organisation,
Ensuring Balance in National Policies on Controlled Substances:
Guideline for Availability and Accessibility of Controlled Medicines
14 World Health Organisation,
Ensuring Balance in National Policies on
Controlled Substances: Guideline for Availability and Accessibility of
Controlled Medicines
15 In particular, the requirement in Article 30 (2)(b)(i) of the Single
Convention that the supply or dispensation of narcotic drugs
be through medical
prescription. See also Submission 21.
4.11 Cannabis is one of a limited number of drugs deemed by the Single
Convention on Narcotic Drugs to be at high risk of diversion.
If the lawful
cultivation of cannabis poses a threat to public health and welfare, or if
lawfully cultivated cannabis is being diverted
into the illicit market, the
Single Convention on Narcotic Drugs requires it to be prohibited.16
Cultivation and manufacturing for medical and scientific purposes
4.12 The Single Convention on Narcotic Drugs requires the cultivation and
manufacture of cannabis for medicinal or scientific purposes
to be undertaken in
a very specific way. Cultivation may take place only under licence to a single
national agency, which must take
physical possession of the total crop from the
licensee.17
4.13 A government-owned enterprise may then either manufacture the cannabis
into another form, or issue licences permitting companies
to engage in
manufacturing.18 Stocks of cannabis must at all times be held by the national
agency or by manufacturers of the medicinal
cannabis products.19 This imposes
an important logistical constraint for the creation of a Victorian medicinal
cannabis scheme.
4.14 The Single Convention on Narcotic Drugs imposes these restrictions to
ensure that stocks of cannabis produced for medical use
are reserved for the
patients to whom they are prescribed and are not diverted into illicit
channels.20
The international system of estimates and assessments
4.15 The requirements that the state license and take physical possession of
cannabis enable signatories to report annually to the
International Narcotics
Control Board about the amount of cannabis they estimate will be legitimately
used for medical and scientific
purposes over the coming year.21 They must
provide statistical information on ‘estimates and assessments of
requirements, manufacture,
trade, consumption, utilization and stocks of
internationally controlled substances’ such as cannabis that are required
or scientific purposes.22
4.16 Based on the estimates, the International Narcotics Control Board
assigns the signatory
an annual quota of the drug that is permitted to be consumed for legitimate
purposes. A signatory that imports or manufactures more
than its quota of a drug
is in breach of the Single Convention on Narcotic Drugs.23 These quotas prevent
the oversupply of narcotic
drugs and are therefore vital to preventing the
diversion of those drugs into the illicit market.24
Responsibility to adopt a nationally consistent approach
4.17 The Commonwealth Government, on behalf of Australia, has a
responsibility to give effect to the rules of the Single Convention
on Narcotic
Drugs.25 The International Narcotics Control Board considers that it has a
further responsibility to ensure that the
rules are not undermined by state
governments.
Single Convention on Narcotic Drugs
1961 art 5(b).
17 Ibid arts 23(2)(d), 28. ‘Crop’ is not defined.
18 Ibid art 29.
19 Ibid art 23(2)(e), although the national agency may waive this right in
respect of medicinal cannabis.
20 Report of the International Narcotics Control Board for 2014 (E/
INCB/2014/1) 55.
21 International Narcotics Control Board, World Health Organization,
on Estimating Requirements for Substances under International
Report of the International Narcotics Control Board for 2014
INCB/2014/1) 20 –1.
23 Single Convention on Narcotic Drugs art 21.
Report of the International Narcotics Control Board for 2014
INCB/2014/1) 13.
25 Single Convention on Narcotic Drugs art 4 (a).
If a State, irrespective of its constitutional framework and legal system,
enters into an international agreement by acceding to the
international drug
control treaties, that State must ensure that all state and/or provincial
policies and measures do not undermine
its efforts to combat drug abuse and
trafficking in narcotic drugs, psychotropic substances and precursor
chemicals.26
4.18 The International Narcotics Control Board recommends that federations
such as Australia ‘should contain, develop and continually
comprehensive system of intergovernmental coordination procedures in order to
ensure that drug control laws and policies
are nationally
consistent’.27
Commonwealth
Narcotic Drugs Act
Narcotic Drugs Act
was introduced by the Commonwealth to
‘regulate the manufacture of, and to make other provision with respect to,
narcotic drugs
in accordance with the Single Convention on Narcotic Drugs
1961’.28 It applies throughout Australia and is central to the
framework of laws that restrict the supply of cannabis.
4.20 Consistent with the Single Convention on Narcotic Drugs, narcotic drugs
may be manufactured in Australia only under a licence
issued by the Minister for
Health.29 The amount that a licensed manufacturer may manufacture and possess,
and over what period, is
specified in a permit issued by the Secretary of the
Department of Health.30
4.21 The Minister for Health may determine and specify any licence
conditions31 and the Chief Executive Officer of Customs may specify
direction any additional requirements concerning security and how the drugs are
labelled and handled.32 The Act also provides
for government-appointed
inspectors to check compliance with the licence conditions and other
requirements.33
4.22 In this way, licences issued under the
Narcotic Drugs Act
Commonwealth both to control the amount and type of narcotic drugs produced in
Australia, within the manufacturing quotas
that the International Narcotics
Control Board imposes, and to provide the Board with accurate estimates on which
to base the future
Under [the Single Convention], estimates of consumption of narcotic drugs for
medical and scientific needs are required to be submitted
annually to the United
Nations. The total quantity of each drug entering the domestic market, either by
importation or
by local manufacture, is then kept within these estimates by the allocation
of quotas. To ensure that Australia’s obligations
under the Single
Convention will be fulfilled the Commonwealth must continue to administer the
estimates system which is an integral
part of national and international
control. It is considered essential, therefore, that the Commonwealth extend its
legislation to
cover all aspects of the manufacture of narcotic drugs.34
4.23 Within Victoria, the
Narcotic Drugs Act
currently applies to the
processing of poppy straw from alkaloid poppies and would apply to any
manufacture of medicinal cannabis
26 International Narcotics Control Board, Contribution to the High-Level
Review of the Implementation by Member States of the Political
Declaration and
Plan of Action on International Cooperation Towards an Integrated and Balanced
Strategy to Counter the World Drug
Problem (2014) 42.
27 Ibid 43.
28 This being the long title of the
Narcotic Drugs Act 1967
Narcotic Drugs Act 1967
‘manufacture’ is defined by the Act as ‘the carrying out of
any process by which the drug may be obtained,
and includes the refining of a
drug and the transformation of one drug into another drug, but does not include
the separation of
opium, coca leaves, cannabis or cannabis resin from the plants
from which it is or they are obtained’:
Narcotic Drugs Act 1967
(2) (definition of ‘manufacture’).
Narcotic Drugs Act 1967
Narcotic Drugs Act 1967
(Vic) s 9 (4).
Narcotic Drugs Act 1967
(Vic) s 12.
Narcotic Drugs Act 1967
(Vic) s 24.
34 Commonwealth,
Parliamentary Debates,
House of Representatives, 16
May 1967, 2181 (Mr Howson).
Drugs, Poisons and Controlled Substances Act
4.24 Victoria’s contribution to the national framework for
restricting the supply of cannabis and other substances controlled
Narcotic Drugs Act
can be found in the
Drugs, Poisons and Controlled Substances
Drugs, Poisons and Controlled Substances Act
Poisons and Controlled Substances Regulations 2006
(Vic) establish when the
cultivation, processing, supply, administration and use of drugs, poisons and
other controlled substances
are legal or illegal in Victoria.35 Cannabis36 is
regulated both as a poison and as a drug of dependence.
Regulation as a poison
4.26 Poisons and controlled substances are regulated in Victoria according to
how they are categorised by the Commonwealth. The categories
are set out as
Schedules 2 to 9 of the Commonwealth’s
Standard for the Uniform
Scheduling of Medicines and Poisons No 6
(SUSMP).37 A range of factors are
taken into account in deciding how a substance should be scheduled, including
how a substance is
scheduled internationally under the Single Convention on
Narcotic Drugs.38
4.27 State and territory governments voluntarily implement the SUSMP through
their legislation. In Victoria, the SUSMP schedules have
been incorporated into
the Drugs, Poisons and Controlled Substances Act.39
4.28 Cannabis is listed in Schedule 9 of the SUSMP. Schedule 9 contains
prohibited substances.
A ‘prohibited substance’ is a poison that may be abused and so
its manufacture, possession, sale or use should be prohibited
by law except for
the purposes of medical use or scientific research.40
4.29 Similarly, tetrahydrocannabinol (THC) and its alkyl homologues are
listed as Schedule 9 poisons, but with the following exceptions:
• when they are included in Schedule 8
• when 50 mg/kg or less of THC or its alkyl homologues is in hemp seed
oil labelled as not for internal use
• when 50 mg/kg or less of THC or its alkyl homologues is in other
products not for human consumption.41
4.30 Nabiximols and dronabinol—synthetic formulations of
cannabis—are listed in Schedule 8, which contains poisons
controlled drugs. A ‘controlled drug’ is a substance that in
principle is able to be made available by a limited
range of health
professionals, but may
be abused by patients.42 The SUSMP recommends controls on its manufacture,
supply, distribution, possession and use.
4.31 This review is principally concerned with the forms of cannabis that
are contained in
Schedule 9. Schedule 9 poisons are highly controlled. There are detailed and
restrictive
35 Victoria,
Parliamentary Debates,
Legislative Assembly, 23 September
1981, 924 (Mr Borthwick).
36 The plant
Cannabis L,
THC and various synthetic cannabinoids are
all drugs of dependence:
Drugs, Poisons and Controlled Substances Act 1981
(Vic) sch 11
. More broadly, the reference to cannabis includes
the drug itself whether it has natural or synthetic forms; its fresh or dried
its salts, analogues, derivatives and isomers; or the salts of those
analogues, derivatives and isomers; and any substance that contains
any of those
Drugs, Poisons and Controlled Substances Act 1981
(definition of ‘drug of dependence’).
Poisons Standard 2015
(Cth) sch 1.
38 Australian Health Ministers’ Advisory Council,
Scheduling Policy
Framework for Medicines and Chemicals
(2015) 26 –7.
Drugs, Poisons and Controlled Substances Act 1981
(definition of ‘poison or controlled substance’).
Poisons Standard 2015
(Cth) (‘Classification’).
Poisons Standard 2015
(Cth) SUSMP sch 9.
Poisons Standard 2015
(Cth) SUSMP
(‘Classification’).
rules about record-keeping,43 storage,44 who may lawfully possess them,45
and who may lawfully prescribe them.46
4.32 Clinical and scientific research into poisons that fall within this
category in Victoria require the approval of both the
Commonwealth and state
governments. To prescribe cannabis in Victoria, a medical practitioner must
apply to the Secretary of the
Victorian Department
of Health and Human Services. In practice, applications to prescribe are not
Regulation as a drug of dependence
Drugs, Poisons and Controlled Substances Act
imposes penalties on
people who unlawfully cultivate a narcotic plant or make a drug of dependence
available. It is an offence to
cultivate, traffic, administer, possess or use
cannabis in Victoria without being authorised or licensed under the Act or
Regulations
to do so.47
4.34 In general terms, those who may be authorised under the current law to
cultivate, administer or possess cannabis are people
who need access to a drug
of dependence in the lawful practice of their profession, in connection with
their work at a testing facility,
or in performing a power, function or duty
under the Act.48
Control of quality, safety and efficacy as a therapeutic good
4.35 When cannabis is used medicinally, it is currently regulated as a
therapeutic good.
Australia has a national framework for the regulation of therapeutic goods
that is designed to protect the health and welfare of the
Australian public
while minimising the costs associated with pharmaceutical regulation.49 Like the
framework for the regulation of
narcotic drugs, it is the product of cooperation
between the Commonwealth and several state governments.
4.36 The core of this framework is the
Therapeutic Goods Act 1989
(Cth) (Commonwealth
Therapeutic Goods Act
), as indicated by the objects of the Act:
(1) The objects of this Act are to do the following, so far as the
Constitution
(a) provide for the establishment and maintenance of a national system of
controls relating to the quality, safety, efficacy and
timely availability of
therapeutic goods that are:
(i) used in Australia, whether produced in Australia or elsewhere; or
(ii) exported from Australia;
(b) provide a framework for the States and Territories to adopt a uniform
to control the availability and accessibility, and ensure the safe handling,
of poisons in
Australia.50
4.37 The Act is administered by the Therapeutic Goods Administration (TGA), a
Division of the
Commonwealth Department of Health.
43 Records of Schedules 8 and 9 poisons must contain the name and address of
the person who supplied the poison:
Drugs, Poisons and Controlled Substances
Regulations 2006
(Vic) r 40 (1)(e), and must reflect a true and accurate
balance of the poisons remaining in the person’s possession after every
transaction, and record the name of the person who carried out each transaction:
r 41(1)(c).
44 Schedules 8 and 9 poisons must be kept in a 10mm steel plate storage
Drugs, Poisons and Controlled Substances Regulations 2006
(Vic) r 35.
45 ‘A person for whom a Schedule 9 poison has been supplied by a
registered medical practitioner, pharmacist or dentist in accordance
Act and these Regulations’ is authorised to have that poison ‘to the
extent and for the purpose for which it
is supplied’:
Drugs, Poisons
and Controlled Substances Regulations 2006
(Vic) r 5(1) Item 3.
46 Only a registered medical practitioner, veterinary practitioner or dentist
who has a permit under
Drugs, Poisons and Controlled Substances
(Vic) may write prescriptions for a Schedule 9 poison:
Poisons and Controlled Substances Regulations 2006
(Vic) r 25(1). The permit
is for a specific patient; it is not a standing authority to supply Schedule 9
Drugs, Poisons and Controlled Substances Act 1981
Drugs, Poisons and Controlled Substances Act 1981
49 Therapeutic Goods Administration,
Medicines Regulation and the TGA
(1999) 2; Kim Forrester, Debra Griffiths,
Essentials of Law for
Practitioners
(2013) 218.
Therapeutic Goods Act 1989
Commonwealth
Therapeutic Goods Act
4.38 The Commonwealth
Therapeutic Goods Act
regulates the importation,
manufacture and supply of therapeutic goods. In particular:
• It establishes the SUSMP which, as discussed above, is incorporated
into the Victorian
Drugs, Poisons and Controlled Substances Act
• It specifies standards for the quality of therapeutic goods51 and
the conditions of their manufacture.52
• It requires goods to be registered before they are sold in
Australia.53
4.39 The TGA:
• evaluates the safety, quality and efficacy of therapeutic goods and
approves them for sale in Australia
• licenses the manufacturers of therapeutic goods
• ensures that therapeutic goods are properly labelled and advertised
if they are to be sold on the Australian market.54
Approval by the Therapeutic Goods Administration (TGA)
4.40 A therapeutic good may not be imported into or manufactured and supplied
anywhere in Australia unless it is on the Australian
Register of Therapeutic
Goods. Before being registered, the TGA assesses its quality, safety and
4.41 Different products are subject to different processes. Prescription
medicines are rigorously assessed to ensure that they are
fit for their intended
purpose and that what is known about them can be stated clearly.55 The risks
and benefits associated with
a prescription medicine will also inform the
prescribing practices of medical practitioners by virtue of the evidence-based
of contemporary medicine.56
4.42 The TGA does not work proactively to approve a medicine. The process
begins when a sponsor—typically a company that wishes
to market a medicine
in Australia—applies for approval to have the product included in the
Australian Register of Therapeutic
for the treatment of a particular indication. The cost of an application for
a new chemical entity is about $250,000.57
4.43 The applicant is required to develop a dossier that includes detailed
product information.
Sponsors bear the responsibility of satisfying the TGA that a medicine should
be approved58 because they stand to gain commercially
from its approval.59 To
demonstrate a medicine’s quality, safety and efficacy, sponsors will
provide data typically obtained
from randomised, double-blind,
placebo-controlled clinical trials.60
The process is then undertaken at TGA to review that, and that involves a
range of evaluators reflecting the nature of the data—clinical
toxicologists, pharmacologists, other experts as needed and appropriate to the
particular application. The time for reviewing
that application varies but our
statutory requirement is to do
that within 255 working days—around a year.... We have an advisory
committee on prescription medicines that will review many
applications and
provide advice to the
Therapeutic Goods Act 1989
. In the absence of a
ministerial standard, ‘default standards’ apply as set out in the
Pharmacopoeia, European Pharmacopoeia
United States
Pharmacopeia—National Formulary
Therapeutic Goods Act 1989
Therapeutic Goods Act 1989
Therapeutic Goods Act 1989
54 Therapeutic Goods Administration,
Access to Unapproved Therapeutic
Goods: Clinical Trials in Australia
55 Some of that information is then used in the Australian Public Assessment
Reports. See Therapeutic Goods Administration,
Australian Public Assessment
Reports for Prescription Medicines
(28 July 2015) <https://
www.tga.gov.au
/australian-public-assessment-reports-prescription-
medicines-auspars>.
56 Commonwealth Department of Health,
The National Strategy for Quality
Use of Medicines: Executive Summary
57 Evidence to Senate Legal and Constitutional Affairs Legislation Committee,
Parliament of Australia, Canberra, 30 March 2015, 37
Studdert, Market Authorisation Group, Therapeutic Goods
Administration, Department of Health).
58 Therapeutic Goods Administration,
Role of the sponsor
2013) <https://
www.tga.gov.au
/role-sponsor
59 Lloyd Sansom, Will Delaat and John Harvath,
Review of Medicines and
Medical Devices Regulation
(2015) 135 (Figure 11).
60 Therapeutic Goods Administration,
Mandatory Requirements for an
Effective Application
delegate in response to specific questions. That comes close to the end of
the process and then the delegate makes a decision. If
that is a positive
decision within a few weeks it is entered onto the Australian Register of
Therapeutic Goods.61
Risk assessment
4.44 Simply because a medicine is approved by the TGA does not mean that it
is harmless.
Medicines have risks, and a part of the assessment is to determine whether
those risks are acceptable in light of the nature of the
condition that is being
treated and the benefits of the medicine overall.62
4.45 Very toxic medicines may be approved because, for example, they improve
a seriously ill patient’s overall quality of life.
This is why more
latitude is given to medicines designed to treat seriously or terminally ill
people, even though they may pose risks.63
4.46 A medicine’s risk can depend upon its side effects and toxicity.
Toxicity aside, a medicine’s risk can also reflect
its potential for
abuse. Therefore the scheduling of a medicine or its ingredients under the SUSMP
will affect the risk assessment.64
Continuing obligations and post-market monitoring
4.47 Sponsors have a number of continuing obligations in respect of medicines
and other therapeutic goods that are approved to be
sold on the Australian
market. A sponsor is required, for example, to ensure that their good has been
manufactured in accordance
with Good Manufacturing Practice.65 Sponsors are
also required to label their good in accordance with the applicable
standard.66
4.48 To ensure that a product is properly marketed in Australia, consistently
with the sponsor’s obligations, the TGA engages
in ‘post-market
monitoring’. For example, if a medical practitioner or the consumer of a
prescription drug reports an
adverse event to the sponsor, the sponsor must
report the event to the TGA.67 The TGA then investigates the event and
disseminates
relevant information throughout the medical community.68
Therapeutic Goods Act
4.49 The Commonwealth relies upon the states to enact complementary
legislation in order to fully implement the framework. Victoria
has enacted the
Therapeutic Goods (Victoria) Act
(Vic), which applies the Commonwealth
Therapeutic Goods Act
law of Victoria to every person in Victoria. Not all state governments have
implemented the framework to the same extent as
Victoria.69
4.50 State governments are also responsible for enacting laws that
implement the SUSMP. As noted above, Victoria has done so
Drugs, Poisons
and Controlled Substances Act
. The SUSMP applies rules about labelling,
advertising, prescription and use according to
a medicine’s risks. These risks include its toxicity, likelihood of
abuse and the way it is controlled under international treaties.
prescription, supply and use of medicines and other therapeutic goods are then
regulated by state governments according to how
their ingredients are scheduled
under the SUSMP.
61 Evidence to Senate Legal and Constitutional Affairs Legislation Committee,
Parliament of Australia, Canberra, 30 March 2015, 37
Studdert, Market Authorisation Group, Therapeutic Goods Administration,
Department of Health).
62 Therapeutic Goods Administration,
The Therapeutic Goods
Administration’s Risk Management Approach to the Regulation of
Therapeutic
63 Therapeutic Goods Administration,
Benefits Versus Risks Approach to
Regulating Therapeutic Goods
(8 February 2015)
http://www.tga. gov.au /benefits-versus-risks-approach-regulating-therapeutic-goods
64 Therapeutic Goods Administration,
Risk Management Approach
(15 August 2011) <
http://www.tga.gov.au /
65 Therapeutic Goods Administration,
Good Manufacturing Practice
April 2013) <https://
www.tga.gov.au
/good-manufacturing-practice-
66 Therapeutic Goods Administration,
TGA Labelling and Packaging
Regulatory Framework
(28 October 2014) <https://
www.tga.gov.au /tga-
labelling-and-packaging-regulatory-framework>.
67 Therapeutic Goods Administration,
Australian Requirements and
Recommendations for Pharmacovigilance Responsibilities Of Sponsors Of
(4 June 2014) <https://
www.tga.gov.au /book
/2-reporting-requirements
68 Therapeutic Goods Administration,
Medicines and Vaccines Post-Market
Vigilance—Statistics for 2014
(26 May 2015) <https://www.tga.
gov.au /medicines-and-vaccines-post-market-vigilance-statistics-2014>.
69 Queensland and Western Australia have not implemented the
Therapeutic
Goods Act 1989
4.51 The public health and consumer rights of Victorians are improved by
their state’s support of a national framework of quality
control over
medicines. Unapproved medicines that
do not go through this process do not currently have their risks and benefits
evaluated; nor are unapproved medicines subject to clear
and enforceable
standards for their manufacture.
4.52 To prevent unapproved medicines circumventing these protections, the
Commonwealth
Therapeutic Goods Act
prohibits companies from importing or manufacturing
them and places restrictions on their administration and wholesale supply.70
The Victorian
Therapeutic Goods Act
extends this regulation beyond companies to
prevent any Victorian person from marketing medicines in Australia that have not
assessed by the TGA for their potential impact.71
Approval of cannabis products
4.53 As discussed above, the TGA employs high-quality processes to evaluate
scientifically the data on the quality, safety and efficacy
of therapeutic
goods. A number of submissions asserted that medicinal cannabis products should
be made available in Victoria only
if they have been tested and approved by the
TGA.72 This was the position of Dr Roger McLennan who contended that ‘it
be foolish to override the Therapeutic Goods Administration and ignore the
Food and Drug Administration and the Medicines and Healthcare
Regulatory Agency’.73
4.54 AMA Victoria, for example, put the view that:
Therapeutic cannabinoids that are scientifically evaluated to be safe and
effective should be made available to patients for whom
existing medications are
not as effective. However, approval for these treatments must be subject to the
same regulatory and quality
control processes that are applied to other
medicines in Australia.74
Scientific testing and evaluation
4.55 The approval process for prescription medicines sets high standards of
purity and consistency, as well as requiring rigorous
clinical trials. Sponsors
would need to do a great deal of work to ‘standardise’ cannabis so
that its purported therapeutic
effect can be measured against a stable and
predictable dose in a clinical trial setting. Professor David Penington has
argued that
these standards are not appropriate:
Cannabis can never be a pharmaceutical agent in the usual sense for medical
prescription, as it contains a variety of components of
variable potency and
actions, depending on its origin, preparation and route of administration.
Consequently, cannabis has variable
effects in individuals. It will not be
possible to determine universally safe dosage of cannabis for individuals based
on a clinical
4.56 Only one non-synthetic medicinal cannabis product has been approved by
Sativex, manufactured by GW Pharmaceuticals, is a whole-plant extract of
cannabis and contains approximately equal parts of THC and
CBD, along with a
small amount of other cannabinoids. It is a pharmaceutical-grade medicine
administered as an oro-mucosal spray.
It was registered by the TGA on 26
November 2012 as a treatment for symptom improvement in patients with moderate
to severe spasticity
due to multiple sclerosis who have not responded adequately
to other anti-spasticity-related symptoms during an initial trial of
Therapeutic Goods Act 1989
Therapeutic Goods (Victoria) Act 2010
72 Submissions 25, 27, 38, 40, 42, 47, 48, 52. See Appendix B for list of
submissions.
73 Consultation 2. See Appendix C for list of consultations.
74 Submission 38. See also Consultation 16.
75 Professor David Penington, ‘Medical cannabis: time for clear
thinking’ (2015) 202
Medical Journal of Australia
76 Pharmaceutical Benefits Advisory Committee,
Public Summary Document:
(July 2013) <
http://www.pbs.gov.au /info
listing /elements /pbac-meetings /psd /2013-07/nabiximols>.
4.57 Before any other medicinal cannabis product is approved for sale in
Australia, it also would need to be standardised, subjected
to clinical trials,
and subsequently evaluated and approved by the TGA. The limited range of
products currently being trialled suggests
that it is likely to be some time
before the state of knowledge develops to the point that an evaluation of
another medicinal cannabis
product by the TGA would have any realistic prospects
of success.
4.58 The above observation applies equally to the rescheduling of cannabidiol
to Schedule 4 of the SUSMP. How a medicine is scheduled
affects how strictly it
is regulated once it is available on the market, and influences how doctors
assess its risks. But a CBD medicine
would still have to be assessed by the TGA
before it could be sold in Australia. Currently, no CBD medicine is included on
the Australian
Register of Therapeutic Goods.
4.59 Even the approval of a medicine after rigorous scientific evaluation
does not ensure that it is sold in Australia. Sativex was
withdrawn from the
Australian market by its sponsor, Novartis, after the decision was made not to
subsidise it under the Pharmaceutical
Benefits Scheme.77 The barriers to entry
into the Australian medical market are commercial as well as scientific.
Commercial considerations
4.60 Sponsors provide the impetus for a medicine to be approved: they fund
the clinical research and make applications to the TGA
with the ultimate aim of
accessing the Australian market. If the costs are unlikely to bring strong
financial returns, there is no
incentive to seek approval. The TGA responds to
applications for approval; it does not seek out products that may meet community
health needs.
4.61 Compounding this problem is that less refined cannabis products are
becoming more widely available, both legally and illegally.
This reduces the
economic incentive for sponsors to bear the costs of undertaking clinical
research with a view to having a product
approved.78 The economic incentive is
further reduced because it can be difficult for a sponsor to protect its
intellectual property
in a cannabis product, and therefore to
prevent competitors from selling something very similar or identical to that
product on the market.79
4.62 Others have observed that there is a lack of interest by sponsors in
making cannabis medicines available in Australia. In 2013,
the New South Wales
Legislative Council’s General Purpose Standing Committee No 4 noted during
its enquiry into medicinal cannabis
that ‘the small market for [cannabis]
medicine is not seen to justify the costs, as the indications for cannabinoids
are uncommon
and more effective drugs have emerged to treat conditions such as
nausea and vomiting’.80
4.63 The market-driven therapeutic goods regime has not resulted in
cannabis-based medications becoming available in Australia. It
follows that for
the Victorian Government to achieve its policy of making cannabis available to
people in exceptional circumstances,
some alternative method of access must be
considered.
77 Dan Harrison, Rania Spooner and Beau Donelly, ‘MPs Call for
Compassion in Case of Mother Who Used Cannabis Oil to Help Sick
Sydney Morning Herald
(20 July 2014).
78 Claire Frezza, ‘Medical Marijuana: A Drug Without a Medical
Model’ (2013) 101
Georgetown Law Journal
1117, 1135.
79 New South Wales Working Party on the Use of Cannabis for Medical Purposes,
Report of the Working Party on the Use of Cannabis for Medical Purposes
(2000) 59; Legislative Council General Purpose Standing Committee No 4,
Parliament of New South Wales,
The Use of Cannabis for Medical Purposes
(2013) [3.62] – [3.63].
80 Legislative Council General Purpose Standing Committee No 4, Parliament of
New South Wales,
The Use of Cannabis for Medical Purposes
(2013) 31–2.
4.64 Limiting a Victorian medicinal cannabis scheme to products that have
been approved
by the TGA would reinforce the status quo. There would be no change to the
products available and the means by which they could be
accessed. Apart from
facilitating clinical trials of products with a view to approval by the
TGA—an initiative which is already
under way—there is no scope for
the Victorian Government to expedite the approval of medicinal cannabis products
under current
Commonwealth law.
4.65 However, the Commission considers that the establishment of a Victorian
medicinal cannabis scheme should supplement the national
framework for the
regulation of therapeutic goods only to the extent that the market does not
produce affordable and appropriate
medicinal cannabis products for eligible
patients. The position of the TGA as the pre-eminent entity responsible for the
and approval of medicines for commercial supply on the Australian
market should be maintained and reinforced.
Access to unapproved products
Importation under the Special Access Scheme
4.66 The Secretary of the Commonwealth Department of Health has the
discretion to allow unapproved medicines to be imported and/or
supplied on a
case-by-case basis.81 As
a matter of policy, the Secretary exercises this discretion through the
operation of a number of schemes established by the TGA, including
the Special
Access Scheme.82 It
was proposed to the Commission that unapproved medicinal cannabis products
could be imported for individual patients under the Special
Access Scheme.83
4.67 The Special Access Scheme allows an unapproved therapeutic good to be
imported with the agreement of an overseas supplier.84
The patient’s
circumstances are assessed against a set of criteria, and the nature of the
assessment depends on whether the
patient is seriously or terminally ill.85 The
prior approval of the TGA is not required for a terminally ill patient, but is
for other patients. The use of unapproved medicines under the scheme
is treated as experimental; the patient and their doctor bear
responsibility for any adverse effects.86
4.68 In practice, the Special Access Scheme provides medical practitioners
with a way of seeking the Commonwealth Government’s
permission for their
individual patients to have access to a medicine that is available in other
countries but for which approval
to supply in Australia has not been sought
from, or given by, the TGA.
4.69 The scheme is not designed to facilitate systematic access to
unapproved medicines by groups of patients suffering from
a particular condition
and associated symptoms. The guidelines for the scheme emphasise that it is not
to be used in this way.87
Importation of Sativex
4.70 Although Sativex has been approved by the TGA, if imported from overseas
it would be
as an unapproved product for the purposes of the Special Access Scheme. This
is because Sativex as labelled and marketed overseas
would not necessarily meet
the requirements the TGA imposes on the local product.
Therapeutic Goods Act 1989
82 Therapeutic Goods Administration,
Access to Unapproved Therapeutic
Goods via the Special Access Scheme
(2009). The other schemes are the
Authorised Prescriber Scheme and the Personal Importation Scheme. See
Therapeutic Goods Administration,
Authorised Prescribers
July 2015) <https://
www.tga.gov.au /form
/authorised-prescribers
>; Therapeutic Goods Administration,
Unapproved Therapeutic
Goods: Personal Importation
83 Consultations 1, 11; Submission 52.
84 Therapeutic Goods Administration,
Access to Unapproved Therapeutic
Goods via the Special Access Scheme
(2009) 8, 10.
85 Terminally ill patients being referred to as ‘Category A’ and
other patients being referred to as ‘Category B’.
86 Therapeutic Goods Administration,
Access to Unapproved Therapeutic
Goods via the Special Access Scheme
87 Ibid 10.
4.71 It follows that a medical practitioner who forms the view that there is
clinical justification for their patient to be treated
with a 1:1 THC/CBD
product may seek to import Sativex from GW Pharmaceuticals/Novartis under the
Special Access Scheme.
4.72 The Commission was given notice of a number of anecdotal estimates of
the cost of importing Sativex. These estimates ranged from
$500 to $1200 per
4.73 The Special Access Scheme has features that are entirely appropriate for
its limited purpose but which make it an inadequate
basis for supply of
medicinal cannabis under a Victorian scheme.
4.74 Only a few medicinal cannabis products have been approved by the
overseas counterparts of the TGA and are therefore potentially
available under
the Special Access Scheme.
Sativex is the most obvious candidate for importation under the scheme but
would not be suitable for all the patients, and all the
conditions and symptoms,
that a Victorian medicinal cannabis scheme would encompass. For example, due to
Sativex’s psychotropic
effect it would not be suitable to treat paediatric
4.75 To reduce the cost burden on patients who may benefit from being treated
with Sativex, the Victorian Government could subsidise
the cost to individual
patients of importing Sativex under the Special Access Scheme. However, it could
not expedite the process
nor provide a means of broadening access to a wider patient group. The
Special Access Scheme is an ad hoc evaluation tailored to a
particular patient,
which turns on the quality of the evidence able to be assembled by the medical
practitioner in each instance.
4.76 Furthermore, if the scheme were able to be used to facilitate the
systematic supply of an unapproved cannabis medicine to Victorians,
undermine the general requirement that sponsors must apply to have their
medicines included on the Australian Register of
Therapeutic Goods before they
are able to market it in Australia.89
Access to unapproved products through clinical trials
4.77 By participating in clinical trials, patients can be provided with
access to unapproved medicinal cannabis products. The TGA
administers two
schemes under which clinical trials for unapproved therapeutic goods may be
conducted, and can permit unapproved
medicines to be imported into Australia for the purposes of a clinical trial
under its Clinical Trial Exemption scheme. The Commission
received a number of
submissions from people who expressed an interest in participating in clinical
trials, to determine whether
cannabis would be effective in their case.90
4.78 While this form of access to medicinal cannabis may assist in individual
cases, it is not a substitute for establishing a scheme
that provides for a
reliable supply of a variety of products to eligible patients. The results of
clinical trials should inform which
products may be supplied under a Victorian
scheme and the eligibility criteria for the patients who participate.
88 Submissions 29, 90. See also Evidence to the Senate Legal and
Constitutional Affairs Committee, Parliament of Australia, Canberra,
March 2015, 18–9 (Professor David Penington, Emeritus Professor,
University of Melbourne).
89 Therapeutic Goods Administration,
Access to Unapproved Therapeutic
Goods via the Special Access Scheme
90 Submissions 67, 78, 83.
Implications for a Victorian medicinal cannabis scheme
4.79 In introducing law reform to allow access to medicinal cannabis, the
Victorian Government could either work within the existing
regulatory frameworks
or depart from them. The extent to which it could depart from them is determined
by the scope of its jurisdiction
and whether it has the support it needs from
the Commonwealth Government for the changes it wants to make.
4.80 Victoria’s jurisdiction to regulate the cultivation, manufacture,
distribution, possession and use of medicinal cannabis
within its borders is
confined in two ways:
• The Commonwealth has overriding jurisdiction, granted by the
Constitution
and exercised under Commonwealth legislation, to regulate many
parts of the supply chain, in particular production and manufacture.
• Victoria has passed legislation that complements the Commonwealth
legislation, in the interests of establishing national regulatory
frameworks.
4.81 This means that Victoria can either establish a stand-alone medicinal
cannabis scheme within the limits of its own jurisdiction
or involve the
Commonwealth in establishing and operating the scheme.91
A stand-alone Victorian scheme
4.82 A number of submissions urged Victoria to act independently in
introducing a medicinal cannabis scheme.92 The Cannabis Policy
Project, for
example, put the view that:
Whilst it is desirable to work with the Commonwealth the Commission should
focus on recommending regulatory changes that can be achieved
4.83 Some individuals argued that Victoria should adopt the approach taken in
the United States, where each state that has legalised
medicinal cannabis has
done so despite federal laws criminalising cannabis for all purposes. Marc
Selan, for instance, said that:
In the USA, the states that have legalised medicinal cannabis issue licences
that protect users but the federal police do not accept
them. Victoria should
take the step to move against the Commonwealth.... If you allow cannabis
production, as in the USA, you have
wealth decentralisation, creating wealth
throughout the community and vast employment opportunities.94
4.84 Others, such as Cannabis Science Ltd, were cautious about Victoria
working in opposition to the Commonwealth:
It is of upmost [sic] importance to avoid the missteps taken by the United
States, and to ensure that the various levels of government
are on the same
page. Additionally, it
is important that we do not put further strain on our already under-resourced
frontline services.95
91 These alternatives are described in the issues paper. See Victorian Law
Reform Commission,
Medicinal Cannabis: Issues Paper
92 Submissions 1, 5, 14, 28, 37, 72.
93 Submission 37.
94 Submission 74.
95 Submission 69.
4.85 The implications of establishing a stand-alone scheme in Victoria would
be different from those in the United States of America,
not least because the
division of powers between the federal and state governments is not the same.
Nevertheless, the experience
in the United States of America illustrates both
the feasibility and the difficulty of introducing a stand-alone medicinal
scheme within a federal system. A problem common to
all of the state schemes is that patients, industry members, and those who
assist them
are confused about their liability under federal criminal laws and uncertain
4.86 The scope for Victoria to establish a stand-alone scheme was discussed
in the issues paper.96 Comments made in submissions and
consultations concurred
with the Commission’s analysis.97
4.87 A medicinal cannabis scheme established solely by Victorian legislation
and without Commonwealth support could not license corporations
to cultivate and
manufacture cannabis products. Individuals could be permitted to cultivate and
possess cannabis but are unable to
be authorised under Victorian law to
manufacture cannabis. The
importation of any cannabis seeds or medicinal cannabis products would still
be subject to Commonwealth law.
4.88 To avoid the reach of the
Therapeutic Goods Act
, the Victorian
Government could enter an agreement with unincorporated entities or natural
persons to cultivate cannabis and manufacture
medicinal cannabis products.
Alternatively, the Victorian Government could create a statutory authority that
did not generate revenue
to perform these activities.
4.89 However, a stand-alone scheme involving unincorporated entities or a
Victorian Government agency is still legally fragile and
potentially exposes
Victorians to criminal liability under Commonwealth law. Unincorporated entities
and natural persons are clearly
subject to the Commonwealth’s Narcotic
Drugs Act. Arguably, even a Victorian agency would require a licence under the
Narcotic Drugs Act
to manufacture cannabis products.98
Participants in a stand-alone Victorian scheme who did not have a licence
would be subject to a considerable risk of criminal liability.
4.90 Similar problems attend a stand-alone grow your own scheme. The
would apply to patients who manufactured their own refined forms of
cannabis, exposing them to criminal liability.
4.91 This discussion shows that the participation of the Commonwealth in a
Victorian scheme is vital to the scheme’s regulatory
and legal stability.
A stand-alone Victorian medicinal cannabis scheme that is not supported by the
Commonwealth is subject to unsatisfactory
and arbitrary limitations on its form
A comprehensive scheme
4.92 Many submissions expressed support for a comprehensive Victorian scheme
in which the Commonwealth has a role.99 It was suggested
that, by regulating
every step of the supply chain, Victoria could avoid the quality control and law
enforcement challenges experienced
by some medicinal cannabis schemes in other
countries. Mullaways Medical Cannabis Pty Ltd observed that:
Setting up a Medicinal Cannabis Industry will take a lot of investment to
achieve. It requires infrastructure for the security, cultivation,
manufacturing, processing, delivery and reporting of regulated
Cannabis/Cannabinoid medications and the removal of criminal convictions
those Licensed to be involved in the Victorian medical Cannabis Industry.100
96 A possible exception is a state agency or statutory authority that is not
a ‘constitutional corporation’. See Victorian
Commission,
Medicinal Cannabis: Issues Paper
(2015) 74–5.
97 Submission 63; advisory committee (Meeting 2).
98 Advisory committee (Meeting 2).
99 Submissions 24, 26, 27, 29, 31, 35, 41, 54, 63, 75, 76; advisory committee
(Meeting 2).
100 Submission 29.
4.93 Others focussed on the need to retain a national approach to the
regulation of narcotic drugs and therapeutic goods:
It would [be] unwise and bureaucratically very difficult to implement this
outside of a national framework. So our recommendation
is that if all other
appropriate safeguards are in place, that a national system would need to be
established, not independent state
activities.101
4.94 As the Commission’s review was conducted at the same time as an
inquiry by the Senate Legal and Constitutional Affairs
Legislation Committee
Regulator of Medicinal Cannabis Bill
, which proposed a national
medicinal cannabis scheme which the states could opt into, those who commented
did not always envisage
that Victoria would be the architect or primary
regulator of the scheme.102
4.95 Professor David Penington, for example, presented both to the Commission
and the Senate Committee a proposal for a national medicinal
cannabis regulatory
framework, of which a Victorian scheme would form a part:
A relatively simple arrangement, explicitly built around State legislation,
with national consultation, through a Standing Committee
of AHMAC, is
preferable. This could provide communication and co-ordination between the
Commonwealth and States in regulating the
production and use of cannabis
products for medicinal purposes. Such an approach would require full
consultation seeking common ground
on important matters, with expert and
professional advice as necessary. Consensus could be sought
on many issues to facilitate Commonwealth support. Appropriate agreement on
sharing of information and products between States would
be desirable.
Commonwealth resolution of the legal obstacles could be made contingent on such
common agreement between States; this
would be a powerful incentive to gain
consensus.103
4.96 Having considered the legal ramifications of confining the scope of the
scheme to the limits of Victoria’s jurisdiction,
the Law Institute of
Victoria expressed the view that collaborating with the Commonwealth is the only
viable option:
A comprehensive medicinal cannabis scheme in Victorian would need to rely on
collaboration with the Commonwealth Government. A stand-alone
Victorian scheme
without Commonwealth amendments would be difficult. The Tasmanian Dam case has
long established that, if the Commonwealth
is a party to an international
convention,
it will retain the power to intervene in state legislation relevant to the
international convention. As the manufacture of medicinal
cannabis falls within
Commonwealth obligations to three international conventions, it is unclear how
Victoria could protect itself
from potential interference from the Commonwealth
without some form of collaboration.104
4.97 Although not all parties to the Single Convention on Narcotic Drugs
comply with all aspects of it, the Convention requires that
the state take
physical possession of medicinal cannabis stocks and distribute it to retail
suppliers in a way that is generally
consistent with Article 23. To foster
collaboration, an option for law reform should be consistent with the
Commonwealth’s
international obligations, as the Commonwealth evaluates
proposals to produce and supply narcotic drugs against the requirements
Convention.105 The importance of such compliance was identified by the Senate
Legal and Constitutional Affairs Legislation
Committee’s report of 11
August 2015 on
Regulator of Medicinal Cannabis Bill
, including by its recommendation
that the Bill be amended to ensure compliance with Australia’s
international obligations under
101 Submission 42.
Regulator of Medicinal Cannabis Bill
is discussed in Chapter 1.
103 Submission 24.
104 Submission 63.
105 Commonwealth Department of Health, Submission No 67 to the Legal and
Constitutional Affairs Legislation Committee,
Inquiry into
Regulator of Medicinal Cannabis Bill 2014
30 March 2015, 2;
Consultation 15.
Convention on Narcotic Drugs.106 A system that enables Victoria to report
accurately to the Commonwealth the amount of cannabis being
produced annually,
and which establishes a process of control that limits diversion to the greatest
possible extent, should be an
attribute of a Victorian scheme.
4.98 The Commission agrees with the Law Institute’s legal analysis.
Victoria’s jurisdiction permits it to regulate only
limited aspects of the
supply chain, and the division of regulatory responsibilities between the
Commonwealth and Victoria does not
align clearly or easily with the
practicalities of cultivating, processing, manufacturing, distributing,
prescribing and using medicinal
cannabis. The arbitrary and unclear reach of
respective jurisdictions would expose Victoria, and Victorians, to legal
liability. It would be preferable for any Victorian medicinal
cannabis scheme to
be established in collaboration with the Commonwealth.
Recommendation
The Victorian Government should seek to work in collaboration
with the Commonwealth Government in establishing any medicinal cannabis
in Victoria.
106 Senate Legal and Constitutional Affairs Legislation Committee, Parliament
of Australia,
Regulator of Medicinal Cannabis Bill 2014
(2015) [5.13].
Options for reform
120 Introduction
121 Importation under amended Commonwealth rules
125 Exemption from prosecution for possession and use
126 ‘Grow your own’
135 Regulated not-for-profit production and distribution
138 Regulated distribution through dispensaries
140 Government-enforced monopoly
142 Multiple licensed producers
5. Options for reform
Introduction
5.1 This chapter sets out a number of options that would allow medicinal
cannabis to be supplied and used in Victoria. In reviewing
them, the Commission
has drawn on its consultations with the public, professional stakeholders and
the advisory committees. It has
considered the written submissions it received
in response to the issues paper and taken into account the experience of other
5.2 All the options build on the assumption that the following regulatory
mechanisms would be in place:
• an administrative unit within the Department of Health and Human
Services, referred to in this report as the Office of Medicinal
Cannabis, to
administer the scheme either alone or in conjunction with other government
agencies, as described in Chapter 1.1
• a system by which medical practitioners authorise eligible patients
to be treated with medicinal cannabis, as recommended
in Chapter 3.2
5.3 The Victorian Government’s decisions as to what is desirable will
be determined by many factors beyond the terms of reference
for this review. For
the purposes of assessing the options, the Commission has been mindful of the
recommended regulatory objectives
and inherent risks set out in Chapter 1, which it has inferred from the terms
of reference.3
5.4 The options for law reform discussed in this chapter are:
Importation
—Victoria could import cannabis for the
purposes of a medicinal cannabis scheme by special arrangement under
Commonwealth law.
Exemption from prosecution
—Eligible patients and their
carers could be authorised to possess small quantities of cannabis for the
patient’s use.
‘Grow your own’
—Eligible patients and their
carers could be authorised to cultivate cannabis plants for the patient’s
Regulated not-for-profit production and
distribution
—Not-for-profit cooperatives
could be licensed to cultivate, manufacture and distribute medicinal cannabis
products among their members.
Regulated distribution through dispensaries
cannabis products could be distributed through licensed, single purpose
dispensaries.
A government-enforced monopoly
—Victoria could authorise
a publicly funded entity to cultivate and manufacture cannabis for distribution
to patients through
pharmacies.
1 See [1.72] – [1.76].
2 See [3.193] – [3.202].
3 See [1.68] – [1.70].
Licensed producers
—Victoria could issue multiple
licences to cultivators and manufacturers to produce medicinal cannabis products
for distribution
to patients through pharmacies.
5.5 All of the options under which medicinal cannabis could be produced and
distributed in Victoria, other than under a grow your
own scheme, would be
contingent on the co- operation of the Commonwealth Government in either or both
of the following forms:
• removing the regulation of medicinal cannabis products that are
produced and distributed under the Victorian medicinal cannabis
scheme from the
Therapeutic Goods Act 1989
• issuing a licence to manufacture cannabis, under the
Drugs Act 1967
5.6 Most of these options would also have an impact upon the frameworks for
the control of narcotic drugs and the quality of medicines
described in Chapter
4. The Commission considers that Victoria should engage with these frameworks to
the greatest possible extent
by avoiding measures that depart substantially from
Australia’s international obligations and preferring measures that:
• allow the quantity of medicinal cannabis produced in Victoria to be
reported accurately to the Commonwealth, so that it may
in turn provide accurate
annual estimates to the International Narcotics Control Board4
• minimise the risk that cannabis will be diverted into the illicit
market,5 consistently with the regulatory objective to preserve
the prohibition
on illicit use of cannabis
• develop medicinal cannabis products that medical practitioners can
‘rationally’,6 consistently with the regulatory objectives to
integrate medicinal cannabis into the patient’s medical
treatment, to
inform patients of any clinical uncertainty and to ensure the quality and
composition of medicinal cannabis products.
Importation under amended Commonwealth rules
5.7 Cannabis can be imported under current Commonwealth law and policy only
if approved on a case-by-case basis by the Secretary of
the Commonwealth
Department of Health, exercising powers under the
Therapeutic Goods Act 1989
(Cth) and the
Customs Act
(Cth). The Law Institute of Victoria proposed that the
Commonwealth provide
special access for state governments to import products for the purpose of
their medicinal cannabis schemes:
As there are currently several states agitating for public access to
medicinal cannabis, the states could negotiate with the Commonwealth
over several options to assist, including facilitating importation. The states
could make an application to
the Secretary of the Commonwealth Department of Health to exercise its
discretion to provide for a special access scheme and provide
excluded goods
declaration.7
5.8 This option would not require legislative reform though, if ongoing, it
could be desirable to have the security of a statutory
avenue of access.
5.9 Bringing in or importing cannabis is specifically prohibited by criminal
law and customs regulations and is also unlawful because
almost all forms of
cannabis are unapproved therapeutic goods for the purposes of the Commonwealth
Therapeutic Goods Act
As discussed in Chapter 4, the Secretary of the Commonwealth Department of
Health has a discretion to make exceptions, which in practice
is exercised
through schemes administered by the Therapeutic Goods Administration (TGA).
4 See [4.15] – [4.16].
5 See [4.14].
6 See [4.10].
7 Submission 63. See Appendix B for list of submissions.
5.10 If the Commonwealth agreed to facilitate the approval of requests by the
Victorian Government to import medicinal cannabis that
has been produced under
regulated conditions into Victoria, the Victorian Government would then need to
enter into contracts with
cultivators and manufacturers who would be willing and
able to export it to Australia.
5.11 The view that Victoria should import medicinal cannabis products from
overseas, and that a way to facilitate this should be found,
was put to the
Commission on a number of occasions.8 The primary reasons identified in support
• The regulatory burden of importing medicinal cannabis products would
be much lower than that of regulating their cultivation
and manufacture.
• It would also enable suitable products of a high quality to be made
available in less time than it would take to establish
a lawful and
therapeutically appropriate local supply.9
Reduced regulatory burden
5.12 As noted by the advisory committees, importing medicinal cannabis could
reduce the cost of administering a medicinal cannabis
scheme while providing
access to products that
have been produced under regulated conditions.10 If it were possible to
import sufficient quantities for all eligible patients, then
the medicinal
cannabis scheme could focus primarily on authorising and monitoring access.
While it could be necessary to subsidise
the cost of the imported product to
allow it to be affordable to patients, the expenditure would be far less than
that of establishing
and regulating the cultivation and manufacture of medicinal
cannabis products.
5.13 The cost advantages diminish if only a small amount of the demand for
products could be met in this way, as local production
would still need to be
established and regulated as well.
5.14 Importation of the state’s supply of medicinal cannabis would also
accord with Australia’s international obligations.
Because it does not
involve local cultivation or manufacture, importation would not engage Articles
23 and 28 of the
Single Convention on Narcotic Drugs 1961.
In addition,
the Commonwealth would be able to meet its obligation to monitor how much
cannabis had been imported each year and accurately
estimate for
the International Narcotics Control Board how much cannabis would be required
Victorian scheme.
Quicker access to licit products
5.15 Even if the medicinal cannabis scheme were designed to provide for
local cultivation and manufacture, importing high-quality
products that have
been produced under regulated conditions could be an interim measure while the
industry is being established in
5.16 Belinda Doonar said in her submission that it is unnecessary to import
cannabis products because ‘we have people on the
ground with extensive
knowledge ready to move ahead’.11 However, under each of the options where
medicinal cannabis products
would be produced (other than grow your own), the
government would have a role in selecting or licensing suppliers, creating
controls and meeting international obligations to control and report on
the amount of cannabis being cultivated. A time delay between
the law being
changed and licit products being made available is inevitable.
8 Advisory committee (Meetings 1 and 3); Submissions 48, 63, 70.
9 Advisory committee (Meetings 1 and 3); Submission 63.
10 Advisory committee (Meetings 2 and 3).
11 Submission 90.
Disadvantages
Scarcity of suppliers
5.17 The fundamental difficulty with relying on importation is the need to
identify an exporter who is willing and able to supply
Victoria with medicinal
cannabis products. In order for the scheme to be viable, an exporter would have
to be able to supply enough
to meet patient demand, at a price that was
sufficiently affordable to justify not having a domestic industry.
5.18 Securing an affordable and reliable supply of medicinal cannabis is
ultimately a question for government, and the Commission
does not exclude the
possibility of securing an agreement to import. However, at the time of writing,
only one country exports medicinal
cannabis.12
5.19 The Netherlands, through its Office of Medicinal Cannabis, permits the
export of the medicinal cannabis that is cultivated under
government regulation
by the sole supplier, Bedrocan BV.13 Cannabis is currently exported from the
Netherlands to Italy, Germany,
Finland, Canada, and the Czech Republic.14
However, the Commission understands that Bedrocan is unable to supply large
of cannabis. The Netherlands gives priority to meeting its domestic
needs rather than facilitating a cannabis export industry, and
it does not allow
substantial quantities to be exported.15
5.20 Uruguay has indicated that it would like to export cannabis, and Israel,
Canada and Chile have also reportedly expressed interest,
but it appears that no
arrangements are yet in place.16 In Canada, there is a process under the
Marihuana for Medical Purposes Regulations
for the export of medicinal cannabis.
Only licensed producers may obtain an export permit.17 However, it appears that,
while technically
possible, exports are not
generally allowed by Health Canada.18 Some Canadian companies have expressed
a wish to become licensed exporters, but it appears this
is unlikely in the
near future.19 Health Canada states that it:
does not support facilitating a regime premised on servicing global demand
given the associated public health, safety and security
risks. For the above
reasons, importation and exportation would be permitted under very limited
circumstances, such as, ... exporting
a unique marijuana strain for scientific
investigation in a foreign laboratory.20
5.21 Although the medicinal cannabis industry in the United States thrives
under the various state schemes, the products it produces
may not be exported
without the approval of the federal government’s Attorney-General.21 As
cannabis is considered illegal
at the federal level, such approval seems
unlikely to be granted.
12 Boaz Wachtel,
International Medical Cannabis Policy
(11 March 2013)
http://www.slideshare.net /SafeAccess /asa-2013-medical-cannabis- in-israel-v3
13 Office for Medicinal Cannabis,
Import and Export
, <https://
www.cannabisbureau.nl /en /
ImportExport /
14 Bedrocan BV,
Welcome to Bedrocan
http://www.bedrocan.nl /english /home.html
15 Consultation 28.
16 Patricia Rey Mallén, ‘Uruguay To Export Marihuana To Canada,
Chile, Israel For Medical Purposes’,
International Business Times
(online), 8
January 2014
http://www.ibtimes.com /uruguay-export-marihuana-canada-chile-israel-medical-purposes-1530930
17 Canada Border Services Agency,
Importation and Exportation of
Controlled Substances and Precursors
(2014) [18];
Marihuana for
Purposes Regulations
, SOR /2013-119, ss 82–88.
18 Tamara Cunningham, ‘Medical Marijuana CEO Has Sights Set On Global
Expansion’,
Nanaimo News Bulletin
(online), 3 March 2015
www.nanaimobulletin.com
/news /294699081.html
19 Brandon Barrett, ‘Whistler Medical Marijuana Company Has Licence
Pique News Magazine
(online), 5 March 2015
http://www. piquenewsmagazine.com /whistler/whistler-medical-marijuana-company-has-license-renewed /Content?oid =2641294
Mike McConnell,
‘Madison Heights businessman sees billions in medical pot’,
The Daily Tribune
(online), 4 March 2014 <
http://www.dailytribune.com /
general-news
/20140304/madison-heights-businessman-sees-billions-in-medical-pot>.
20 Health Canada,
Import and Export of Marijuana by Licensed
Producers—Information Bulletin
, 8 June 2015
http://www.hc-sc.gc.ca
Controlled Substances Import and Export Act
, 21 USC § 953.
Limited choice of products
5.22 Another drawback of relying on imports is that the cannabis exported
from the Netherlands is only in dried plant form because
this is the only form
available domestically. The Dutch government is currently preparing to amend the
law so that cannabis oil can
also be supplied, with scientists and pharmacists
working on a method for its safe and consistent production.22 Similarly, if
companies were to be permitted to export cannabis, it would be only in
dried form or as an oil.23
5.23 Israel may allow exports in the future. But while significant quantities
of cannabis are grown and refined in Israel, in a range
of strains and
formulations,24 quality control is said to be poor.25
5.24 The United States produces a wide range of products and strains—in
most jurisdictions producers are free to cultivate whatever
strains and
manufacture whatever products they wish, including a large number of refined
products. However, as mentioned above, the
United States does not permit export
without a permit from the Attorney-General, which is unlikely to be
5.25 If Victoria were to import cannabis in dried form, it could then be
processed into other forms. As this would be manufacturing,
it would need to be
conducted under regulatory architecture that is compliant with Article 29 of the
Single Convention on Narcotic
Drugs. In any event, the cost advantage of
importing rather than cultivating and processing locally would be significantly
diminished,
if not lost.
5.26 There may be benefit in Victoria reviewing with the Commonwealth the
potential for streamlining the approval processes for the
facilitating imports under the Victorian scheme. For example, it may be possible
to facilitate the importation of Sativex
for individual patients who are
eligible to participate in the Victorian scheme or whose application is
supported by the Office of
Medicinal Cannabis. Perhaps this could be accompanied
by a Victorian Government program to subsidise the cost of the product
to patients and their families. It could also be useful if the importation
processes were streamlined to facilitate the importation
of cannabis seeds so
that a suitable variety and quality of strains could be developed in Victoria.
These measures could operate
in tandem with any of the other options.
5.27 As a means of meeting all or most of the demand for medicinal cannabis
under the scheme, however, importation is not feasible
in the current
international environment. The available products would need to be processed in
Victoria under regulations that accord
with Articles 23 and 29 of the Single
Convention on Narcotic Drugs, and the quantity
that could be sourced would not obviate the need to produce a local supply
under such regulations.
22 Catherine Sandvos, ‘Affidavit’,
Allard v The Queen,
January 2015, [13].
Marihuana for Medical Purposes Regulations
SOR /2013-119 s 3;
Health Canada,
Statement on Supreme Court of Canada Decision in R v
, 7 July 2015
http://www.hc-sc.gc.ca
24 See, eg, Tikum Olam,
Our Strains
http://www.tikunolam.com /our-Strains
25 Bedrocan BV,
Global Cannabis Programs
, <https://bedrocan.ca
/resources /regulatory-compliance /global-cannabis-programs />.
Exemption from prosecution for possession and use
5.28 The issues paper sought comments on whether the law should be amended to
protect patients and their carers from prosecution for
possessing or using
cannabis for medicinal purposes. An eligible patient who has been authorised to
be treated with medicinal cannabis
could be made exempt from criminal
prosecution for use or possession of the amount they need. This option could be
achieved by amending
Drugs, Poisons and Controlled Substances Act 1981
(Vic) to create an exception to the offences of possessing or using a drug
of dependence26 for small amounts of dried cannabis or
cannabis extract where a
person is an authorised medicinal cannabis user.
5.29 The exception would extend to the patient’s carers, to allow them
to possess the cannabis that the patient may lawfully
use, and would require an
additional exception to the
offence of introducing a drug of dependence into the body of another
5.30 This option was canvassed in the issues paper because a similar reform
was recommended by General Purpose Standing Committee
No 4 of the New South
Wales Legislative
Council in 2013.28 The committee recommended a complete defence to the
offences of possession and use for terminally ill patients
and those who had
moved from HIV to AIDS, for possession of up to 15 grams of dried cannabis or
equivalent amounts of cannabis products.
The defence was to have applied to a
patient or carer where the patient had been certified by their treating
specialist medical practitioner
as having been diagnosed with a specified
condition and had been listed on a register of ‘authorised cannabis
patients and
5.31 The advantage of this option is that it would protect patients and their
carers from the risk of being prosecuted, and the associated
uncertainty and
pressure of sourcing cannabis for medicinal purposes illegally. The Commission
was told on a number of occasions
prosecution for using cannabis for medicinal purposes. The idea drew some
support in submissions,
but mostly only as an initial step in introducing
broader reforms.30 Others saw no need for it, because they want to see broader
reforms introduced immediately.31
Disadvantages
5.32 Some submissions opposed this option because they did not agree that
medicinal cannabis products that are not available on prescription
used for medical treatment.32 One submission expressed concern about the wider
implications for legislative reform:
There should be under NO circumstances any forms of raw product or cannabis
derivatives in the possession of any ‘patient’
that have not been
prescribed and supervised under strict medical and TGA guidelines. These exact
caveats are exactly what the pro-pot
lobby want [to] ensure lower
accountability/scrutiny and a furtherance of ‘self-medication’
practices and ultimately
recreational use.33
Drugs, Poisons and Controlled Substances Act 1981
Consideration may also need to be given to amending section 71B
of the Act (supply of drug of dependence to a child).
28 Legislative Council General Purpose Standing Committee No 4, Parliament of
New South Wales,
The Use of Cannabis for Medical Purposes
(2013) 71 (Recommendation 2).
30 Submissions 12, 14, 28, 29, 30, 37, 49, 89, 95.
31 Submissions 4, 11, 16, 18, 19, 32, 35, 54, 84.
32 Submissions 42, 47, 48.
33 Submission 42.
5.33 The Royal Australasian College of Physicians noted that an option such
as this would allow carers to administer cannabis without
fear of prosecution
but would not ensure the safety or reliability of the composition of the product
consumed.34 The Australian
Lawful Use of Cannabis Alliance similarly observed
that it ‘would not provide a safe and consistent system of access to
cannabis treatments’.35 The Law Institute of Victoria pointed
out that it would not address the broader issues of cultivation,
manufacture
and supply.36
5.34 The Commission is of the view that, when assessed against the
regulatory objectives, the disadvantages of this option outweigh
the advantages.
It fails to provide access to a safe and reliable supply of medicinal cannabis
products. Thus, it would not integrate
cannabis effectively into a health regime: doctors would authorise patient
access to cannabis, but would not have any mechanism for
controlling or
supervising use. The products available to the patient would not necessarily be
therapeutically appropriate, as they
could have unknown or inappropriate THC/CBD
levels and may contain unsafe contaminants.
5.35 Because the cultivation and supply of cannabis would remain unlawful,
any person selling cannabis to an authorised patient or
their carer would still
be committing a serious criminal offence. The legislative change would only
assist users willing to purchase
cannabis that
has been grown and supplied illegally. This in turn would strengthen the
illicit market.
‘Grow your own’
5.36 A large number of people who made submissions and attended consultations
argued for a
‘grow your own’ scheme.37 Eligible patients could be licensed by
the government to cultivate a designated number of cannabis
plants at home for
medicinal purposes. They could be
able to nominate carers to assist them. The patients and carers would be
responsible for manufacturing the raw cannabis into a form
appropriate for the
patient to use.
5.37 This option was often put forward as a scheme that would co-exist with
cultivation by community-based, government or commercial
enterprises.38 Marie
Gladman of the HEMP Party summed up this view in her submission:
People can grow, people can make medicine, people can do whatever they like
with their own cannabis, but the minute they sell the
cannabis or cannabis
products, then they register a business and pay tax like everyone else.39
5.38 Schemes of this type are most prevalent in the United States, notably in
the jurisdictions that pioneered the legalisation of
cannabis for medicinal
purposes. Where patients are permitted to cultivate their own supply in the
United States, the law will generally
specify the maximum number of mature
plants they are permitted to possess (ranging between two and six plants, with
extra allowances
for seedlings).40 A number of states, but not
all, require that the patient be registered with the state or hold an ID card
in order to be permitted to grow cannabis.41 In Arizona,
patients are only
permitted to grow their own supply if they are sufficiently geographically
distant (at least 25 miles) from a licensed
dispensary.42
34 Submission 52.
35 Submission 35.
36 Submission 63.
37 Consultations 2, 4, 5, 6, 7, 9 (See Appendix C for list of consultations);
Submissions 6, 7, 9, 10, 11, 14, 18, 19, 23, 30, 33,
37, 53, 68, 72, 77,
80, 86, 87, 90, 93, 95.
38 Submissions 10, 11, 19, 28, 30, 37, 73, 95.
39 Submission 10.
40 For example, California has a maximum of six mature or 12 immature plants
(Cal Health & Safety Code §§ 11362.77);
Oregon has a maximum of
six mature and 18 immature plants (Or Rev Stat § 475.320); Vermont permits
a maximum of two mature
and seven immature plants (18 Vt Stat Ann §
41 ID cards must be possessed by growers in Oregon (Or Rev Stat §
475.320) and Vermont (18 Vt Stat Ann § 4474b); Licences
are not required
in California (Cal Health & Safety Code §§ 11362.5,
11362.71(f)).
42 Ariz Rev Stat Ann § 36-2804.02(A)(f).
5.39 In Australia, a grow your own scheme was recommended in 2000 by a New
Wales Working Party on the Use of Cannabis for Medical Purposes. More
recently, it was proposed by a Bill that was introduced into
the New South Wales
Parliament in 2014 and lapsed during 2015, and a draft Bill that is currently
under consideration by a committee
of the Legislative Assembly of the Australian
Capital Territory.
5.40 The Victorian
Drugs, Poisons and Controlled Substances Act
cultivation unless it is authorised by or licensed under the Act or regulations.
The Act could be amended to provide that
a licensed patient who operates within
the conditions of the licence would not be engaging in the unauthorised
trafficking, cultivation,
possession or use of a drug of dependence within the
meaning of the Act. The legislation would also need to permit the patient to
possess the necessary substances, materials, and equipment at
their residential address for this purpose. Cultivators would have to be
exempted from the operation of the
Therapeutic Goods Act 1989
5.41 A licensed patient would be permitted to cultivate the designated number
of cannabis plants at home without attracting the prohibitions
in the Act. The
legislation could
also be amended so that a licensed patient who manufactures products at home
from the cannabis they have grown, for personal use,
would not be committing
‘trafficking’ within the meaning of the Act. The patient would be
permitted to possess the necessary
substances, materials or equipment at their
residential address only for this purpose.
5.42 Further regulatory controls could include:
• requiring the patient to grow the cannabis indoors
• requiring the patient to give the Office of Medicinal Cannabis a
‘cultivation plan’
containing information about the cultivation site
• allowing authorised officers to conduct periodic inspections of any
cultivation site and report any significant failure to
comply with the
cultivation plan to the Office of Medicinal Cannabis
• treating the cultivation of more than the permitted amount of
cannabis as the unauthorised cultivation of a narcotic plant
within the meaning
sections 72
Drugs, Poisons and Controlled Substances Act
Outdoor cultivation would also be unauthorised cultivation and captured under
sections 72
5.43 This option could provide eligible patients with a readily available and
inexpensive supply of cannabis. They would have control
over their dosage,
frequency of use, and form of administration. They would no longer need to rely
on the illicit market for the
purchase of prepared cannabis, provided they were
able and inclined to grow their own, and they would be aware of the conditions
in which the cannabis is grown and processed.
43 Either by the Commonwealth, exercising
Therapeutic Goods
(Cth), or in Victoria, by making regulations under
Therapeutic Goods (Victoria) Act 2010
Patient autonomy
5.44 Ultimately, a grow your own scheme places responsibility on the patient
for their own treatment. The core feature of such a scheme
is that it gives
patients the freedom to experiment with cannabis and determine the dosage and
form that works for them. Many people
who made submissions and attended
consultations argued for a grow your own scheme on the basis that it would give
them substantial
personal freedom in and responsibility for their medical
treatment.44 Medical practitioners were said to have insufficient knowledge
for controlling access to cannabis or determining
whether it was appropriate for
a patient.45
Ease of access
5.45 A grow your own scheme was favoured also because it was seen as
accessible, in that medicinal cannabis was expected to be affordable
and easy to
obtain.46 For some it was a matter of personal choice:
I just want to be able to access it myself, growing my own Cannabis medicine
in my garden in a similar way that I grow my vegetables
to sustain my
lifestyle.47
5.46 For others, it was a matter of principle:
I am not opposed to legal growing of a small supply of the plant if a
manufactured supply becomes too expensive to those who need
it but a medicine
is more useful to us and we could pay.48
5.47 Another sentiment that was expressed a number of times, and which
is related to the issue of costs, was that a Victorian
medicinal cannabis scheme
should not be directed by the interests of ‘big pharma’. Cheryl
Wright said that cultivation
‘should not be
left to pharmaceutical companies who are interested only in profits, not
Another submission put the view that cultivation should not be regulated at
all, so ‘big pharmaceutical business has some competition,
FINALLY!’50
Disadvantages
Product quality
5.48 Under a grow your own scheme, the patient may not obtain cannabis that
is of a sufficient quality or consistent composition.
Significant variability is
caused by different cannabis strains and growing conditions, which only
sophisticated growing operations
are able fully to control. In addition,
patients and their authorised growers may have limited expertise in producing
refined products,
which can be difficult and dangerous to produce.51
5.49 Canada and Israel initially established grow your own schemes but then
moved away from them for various reasons, including quality
control concerns. In
Canada, there were concerns about the quality of the product that the patients
were using and the inability
of doctors to adequately monitor its use.52 It was
abandoned in Israel partly because there was ‘no quality control on
yield quantity and cannabis quality’.53
44 Submissions 3, 6, 7, 9, 10, 14, 16, 43, 45, 90, 97.
45 Consultation 6; Submissions 12, 59.
46 Submission 6.
47 Submission 68.
48 Submission 49.
49 Submission 2.
50 Submission 9. Emphasis in original.
51 Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) 153.
52 Health Canada,
Proposed Improvements to Health Canada’s Marihuana
Medical Access Program
(31 March 2013)
http://www.hc-sc. gc.ca
53 Submission 61.
5.50 One of the regulatory objectives recommended by the Commission is to
ensure that patients have access to medicinal cannabis products
of reliable
quality and composition. This is a priority for many of the people who spoke to
the Commission,54 some of whom have
encountered significant variability in the
products they have obtained from well- meaning individuals.55 There is no
guarantee that
personally cultivated cannabis will achieve standards appropriate
for medical treatment.
5.51 This issue is not whether patients who want to grow cannabis have
the skills to do so; it is whether the cannabis produced
is of suitable and
consistent composition and quality. This was noted in the submission from the
Drug Policy Modelling Program:
While it is possible for non-regulated growers to produce stable cannabis
free from adulterants, the reliance on unregulated suppliers
manufacturer of medicinal products poses substantial risks for patients who
cannot be guaranteed product stability and purity.56
5.52 The medical profession is generally opposed to a grow your own scheme
primarily because of concerns about quality and dosage
Engagement with professional medical care
5.53 If cannabis is to be treated as a medicine on a rational basis, it is
necessary to ensure that ‘the smallest dose is prescribed
for the shortest
period required to gain the desired therapeutic effect, under medical
supervision’.58 Under a grow your own
scheme, little can be done by a
medical practitioner to supervise how much cannabis the patient uses and in what
form. It has been
observed in the United States that ‘allowing
cultivation for any qualifying patient sacrifices too much control over a
substance currently classified as having a high risk of
5.54 Supporters of a grow your own scheme have pointed out that cannabis has
a relatively low risk profile and has the potential to
Commission was informed that:
To suggest that somehow strains becoming more potent is a problem for home
growers is not based on any independent scientific or historical
5.55 Valid points are made about the relative health risks of cannabis
compared to some legal medications. Nevertheless, if participating
your own scheme causes or encourages patients to disengage from or not engage
with the care of a medical practitioner,
the patient’s health could be put
at risk. The patient’s health could
deteriorate not because of the cannabis treatment but because of the absence
of other treatment as well.
5.56 One of the regulatory objectives recommended by the Commission is to
integrate the use of medicinal cannabis products into the
medical treatment. As stated in Chapters
2 and 3, the Commission considers that an option for law reform must enable
doctors to respond to the development of side effects
in their patients and
manage the titration of dosages and the forms of administration used. Where
there is a grow your own scheme,
doctors have little knowledge of or control
over a patient’s dose of cannabis and lack the capacity to assess its
efficacy.62
Their role in a grow your own scheme would be limited to certifying
that a patient’s condition and associated symptoms make
them eligible to
use medicinal cannabis, and discussing with the patient the risks associated
with excessive use.
54 Consultations 2, 4, 5, 6, 7, 8, 9.
55 Submission 49.
56 Submission 21.
57 Submissions 38, 39, 52, 57.
58 Laurence E Mather et al, ‘(Re) introducing Medicinal
Cannabis’ (2013) 199
Medical Journal of Australia
59 Claire Frezza, ‘Medical Marijuana: A Drug Without a Medical
Model’ (2013) 101
Georgetown Law Journal
1117, 1144.
60 Submissions 10, 59.
61 Submission 53.
62 Claire Frezza, ‘Medical Marijuana: A Drug Without a Medical
Model’ (2013) 101
Georgetown Law Journal
1117, 1135.
5.57 Some advocates of a grow your own scheme supported the idea that doctors
should only be peripherally involved, 63 the suggestion
in one submission being
that a medical practitioner should only have the ‘ability to sign a form
saying this person can use
medicinal cannabis. That’s it.’64
Indeed, there is evidence that patients who grow their own cannabis begin to
from the conventional medical system.65
5.58 A scheme that separates treatment with cannabis from the conventional
principles of medical treatment means that a patient with
a serious condition is
not receiving care based upon a holistic understanding of the patient’s
treatment. Furthermore, a grow
your own scheme provides little scope for a
medical practitioner to determine whether a person’s use of cannabis is
therapeutically
effective or is being abused.
5.59 Creating a system that prevents medical practitioners from monitoring
their patient’s use would be inconsistent with the
national designation of
cannabis as a Schedule 9 drug that is liable to abuse. Some argue that treating
cannabis as a Schedule 9
drug is fundamentally wrong, and that cannabis should
be rescheduled or de-scheduled from the SUSMP to facilitate wider access.66
However, the reason why cannabis is presently a Schedule 9 poison is not because
of its toxicity and capacity for physical damage
but substantially because of the concern that it can be abused.67 The
dependence- forming tendencies of cannabis were discussed in
the issues paper
and the effects of its unmodulated recreational use are the subject of recent
5.60 A Victorian grow your own scheme would compromise the ability of medical
practitioners to prevent their patients from abusing
cannabis, because a medical
practitioner would
have no option but to rely on the patient to report accurately the amount
that was actually being used. Such reports would not be
able to address the
actual amount of active constituents that were being taken. There is very little
that can be done to address
these issues in a grow your own scheme. It is a
consequence of a scheme that makes the patient responsible for deciding how much
cannabis they will use and in what form, thereby removing the capacity from the
medical practitioner, which exists in relation to
orthodox medications, to
titrate usage on the bases of dose-response and dose-side-effect.
Potential for diversion
5.61 Patients and their carers participating in other schemes of this type
have been selling on the illicit market, or giving away,
cannabis they have been
licensed to cultivate for personal use.69 Diversion in these and other ways
could occur in a Victorian grow
your own scheme as well.
5.62 A study of Canada’s scheme in 2012 estimated that that 36 per cent
of grow your own licences were subject to ‘misuse’,
defined as the
sale of cannabis grown under such a licence into the illicit market.70 Another
example is found in the United States,
where the Chair of Oregon’s Liquor
Control Commission estimated that up to 75 per cent of Oregon’s medicinal
was diverted into the illicit market.71
5.63 The submissions that raised this issue noted that it is difficult to
ascertain how much personally cultivated cannabis is moving
into the illicit
market,72 and this is reinforced by the research.73
63 Submissions 2, 10, 30, 37, 52, 59, 64.
64 Submission 10.
65 Pekka Hakkarainen et al, ‘Growing medicine: Small-scale cannabis
cultivation for medical purposes in six different countries’
International Journal of Drug Policy
66 Submission 59; Consultations 1, 9.
67 Advisory committee (Meeting 3).
68 Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [3.75] – [3.79]; Wayne Hall, ‘What Has Research Over The
Two Decades Revealed About the Adverse Health Effects of
Recreational Cannabis Use?’ (2014) 110
69 Yu-Wei Luke Chu, ‘The Effects of Medical Marijuana Laws on Illegal
Marijuana Use’ (2014) 38
Journal of Health Economics
Final Report: Cost-Benefit Analysis of Regulatory Changes for
Access to Marihuana for Medical Purposes
(2012) 74–75.
71 Jeff Mapes, ‘Medical marijuana growers may see new limits as Oregon
legislators move to curb black market’,
The Oregonian
http://www.oregonlive.com /mapes /index.ssf/2015/ 03/medical_marijuana_growers_may.html
72 Submission 74.
73 Gerald Caplan, ‘Medical Marijuana: A Study of Unintended
Consequences’ (2012) 43
McGeorge Law Review
127, 143– 4.
5.64 Even a small crop of cannabis is worth a substantial amount of money on
the illicit market, and this has led other governments
to disallow grow your own
because of the risk to patients. For example, in deciding to prohibit grow your
own on the basis that
it was a ‘public nuisance’, the Californian City of Galt
estimated that six mature plants lawfully cultivated in an individual’s
cannabis garden would have a market value of US$12,000.74
5.65 Therefore, even with restrictions limiting cultivation to a small number
of plants there remains the risk that patients will
be targeted by criminals for
their cannabis.75 It was observed in one submission that ‘we don’t
want people put at risk
because they have a high value crop or having their
medicine stolen and putting their health at risk’.76 Another observed
that ‘[t]he risk to growers may be significant, and thus invasion of
private property and risk to personal safety, being the
concern’.77
5.66 Victoria Police expressed the view in its submission that the police
would not be able to protect personal cultivators from being
targeted by
Personal crops would be a likely target for theft. Theft has the potential to
escalate into crimes against the person, for example
through owners protecting
their crops, or through retaliatory actions. It would be extremely difficult for
police to protect potentially
large numbers of personal crops and their owners
from targeted criminal activity.78
5.67 To reduce the risk that personally cultivated cannabis will be targeted
by criminals, other jurisdictions have required cultivation
to be undertaken
indoors79 or simply prohibited grow your own schemes entirely.80 Indoor
personal cultivation is thought to reduce
the public visibility and smell of
cannabis, making it less of a target.81 The Californian cities that permitted
indoor cannabis
cultivation prescribed the maximum dimensions of the cultivation
space (both in area and height), restricted the maximum number of
could be grown (notwithstanding the number of qualified patients or
caregivers engaging in cultivation) and prohibited exposing cannabis
public view.82
5.68 Some supporters of a grow your own scheme argued for this approach:
Cannabis cultivation can be controlled to a very high extent, meaning that it
done indoors, under completely artificial conditions. It can also be strictly
limited by such conditions, such as by a restriction
on growing area or
available lighting. It follows that
a framework restricting a patients growing space indoors would limit the
production of the medicine and prevent commercial cultivation.
One should need
to prohibit
the outdoor cultivation absolutely, but there are legitimate security and
public safety issues that justify such a policy in any case.
As with potentially
dangerous weapons, cannabis ought to be kept under lock and key, and restricted
to a scale and ‘firepower’
commensurate with the need. 83
74 City of Galt, Ordinance No. 2015-01, s 1.
75 In Canada, these have become known as ‘grow rips’: see Ian
Freckelton, ‘Medicinal Cannabis Reform: Lessons from
Litigation’ (2015)
Journal of Law and Medicine
76 Submission 53.
77 Submission 70.
78 Submission 44.
79 See for example the account of the city-by-city regulation of medicinal
cannabis in California provided by the City of Martinez,
City Council
(April 16, 2014), 6 –10. Berkeley, Oakland, San Diego
and San Francisco are four prominent exceptions.
80 Stephen C Collett, Tom Gariffo and Marisa Hernandez-Morgan, Evaluation of
the Medical Marijuana Program in Washington, DC, (University
of California, Los
Angeles Luskin School of Public Affairs, 2013) 15; Health Canada, Medical
Marihuana Regulatory Reform 2011
Consultations Results, (31 January 2013)
http://www.hc-sc.gc.ca /dhp-mps /consultation /marihuana /_2011/program /consult_reform-eng. php
81 City of Galt, Ordinance No. 2015-01, s 1. See also Submission 53.
82 City of Martinez,
City Council Agenda
(April 16, 2014), 6
–10. See, eg City of Ferndale, Ordinance No. 2013-03 § 6.2.9.
83 Submission 23.
5.69 Indoor cultivation may reduce the risk that a patient will be targeted
by criminals but
only to a modest degree; risks remain of the commission of break and enter
and robbery
(including armed) offences to steal what is otherwise an illegal and valuable
5.70 In addition, there are significant risks to the health and safety of
those who grow their own and to the health and safety of
the community.
5.71 If cannabis is not cultivated responsibly and diligently, it can become
contaminated in
a way that threatens the health of the person who consumes it. For example,
cannabis may become contaminated with mould or harmful
bacteria;84 pesticides;85
or metals like lead, mercury, and zinc.86 These risks are exacerbated by indoor
cultivation.87
Additionally, certain techniques for cultivating cannabis indoors use a great
deal of power. If the electrical system of a residence
is not designed to cope
with the increased load or is poorly wired, it can cause fire or electrocution.
In Canada, for example, the
Royal Canadian Mounted Police found that the risk of
fire was 24 times higher than in residences in which cannabis was not
cultivated.88
5.72 Contaminated cannabis poses an elevated risk to patients with serious
illnesses. For example, patients with AIDS or otherwise
compromised immune
systems have reportedly developed lung infections when smoking cannabis
contaminated with
Aspergillus
5.73 Consistently with their emphasis on personal freedom in medical
treatment, advocates for a grow your own scheme tended to argue
that avoiding
these risks was a matter
of ‘due diligence’ for the cultivator roughly equivalent to that
required to cultivate vegetables safely.90 The Commission
was told on a number
of occasions that cultivating cannabis does not require a great deal of
expertise,91 although the opposite
has also been suggested.92 Furthermore it
was suggested that there is a significant amount of material available that
patients and carers develop the necessary skills and that
need to learn how to deal with this’.93
A partial solution
5.74 No matter how many patients were able to grow their own cannabis and
make their own products safely, a grow your own scheme would
be only a partial
solution. The Commission also heard that many people did not want to prepare
their own medicinal cannabis.94 Some
of them were unfamiliar with cannabis,
cautious about personally cultivating cannabis and did not want to learn about
it.95 Michelle
Whitelaw, for instance, was unequivocal: ‘I do not wish to
cultivate or be my son’s pharmacist.’96
84 John McPartland, ‘Contaminants and adulterants in herbal
cannabis’ in Franjo Grotenhermen and Ethan Russo (eds)
Cannabis and
Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential
Press, 2002) 337–9; Jennifer McLaren et al, ‘Cannabis potency and
contamination: a review of the literature’
(2008) 103 Addiction 1100,
85 John McPartland, ‘Contaminants and adulterants in herbal
cannabis’ in Grotenhermen and Russo (eds)
Cannabis and Cannabinoids:
Pharmacology, Toxicology, and Therapeutic Potential
(Haworth Press, 2002)
86 ‘Symposium, ‘Practical, Legal, and Ethical Perspectives on
Medical Marijuana’ (Transcription of Speakers’
(2012) 16 MSU
Journal of Medicine and Law
87 John W. Martyny et al,
Health Effects Associated with Indoor Marijuana
Grow Operations
88 Ian Freckelton, ‘Medicinal Cannabis Reform: Lessons from Canadian
Litigation’ (2015)
Journal of Law and Medicine
89 Mark Ware and Vivianne Tawfik, ‘Safety Issues Concerning the Medical
Use of Cannabis and Cannabinoids’ (2005) 10
Pain Research and
90 Submission 53.
91 Submissions 6, 14, 53.
92 Alex Wodak and Laurence Mather, ‘Australia Has No Reason To Disallow
Medical Cannabis Use’ The Conversation (online)
http://theconversation.com /australia-has-no-reason-to-disallow-medical-cannabis-use-24717
Families and Friends for Drug Law Reform, Submission No 82 to the ACT Standing
Committee on Health, Ageing, Community and Social
Exposure Draft of
the Drugs of Dependence (Cannabis Use for Medical Purposes) Amendment Bill
, 16 February 2015, 5. The submission from the cannabis community of
Victoria also noted these issues: Submission 95.
93 Submission 53.
94 Consultations 2, 13, 23; Submissions 29, 31, 42, 54, 70, 71
95 Consultation 13; Submissions 70, 71.
96 Submission 71.
5.75 The opponents of grow your own were generally eager to try medicinal
cannabis products, but only if regulated and supplied in
a way that is similar
to prescription medicines.97 Some were dealing with serious, debilitating
conditions, or were parents caring
for children suffering from such conditions.
For them, requiring or encouraging seriously ill patients to cultivate cannabis
This is not the dark ages and it seems quite disrespectful and unfair to
those who are in need, to have to grow their own or suffer
without. Those people
who are so debilitated they can barely manage to get out of bed may qualify to
grow their own, but it poses
the question, how?... How will they maintain and
grow a crop for personal use if they are physically infirm or in pain ... Would
this not be a foolish exercise when the probability of gain may be ruined
entirely by not having the appropriate skills necessary?
A ruined crop may mean
that person has to go without. This is certainly not a compassionate nor safe
5.76 These concerns were underscored by the submission from Cancer Action
Victoria, which noted that it ‘was not in favour of
a “grow your
own” scheme. This is not feasible for patients who are debilitated by
their illness’.99 The problem
is exacerbated by the issue that the most
obvious method of ingesting cannabis under a grow your own scheme is through
smoking,100
which many people are unwilling to do for health reasons.101
5.77 As noted above, a number of the advocates for a grow your own scheme
envisaged that it would operate alongside a scheme that
provided for medicinal
cannabis products to be produced by regulated community, government or
commercial entities. This means that
the Victorian Government would still need
to establish a scheme for the production of medicinal cannabis products, in
collaboration
with the Commonwealth and in compliance with the Single Convention
on Narcotic Drugs, but for a smaller patient group.
5.78 The co-existence of a grow your own scheme and production by regulated
entities is not advisable. Some advocates have drawn analogies
with home-grown
and commercially grown vegetables. However, cannabis would remain illegal for
most Victorians, and there would continue
to be an illicit market for
recreational and other unauthorised use.
5.79 One submission noted that, where both personal and government-regulated
cultivation are permitted, it is more difficult to track
what goes onto the
black market.102 Mullaways Medicinal Cannabis Pty Ltd expressed the view that a
grow your own scheme is ‘nearly
the worst of all options’ for the
patient, for medical practice and from a policing perspective.103 The Law
Institute of Victoria
maintains that:
any schemes that would self-regulate the end user as a grower should be
avoided, as it would undermine the regulatory system around
cultivation and
supply of drugs and weaken public confidence in the regulatory system.104
97 Consultations 2, 4.
98 Submission 70.
99 Submission 54.
100 Arno Hazekamp and George Pappas, ‘Self-Medication with
Cannabis’ in Roger Pertwee (ed)
Handbook of Cannabis
Press, 2014) 329–30.
101 Advisory committee (Meeting 1); Consultations 8, 9, 12, 13, 23;
Submissions 47, 70, 74.
102 Submission 74.
103 Submission 29.
104 Submission 63.
Compliance with international law
5.80 Furthermore, any scheme that includes grow your own is at odds with the
system of control prescribed by international law.105
The International
Narcotics Control Board has recently made clear its view that grow your own
schemes do not comply with the Single
Convention on Narcotic Drugs:
The Board has reviewed the issue of cultivation of cannabis for personal
medical use and has determined that, in the light of the
heightened risk of
diversion it represents, such cultivation does not meet the minimum control
requirements set out in the Single
Convention. Accordingly, the Board has
consistently maintained the position that a State which allows individuals to
cultivate cannabis
for personal use would not be in compliance with its legal
obligations under the Single Convention.106
5.81 Given this position, Australia’s international obligations pose a
major impediment to the adoption of a scheme that includes
grow your own. This
would affect the legal stability of a grow your own scheme in Victoria, because
of the incompatibility of Australia’s
international obligations under the
Convention and an essentially unregulated grow your own scheme.
5.82 Medical and regulatory experts overwhelmingly rejected this option when
discussed at consultations, as did a significant number
of patients and their
families who want medicinal cannabis to be made available in the same way as
prescription medication. The Commission
shares their concerns. A grow your own
scheme would not provide all eligible patients with access to medicinal cannabis
would exclude those who
do not have the wish, resources, skills and ability to grow their own plants
or have them grown on their behalf. It would not ensure
that the patient’s
cannabis use is integrated with their other medical treatment because their
medical practitioner would not
know of, or be able to monitor, what they were
using or its effects. A patient using home-grown cannabis may not be using a
of sufficient quality or consistent composition because of the
significant variability caused by different cannabis strains and growing
conditions, which only sophisticated growing operations are able fully to
5.83 The Commission considers that the products that are made available under
any medicinal cannabis scheme should not be able to
be smoked, which is more
likely in a grow your own scheme. It also considers that a grow your own scheme
would be a substantial diversion
risk, as there would be no distinction between
licit and illicit dried plant products and the limits on production and
distribution
would be very difficult to enforce. This
would undermine efforts to preserve the continuing prohibition of unlawful
trafficking, cultivation, supply and use.
5.84 This option would not ease the regulatory burden and the related costs
to the Victorian Government compared to other options,
because an alternative
scheme would still need to be introduced for patients who are unable—or do
not wish—to be responsible
for producing their own medicine.
105 Standing Committee on Health, Aging, Community and Social Services, ACT
Legislative Assembly,
Inquiry into Exposure Draft of the Drugs of Dependence
(Cannabis Use for Medical Purposes) Amendment Bill 2014 and Related Discussion
Report of the International Narcotics Control Board for 2014
International Narcotics Control Board, E/ INCB/2014/1 36.
Regulated not-for-profit production and distribution
5.85 Some submissions advocated the creation of regulated not-for-profit
cooperatives, collectives or clubs which would arrange for
the collective
cultivation and manufacture of medicinal cannabis products for distribution to
their members.107 A submission made
on behalf of the cannabis community of
Victoria described these cooperatives as follows:
[M]embers of the Compassion Club or Co-operative join the club for an annual
membership fee and come together sharing skills and resources
to cultivate,
distribute and or manufacture cannabis and cannabis products in accordance with
a clubs constitution, rules and or
regulations.108
5.86 Victoria could exempt associations such as these from the
Therapeutic
(Cth) without the co-operation of the Commonwealth, as long as
they are unincorporated. Victoria could make regulations under
section 6(3)
Therapeutic Goods (Victoria) Act 2010
(Vic) to exclude the operation
of the Commonwealth Act for the purposes of the production and distribution of
medicinal cannabis by
authorised unincorporated cooperatives.
5.87 As the submission on behalf of the cannabis community of Victoria noted,
cooperatives can in principle be incorporated or unincorporated.109
Commonwealth would have to exempt medicinal cannabis from the
Therapeutic
Goods Act 1989
(Cth) in order to allow incorporated cooperatives to produce
medicinal cannabis products.
5.88 Any cooperative that wished to refine cultivated cannabis into other
forms such as oils
or tinctures would still need to obtain a manufacturing licence from the
Commonwealth under the
Narcotic Drugs Act
. This option therefore relies on the
Commonwealth
agreeing to license cooperatives so they may provide patients with cannabis
in a form that is appropriate for their medical needs,
rather than forcing
patients to resort to smoking.
5.89 To create the scheme, Victoria could amend the
Drugs, Poisons and
Controlled Substances Act
to provide for licences to be issued either to a
cooperative (to produce medicinal cannabis products for its members), or to a
nominated by the cooperative (to cultivate a certain amount of cannabis,
or produce products, as determined by the cooperative and
approved by the
government).
5.90 The licensees would need to comply with detailed rules, which could be a
combination of licence conditions, statutory provisions
and regulations, to
ensure that the products are
of good quality and provided to authorised patients. The cannabis community
of Victoria put forward a detailed proposal, based on
the British Columbia
Compassion Club Society, in which the cooperative would operate a closed system
encompassing all steps of the
production and supply of the product as well as
patient care.
107 Consultation 1; Submissions 13, 15, 35, 95.
108 Submission 95.
Simple and cheap to regulate
5.91 Regulating cooperatives is thought to be simple because its members are
responsible for arranging for cultivation and guaranteeing
the quality of the
cannabis they purchase from cultivators and manufacturers. All of the activities
associated with cannabis production
and supply are concentrated in a single
association of patients and carers, and this is
said to reduce the regulatory burden and cost of medicinal cannabis.110 The
submission made on behalf of the cannabis community of
Victoria noted that the
British Columbia Compassion Club Society screens its cultivators. The Society
goes so far as to inspect cultivation
sites for cleanliness, safety, plant
quality, and security.111
Viable alternative to illicit market
5.92 Because cooperatives are thought to provide a simple and cheap source of
cannabis, they are asserted to undermine the illicit
market for cannabis. For
example, it was noted that cooperatives provide a viable alternative to the
black market that can be taxed
and that reduce diversion.112 Trich from the
Cannabis Social Club Australia said that criteria
of access to medicinal cannabis should not be too restrictive because
‘one of the main aims of legalisation—to reduce
the size of the
criminal market—will not be met’.113 This reasoning is commonly
associated with advocacy for legal
cannabis for recreational purposes.114
Indeed, the advocates for this option generally assumed in their submissions
that they would
be permitted to supply cannabis to a large market. Trich said
that ‘millions of reasonable users’ could be supplied under
compassion club scheme.115
5.93 The Commission notes that any scheme established by the government
would provide an alternative to the illicit market, as
well as creating a risk
that products produced under the scheme would be diverted to it.
5.94 The purpose of the proposed reform, conveyed by the terms of reference,
is on providing cannabis for medicinal purposes to a
confined group of patients.
This would limit the potential membership base for cooperatives of this type to
people with complex medical
Disadvantages
5.95 The Commission is concerned that adapting cooperatives to suit
Victoria’s requirements would require significant regulatory
intervention
which is unlikely to be feasible. As has been identified in Chapter 4, for a
scheme to support Australia’s international
obligations it must take
specific regulatory measures to limit diversion and ensure that accurate
estimates can be reported to the
Commonwealth. Furthermore, patients are
entitled to expect that any medicine they receive is of sufficient quality and
is not unduly
harmful to their health.
110 Submission 95.
112 Submission 13.
113 Submission 15.
114 Pekka Hakkarainen and Jussi Perala, ‘With a Little Help From My
Friends – Justifications of Small-Scale Cannabis Growers’
Decorte et al. (eds)
World Wide Weed: Global Trends in Cannabis Cultivation
and its Control
(Ashgate, 2011) 83.
115 Submission 15.
An alternative to conventional medical treatment
5.96 A cooperative scheme is designed to concentrate expertise in growing and
using cannabis within the cooperative. Some supporters
of cooperatives argued
that a system of distributing medicinal cannabis should not be merged with the
general medical system.116
However, as is explained below in relation to dispensaries, the risk of
concentrating treatment with cannabis in cooperatives is
that patients may begin
to disengage from the conventional medical system.117 This would be
incompatible with the regulatory objectives.
A scheme should ideally be
integrated with a patient’s conventional medical treatment, not act as a
replacement.
Diversionary risks
5.97 Substantial diversionary risks are associated with cooperatives. The
submission made on behalf of the cannabis community rejected
this, asserting
that ‘[d]espite suggestions that these organizations may operate as a
front for organised crime and diversion
to the illicit market, there is little
evidence to support these claims’.118 The submission claimed that
in Canada ‘police organizations recognize this fact and tolerate the
operation of both Compassion Clubs /Medicinal Cannabis
Dispensaries’.119
The Commission notes that in light of concerns about diversion120 Canada moved
to replace illegal cooperatives
with what is effectively a regulated dispensary
5.98 Furthermore, there is some evidence in other jurisdictions that
cooperatives are targeted by criminals who wish to take advantage
legitimate front for cultivation and manufacture they provide. For example, in
Belgium it has been reported that cooperatives
are frequently approached by
potential cultivators who are uninterested in complying
with the cooperative’s rules, have cultivated cannabis of poor quality
deliberately to offset costs, and have cultivated more
cannabis than is required
in order to sell it to others illegally. Belgian cooperatives have reported that
they are in greater fear
of ‘systematic violence from criminal
entrepreneurs than of police intervention’.121 Spain, which permits the
of not-for-profit cooperatives, also suffers from this problem.122
5.99 The Commission notes that these risks could be managed through robust
regulatory oversight. However, such regulation would reduce
the capacity of the
cooperative to self-regulate and weaken its autonomy. It would also increase the
costs of the scheme, weakening
the reasons for preferring it over alternatives.
This calls into doubt a core rationale of a cooperative scheme: that it is cheap
to regulate.
Quality control
5.100 As noted above, members of a cooperative could take steps to ensure
that they are obtaining cannabis of sufficient quality from
cultivators.
However, there is some evidence that, like people who grow their own,
cooperatives encounter difficulties ensuring the
quality and safety of cannabis.
For example, cooperatives in Belgium claim that they
test their cannabis for contaminants but the practicality of their methods
has been questioned.123 The actual THC content of the
cannabis produced by
Belgian cooperatives is often unknown, making it impossible to estimate dosages
with any accuracy.124 The procedures
Belgian cooperatives have adopted to
guarantee quality control have been described as ‘superficial and rather
subjective’.125
116 Submission 15.
117 See [5.113].
118 Submission 95.
120 Health Canada,
Proposed Improvements to Health Canada’s
Marihuana Medical Access Program
(31 March 2013)
http://www.hc-sc. gc.ca
Ian Freckelton, ‘Medicinal Cannabis Reform: Lessons from
Canadian Litigation’ (2015)
Journal of Law and Medicine
121 Tom Decorte, ‘Cannabis Social Clubs in Belgium: Organizational
Strengths and Weaknesses, and Threats to the Model’
International Journal of Drug Policy
122 Jonathan Caulkins et al, Considering Marijuana Legalisation: Insights for
Vermont and other Jurisdictions (RAND Corporation, 2015)
123 Tom Decorte, ‘Cannabis social clubs in Belgium: Organisational
strengths and weaknesses, and threats to the model’
International
Journal of Drug Policy
125 Ibid 129.
Compliance with international obligations
5.101 It would not be feasible for a cooperative to be compliant with
Australia’s obligations under international law. Advocates
not-for-profit cooperative scheme argued that it complied with the Single
Convention on Narcotic Drugs.126 The argument is
that that the international
conventions allow states to decriminalise cannabis for personal consumption, and
that this latitude extends
to the cultivation of cannabis for personal
consumption.127
Interpretations like these take cooperatives into ‘uncertain
territory’ from an international law perspective.128
5.102 If a decision were made to regulate cooperatives as a system of
cultivation and distribution for the purposes of medical treatment,
them consistently with international law would become difficult. If the state
took positive legislative steps
to regulate the cultivation of cannabis for medicinal purposes, as opposed
to merely decriminalising its personal cultivation and
use in small amounts, the
Single Convention
on Narcotic Drugs requires a government agency to license cultivators129 and
take physical possession of the crops of cannabis.130
If Victoria wished to
impose these requirements, it would further increase the regulatory costs of a
cooperative scheme.
5.103 The Commission does not consider that this option is suited to
Victoria. The Commission was told on several occasions that patients
families would like medicinal cannabis to be treated as much as possible like
conventional medications. However, having
medicinal cannabis cultivated by and
for closed communities of users could reinforce negative perceptions about using
it, perpetuate
doubts about its efficacy, and undermine efforts to encourage
communication between patients and their medical
practitioners about whether it could provide them relief. It would also
significantly exclude the involvement of medical practitioners
in monitoring the
effectiveness of the medicinal cannabis and taking suitable measures to address
any risks or side effects.
5.104 The Commission also notes that this option would provide little, if
any, opportunity for the government to take possession of
the medicinal cannabis
before it is distributed to patients, as required by the Single Convention on
Narcotic Drugs. The lack of
such an opportunity may deter the Commonwealth from
agreeing to issue the manufacturing licences on which the scheme would
Regulated distribution through dispensaries
5.105 Many submissions suggested that medicinal cannabis products could be
distributed through dispensaries.131 Dispensaries have
been established in a
number of jurisdictions overseas as outlets for producers of medicinal cannabis
products or in connection with
a clinic that specialises in the use of those
5.106 Dispensaries arrange for the production by cultivators and
manufacturers of medicinal cannabis products, which they then supply.
make dispensaries ‘sponsors’ within the Commonwealth’s
therapeutic goods framework. Accordingly, the
Commonwealth would need to provide
an exemption under the
Therapeutic Goods Act
enabling Victoria to regulate the
distribution of medicinal cannabis products by dispensaries.
126 Submission 15.
127 Amber Marks,
The Legal Landscape for Cannabis Social Clubs in Spain
(Observatorio Civil De Drogas, 2015) 10.
128 David Bewley-Taylor,
International Drug Control: Consensus Fractured
(Cambridge University Press, 2012) 190.
Single Convention on Narcotic Drugs 1961
art 23(2)(b).
131 Submissions 12, 30, 37, 53, 54, 55, 61, 71, 76, 84, 91.
Drugs, Poisons and Controlled Substances Act
could be amended to
provide for a licence to be issued to the entity to distribute medicinal
cannabis products.132 The amount and
content of the associated rules would
depend on the entity, but probably would be directed to the risk of diversion to
the illicit
5.108 The form and function of medicinal cannabis dispensaries that operate
overseas vary.
The common elements are that they supply only cannabis products and usually
offer the customer a variety of products, information
and effects of each, and advice about which could be most suitable in treating
their conditions.
5.109 By specialising only in the distribution of cannabis products,
dispensaries are able to provide patients with a broad choice
in obtaining the
cannabis they are permitted to use, together with advice about which products
could be most suitable for them.133
Disadvantages
Replacing medical decision making
5.110 The operation of dispensaries, like not-for-profit cooperatives, could
discourage or replace the need for medical professionals
to make decisions about
whether the patient’s use of cannabis is therapeutically appropriate.
5.111 Like cooperatives, dispensaries purport to perform many functions
conventionally performed by a prescribing doctor.134 The submission
on behalf of
the cannabis community of Victoria observed that medicinal cannabis dispensaries
‘provide health care services
to the patient and assist patients in
achieving therapeutic outcomes’, and
‘educate and assist patients in selecting appropriate cannabis strains
and or products... for specific therapeutic needs and
outcomes’. The submission stated that dispensaries provide detailed advice
on the risks, benefits, contra-indications,
undesired effects, dosage,
application, and safe use of cannabis.135
5.112 Some argued that this was an advantage of dispensaries, and that the
current lack of medical or pharmacist expertise or interest
in cannabis made
dispensaries necessary.136
For example, Fred Andronikos argued that dispensaries would be necessary in
Victoria because ‘[m]ainstream doctors and pharmacy
preparations are a
decade or more away and until then its going to take a specialist dispensary
doctors, to work with the patients
specialist physicians to make this
5.113 The role that the Commission recommends that medical practitioners
would have under a Victorian scheme is intended to encourage
them to increase
their knowledge about medicinal cannabis and engage with their patients about
using it in tandem with any other
medications. Without such integration,
specialists may refuse to treat patients
who use cannabis because it does not form part of the patient’s
conventional treatment. Patients in this situation may be forced
between dispensaries and specialist doctors, which may negatively affect the
patient’s health.138
132 As required by the
Single Convention on Narcotic Drugs 1961
133 Arno Hazekamp and George Pappas, ‘Self-Medication with
Cannabis’ in Roger Pertwee (ed)
Handbook of Cannabis
Press, 2014) 328.
134 Rita Marcoux, E Paul Larrat and F Randy Vogenberg, ‘Medical
Marijuana and Related Legal Aspects’ (2013) 38
Pharmacy and
Therapeutics
135 Submission 95.
136 Submissions 37, 53, 76, 84, Consultation 3.
137 Submission 53. Dispensaries in which specialist doctors work were
described by the cannabis community of Victoria as ‘medicinal
138 As has been reported in other jurisdictions: Rod Meloni,
‘University of Michigan Doctor Refuses To Treat Girl Who Is Using
Marijuana to Stop Seizures’
Click on Detroit,
1 April 2015
http://www.clickondetroit.com /news /university-of-michigan-doctor-refuses-to-treat-girl-who-is-using-medical-marijuana-to-stop- seizures
Compliance with international obligations
5.114 It would be very difficult to create an opportunity for the state to
take possession of medicinal cannabis under a dispensary
system without imposing
a substantial and contrived regulatory burden. Dispensaries typically purchase
cannabis wholesale from producers.
If the state were to take possession of
cannabis and arrange for its distribution to dispensaries it would increase the
costs of the scheme. These costs would either be passed on to
patients by dispensaries (as usually occurs in private markets) or
be absorbed
by the state of Victoria.
5.115 Nor does the introduction of dispensaries resolve the problem of how to
regulate cultivation and manufacture. As the submission
on behalf of the
cannabis community of Victoria indicated, dispensaries operate as stand-alone
operations that contract with independent
cultivators, or act as a retail front
for commercial cultivators or a
cooperative.139 It would be necessary to create an additional layer of
regulation to allow dispensaries to be lawfully supplied with,
distribute, cannabis.
5.116 The Commission is not persuaded that there is such a need for
dispensaries as to justify additional regulation. It considers
it appropriate
that pharmacies dispense cannabis, in light of the views expressed in
submissions and at consultations that pharmacies
are convenient, form part of
conventional medicine, employ trained staff and are already established
throughout urban and rural Victoria.140
5.117 Accordingly, setting up a dispensary system is not likely to reduce the
regulatory costs of a Victorian scheme or reduce the
cost of cannabis supplied
under that scheme. On the contrary, it would add an additional, unnecessary
layer of regulation.
5.118 The Commission does not consider this option appropriate for a
Victorian medicinal cannabis scheme. Unlike the United States,
not-for-profit dispensaries have been established under state medicinal cannabis
schemes because the federal government prohibits
the sale of cannabis for
profit, there is no regulatory incentive in Victoria to find an alternative to
distribution by pharmacies.
Government-enforced monopoly
5.119 Under this option, a single entity with the necessary ability and
capacity would cultivate and distribute cannabis and deliver
government, for distribution through pharmacies. The entity could be any of the
• a government agency or government-owned corporation
• a university or research institute
• a privately owned corporation.
5.120 For this option to be legally stable, Commonwealth support would be
needed for each of these alternatives. The entity would
need to be licensed
Narcotic Drugs Act
and granted an exemption from regulation under the
Therapeutic Goods Act
. It is possible, however, that neither of these
requirements applies to a Victorian agency or a statutory authority that does
generate revenue from its activities.141
139 Submission 95.
140 Submissions 2, 20, 24, 29, 39, 48, 69, 97; Consultations 1, 9, 13, 18,
141 Advisory committee (Meeting 2).
5.121 The option could be established in either of two ways. The
Poisons and Controlled Substances Act
could be amended to permit a specified
government-funded or owned entity to cultivate and manufacture cannabis for
medicinal purposes
and exempt it from
of the Act (concerning offences
relating to drugs of dependence). Alternatively, the
Drugs, Poisons and
Controlled Substances Act
could be amended to provide for a licence to be issued
to cultivate and manufacture cannabis products and deliver them to the
government.
5.122 A government-enforced monopoly would allow the Victorian Government to
take advantage of an entity with existing expertise in
producing plant products
of high quality in a safe and controlled environment. Because only one producer
can ever be involved, the
scheme would not involve a substantial regulatory
burden. The Secretary of the Department of Health and Human Services through
Office of Medicinal Cannabis would only have responsibility for
administering a single producer. The amount and quantity, form and
composition
of the cannabis to be produced by the single producer would be set out in a
contract negotiated with the Victorian Government.
Preventing diversion
5.123 Allowing for a single producer that is solely responsible for
cultivating and manufacturing cannabis for delivery to the Victorian
Government,
and which acts under a monopoly granted by the government, would be unlikely to
give rise to diversionary concerns
and would enable the accurate and prompt reporting of estimates and quotas to
the Commonwealth. Accordingly, the scheme would comply
with the objectives of
the Single Convention on Narcotic Drugs.
Concentrating expertise
5.124 The viability of such a scheme depends on whether Victoria could
identify a single entity with a capacity to produce cannabis
‘in-house’. Potentially, a government- controlled scheme can be
quite large. The University of Mississippi,
for example, has had its contract to
cultivate cannabis renewed at US$68.8 million to grow 30,000 plants.142
However, the University has been cultivating cannabis for research purposes
since 1968, operates a ‘Marijuana Research Project’,
and is solely
responsible for supplying cannabis to researchers for their clinical trials.
This demonstrates the importance of the
expertise and capacity of the entity,
across every aspect of the production chain, to the success of a monopolistic,
government-controlled
Disadvantages
5.125 Some submissions suggested that the experience overseas does not
support, on balance, the use of a government-enforced monopoly
to control the
production of medicinal cannabis. For example, Alkman Management Services Pty
Ltd argued against the Victorian Government
exercising monopolistic control over
the cultivation and manufacture of medicinal cannabis, asserting that a monopoly
over cultivation
and manufacture has contributed to problems with cost and
quality in Canada and the Netherlands.144
Similarly, UTT BioPharmaceuticals argued that ‘a single entity is not
advised, since it could create a monopolistic environment,
which could slow down
research and development of new drugs’.145
142 ‘Uncle Sam Will Buy $69 Million Worth of Pot from Ole Miss’,
Time Magazine,
(online), 23 March 2015 <
http://time.com /3755253/
university-mississippi-marijuana />.
143 Evan Halper, ‘Mississippi, Home to Federal Government’s
Official Stash of Marijuana’,
Los Angeles Times
, (online), 28 May
2014 <http://
www.latimes.com /nation
144 Submission 41.
145 Submission 60.
Reliance on a single producer
5.126 Furthermore, if a single agency, university, or government-owned
corporation is solely responsible for producing and supplying
cannabis, a great
amount of risk is concentrated in that single producer. If any step in the
production chain failed—for example,
if a crop of cannabis were
lost—it would significantly reduce the amount of medicinal cannabis
available to patients.
Inflexibility
5.127 Although a government monopoly scheme is relatively straightforward, it
is also inflexible.
The scheme is not designed to evaluate the eligibility of multiple producers.
adopted regulatory
structures that can accommodate multiple producers (regardless of whether
multiple producers actually participate
in the scheme).
5.128 Because only one producer would ever be involved, the scheme would not
involve a substantial regulatory burden. It would create
a simple mechanism that
is substantially compliant with international law and allow for an experienced
entity to start producing
cannabis medicines relatively quickly.
5.129 The government would have to identify a producer that it trusts to
operate across all aspects of the production chain and which
can consistently
produce enough cannabis of sufficient quality to satisfy the requirements of a
Victorian medicinal cannabis scheme.
The scheme turns on the capacity of that
single producer to manage risks
and supply enough product without subcontracting its functions to other
cultivators and manufacturers. If a suitable entity could
be identified, this
option could be an intermediate step in establishing a scheme that is
sustainable in the long term.
5.130 Unlike the licensed producer scheme set out below, a
government-enforced monopoly would not provide the regulatory framework
accommodate multiple cultivators and manufacturers. It would be preferable,
given the risks associated with a single producer,
to establish a flexible
regulatory framework that is capable of accommodating multiple producers.
Multiple licensed producers
5.131 Many submissions proposed that Victoria should license multiple
private-sector cultivators and manufacturers similarly to the
framework used to
regulate poppies.146 This option would provide ‘a comprehensive scheme
regulated through every step of the
supply chain which includes cultivation,
manufacturing, processing, distribution and use’.147
5.132 This option resembles the Israeli and Dutch arrangements for the
production and distribution of cannabis, using the Victorian
poppy straw
regulatory framework and drawing on the Commonwealth scheme for licensing
manufacturers of therapeutic
goods. Broadly, it would involve the cultivation and manufacturing of
cannabis by licensed cultivators and manufacturers respectively.
Standards would
need to be established to ensure that licensed cultivators and manufacturers
produce products of sufficient quality
to be used as a medicine.
146 Advisory committee (Meeting 2); Consultations 3, 4, 5, 12, 26;
Submissions 24, 26, 29, 41, 44, 49, 54, 60. Others expressed a
more general
preference for a closely regulated system of private cultivators and
manufacturers: Consultations 8, 13, 24.
147 Submission 29.
5.133 To implement controls akin to those in Article 23 of the Single
Convention on Narcotic Drugs, the State of Victoria would have
possession of the products from commercial producers and arrange for their
labelling and distribution to pharmacies.
5.134 This option would allow multiple cultivators and manufacturers to be
assessed against statutory criteria and other checks and
balances derived from
Victoria’s poppy scheme. The government would be able to exercise the
degree of regulatory control required
by the Single Convention on Narcotic
Drugs. In addition, the scheme would be adaptable to any changes to law or
policy, either in
Victoria or at the Commonwealth level, which could affect the
reach or focus of the scheme.
5.135 To enable the scheme, a new Part could be inserted into the
Poisons and Controlled Substances Act
authorising various dealings that are
currently illegal. Commonwealth support would be needed, by exempting the
manufacture and production
of medicinal cannabis from regulation under the
Therapeutic Goods Act
and by granting licences under the
Narcotic Drugs Act
5.136 The submissions that supported this option argued that it was a tested
and successful model for managing the risks associated
with cultivating
prohibited substances that have a value on the illicit market.
Building on an existing framework that is preferred by industry
5.137 Mullaways Medicinal Cannabis Pty Ltd observed that ‘it is not
necessary to reinvent the wheel’ and that ‘any
medical cannabis
system set in place should follow similar guidelines to that of Opium Poppies in
Australia’:
The cultivation of high grade Opium Poppies are allowed in Tasmania (and
Victoria) under regulation, to produce medication of varying
dosages, as long as
the end product meets the designated medication criteria for safety and
effectiveness there is no current concern.148
5.138 Similarly, TPI Industries observed that: ‘[u]sing the opium poppy
framework, the legislation and regulations would enable
cultivation to occur in
a highly controlled and regulated environment with complete government
oversight’.149 TPI observed
that: ‘the cultivation, manufacture and supply of medicinal cannabis
and its extracts is the same process and involves compounds
of similar Schedules
in the SUSMP as the cultivation, manufacture and supply of NRM and Active
Pharmaceutic Ingredients’.150
UTT BioPharmaceuticals made a similar
point, suggesting that: ‘[c]annabis and opium have a
lot in common, as they contain many compounds of therapeutic use and at the
same time can be abused for their psychoactive properties’.151
5.139 However, the Commission notes Mullaways’ observation that the
poppy scheme was
not a ‘blueprint’ because it would still be necessary to develop
manufacturing, reporting and labelling standards such
as are required by the
TGA.152 In other words, the system of licences established by the poppy scheme
could underpin the cultivation
and manufacture of cannabis but its
transformation into a medicine would require other regulation.
148 Submission 29.
149 Submission 26.
151 Submission 60.
152 Submission 29.
Building on an established framework for reporting to the Commonwealth
5.140 The poppy scheme is designed to enable commercial producers to report
to the Commonwealth on the amount of poppy straw produced
per year.153 As John
Ramsay & Associates noted in its review of the Tasmanian scheme:
The [poppy] processor role in the identification and reporting of the area of
crop sown and harvested, and the volumes processed and
product recovered is
absolutely critical to Australia’s ability to report on activity to the
INCB and to meet its Convention
obligations.154
5.141 The Commission notes that cannabis is treated differently to poppy
straw under the Single Convention on Narcotic Drugs. The
Single Convention
requires the state to take physical possession of cultivated cannabis, providing
an opportunity to take stock of
of cannabis for report to the Commonwealth. Regardless, the accountability
frameworks established under the poppy scheme provide an
established,
alternative basis upon which to build in order to ensure that reporting is as
accurate as is possible. In particular,
would be important for manufacturers in a Victorian scheme to accurately
account for the wholesale stocks of medicinal cannabis they
Limiting diversion and promoting quality
5.142 The terms of reference indicate that the prohibition on unlawful uses
of cannabis would need to be preserved under any Victorian
medicinal cannabis
scheme, and the poppy scheme provides a successful template by which to achieve
this regulatory objective. As
UTT BioPharmaceuticals observed:
The whole idea behind Poppy cultivation for the production of opioids for
clinical [use], is to have stringent controls in place to
make sure there is not
illicit businesses... generated from the cultivation/production activity.
Production of cannabis raw material
must be for clinical purpose only, unless
legislation modifications are enacted in the future.156
5.143 The security arrangements put in place by the Tasmanian poppy scheme,
which has existed since 1971, have successfully prevented
diversion of opium
poppies into the illicit market.157 Victoria Police supported an adaptation of
the poppy scheme as a way of addressing
the potential for diversion of cannabis.
It suggested that the value of cannabis on the illicit market would require any
scale production of medicinal cannabis to be strictly regulated, and
that ‘the regulations surrounding the poppy industry provide
instructive example’ for the Commission in dealing with issues of
diversion.158
5.144 Others expressed the view that adapting the poppy scheme to the
regulation of cannabis would resolve problems around the quality
as well as the
security of the product.159
Shirley Humphris suggested that the regulation of cultivation and manufacture
‘[p]resumably similar to the poppy industry. It must be possible to
grow and manufacture a secure supply’ and ‘a
supply that is clean
and grown under controlled conditions’.160
153 Victoria,
Parliamentary Debates
, Legislative Assembly, 11 December
2013, 4539.
154 John Ramsay & Associates,
Review of the Tasmanian Poppy Industry
Regulation: Report
(July 2013) 28.
155 This being permitted under art 23(2)(e) of the
Single Convention on
Narcotic Drugs 1961.
156 Submission 60.
157 Australian Lawyers Alliance, Submission No 55 to the Senate Legal and
Constitutional Affairs Legislation Committee,
Inquiry into the
Regulator of Medicinal Cannabis Bill 2014
2015, 11–12.
158 Submission 44.
159 Consultation 8.
160 Submission 49.
Research, innovation and product choice
5.145 A scheme in which multiple cultivators and manufacturers participate
could foster research and innovation, consistently with
the recommended
regulatory objectives. The success of the poppy scheme model in fostering
research was reinforced by John Ramsay
& Associates, which in its review of the Tasmanian scheme made a similar
observation regarding the importance of using industry
investment and
The success of the Tasmanian industry is in no small way due to the expertise
and efficiency of these two processors who both occupy
a significant position in
the international market. They have maintained continued research and
development programs. Innovation
has resulted in the developments of different
varieties of poppies and improvements to alkaloid extraction methods, both to
significant
product recovery advantage.161
5.146 Allowing for the creation of a range of products that cater to the
spectrum of patient demand is integral to encouraging patients
to choose those
products over the products available on the illicit market. The lack of choice
has created problems in the Netherlands
and initially in Canada, where patients
have been supplied cannabis by a single producer.162
Adaptability
5.147 The Commission’s view is that a scheme that permits multiple
cultivators and manufacturers to participate would be adaptable
changes in the regulation of medicinal cannabis. If the market expanded because
other states or territories established
medicinal cannabis schemes, more
licences could be issued or the conditions of the existing ones could be varied.
If the Commonwealth
entered the field, some aspects
of the Victorian scheme could be discontinued. If demand for new products
emerged, mechanisms would be in place to assess and approve
them for manufacture
and sale in Victoria.
Disadvantages
5.148 This option is the most comprehensive of the options reviewed and is
therefore administratively more complex to establish. Once
the regulatory
framework is in place, however, the ongoing administration would be more
straightforward.
5.149 Some submissions expressed concern that the market for poppies is
significantly different from that for cannabis. For example,
the Law Institute
of Victoria observed that the poppy scheme is different because it relates to
‘an established and regulated
pharmaceutical product approved under the
Therapeutic Goods Act 1989
(Cth)... that had a large international
demand’.163 Given that a Victorian scheme is expected to supply
only to patients in exceptional circumstances, the consumer base
could—initially—be small, and the costs of production
would have to
be offset by the Victorian Government. The Commission notes that this would be
true of any scheme that involves the
industrial production of cannabis for the
purposes of purchase and distribution by the state.
5.150 What is attractive for these purposes about the poppy scheme is that it
serves as a template for the secure cultivation and
manufacture of a product
with high illicit value
that has received the support of the Commonwealth. The Commission also notes
that the Dutch medicinal cannabis scheme, although not
as comprehensive as this
option, is self- funding.
161 John Ramsay & Associates,
Review of the Tasmanian Poppy Industry
Regulation: Report
(July 2013) 26.
162 Philippe Lucas, ‘It Can’t Hurt to Ask; A Patient-Centred
Quality of Service Assessment of Health Canada’s Medical
Cannabis Policy
and Program’, (2012) 9
Harm Reduction Journal
2. See also Amanda
Reiman, ‘Cannabis Distribution: Coffee Shops to Dispensaries’,
Handbook of Cannabis
(Oxford University Press, 2014) 349.
163 Submission 63. Similar concerns were expressed at Consultation 8.
5.151 A system of multiple licensed producers is the Commission’s
preferred option and it recommends that it be adopted as the
model for a
Victorian medicinal cannabis scheme.
Recommendation
The Victorian Government should create a scheme to regulate the
production of medicinal cannabis by:
(a) licensing private entities to cultivate and manufacture medicinal
cannabis products under regulatory arrangements that are based
on those that
apply to the cultivation of alkaloid poppies, the processing of poppy straw and
the manufacture of therapeutic goods
(b) establishing a process for approving medicinal cannabis products and
ensuring that they are of appropriate quality
(c) providing the Secretary of the Department of Health and Human Services
with the power to administer the scheme and the authority
to take possession of
medicinal cannabis products, account to the Commonwealth for those products, and
arrange their transfer to
pharmacies.
Regulating supply
148 Introduction
148 Nature of Commonwealth/state collaboration
150 Cultivation and manufacture
165 Distribution
6. Regulating supply
Introduction
6.1 There are several reform options available to the Victorian Government to
supply eligible patients with medicinal cannabis, surveyed
in the previous
chapter. The supply option which best meets the Commission’s regulatory
objectives is one in which cannabis
is cultivated and manufactured under licence by private entities under
regulatory arrangements that are based on those that apply
to the cultivation of
alkaloid poppies, the processing of poppy straw and the manufacture of
therapeutic goods. This chapter details
how this option could be put into
6.2 New regulatory frameworks would need to be created. In the case of
cultivation,
a new framework would be required because cultivation of cannabis for
medicinal purposes is currently not allowed. In the case of
manufacture and
product approval,
a new framework would be needed because this activity is not presently
regulated by the Victorian Government, but by the Commonwealth.
Importantly,
though, the scale of the new regulation required turns on what agreement is
reached between Victoria and the Commonwealth,
and the extent to which this
results in a transfer of regulatory responsibility to Victoria.
6.3 Subject to the scope of collaboration between Victoria and the
Commonwealth, the Commission has produced a model that incorporates
new regulatory frameworks into Victorian legislation. In doing so, it has sought
• integrate legislative changes with existing provisions wherever
• use familiar regulatory tools
• impose the least regulatory burden necessary to achieve the scheme
• give flexibility to the regulator to manage risks
• have regard to the requirements of the
Single Convention on
Narcotic Drugs 1961
Nature of Commonwealth/state collaboration
6.4 As discussed in Chapter 4, for Victoria to enact laws giving effect to a
legally stable medicinal cannabis scheme, collaboration
with the Commonwealth
should be pursued. This could take a number of different forms, but in each case
would have the effect of removing
medicinal cannabis from the
Therapeutic
Goods Act 1989
(Cth) and placing the regulation of medicinal cannabis with
the Victorian Government.
6.5 The most efficient solution, in the Commission’s view, would be for
the Commonwealth Minister for Health to determine that
medicinal cannabis
products of a specified kind would be more appropriately regulated under a
Victorian scheme, by way of a declaration
section 7AA
of the Therapeutic
Goods Act.1 The effect of such action would be
that medicinal cannabis products intended to be used therapeutically would be
excluded from the application of the
Therapeutic Goods Act
and instead regulated
under cannabis- specific Victorian laws. Only medicinal cannabis products
manufactured in compliance with the
Victorian scheme and approved for sale in
Victoria would be included in such an arrangement.
6.6 Before making such a determination, the minister would need to have
regard to (but is not limited to considering):2
• the likelihood that, if not regulated under the
Therapeutic Goods
, the goods could cause harm to the public
• whether it is appropriate to regulate the goods under the
Therapeutic
• whether the risks posed by the goods would be dealt with more
appropriately under another scheme.3
6.7 The purpose of affording the minister this power was intended to:
ensure the Therapeutic Goods Administration (TGA) is not involved in the
regulation of products for which there is no public health
focus or for which
there may be
sound public policy reasons for their not being regulated under the
therapeutic goods legislation.4
6.8 If an exclusion determination were made in respect of Victorian-compliant
cannabis products, the products covered by the determination
would cease to be
‘therapeutic goods’ for the purposes of the Therapeutic Goods Act.5
Because other legislation relies
on this definition, consequential amendments to
avoid cannabis products being captured by other schemes would be needed.6
6.9 An alternative form of Commonwealth-state collaboration would be for the
Commonwealth Health Minister to partially exempt certain
medicinal cannabis
products from portions of the Therapeutic Goods Act.7 In the Commission’s
view, this option would not serve
the regulatory objectives as well as a
declaration that excluded Victorian medicinal cannabis products from the
legislation entirely,
and could lead to regulatory confusion.8
section 7AA
exclusion determination is a legislative instrument. While
the determination is the decision of the Commonwealth Minister, it can
disallowed by Parliament: Explanatory Memorandum,
Therapeutic Goods Amendment
(2013 Measures No.1) Bill 2013
(Cth) 20. Such a declaration would ensure that
the manufacture of cannabis products that are considered ‘unapproved
the manufacture
of cannabis products without a manufacturing licence granted by the
Therapeutic Goods Administration, and the wholesale supply of
cannabis products could take place under a Victorian scheme without involving a
contravention of the
Therapeutic Goods Act
. See Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [4.85] , [4.107].
Therapeutic Goods Act 1989
4 Explanatory Memorandum,
Therapeutic Goods Amendment (2013 Measures No.1)
Therapeutic Goods Act 1989
(definition of
‘therapeutic goods’, para (g)).
6 For example, the
Food Act 1984
(Vic) operates on the principle that
products should not be regulated as food if they are regulated as medicines.
Consistently with
this, the legislation excludes ‘therapeutic goods’
as defined in the
Therapeutic Goods Act 1989
(1) (definition of ‘therapeutic
good’). Consequential amendments may also be required to the
Therapeutic Goods
(Victoria) Act 2010
(Vic) and the
Public Health and Wellbeing Act
7 That is, by doing one of two things: (1) removing the registration
requirements in pt 3-2 of the Act, which generally requires therapeutic
supplied in Australia to be listed or registered on the Australian Register of
Therapeutic Goods, by exempting cannabis products
produced in compliance with a
Victorian scheme from that Part pursuant to s 18 of the Act; or (2) removing the
manufacturing restrictions
Therapeutic Goods Act 1989
(Cth) by exempting cannabis products produced in compliance with a Victorian
scheme from that part pursuant to
Therapeutic Goods Act 1989
8 The difficulty arises from the interlocking system of controls over product
approval and manufacturing licensing operated by the
TGA. On the one hand, a
exemption, which would remove registration requirements but continue to
require manufacturers to hold licences issued by the TGA,
would lead to
regulatory confusion because, for example, should the Victorian Department of
Health and Human Services receive notification
that a cannabis product supplied
to a patient was contaminated or somehow dangerous, it would have no power to
inspect the relevant
facility or impose conditions on the relevant manufacturing
licence, because these functions would remain the responsibility of the
the other hand, a
exemption, removing only the manufacturing requirements,
would mean that
manufacturers would no longer require licences from the TGA, but would be
constrained to manufacture of products which were approved
or already exempt,
something which is unlikely if their manufacture is not regulated by the
6.10 Whichever option is agreed on, Victoria would also need Commonwealth
the form of licences and permissions for cultivators and manufacturers to
operate under the Victorian scheme. First, the Commonwealth
Health Minister
would need to grant licences to Victorian-licensed manufacturers under
Narcotic Drugs Act
9 This would enable relevant entities in Victoria to manufacture
cannabis products without contravening the prohibitions in the
Narcotic Drugs
. Second, Commonwealth assistance would be required to import cannabis seeds
and/or plants for use by
cultivators in starting their crops. An import permission would need to be
granted by the Commonwealth Secretary of the Department
of Health.10 In
addition, an import permit would be required from a Director of Quarantine for
the importation of cannabis seeds
or live plants.11
Cultivation and manufacture
6.11 In considering how cultivation and manufacture should be regulated in
Victoria, the following questions must be answered:
• Who should be allowed to cultivate and manufacture cannabis
• Who should be required to hold a licence and what form should
licences take?
• What regulatory tools should be used to uphold quality and ensure
security, and who will be responsible for their enforcement?
• How can the government ensure that the quantity of cannabis produced
is appropriate to satisfy patient demand?
• How should the cultivation and manufacturing scheme interact with the
chosen distribution model?
Industry structure
6.12 Two options are available for the Victorian Government to structure the
cannabis production industry:12
• separate entities to cultivate cannabis plants and manufacture
refined medicinal cannabis products
• single entities to cultivate cannabis and convert it to refined
6.13 Each option has its advantages. In the case of separate cultivation and
manufacture, the expertise necessary to cultivate cannabis
is distinct from the
expertise involved in making extracts,13 so that using separate companies may
allow specialist expertise to
be utilised more effectively. Separation also
mitigates the risks associated with crop failure, although with cannabis grown
this may be less of a concern than in other industries.14
Some United States jurisdictions operate on a separate licensing model, most
9 The Health Minister must grant the licence unless the applicant had failed
to furnish requested materials, the manufacturing premises
had been stated
inaccurately or it appeared the proposed manufacturer would be inconsistent with
the Single Convention on Narcotic
Narcotic Drugs Act 1967
10 ‘Cannabis’ is a ‘drug’ for the purposes of the
Customs (Prohibited Imports) Regulations 1956
(Cth) and a person wishing
to import it must obtain an import licence and import permission: r 5(1)(a) and
Sch 4. While not stated
explicitly, the regulations presumably capture seeds and
living plants. Note that r 5(10)(b)(i) requires the importer to hold a licence
Narcotic Drugs Act 1967
(Cth) if they intend to use the
imported product to manufacture cannabis products.
Quarantine Act 1908
(Cth) s 13(1)(f) and (2A);
Proclamation 1998
(Cth) ss 63 and 65. No species of cannabis appears in the
list of ‘permitted seeds’ in sch 5 of the Quarantine Proclamation,
meaning that cannabis seeds would require an import permit: s 63(1). All
species of plants require an import permit if living, as
they can be used for
propagation:
Quarantine Proclamation 1998
(Cth) s 65(3). Some cannabis
producers have, when setting up operations in a new jurisdiction, obtained
permission to import live
plants with which to start their cultivation, which
are propagated by cloning—for example, when Bedrocan set up its Canadian
12 As detailed at [7.79] – [7.83] below, manufacturing of cannabis
extracts and other products will be required if, as recommended,
smokable forms of cannabis are sold.
13 Marc Selan noted that ‘different qualifications, skills and
knowledge are needed for the different products’: Submission
14 Crop failure is an issue in the poppy industry, where crops are grown
outdoors and are susceptible to disease. A fungal disease,
downy mildew, has
cause the destruction of large amounts of poppy crops in Tasmania in recent
years: Alex Blucher, ‘A Systemic
Mildew That’s Causing Entire
Paddock Losses in Poppy Crops Across Tasmania has Sparked an Industry-Wide
(online), 7 November
http://www.abc.net.au
is not known whether cannabis grown indoors would be susceptible to crop failure
due to disease; however, it is assumed
that because exposure to climactic
conditions and contaminants can be more readily controlled, the risks would be
Colorado.15 It is possible that the benefits associated with separate
cultivation and manufacture are only seen when the industry
has reached quite a
large scale, as is the case in Colorado.
6.14 Other jurisdictions which allow the production of refined cannabis
products tend to regulate the industry on the basis that a
single entity will
both cultivate and refine cannabis.16 There are many benefits to doing so.
There are fewer security concerns
where cannabis does not have to be transported
from a cultivator to a manufacturer. There
are fewer entities for the authorities to oversee, reducing the cost of
administering the scheme. More sophisticated research and
development may be
able to take place where the company controls both aspects of production. It may
also be easier to regulate the
quality of the finished product, as many features
of cannabis quality control relate to cultivation conditions. The selection of
licensees would also be simpler. Finally, cannabis for medicinal purposes tends
to be grown indoors, and it may be inefficient to
prevent a cultivator from
incorporating a manufacturing section into their existing facility.
6.15 These and other factors that would influence a decision as to whether to
keep the cultivation of cannabis plants separate from
the manufacture of refined
medicinal cannabis products, or whether a single entity should be able to be
both a cultivator and manufacturer
of medicinal cannabis, are discussed in more
detail in the following sections.
Coordination of regulatory processes
6.16 Expertise associated with regulating alkaloid poppy cultivators, which
could be employed in regulating the cultivation of cannabis,
is concentrated in
the Department of Economic Development, Jobs, Transport and Resources (DEDJTR).
The supervision of the manufacture
of medicinal cannabis products would more
naturally be a function performed by the Department of Health and Human
Services. However,
the need to have separate licences, administered by
different government agencies, does not mean
that single entities could not perform both functions. It would simply mean
that a single licensed cultivator and manufacturer would
be subject to
inspections from two different agencies in respect of different aspects of its
commercial activity.
Comparison with alkaloid poppy industry
6.17 Although the Commission’s proposals draw from the regulatory
mechanisms that are already in place for the alkaloid poppy
industry,17 there
are features of that industry that set it apart from the proposed cannabis
industry and limit the extent to which
the way its regulations can be replicated
in a medicinal cannabis scheme.
6.18 The structure of the alkaloid poppy industry is premised on a different
model of production from the proposed manufacture of
cannabis. The end product
of poppy cultivation is a set of pharmaceuticals—various opiates, all of
which have been approved
by the TGA. These products are manufactured by
companies that hold manufacturing licences under the
Therapeutic Goods Act
Separate licences for the cultivators are required, in part because cultivation
is regulated by the Victorian Government while the
15 Colorado provides two categories of licence: Medical Marijuana Center
Licenses, which permit the cultivation of cannabis and its
sale to the public
(i.e. ‘dispensaries’), and Medical Marijuana-Infused Products
Manufacturing Licenses, which permit
the (optional) cultivation of cannabis and
the manufacture of oils, tinctures and other infused products, but not sale to
the public:
Colo Rev Stat §§ 12-43.3-401 to
404. Medical Marijuana Centers can supply the cannabis they cultivate to
manufacturers for refinement, and manufacturers must sell
their products to
Medical Marijuana Centers for sale to patients: Colo Rev Stat §§
12-43.3-404. A company can hold both
a Medical Marijuana Center License and a
Manufacturing License.
16 Israel’s licensed producers both cultivate and manufacture (for
example, Tikun Olam). In Minnesota, where dried cannabis
must be converted to a
refined form, manufacturers cultivate and process cannabis at a single facility,
from which the product must
also be sold (Minn Stat § 152.29), with the
same approach to be adopted in New York (NY Public Health Law § 3364).
Alternative
treatment centres in New Jersey both cultivate and refine cannabis
(NJ Stat Ann § 24:6I-7), as do registered dispensaries in
Maine (22 Me Rev
Stat Ann § 2428).
17 As recommended by Submissions 24, 26, 41, 44, 49, advisory committee
(Meeting 2), Consultation 3.
regulation of manufacture is the responsibility of the Commonwealth.18
6.19 Because poppies are grown outdoors and are harvested only once per year,
there is a need for a large amount of land to cultivate
them, and this activity
is more naturally carried out by specialist farmers. Similarly, the process of
manufacturing the opiates
is a sophisticated, industrial-scale exercise,
requiring significant plant and capital.19 In short, the cultivation activities
not well suited to the entities carrying out the manufacture, and vice
versa. For this reason, the industry involves a small number
of licensed
manufacturers purchasing poppy straw from a large number of licensed
cultivators.
This is also partly a consequence of the large demand for opiates
(domestically and internationally).20
The Single Convention on Narcotic Drugs
6.20 Article 23(2)(d) of the Single Convention on Narcotic Drugs provides
that all cultivators of cannabis plants shall be required
to deliver their total
‘crops’ of cannabis (that is, flowering tops and resin) to the
government agency that has responsibility
for regulating cannabis production.21
It is possible that, by allowing licensed cultivators to deliver products to a
separately licensed
manufacturer, which then delivered finished products (not
the ‘crop’)
to the government agency, Victoria’s scheme would not be in strict
compliance with the Single Convention on Narcotic Drugs.
The counter-argument is
that the system of licences proposed below, while not demanding delivery of
crops to the state, is nonetheless
up to ensure that cannabis products cannot be delivered to any entity other
than the government, thereby upholding the purpose of
Article 23.
Allowances for alternatives within recommendations
6.21 The decision as to how to structure the industry is a complex one that
requires detailed economic analysis by government and
consultation with
industry. The recommendations in this chapter are advanced on the assumption
that separate licences would be granted
in respect of the cultivation function
and the manufacturing function.
6.22 If the government were to decide to proceed with an industry structured
combined cultivating and manufacturing facilities, the structure conveyed in
the discussion below could still be used, with dual licensing
facilities.22 Alternatively, the licences for cultivation and manufacture could
be merged, with responsibility for administering
the combined licence concentrated in a single agency. This is a matter for
government to resolve.
6.23 A further variation, not discussed below, would be for cannabis to be
cultivated by licensed cultivators and turned into refined
cannabis products
(such as oils and tinctures) by compounding pharmacists. Pharmacists are exempt
from the requirement to hold
a TGA manufacturing licence and from the prohibition on the supply of
unapproved goods, provided they ‘extemporaneously’
medicine, on the premises where it is to be supplied, for a particular person.23
A pharmacist could obtain dried cannabis
from the Secretary of the Department of
Health and Human Services (which would have
18 As a consequence of this arrangement, the companies that manufacture
opiates in Australia are dually licensed: they hold a manufacturing
licence from
the Commonwealth under the
Therapeutic Goods Act 1989
(Cth) and a
‘processing licence’ from Victoria under the
Drugs, Poisons and
Controlled Substances Act 1981
(Vic). The processing licence allows only
rudimentary steps to be taken, involving essentially the chopping of poppy heads
separation from the seeds. This would not be required under a
medicinal cannabis scheme, as the state would control both aspects
of licensing
and could include simple processing of this kind (including trimming, chopping
and drying) in the activities allowed
under one of the licences.
19 The Law Institute of Victoria observed that the manufacture of opiates
results in an established and regulated pharmaceutical product,
for which there
is significant commercial demand, which may not be the case for cannabis:
Submission 63.
20 Advisory committee (Meeting 2).
21 Further consequences of this clause, regarding distribution arrangements,
are discussed at [6.68] – [6.72] below.
22 This could be made somewhat like the process now adopted in Canada for the
production of cannabis oil. Following the recent decision
of the Supreme Court
of Canada (
[2015] SCC 34), which held that the Canadian
prohibition on forms of cannabis other than dried marijuana was
unconstitutional, Health
Canada announced that licensed producers of dried
cannabis will be permitted, in addition to cultivating and processing dried
to refine it into oils. However, prior to doing so, licensed producers
will have to obtain a
‘supplemental licence’, making them subject to separate
regulations on quality: Health Canada,
Class Exemption for
Licensed Producers Under the Marihuana for Medical Purposes Regulations to
Conduct Activities with Cannabis
(8 July 2015)
http://www.hc-sc. gc.ca
Therapeutic Goods Regulations 1990
(Cth) r 18 and sch 8 item 2, r
12(1) and sch 5 item 6. See also Pharmacy Board of Australia,
Background on the Regulation of Compounding by Pharmacists
http://www.pharmacyboard.gov.au
been purchased from a licensed cultivator) and refine it at the premises of a
pharmacy or pharmacy department.
6.24 The Commission considers that this would not be a useful option.
Although exempt from the listing and manufacturing requirements
Therapeutic Goods Act
when compounding, pharmacists would still be subject to
Narcotic Drugs Act
, such that without a licence under that legislation their
compounding activity would be unlawful. There would also be administrative
difficulties regarding reporting of quantities of drugs manufactured. Finally,
as cannabis products are no longer included in pharmacopoeias
and formularies to
which pharmacists turn for reference, few may consider themselves qualified to
prepare cannabis-derived products.24
Licensing cultivation
6.25 Licences to cultivate should be granted by the Secretary of DEDJTR.
Recipients could be either individuals or corporations.
The licensing scheme
should be set out in the
Drugs, Poisons and Controlled Substances Act 1981
(Vic) in very similar terms to the provisions
allowing for licensing of alkaloid poppy cultivators.25
Recommendation
Cannabis should be grown for medicinal purposes by cultivators
licensed by the Secretary of the Department of Economic Development,
Transport and Resources.
Managing the risks
6.26 Submissions and consultations drew attention to the diversion risks
associated with the cultivation of cannabis by private industry.
addressed in the proposed scheme, as they are in the alkaloid poppy scheme,26
through the use of licences, licence conditions,
risk management plans,
inspections and potential enforcement.
6.27 Victoria Police recommended that ‘if commercial cultivation is to
be included in the scheme, then strong consideration
must be given to the
security of the product’.27 ACES Group submitted that ‘proper and
robust security measures will
need to be a focal point in the current
debate’.28 Against this, it was observed that cannabis is the most
accessible illicit
drug and one of the most affordable, meaning that there would
low incentives for diversion.29
24 See Pharmacy Board of Australia,
Guidelines on Compounding of Medicines
(April 2015)
http://www.pharmacyboard.gov.au
which set out standards and other references to which compounding pharmacists
must have regard. The Guidelines also state that,
when compounding medicines,
‘pharmacists must ensure that there is good clinical and pharmaceutical
evidence to support the
quality, stability (including appropriate expiry
periods), safety, efficacy and rationality’ of the treatment, and
be satisfied that the dispensing and supply of a compounded medicine
is consistent with the safety of the patient’: [6]. This
difficult for pharmacists to assess in relation to cannabis preparations.
Drugs, Poisons and Controlled Substances Act 1981
establishes a licensing regime with a significant amount of detail regarding
the grant of licences, licence conditions, inspections
and so on. This stands in
contrast to the Tasmanian legislative arrangements for licensing poppy
cultivators, which is extremely
Poisons Act 1971
Instead of cultivators being regulated through legislation or regulation, the
bulk of the rules are contained in licence conditions:
John Ramsay &
Associates,
Review of the Tasmanian Poppy Industry Regulation: Report
(July 2013) 17.
26 See Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [4.156].
27 Submission 44. Submission 23 also commented that owners, workers and
distributors would be tempted by financial incentives to sell
to recreational
users. See Appendix B for list of submissions.
28 Submission 58.
29 Submission 46.
6.28 The way in which specific risks would be addressed under the proposed
scheme is set out in the following table:
Table 2: Risks associated with cultivation of medicinal cannabis and the
regulatory responses proposed to control these risks
Regulatory response
Diversion occurs because of
criminal intervention by third parties (potentially causing risks to public
Risk management plan addresses facility security measures, location,
secrecy, surveillance
Diversion occurs because of criminal conduct by employees or
contractors
Risk management plan addresses assessment, training and supervision of
employees and contractors
Criminal record checks required for employees
Licence conditions require destruction of unused cannabis
Diversion occurs because of criminal conduct by managers/owners
Fit and proper person test before licence is granted
Chief Commissioner of Police has veto power
Licence conditions require:
• that all cannabis cultivated is delivered to a licensed
manufacturer or destroyed
• that all unused cannabis is destroyed
Diversion occurs during transport
Risk management plan addresses how transportation will be securely
Cannabis grown is of poor quality
Addressed through quality control regime
6.29 Controlling diversion to the illicit market is also a requirement of
international law. The Single Convention on Narcotic Drugs
requires states to
‘adopt such measures as may be necessary to prevent the misuse of, and
illicit traffic in, the leaves of
the cannabis plant’.30
6.30 As observed in consultations, the scheme must be designed to control the
risk that cannabis will be diverted to the illicit market
points’ in the supply chain.31 This requires careful assessment, properly
resourced. It would be inappropriate
merely to duplicate the policies associated
with the alkaloid poppy scheme, because the risks associated with cultivating
are different from those associated with the cultivation of cannabis.
For example:
• Cannabis with significant THC content can readily be used illicitly,
while alkaloid poppies require sophisticated processing,
making cannabis a more
attractive target for theft.32
• The waste products of medicinal cannabis production (the leaves) have
value on the illicit market, if they have significant
THC content, while poppy
straw remnants do not.
• Medicinal cannabis tends to be grown indoors, while alkaloid poppies
are grown in the field, meaning the risk of theft of
cannabis by third parties
Single Convention on Narcotic Drugs 1961
, art 28 (3).
31 Advisory committee (Meeting 2); Consultations 4, 19.
32 Submission 44.
• Alkaloid poppies are typically grown as a rotation crop (alternated
with other crops), while there is no need to rotate cannabis,
meaning that
cannabis licensees would probably only grow cannabis.
• Recreational use of alkaloid poppies can result in harm or death to
the user, which is not the case for cannabis.
• Organised crime would be likely to have a greater interest in
high-THC cannabis, as it is easier to transform into an illicit
substance, and
less interest in high-CBD cannabis.
• There is a greater illicit market for cannabis than heroin, making
cannabis a more attractive criminal target than alkaloid
6.31 Victoria Police underlined the need for careful consideration of the
risk of diversion in its submission:
If commercial cultivation is to take place in Victoria, Victoria Police
recommends that strong consideration be given to implementing
stringent security requirements around cannabis cultivations to prevent theft
and diversion. Such security requirements
should be developed by subject matter
experts, and these requirements will need to be heightened in comparison to
poppy cultivations.34
6.32 Submissions made a range of suggestions for how security should be
safeguarded, including through background checks, auditing
and inspection of
potential cultivators, location of cultivation facilities, security systems and
monitoring of facilities, tracking
of products, harvesting and transport of raw
material, and destruction of waste.35 ACES Group observed that a security
around medicinal cannabis could be drawn from ‘overseas
experience with managing security around medicinal and retail cannabis provides
valuable insights for any future development’.36
6.33 In the Commission’s view, risk management plans are a better tool
for controlling diversion risks than prescriptive regulations.
This approach
allows the controls to be calibrated to the level of risk.37 The detail of the
government’s industry-wide risk
assessment would then be reflected in
departmental policies on and the assessment of risk management plans, rather
than uniform regulations.
Diversion should also be
controlled by requirements, described below, requiring that licensed
cultivators deliver to licensed manufacturers.38
Who could obtain a licence?
6.34 The requirements for an applicant to obtain a cultivation licence
should be based on the requirements in the alkaloid poppy
scheme. In particular,
to obtain a licence, a cultivator should be required to overcome the following
• satisfying the Secretary that they are a fit and proper person40 to
hold a cultivation licence, entailing criminal history
checks of the applicant
and associates and an assessment of the suitability of the applicant, including
consideration of their reputation
and character, whether they have a history of
non-compliance with cultivation obligations, their corporate structure and
and their financial circumstances
35 Submissions 26, 58, 69, 74.
36 Submission 58.
37 Diversion risks could vary from one cannabis cultivator to the next. A
cultivation facility in a remote area may attract a greater
diversion risk than
one in a built-up area. A facility at which only high-CBD cannabis was
cultivated would be at a lower risk of
diversion than high-THC forms of
38 This requirement operates on a similar principle to the ‘secured and
closed medicinal cannabis circuit’ implemented
in some United States
essentially been [to] create a
secure and closed circuit where medicinal
cannabis will only circulate between cultivation centres, dispensaries, patients
their caregivers’: Submission 58.
Drugs, Poisons and Controlled Substances Act 1981
• suitability of the premises, including location, facilities and
proposed security arrangements
• submission of a satisfactory risk management plan
• satisfying the Secretary of their intended commercial activities
• payment of the prescribed fee.
6.35 The Secretary should be enabled to investigate the above matters for the
purpose of determining whether to grant a licence, including
by inspecting the
nominated premises and requesting criminal record checks.41 The Chief
Commissioner of Police should have the power
to object to the issue of a
cultivation licence.42
Risk management plans and licence conditions
6.36 As mentioned above, the risk management plan submitted by the applicant
would be an opportunity for the applicant to prove its
capacity to control the
following matters:
• secure facility (building type, alarms and surveillance, lighting,
signage, fencing and so on)
• appropriate location
• employee and contractor management
• auditing and record-keeping processes
• transportation without diversion.43
6.37 As in the poppy cultivation scheme, DEDJTR officers should assess the
risk management plan of each applicant against departmental
guidelines, to
ensure that sufficient security measures have been implemented. Experience with
the alkaloid poppy scheme suggests
that this should not be an overly burdensome
exercise, with only a modest number of personnel required for the task
(depending on
the number of licensees). The cost could be borne by the
cultivator.
6.38 Terms and conditions imposed on the licence should allow DEDJTR to
control the activities of the cultivator. Conditions would
include at a
• that all cannabis grown must be delivered to a licensed manufacturer
or destroyed45
• that the cultivator must comply with their risk management plan46
• specification of the amount and area of cannabis that may be
• that only suitable employees may be employed.48
6.39 Other optional conditions could also be specified by DEDJTR on grant of
the licence.
6.40 Under the alkaloid poppy scheme, a further mandatory condition of a
cultivation licence is that cultivators must at all times
have a current
contract with a licensed processor.49
This would not be necessary if the industry were based around combined
cultivator- manufacturer entities. If single licences were
granted, the
condition would be removed; if dual licences were granted to single entities,
the condition could be altered to require
that the two types of licence be held
concurrently.
43 Australian Concert and Entertainment Security Pty Ltd provided a detailed
overview of relevant security systems in their submission:
Submission 58.
Drugs, Poisons and Controlled Substances Act 1981
45 This is not an express statutory licence condition under the poppy scheme.
DEDJTR may impose conditions relating to the disposal
of harvested material and
crop residue, or relating to the destruction of alkaloid poppies, poppy straw
and material derived from
Drugs, Poisons and Controlled Substances
s 69OC(6)(f)
and (h). The Commission suggests that, due to
the higher diversionary risk associated with unused cannabis (particularly
leaves), this should be made an express statutory condition.
Drugs, Poisons and Controlled Substances Act 1981
47 The purpose of this condition is to satisfy the requirements of the
Single Convention on Narcotic Drugs 1961
, which requires member states to
ensure that cultivation licences specify the extent of the land on which
cultivation may take place:
arts 23(2)(c), 28.
Drugs, Poisons and Controlled Substances Act 1981
6.41 Chapter 7 of this report considers the quality-control standards that
should be imposed
on cultivators. As set out there, the Commission considers that it is
appropriate for quality standards to be imposed on cultivators
of medicinal
cannabis. These standards should be enforced through licence conditions.
6.42 The various decisions that could be made that would adversely affect the
holder of a cultivation licence should be capable of
review by the Victorian
Civil and Administrative Tribunal.50
Recommendation
The licensing and regulation of medicinal cannabis cultivators
should be modelled on
Drugs, Poisons and Controlled
Substances Act 1981
(Vic) as it applies to alkaloid poppy cultivation. Key
features of the scheme should be as follows:
(a) Applicants for a cultivation licence would be subject to a fit and
proper person test, required to satisfy the Secretary of
their intended
commercial activities, and pay a prescribed fee.
(b) The Chief Commissioner of Victoria Police would be able to oppose the
issuing or renewal of a licence to an applicant, in which
case the Secretary
would be unable to issue or renew it.
(c) Licensees would be required to ensure that their employees are of
suitable character.
(d) Licensees would be required to prepare and submit a risk management
plan addressing safety and diversion risks associated with
cultivation and how
they will be addressed.
(e) Licensees would be required to comply with appropriate quality
control measures.
(f) All cannabis grown would be required to be delivered to a licensed
manufacturer or destroyed.
(g) Licensees would be required to have a contract with a licensed
manufacturer at all relevant times.
(h) The Secretary would have the power to suspend or cancel a licence,
including at the request of the Chief Commissioner of Police.
(i) Applications would be able to be made to the Victorian Civil and
Administrative Tribunal for review of a decision by the Secretary
to refuse to
issue or renew a licence, or to suspend, cancel or amend it.
Inspections and enforcement
6.43 The holder of a cultivation licence would be inspected regularly by
DEDJTR inspectors to ensure compliance with the conditions
of the licence.51 In
particular, inspectors would review the cultivator’s adherence to their
risk management plan.52 A variety
of enforcement actions (such as imposition of
licence conditions, product forfeiture and
infringement notices) would be available to inspectors if non-compliance were
observed, with the ultimate sanction of licence suspension,
cancellation or
non-renewal available.53
Licence sanctions would also be available if information came to the
attention of DEDJTR
suggesting that the licensee was no longer fit and proper to hold a
Recommendation
The Secretary of the Department of Economic Development, Jobs,
Transport and Resources should:
(a) monitor and enforce compliance by licensed cultivators with licence
conditions and risk management plans
(b) be empowered to appoint inspectors for this purpose
(c) be resourced accordingly.
Authorised low-THC cannabis producers
6.44 As discussed in the issues paper, it is already possible for a
person to cultivate cannabis in Victoria. However, they are
only able to do so
under an authority, and are only permitted to cultivate cannabis with less than
0.35 per cent THC,55 for non-therapeutic
purposes.56
This variety of cannabis is known as low-THC cannabis or industrial hemp.
Therefore, at present, authorised low-THC cannabis producers
could not cultivate
cannabis (even low- THC cannabis) for the purposes of producing medicinal
6.45 It would be a straightforward legislative amendment to expand the
activities permitted to be conducted by authorised low-THC
cannabis cultivators,
so that they could cultivate cannabis to be used in the manufacture of medicinal
cannabis products.57 However,
the Commission’s view is that this would not
be a good policy outcome. The risk assessment undertaken in the decision to
an authority to a low-THC cannabis cultivator in Victoria is specific to
the purposes for which cultivation occurs (and to the cultivation
adopted) and would not be well adapted to medicinal cannabis. In addition, both
Commonwealth and international law draw
a clear distinction between low-
THC cannabis grown for fibre and seed, on the one hand, and cannabis grown
Drugs, Poisons and Controlled Substances Act 1981
52 This is a consequence of compliance with the risk management plan being a
condition of the licence.
Drugs, Poisons and Controlled Substances Act 1981
(imposition of licence conditions); 69RM (crop forfeiture, harvest and
destruction); 69RQ (infringement notices). Licences may be
suspended or
cancelled under
The Secretary has discretion to refuse to renew a
licence under
, but will take into account more than just compliance with
licence conditions in doing so.
Drugs, Poisons and Controlled Substances Act 1981
(1)(d), (g).
55 This is the maximum quantity in the leaves and flowering heads; a
different maximum THC concentration applies to cannabis which
is supplied to
third parties.
56 Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [4.145] – [4.148];
Drugs, Poisons and Controlled Substances
. While not prohibited by Victorian
legislation, low-THC cannabis cannot be processed into or sold as food in
Australia and New Zealand Food Standards Code
, Standard 1.4.4.
The matter remains under review by the Ministerial Forum: ‘Australia and
New Zealand Ministerial Forum on
Food Regulation’, (Final
Communiqué, Auckland, 30 January 2015 and Final Communiqué,
Hobart, 3 July
57 By way of illustration,
Drugs, Poisons and Controlled
Substances Act 1981
(Vic) could be amended to remove the restriction on
non-therapeutic use.
cannabinoids (whether medicinal or recreational) on the other.58
6.46 Nonetheless, cultivators of low-THC cannabis already authorised to
operate in Victoria59 may have useful expertise which could
be harnessed in the
establishment of a Victorian medicinal cannabis scheme. It may be appropriate to
allow low-THC cannabis cultivators
to supply seeds to licensed medicinal
cannabis cultivators,60 or to hold a medicinal cannabis cultivation licence in
addition to
their existing low-THC cannabis authority, for the purpose of
obtaining cannabinoids other than THC.
Licensing manufacture
6.47 Like cultivators, manufacturers of cannabis products should be required
to hold licences issued by the State of Victoria. Licences
to manufacture
refined cannabis products should be able to be granted by the Secretary of the
Department of Health and Human Services,
but as a practical matter would be
administered and supervised by the Office of Medicinal Cannabis. Recipients
could be either individuals
or corporations.
Recommendation
Medicinal cannabis products should be made by manufacturers
licensed by the
Secretary of the Department of Health and Human Services.
Interaction with
Therapeutic Goods Act 1989
6.48 The Commission assumes for the purposes of this section that entities
producing medicinal cannabis in Victoria would be licensed
by the Secretary of
the Department of Health and Human Services to manufacture cannabis products.
They would not be
regulated by the TGA,61 nor be required to hold concurrent manufacturing
licences under the Therapeutic Goods Act.62 However, as discussed
division of regulatory responsibility is a matter for negotiation between the
Commonwealth and the State of Victoria.
Single Convention on Narcotic Drugs 1961
, art 28.2 (‘This
Convention shall not apply to the cultivation of the cannabis plant exclusively
for industrial purposes (fibre
and seed) or horticultural purposes’); the
SUSMP definition of ‘cannabis’ (which excludes ‘processed hemp
fibre containing 0.1 per cent or less of tetrahydrocannabinol and products
manufactured from such fibre’) and its definition
of THC (which excludes
THC found in hemp seed oil, containing 50 mg /kg or less of
tetrahydrocannabinols when labelled with a warning
statement ‘not for
internal use’ or ‘not to be taken’).
59 Several individuals are cultivating low-THC cannabis in Victoria at
present: Consultation 19.
60 This activity appears to be presently prohibited by
Drugs, Poisons and Controlled Substances Act 1981
(Vic), which permits
authorised low-THC cannabis cultivators to sell or supply seeds harvested from
low-THC cannabis, but only for
purposes ‘relating to non- therapeutic
use’. Supply of seeds to a medicinal cannabis cultivator could be
considered supply
for a therapeutic use.
Therapeutic Goods Act 1989
. If, as specified
elsewhere, medicinal cannabis products supplied in Victoria are not approved by
the TGA, there would be fundamental
problems with the scheme relying on the TGA
to regulate manufacturers. The supervision of products and sponsors by the TGA
on information about their products and facilities that is extensively
interconnected. Regulatory supervision which looked at only
the quality of
manufacturing facilities, and had no role in product approval, could lead to
inefficient and fragmented oversight:
see Evidence to Senate Legal and
Constitutional Affairs Committee, Parliament of Australia, Canberra,
30 March 2015, 41 (Dr Lisa Studdert and Philippa Horner).
62 That is, a Victorian manufacturing licence would not be ‘added
on’ to a Commonwealth manufacturing licence granted
by the TGA. It would
be entirely separate. Such a requirement could be problematic, as holders of TGA
manufacturing licences are
required to specify upon application the therapeutic
goods they intend to manufacture at the relevant premises:
Therapeutic Goods
s 37(1)(b).
Managing the risks
6.49 As is the case with cultivation, there are risks that would need to be
addressed under the proposed scheme. In broad terms, this
is how the recommended
legal arrangement would respond to the major risks:
Table 3: Risks associated with manufacture of medicinal cannabis products
and the regulatory responses proposed to control these risks
Regulatory response
Diversion occurs because of
criminal intervention by third parties (potentially causing risks to public
Risk management plan addresses facility security measures, location,
secrecy, surveillance
Diversion occurs because of criminal conduct by employees or
contractors
Risk management plan addresses assessment, training and supervision of
Criminal record checks required for employees
Licence conditions require destruction of unused cannabis
Diversion occurs because of criminal conduct by managers/owners
Fit and proper person test before licence is granted
Chief Commissioner of Police power to oppose
Licence conditions require:
• that all cannabis products are delivered to the government or
• that all unused cannabis is destroyed
Diversion occurs during transport
Risk management plan addresses how transportation will be securely
Cannabis products are of variable quality
Manufacturing licences may only be granted where applicant satisfies
Secretary of capacity to comply with production standards
Products are subjected to testing
Cannabis products contain unsafe contaminants and harm public health
Manufacturing licences may only be granted where applicant satisfies
Secretary of capacity to comply with production standards
Products subject to testing for contaminants
Premises subject to inspections
Recall procedures in place
6.50 Like the licensing of cultivators, the regulation of licensed
manufacturers by the Department of Health and Human Services would
have as its
objective both ensuring security and maintaining quality standards. In addition
to licence conditions, because the state
would be the sole purchaser of cannabis
products, it could also exercise control through the terms on which cannabis is
purchased.63
63 If cultivation and distribution are carried out by single entities,
control over cultivation practices may be simpler, which could
be seen as a
reason for combining these functions. See [6.12] – [6.20].
Who could obtain a licence?
6.51 The requirements for an individual or corporation to be granted a
manufacturing licence ought to include all those set out above
for cultivation
licences.64 The Secretary of the Department of Health and Human Services
should have equivalent powers to investigate
licence applications in this
regard.65 Only entities which succeeded in the competitive selection process
would be eligible to be
granted a licence.66
6.52 In addition, an applicant for a manufacturing licence should be required
to demonstrate, to the satisfaction of the Secretary
of the Department of Health
and Human Services, that it is capable of complying with the relevant quality
standards and that its
proposed operating facilities are appropriate.67 The
applicant’s suitability would be established by
submitting documentation showing its ability to comply with the standards,
together with an initial inspection by a delegate of the
Secretary. Further
detail on the possible quality standards and their enforcement is described in
Risk management plans and licence conditions
6.53 The risk management plan submitted by an applicant for a manufacturing
licence should serve a similar function to that submitted
by an applicant for a
cultivation licence. In addition, applicants should be required to submit
details of the manufacturing processes
they will follow, and how these are
compliant with applicable standards (set out in Chapter 7).
6.54 As would be the case for cultivators, the terms and conditions imposed
on the manufacturing licence would allow the Secretary
of the Department of
Health and Human Services to exercise control over the activities of the
manufacturer. Conditions should include:68
• where manufacture is permitted to take place69
• that only suitable employees may be employed
• compliance with manufacturing quality standards70
• that all cannabis products must be delivered to the Secretary of the
Department of
Health within four months of the harvest date71 or be destroyed72
• that the licence holder must at all times hold a manufacturing
licence under the
Narcotic Drugs Act.73
64 Namely, a ‘fit and proper’ assessment, suitability of
premises, a satisfactory risk management plan, proof of intended
activities and payment of a fee. See [6.34].
65 See [6.35].
66 See [6.58] – [6.62].
Therapeutic Goods Act 1989
(1), under which an
applicant for a licence to manufacture must be able to comply with the
manufacturing principles (that is, the
PIC/S Guide to GMP) and propose to carry
out the manufacture at a suitable location.
Drugs, Poisons and Controlled Substances Act 1981
69 To satisfy the requirements of art 29 (2)(b) of the
Single Convention
on Narcotic Drugs 1961
. Note that the licence granted to the manufacturer
Narcotic Drugs Act 1967
(Cth) will also specify the premises at
which manufacture is to take place:
70 Described in Chapter 7.
71 This is required in order to comply with the
Single Convention on
Narcotic Drugs 1961
, which requires member states to ensure that cultivators
deliver their total crops of cannabis to the government within four months
the end of harvest: arts 23(2)(c) and 28.
Single Convention on Narcotic Drugs 1961
requires that states
‘prevent the accumulation, in the possession of drug manufacturers, of
drugs [including cannabis, cannabis
tinctures, extracts and so on] in excess of
those required for the normal course of business’: art 29 (2) (c). A
licence requirement
along these lines should satisfy this requirement in the
Single Convention.
Drugs, Poisons and Controlled Substances Act 1981
6.55 The holder of a manufacturing licence should be subject to inspection by
appointed inspectors working in the Department of Health
and Human Services to
ensure their compliance with the conditions of the licence. A new category of
inspectors should be created
Drugs, Poisons and Controlled Substances
, to inspect manufacturers.74 The Department of Health and Human Services
already has a body
of authorised officers responsible for inspections relating to, among other
things, food safety,75 radiation,76 and public health
generally.77 Staff could
be appointed specifically to inspect cannabis manufacturers, or the
Department’s existing authorised
officers could
be given an additional role as inspectors of medicinal cannabis manufacturing
facilities (as currently occurs for alkaloid poppies
in the DEDJTR).
6.56 Inspectors should review both whether the manufacturers had adhered to
their risk management plans and applicable quality rules
(discussed in detail
below). A variety of enforcement actions (including licence conditions, product
forfeiture and infringement
notices) would be available to inspectors if
non-compliance were observed, with the ultimate sanction of licence non-renewal,
or cancellation available to penalise unrectified non-compliance.78
As with cultivation licences, if information came to the attention
Department suggesting that the licensee was no longer fit and proper, action
could be taken in relation to the manufacturing
6.57 As in the case of cultivation licences, any decision of the Secretary
that would adversely affect the holder of a manufacturing
licence should be
capable of review by the Victorian Civil and Administrative Tribunal.80
Drugs, Poisons and Controlled Substances Act 1981
(Vic) allows
inspectors to be appointed for the purpose of monitoring compliance by licensees
and gives them a range of powers
Food Act 1984
Radiation Act 2005
Public Health and Wellbeing Act 2008
78 Cf ss 69Q (imposition of licence conditions); 69RM (crop forfeiture,
harvest and destruction); 69RQ (infringement notices). Licences
be suspended or cancelled under s 69QA. The Secretary has discretion to
refuse to renew a licence under s 69PI, but will take into
account more than
just compliance with licence conditions in doing so.
Drugs, Poisons and Controlled Substances Act 1981
(1)(d) and (g).
Recommendations
Medicinal cannabis products should be made by manufacturers
licensed by the Secretary of the Department of Health and Human Services
arrangements modelled on those for licensing manufacturers under the
Therapeutic Goods Act 1989
(Cth) and processors of poppy straw under the
Drugs, Poisons and Controlled Substances Act 1981
(Vic). Key features of
the scheme should be as follows:
(a) Applicants for a manufacturing licence would be subject to a fit and
proper person test, required to satisfy the Secretary of
their intended
commercial activities, and required to pay a prescribed fee.
(b) Applicants for a manufacturing licence should be required to
demonstrate to the Secretary their capability to comply with quality
(c) The Chief Commissioner of Victoria Police would be able to oppose the
issuing or renewal of a licence to an applicant, in which
case the Secretary
would be unable to issue or renew it.
(d) Licensees would be required to hold a manufacturing licence under
Narcotic Drugs Act 1967
(Cth) at all relevant times.
(e) Licensees would be required to ensure that their employees are of
suitable character.
(f) Licensees would be required to prepare and submit a risk management
plan addressing safety and diversion risks associated with
cultivation and how
they will be addressed.
(g) Licensees would be required to comply with appropriate quality
control measures.
(h) Licensees would be required to deliver all medicinal cannabis
to the Secretary within four months of the harvest date and destroy any
unused material.
(i) The Secretary would have the power to suspend or cancel a licence,
including at the request of the Chief Commissioner of Police.
(j) Applications would be able to be made to the Victorian Civil and
Administrative Tribunal for review of a decision by the Secretary
to refuse to
issue or renew a licence, or to suspend, cancel or amend it.
The Secretary of the Department of Health and Human Services
(a) monitor and enforce compliance by licensed manufacturers with licence
conditions and risk management plans
(b) be empowered to appoint inspectors for this purpose
(c) be resourced accordingly.
Selection of licensees
6.58 If it were intended that the production of cannabis products in Victoria
would result in a commercial, market-driven industry,
limited only by consumer
demand for medicinal cannabis, there would be no need to control the number of
entities permitted to take
part in the industry. Any entity capable of
satisfying the legal requirements would be eligible to be granted a cultivation
or manufacturing
licence, and the market would determine how many such entities
could be accommodated. Some would see this as a preferable state of
affairs—for example, Cannabis Science Australia submitted that ‘any
farming concern that can meet the necessary standards
should be allowed to grow
the product’, because otherwise companies that are financially sound but
know little about the medical
science around cannabis would be able to
‘buy their way into the industry’.81
6.59 However, this is not the system suggested by the terms of reference,
which reflect the intention to make medicinal cannabis available
patients in ‘exceptional circumstances’. In practice, this amounts
to a cap on the demand for medicinal cannabis
products. Therefore, if private
industry were to be involved in the production of medicinal cannabis in
Victoria, the government
would need to control the number of companies and/or
individuals licensed to cultivate and manufacture cannabis products for
purposes, or at least restrict significantly the amount of cannabis
each could cultivate/ manufacture; otherwise the amount of cannabis
could greatly exceed the amount required to be supplied, leading to significant
diversion risks.82
6.60 The Law Institute of Victoria also made this observation, noting that
‘a regulated scheme should balance supply and demand
to limit the risk of
diversion’.83 This is also necessary to ensure that, as required by
international law, the state government
can ‘control’ the
cultivation and distribution of cannabis.84 The Single Convention on Narcotic
places obligations on signatories to limit the amount of cannabis produced to
that which has been ‘estimated’ in advance
to the International
Narcotics Control Board.85 The Commonwealth would be unable to comply with this
obligations unless Victoria
exercised control over the number of market
participants and the amount they were permitted to produce.
6.61 Some jurisdictions limit the number of entities that are permitted to
cultivate and/or manufacture cannabis by stating in legislation
licences of each kind may be granted, and running a ‘competitive
selection’ process to choose those that will
receive the licences.86
However, these jurisdictions allow for the private distribution of medicinal
cannabis (that is, directly
from producer to patient). Under the Victorian
scheme, all medicinal cannabis produced would be purchased by the state
government,
meaning that it would also have the ability to exercise control over
licensees’ activities through contract.87
81 Submission 69.
82 Media reports suggest significant commercial interest in producing
medicinal cannabis in Australia: Mandie Sami, ‘Australian
Company Granted
First License to Grow and Export Medicinal Cannabis’,
ABC The World
, 21 May 2015; Scott Hannaford, ‘Investors Lining Up to Make
Canberra the Cannabis Capital’,
The Canberra Times
, 19 June 2015;
Sally Rose, ‘New CEO of Cannabis Group Michael Sautman Wants Australia to
Legalise It’,
Sydney Morning Herald
, 19 March 2015; Christopher
Harris, ‘Australia a New Growth Market for Medicinal Cannabis’,
Sydney Morning Herald
, 1 February 2015. Cannabis Science Ltd agreed,
commenting that ‘there will be a very high demand to
become a preferred grower. Most successful business people are quick to seek
the next big thing to go, and the opportunity in this
industry will be no
different. Already we can see this happening ... that in itself will create a
demand on the government when issuing
licenses’: Submission 69.
83 Submission 63.
Single Convention on Narcotic Drugs 1961
85 Ibid arts 19 and 21.
86 See Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [6.62]; Minn Stat § 152.25(1); Consultation 25.
87 It is likely the purchase of medicinal cannabis would be subject to
Victorian Government Purchasing Board policies, made under
Management Act 1994
While a health-specific procurement body
exists (Health Purchasing Victoria), it appears that this activity would fall
outside its
statutory functions:
Health Services Act 1988
6.62 The Commission considers that the Victorian Government should control
the number of entities granted cultivation and manufacturing
licences,88 and
that this process should
be integrated with the purchasing process. This exercise would be simpler and
faster if cultivation and manufacturing were carried
out by single entities. The
Commission also considers that the government should use its position as sole
purchaser of medicinal
cannabis products to set standards for the production of
medicinal cannabis—for
example, to establish more stringent production practices, set performance
targets, set an expected product range or quantity, or
provide research and
development incentives.89
Licence duration
6.63 Under the poppy scheme, cultivation licences can be granted for a period
of up to three years90 while processing licences can
be granted for up to one
year.91 This arrangement was considered necessary in order to comply with the
system of estimates imposed
on the Commonwealth by the International Narcotics
Control Board.92
6.64 In the Commission’s view, it would be undesirable to limit the
duration of medicinal cannabis manufacturing licences to
one year, as occurs for
processors in the poppy scheme. While acknowledging the importance of making
arrangements that enable the
Commonwealth to comply with the system of annual
quotas and estimates, the
Commission does not consider it necessary to limit licence duration to one
year in order to do so.
6.65 Should the government need to alter the amount produced from year to
year, it could do so through contractual arrangements and
licence conditions.
More importantly, the cultivation and manufacturing licences issued must be of
sufficient duration for the licensees
to develop compliant cultivation and
refining technology and expertise,93 and to make engagement with the
competitive selection
process financially worthwhile.
Distribution
6.66 A Victorian medicinal cannabis scheme would need to provide for cannabis
products to
be distributed to patients. As reflected in submissions received, there is a
tension between two key concepts in designing a distribution
accessibility and control.
6.67 Having regard to Australia’s obligations under the Single
Convention on Narcotic Drugs, the Commission considers that the
distribution should be as follows:
• All licensed manufacturers are obligated by the terms of their
licence to deliver all cannabis products they make to the Victorian
Government,
specifically the Secretary of the Department of Health and Human Services.
• The Secretary of the Department of Health and Human Services
distributes the finished cannabis products to pharmacies.
• Patients are dispensed cannabis products by their local pharmacy,
which has been designated by their doctor.
88 Processes already exist for the granting of licences where the total
number is limited: see, eg,
Mineral Resources (Sustainable Development) Act
, which requires that, where multiple applications for
certain mining licences are received, the application that ranks the highest
merit and against the objectives of the Act must be given priority in the
assessment process (see also s 15).
89 In the Netherlands, Bedrocan BV is subject to constraints on its
production practices through the purchasing process which go
beyond those
required by the regulations: Consultation 28. In Minnesota, where licensed
cultivator/manufacturers were selected through
a competitive selection process,
applicants were asked to address, among numerous other issues, production
capacity (including capacity
to expand), proposed product range, pricing,
anticipated number of customers, marketing plan (including education of patients
medical practitioners), security of premises, how contaminants will be
minimised and cannabinoids will be made consistent, proposed
chemical usage,
recall protocols, proposed extraction methods and solvent control, testing and
stability control, packaging and labelling:
Consultation 25; Minnesota
Department of Health— Office of Medical Cannabis,
Request for
Application for the Registration of Medical Cannabis Manufacturers
September 2014)
http://www.health.state.mn.us
Drugs, Poisons and Controlled Substances Act 1981
92 Victoria,
Parliamentary Debates
, Legislative Assembly, 11 December
2013, 4540 (Peter Walsh, Minister for Agriculture and Food Security).
The estimates requirement imposed by the
Single Convention
on Narcotic Drugs 1961
is described above at [4.15] – [4.16].
93 The Commission was told that it can take some time to develop appropriate
strains and to sufficiently control cannabinoid content,
as each crop takes
3– 4 months to cultivate, and several crops may need to be grown before
consistency is achieved: Consultation
30. Similar considerations would apply to
the development of extraction technology, product stability and so on. See
Chapter 7 for
more detail on the quality standards that licensees would be
expected to attain.
Government as single purchaser
6.68 As explained in Chapter 4, the Single Convention on Narcotic Drugs
requires distribution to be co-ordinated by a government agency.
Countries which
permit the cultivation
of the cannabis plant for the flowering tops or resin must set up a system in
‘[a]ll cultivators of [the cannabis plant] shall be required to deliver
their total crops
of [cannabis]’94 to ‘a government agency’,95 which must
‘purchase and take physical possession’ of
6.69 A system in which the government purchases all medicinal cannabis
produced has been implemented in the Netherlands and Israel,
although those
nations adopt slightly different models in practice. In the Netherlands, there
is only one licensed producer97 (Bedrocan
BV), which produces a number of
strains of cannabis. The cannabis produced is supplied to the government in
dried form, in bulk.
The product is divided, packed, labelled and distributed to
pharmacies by a company under contract to the government. It is then
on a doctor’s prescription. The Dutch Office of Medicinal Cannabis does
not itself process and distribute the products,
but an employee of the Office
attends at the time of delivery. The Dutch Office of Medicinal Cannabis also
arranges for testing of
the cannabis, to test for contaminants and cannabinoid content, and will only
distribute cannabis that passes these quality tests.98
6.70 In Israel, licensed producers, of which there are many, produce a range
of cannabis products, including dried plant matter, edibles,
oils, tinctures and
so on, and deliver these to Sarel Corporation, a government-affiliated
company.99 Sarel then delivers the cannabis
products to patients. Unlike the
Netherlands, patients do not fill prescriptions, but are associated with a
particular producer and
registered with the government.100
6.71 One World Cannabis drew on the Israeli system to comment on the
advantages of the state controlling distribution:
Israel ... decided for a division between growers and supply to patients for
the same reasons Israel does not allow any pharma companies
straight access to
patients. ... This [separate] distributor will also be the long arm of the
national cannabis agency to
purchase and hold all the cannabis products that [have] been harvested. The
distributor will also perform quality assurance on the
cannabis it buys from the
cultivators or refuses to buy due to lack of quality.101
6.72 As mentioned above, manufacturers should be required, under the
conditions of their licence, to deliver all finished cannabis
products to the
Secretary of the Department
of Health and Human Services (formally, pursuant to a contract with the
associated body corporate).102 The price would be set by
agreement with the
government. The Secretary could elect, as other jurisdictions have, to arrange
for a contractor to complete deliveries
to pharmacies. The purchasing process
would also specify whether dividing and packaging should be the role of the
government or licensed
manufacturers.
94 ‘Cannabis’ is defined in Schedule 1 as including cannabis
resin, extracts and tinctures.
95 It is not clear whether the government agency must be set up specifically
for the purposes of regulating cannabis production: see
art 23(1), which states
‘A Party that permits the cultivation of the [cannabis plant] for the
production of [cannabis and cannabis
resin] shall establish,
if it has not already done so, and maintain, one or more government agencies
(hereafter in this article referred to as the Agency)
to carry out the functions
required under this article.’
Single Convention on Narcotic Drugs 1961
, Arts 23(2)(d) and 28.
97 The Dutch legislation does not limit production to one entity; rather, the
contract is regularly put out to tender and Bedrocan
was recently the only
successful applicant. In the past, two companies were licensed to cultivate
cannabis, but one of these companies
was unable to meet government requirements:
Consultation 28.
98 Consultation 28. The cannabinoid content of the product delivered must be
within 20% of the labelled quantity.
99 Sarel Corporation is owned by the Association of Public Hospitals for the
Public, a not-for-profit organisation which may only
serve public purposes. Its
sole business is supplying goods and services to hospitals and medical
institutions. It serves as a purchasing
agent /group purchasing organisation for
the Israeli Ministry of Health: Sarel Corporation,
Business Profile
September 2013,
http://www.sarel.co.il
100 The Government of Israel has recently indicated that it intends to move
away from this policy towards a system of prescriptions:
Jonathan Lis and Ido
Efrati, ‘Medical Marijuana—Coming Soon to an Israeli Pharmacy Near
(online), 28 July 2015
http://www.haaretz.com
101 Submission 61.
102 That is, the body corporate established under
Health and Wellbeing Act 2008
(Vic). The body corporate has the functions
of that Act, which include performing any functions and
exercising any powers conferred on the Secretary of the Department of Health
Human Services by any legislation. See above at [1.75].
Recommendation
All medicinal cannabis products made by licensed manufacturers
should be purchased by the Secretary of the Department of Health and
Distribution through pharmacies
6.73 A number of submissions supported distribution through pharmacies.103
the main alternative proposed to collectives or ‘dispensaries’.
As discussed in Chapter
5, neither a collective-based model nor a dispensary model would be well
suited to achieving the Commission’s regulatory objectives.104
6.74 The Commission considers that cannabis should be distributed to patients
through pharmacies. There are many reasons for this.
Pharmacists have expertise
in advising patients on the use of medicines,105 and patients are accustomed to
collecting medication
from their local pharmacy. Pharmacies have security
arrangements in place so that cannabis can be stored securely.106 Importantly,
pharmacists and pharmacies are already licensed,107 so that enforcement action
can be taken if a pharmacist deals inappropriately
with cannabis, and a new set
of licences need not be established. Finally, pharmacies
are already distributed throughout the state, making them readily accessible
by patients, including in regional areas. There appears
to be no legal
impediment to the distribution of medicinal cannabis by pharmacies, even if such
products are not approved by the
6.75 EROS raised concerns about distribution by pharmacies, contending that a
pharmacy owner who has a personal objection to cannabis
may decline to stock
medicinal cannabis products.109 The Commission acknowledges this is a
possibility, but considers that the benefits
of using the large number of
pharmacies in Victoria outweigh this potential risk.
6.76 Where a patient is an inpatient in a hospital, pharmacy departments
could be used to distribute medicinal cannabis to patients.110
Recommendation
Medicinal cannabis products purchased by the Secretary of the
Department of Health and Human Services should be dispensed to patients
pharmacies and pharmacy departments.
103 Submissions 8, 20, 24, 39, 56 and 60; advisory committee (Meeting 2);
Consultations 7, 13, 18, 24.
104 See above at [5.85] – [5.104] and [5.105] – [5.118].
105 Submission 39.
106 Namely, the requirements which exist for Schedule 8 poisons, set out in
Drugs, Poisons and Controlled Substances Regulations 2006
(Vic) r 35.
107 Under the
Health Practitioner Regulation National Law
Pharmacy Regulation Act 2010
(Vic) pt 3, respectively.
108 Pharmacists are already authorised to possess any drug of dependence in
the lawful practice of their profession:
Drugs, Poisons and Controlled
Substances Act 1981
ss 13(1)(a)
Drugs, Poisons and
Controlled Substances Regulations 2006
(Vic) r 7 would require pharmacists
to hold a permit were cannabis to be treated as a Schedule 9 poison, but as
discussed at [3.223]
, this approach is not recommended. In any event,
pharmacies and pharmacists are regulated under Victorian law, as is the retail
supply of therapeutic goods, so being asked to supply products endorsed by the
Victorian Government should not raise objections from
pharmacists. Pharmacists
are, however, approved by the Commonwealth for the purposes of Pharmaceutical
Benefits Scheme payments.
109 Submission 76.
110 Pharmacy departments are also registered under Victorian law (
Regulation Act 2010
(Vic) s 45) and participate in the opioid replacement
therapy program.
6.77 The rules imposed on pharmacies and pharmacy departments regarding the
dispensing of cannabis could be modelled on the program
for opioid replacement
Victoria, as suggested by the advisory committee and others with whom the
Commission consulted.111 While there would be a diversion
risk associated with
medicinal cannabis,112 not all features of the opioid replacement therapy scheme
would be required—for
example, patients receiving opioid replacement
therapy must in general consume their dose of methadone (or other product) while
are at the pharmacy unless specifically authorised to obtain a ‘take
away’ dose. This would not be necessary or practical
for cannabis. In
addition, the therapeutic index113 of opioid replacement drugs such as methadone
is very small, and the risk of
overdose correspondingly high, while the dangers
associated with patients ‘double dosing’ is much lower in relation
cannabis products.
6.78 An adapted version of the opioid replacement therapy scheme could
function as follows:114
• A patient’s doctor nominates the pharmacy at which they will
collect medicinal cannabis.
• The patient may attend only the nominated pharmacy to collect
medicinal cannabis.
• The patient may be dispensed the medicinal cannabis product they have
been prescribed, and may only receive a one-month supply.
• Pharmacies would stock medicinal cannabis on an ‘opt in’
basis, and would need to notify the Department of their
wish to participate.
However, training on the system is available.
• Pharmacies could charge a dispensing fee or mark up to patients, on
top of the cost of the medicinal cannabis.115
• Patients could be transferred to another pharmacy; the new pharmacy
must make contact with the previous pharmacy to confirm
the patient’s
details, last dose and so on.116
• Guidelines issued by the Office of Medicinal Cannabis would be used
to encourage a dialogue between the pharmacy and the authorising
practitioner.
6.79 Much of the above process could be established through departmental
guidelines, as occurs with the opioid replacement therapy
program. Pharmacists
should be required to store cannabis in accordance with the requirements for
Schedule 8 and Schedule 9
poisons.117 Once the scheme is established, consideration could be given to
less restrictive arrangements, particularly for low-THC
products. If the scheme
established allowed for the production of vaporisable forms of cannabis (that
is, cartridges or refill vials
of liquid), patients would need to have a means
of accessing vaporising devices.118
111 Advisory committee (Meeting 2); Consultations 2 and 24.
112 Advisory committee (Meeting 2); Consultations 23 and 24. This risk exists
even for non-smokable forms (discussed below at [7.79]
Consultation 23.
113 The gap between a prescribed dose of the drug and a lethal dose.
114 See Victorian Department of Health,
Policy for Maintenance
Pharmacotherapy for Opioid Dependence
(2013) for detail on the
pharmacotherapy program.
115 Subject to price controls imposed by the Victorian Government, discussed
116 This may not be necessary given the much lower risk of overdose for
cannabis medications.
117 Set out in the
Drugs, Poisons and Controlled Substances Regulations
(Vic) r 35. That regulation requires, in essence, that such drugs be
held in a lockable storage facility meeting minimum requirements,
pharmacy take reasonable steps to ensure that it is locked at all times except
when used, and that it is only used to store
Schedule 8 and Schedule 9 poisons.
More stringent security may be needed at the outset of the scheme because of the
novelty of medicinal
118 It appears that the sale, use and possession of such devices, which heat
a liquid form of cannabis to a temperature at which the
cannabinoids form a
vapour which can be inhaled, is not currently prohibited in Victoria. The sale
and display for sale of cannabis
water pipes, hookahs and bong kits is
prohibited by
Drugs, Poisons and Controlled
Substances Act 1981
(Vic), but the definition of ‘cannabis water
pipe’, while it includes devices which allow the drawing of fumes from
by heating, requires that this be done ‘through water or another
liquid in the device’. This does not occur with a vaporiser.
Nonetheless,
it may be prudent to explicitly authorise their sale and display by pharmacists
to ensure patients can continue to access
them if restrictions are later
introduced.
6.80 In summary, the risks associated with the distribution of cannabis would
be addressed under this scheme as follows:
Table 4: Risks associated with distribution of medicinal cannabis products
to patients and the regulatory responses proposed to control
these risks
Regulatory response
Patients give or sell their authorised supply to non-authorised users
Limited amounts may be dispensed
Patients use the same authority at
a number of pharmacies, obtaining multiple quantities
Patients must attend a single pharmacy designated by their doctor and
follow a set process if they wish to transfer to another.
Patients obtain cannabis using forged authorities
Communication encouraged between pharmacists and medical
practitioners
Forging an authority would be an offence
Pharmacists or pharmacy staff misappropriate cannabis
Professional obligations on pharmacists and regulatory obligations on
Record-keeping requirements for cannabis products
Theft of cannabis from pharmacies through burglary
Secure storage requirements for cannabis products
Recommendations
Dispensing of medicinal cannabis products to patients should be
through pharmacies and pharmacy departments that elect to participate
Dispensing of cannabis by pharmacies and pharmacy departments
should be modelled on the Victorian program for opioid replacement
and include the following features:
(a) Patients or carers specified in the Authority to Dispense Medicinal
Cannabis would be able to obtain medicinal cannabis products
only by attending
at the specified pharmacy or pharmacy department.
(b) Pharmacies and pharmacy departments would be able to dispense to
patients or carers only the medicinal cannabis product(s) specified
Authority to Dispense Medicinal Cannabis.
(c) Pharmacies and pharmacy departments would be required to store
medicinal cannabis products pursuant to requirements comparable
to those that
apply to the storage of Schedule 8 and Schedule 9 poisons.
6.81 To combat diversion and ensure patient safety, a medicinal cannabis
scheme would need to limit the amount of medicinal cannabis
a patient could
purchase at any one time. For prescription medicines, these restrictions are
imposed largely through limits on Pharmaceutical
Benefits Scheme payments,119
and these would need to be replicated in
a Victorian scheme. Other restrictions placed on dispensing by Victorian law
may also need to be replicated.120 There would need to
be a means for the
Victorian Government to monitor the type and amount of medicinal cannabis
dispensed to patients through pharmacies
and pharmacy departments. This
information would be important for an effective review to be undertaken of the
scheme, and for preparing
manufacturing
estimates for the forthcoming year. These requirements could be imposed on
pharmacists in conjunction with the record-keeping requirements
consistently with Schedule 8 and Schedule 9 poisons, should be imposed in
respect of medicinal cannabis.121
Recommendation
The Secretary of the Department of Health and Human Services
should require pharmacists to notify the Secretary about the amount and
products they dispense to patients under an Authority to Dispense medicinal
Cost considerations
6.82 Several submissions drew attention to the importance of cost in any
medicinal cannabis scheme, with many commenting on the need
to ensure cannabis
products were affordable.122 Cheryl Wright stated that ‘[t]he price needs
to be regulated as well. Otherwise
it will be out of the reach of the average
family.’123 A submission from the cannabis community of Victoria observed
that ‘[m]any
chronically and terminally ill patients suffer financial
hardship.’124 Cancer Council Victoria observed:
There is a risk that if patients cannot afford the approved product they will
resort to sourcing illicit cannabis in respect of which
product quality and
consistency cannot be guaranteed.125
6.83 As the Victorian Government would be the sole seller of medicinal
cannabis under the scheme described above, it would have the
ability to control
the price. While pharmaceuticals listed on the Pharmaceutical Benefits Scheme
are sold to pharmacists by private
wholesalers, then subsidised by the
Commonwealth through reimbursement on claim by the pharmacy, the proposed scheme
would involve
a direct transaction between the government and the pharmacy.
119 The maximum amount of a medicine that can be prescribed and the maximum
number of repeats is set by the Pharmaceutical Benefits
Advisory Committee. The
maximum can be exceeded but only by using an ‘authority
prescription’. See Pharmaceutical Benefits
Prescribing
Medicines—Information for PBS Prescribers
, (1 July 2015)
http://www.pbs.gov.au
120 See, eg,
Drugs, Poisons and Controlled Substances Regulations 2006
(Vic) rr 26 (style and required particulars for prescriptions), 29
(labelling), 30 (duration of prescriptions) and 33 (retention of
prescriptions).
Drugs, Poisons and Controlled Substances Regulations 2006
122 Submissions 2, 3, 24, 49, 57, 63, 95; advisory committee (Meeting 2);
Consultations 2, 3, 4, 5, 6.
123 Submission 2.
124 Submission 95.
125 Submission 57. David and Cheri O’Connell agreed with this
observation: Consultation 18.
6.84 The government should impose price controls on pharmacies, consistently
with arrangements for therapeutic goods subsidised under
the Pharmaceutical
Benefits Scheme.126 This is because participation in the scheme at its outset
is important, and
price controls are fundamental to ensuring the scheme is accessible for
vulnerable people. However, this must be balanced against
the fact that
pharmacists should be permitted
to earn some mark-up or fee to make their participation in the scheme
financially worthwhile.
Recommendation
The Secretary of the Department of Health and Human Services
should from time to time designate a price above which medicinal products
be sold, incorporating the mark-up able to be charged by pharmacists.
126 For medicines which are subsidised through the Commonwealth’s
Pharmaceutical Benefits Scheme, there are caps placed on the
maximum mark-up and
dispensing fee pharmacists are permitted to charge, established by the Fifth
Community Pharmacy Agreement between
the Commonwealth of Australia and the
Pharmacy Guild of Australia: see
http://5cpa.com.au
the product
174 Introduction
175 Product control: form and regulation
175 Quality control
187 Forms of medicinal cannabis
7. Regulating the product
Introduction
7.1 This chapter considers the question of which products should be supplied
under a Victorian medicinal cannabis scheme, assuming
that they are produced
under arrangements set out in Chapter 6.
7.2 These products would need to be quality controlled and available in
therapeutically appropriate forms. In this regard, one of
the Commission’s
recommended regulatory objectives is that the any Victorian medicinal cannabis
scheme ought to ‘ensure
that medicinal cannabis products are of reliable
quality and known composition’.1
7.3 Several submissions received by the Commission endorsed this objective.2
The Australian Nursing & Midwifery Federation (Victorian
Branch) expressed
its support for ‘a clear legislative and regulatory framework to ensure
quality, efficacy and reliability
of the end product’, which it said is
‘necessary for the protection of patients’.3
7.4 In a joint submission to the Senate Legal and Constitutional Affairs
Committee’s inquiry into the
Regulator of Medicinal Cannabis Bill
cannabis researchers from the University of Sydney emphasised the importance of
quality control when something is used as a medicine:
Vulnerable patients source cannabis preparations from the black market. These
preparations are unregulated with potential for inappropriate
cannabinoids for
certain indications (eg high THC for pediatric epilepsy), contamination with
pesticides or heavy metals, tinctures
with no cannabinoids sold as medicine,
and poor understanding of appropriate dosing schedules. These safety concerns
could be controlled...
to help deliver safe and reliable cannabis based
medicines to those who would benefit.4
7.5 To date, only one pharmaceutical-grade cannabis extract (Sativex) has
been made available in Victoria, and then only through special
importation
schemes,5 not through being marketed in Australia. No cannabis products have
been lawfully marketed or manufactured in
Victoria before. For this reason, it
is essential that Victoria takes a cautious approach to ensuring that the
cannabis products
supplied are of good quality.
7.6 Likewise, medicinal cannabis supplied in Victoria should be available in
forms that are appropriate to the patient’s particular
needs. In ensuring
this, both the formulation and the cannabinoid content need to be controlled.
Quality and consistency are also
important to medical practitioners, who would
be more likely to approve the use of medicinal cannabis where its quality and
consistency
could be guaranteed.6
1 See [1.47] – [1.49].
2 Submissions 14, 25, 35, 57, 60, 69; Consultation 13. See Appendices and C
for lists of submissions and consultations.
3 Submission 75.
4 David Allsop et al, Submission No 52 to the Senate Legal and Constitutional
Affairs Committee, Parliament of Australia,
Inquiry into the
Regulator of Medicinal Cannabis Bill 2014
, 13 March 2015, 2.
5 For example, the Special Access Scheme and through clinical trials. See the
Therapeutic Goods Act 1989
6 Submission 99.
Product control: form and regulation
7.7 There is no single type of medicinal cannabis. Taking overseas
experience as a guide, medicinal cannabis can be supplied as dried
and/or in a range of refined forms. In addition, products can vary greatly in
the stringency of regulation applied to them.
A description of the products
available under any given scheme must identify how the dual variables of form
and regulation intersect.
7.8 As set out in Chapter 2, the products potentially available under a
medicinal cannabis scheme can be placed into three groups:
pharmaceutical-grade
products approved by a regulator like the Therapeutic Goods Administration
(TGA), quality-controlled products
that have not been conventionally approved,
and products that have not been approved or regulated. Examples of each type can
around the world:
Pharmaceutical grade
—The only non-synthetic medicinal
cannabis product that has been approved to date is the cannabis extract Sativex,
manufactured
by GW Pharmaceuticals. No dried cannabis products have been given
conventional approval to date.
Quality controlled
—In Minnesota, for example, a range of
non-smokable forms of medicinal cannabis are made available to patients, all of
are subject to quality regulations regarding manufacturing processes and
testing. In the Netherlands, on the other hand, various
forms of dried cannabis
are supplied, and these are also quality controlled through strict rules and
Unregulated
—In Arizona, medicinal cannabis dispensaries
supply patients with various cannabis extracts that are not subject to medical
quality controls.7 Likewise, in Hawaii, which currently allows only ‘grow
your own’ medicinal cannabis, dried cannabis
is not subject to any
regulation on quality.8
7.9 The Commission has sought to identify what combination of form and
regulation should be adopted under a Victorian scheme. As explained
cannabis products the Commission considers should be provided in Victoria are
quality-controlled cannabis extracts. While
these products would not be approved
as conventional pharmaceuticals, they would be standardised and regulated for
Quality control
7.10 A system of quality control must specify: the standards to which
manufacturers are required to adhere, how the standards are
applied in law, and
what measures can be used to ensure products have been produced in compliance
with the standards.
Objectives of quality control
7.11 A ‘quality controlled’ product is one which is of a known
and consistent composition, both in terms of ingredients
and active compounds,
and which does not contain dangerous levels of unsafe contaminants.9 A system
of quality control for a herbal
medicine therefore needs to address three
aspects of the product:
• identity (containing just one plant)
• purity (freedom from contaminants)
• content (active constituents within defined limits).10
7 Regular food safety rules apply, but only to edible products: Ariz Admin
Code r 9-17-319.
8 Hawaii’s medicinal cannabis scheme relied exclusively on patients and
their carers ‘growing their own’ cannabis
until this year. House
Bill 321, which was signed into law on 15 July 2015, will enable the Hawaiian
Department of Health to license
dispensaries to distribute medicinal cannabis to
Hawaiian patients. However, no such dispensaries will open until 2016.
9 Submission 21.
10 Arun Rasheed, Sravya Reddy B and Roja C, ‘A Review on
Standardisation of Herbal Formulation’ (2012) 2
International Journal
Phytotherapy
7.12 Consistency was a key focus of submissions.11 It was observed that
patients should receive a product which is known to be the
same in every
bottle,12 and ‘legal standardisation’
was called for to ensure products are of ‘consistent quality and
efficacy’.13 Cassie Batten and Rhett Wallace told the
Commission that they
do not know what is in the product they use, and that variation in what they
receive (which they can only assess
through the appearance and odour of the
product) can cause variation in the condition of their son, Cooper.14
Consistency is particularly
important because of the botanical, herbal
of cannabis products. The cannabinoid content of the cannabis plant can vary
greatly, depending on the genetic makeup of the plant
and an array of growing
conditions.15
7.13 The need for safety of medicinal cannabis products was also emphasised
in submissions, with particular calls for pesticides to
be banned or
controlled.16 Cannabis which has not been regulated for quality, such as
‘street’ cannabis, has been found
to have a range of safety issues,
• unsafe levels of mould and bacteria17
• unsafe levels of solvent residue in concentrates made using
hydrocarbon extraction methods18
• contaminants, including ground glass19 and fly spray20
• unsafe levels of toxic pesticides21
• releasing ammonia when heated (including in a vaporiser)22
• heavy metal contamination.23
Regulation of herbal medicines in Australia
7.14 Plant-based medicines are by no means uncommon in modern medical
practice. Some common pharmaceuticals, including morphine, paclitaxel
number of cancer drugs were isolated from and continue to be derived from plant
sources.24 Plant-based medicines are also made
available for therapeutic use in
less refined forms, containing
more than just one isolated molecule.25 ‘Herbal’ medicines of
this kind are primarily found in the field of complementary
11 Submissions 2, 24, 25, 26, 34, 57, 75; Consultations 2, 13.
12 Submission 2.
13 Submission 34.
14 Consultation 13.
15 Consultation 30. Using genetically identical plants, controlling growing
conditions and adopting a consistent manufacturing process
can help to control
this, but variation still occurs: Victorian Law Reform Commission,
Cannabis: Issues Paper
(2015) [2.9].
16 Submissions 22, 29, 43, 49, 95; Consultation 6.
17 Arno Hazekamp, ‘An Evaluation of the Quality of Medicinal Grade
Cannabis in the Netherlands’ (2006) 1
Cannabinoids
‘Bacteria in Bud Prompts Nanaimo Firm to Recall Medical Marijuana’,
The Canadian Press
, 23 March 2015
http://www.vancouversun.com
the microbes detected in the unregulated cannabis include known carcinogens and
neurotoxins, and are a particular danger
for people with compromised immune
system, such as those with AIDS. See also J M McPartland and P L Pruitt,
‘Medical Marijuana
and Its Use by
the Immunocompromised’ (1997) 3
Alternative Therapies in Health and
39; R Hamadeh et al, ‘Fatal Aspergillosis Associated with
Smoking Contaminated Marijuana, in a Marrow Transplant Recipient’
432 (note that while the bulk of studies associated with the
harms of mould in cannabis relate to smoked cannabis, it is assumed that
also exist when cannabis extracts are produced).
18 Luigi Romano and Arno Hazekamp, ‘Cannabis Oil: Chemical Evaluation
of an Upcoming Cannabis-Based Medicine’ (2013)
Cannabinoids
19 J Delourme et al, ‘Respiratory Consequences of Inhalation of
Adulterated Cannabis’ (2009) 26
La Revue des Maladies Respiratoires
20 Consultation 23.
21 Noelle Crombie, ‘It Doesn’t Pay to Be Honest’,
, 11 June 2015
http://www.oregonlive.com
Los Angeles
City Attorney,
‘City Attorney’s Office Secures Injunction Prohibiting Sales of
Marijuana from Medical Marijuana Facility’ (Press
Release, 29 January
http://atty.lacity.org
22 Roger Bloor et al, ‘Ammonia Release from Heated ‘Street’
Cannabis Leaf and Its Potential Toxic Effects on Cannabis
Users’ (2008)
23 Heavy metals can be taken up by the plant from soil: P Linger, A Ostwald
and J Haensler, ‘Cannabis Sativa L. Growing on
Heavy Metal
Contaminated Soil: Growth, Cadmium Uptake and Photosynthesis’ (2005) 49
Biologia Plantarum
24 Wai Liu, ‘Why Anti-Cancer Properties in Cannabis Must be
Investigated’,
The Conversation (online)
, 26 June 2015
http://theconversation. com /why-anti-cancer-properties-in-cannabis-must-be-investigated-42653
25 According to the World Health Organisation, a medicine ceases to be
considered ‘herbal’ if it is a finished product
containing a
chemically defined isolated constituent from a plant. A ‘herbal
preparation’, by comparison, ‘may
include comminuted or powdered
herbal materials, or extracts, tinctures and fatty oils of herbal materials ...
produced by extraction,
fractionation, purification, concentration, or other
physical or biological processes.’ A ‘finished herbal product’
is made from one or more herbal preparations, and may contain excipients,
provided no chemically defined active substances are added: World Health
Organisation,
General Guidelines for Methodologies on Research and Evaluation
of Traditional Medicine
(2000) UN Doc WHO/ EDM / TRM /2000.1, 3.
Australian Register of Therapeutic Goods
7.15 Herbal medicines may be either ‘listed’ or
‘registered’ on the Australian Register of Therapeutic Goods
sold in Australia, with the vast majority going through the listing route to
approval.26 Listed goods are considered to be
lower risk than registered goods,
and a correspondingly less intense level of scrutiny is applied to
applications.27
7.16 The medicinal cannabis products made available to patients overseas, and
currently used illicitly in Australia, are in the nature
of herbal medicines.
The conventional way for such products to be regulated is through the
‘listing’ process.28 However,
products containing cannabis cannot be
listed on the Australian Register of Therapeutic Goods.29 This reflects an
underlying purpose
of the listing process, namely that it is to be used for
lower-risk goods, the safety of which is known.
PIC/S Guide to Good Manufacturing Practice for Medicinal Products
7.17 Whether listed or registered, the manufacture of herbal medicines must
comply with the same manufacturing standards as synthetic
pharmaceuticals: a set
of rules commonly referred to as ‘Good Manufacturing Practice’
(GMP).30 Australia has adopted
an international code, the ‘Guide to Good
Manufacturing Practice for Medicinal Products,’ developed by the
Pharmaceutical
Inspection Convention and Pharmaceutical Inspection Co-operation
Scheme (jointly known as PIC/S) as the standard to be observed in
manufacture of therapeutic goods.31
7.18 The PIC/S Guide to Good Manufacturing Practice for Medicinal Products
and its annexes are not prescriptive as to what manufacturers
must do or how
their facilities need to be set up. Rather, they set out a series of
aspirational, product-neutral statements to guide
industry participants on the
sorts of procedures they need to adopt and follow. While the PIC/S Guide
frequently states that manufacturers
‘should’ do certain things, in
Australia these are treated as compulsory requirements.32
7.19 The PIC/S Guide has a number of Annexes. Annex 7 relates to the
Manufacture of Herbal
Medicinal Products. It is based on the following principle:
Because of their often complex and variable nature, and the number and small
quantity of defined active ingredients, control of starting
materials, storage
and processing assume particular importance in the manufacture of herbal
medicinal products.33
26 Fewer than 200 of the 20,000 approved complementary medicines in Australia
are ‘registered’ goods: Lloyd Sansom, Will
Delaat and John Horvath,
Review of Medicines and Medical Devices Regulation
Regulation of
Complementary Medicines—Addendum to Discussion Paper
(February 2015)
6. Medicines may be listed if they contain only certain compounds. Among the
permitted ingredients are herbal substances
other than those derived from
specified (high risk) plants:
Therapeutic Goods Regulations 1990
27 Lloyd Sansom, Will Delaat and John Horvath,
Review of Medicines and
Medical Devices Regulation
Regulation of Complementary
Medicines—Addendum to Discussion Paper
(February 2015) 6. In addition,
listed goods cannot make therapeutic claims about any disease, condition,
ailment or defect listed
in Part 1 or 2 of Appendix 6 of the
Therapeutic
Goods Advertising Code 2007
Therapeutic Goods Regulations 1990
sch 4. The prohibited claims generally relate to more serious conditions, and
when considering the addition of conditions, consumer
vulnerability and impacts
on public health must be taken into account, including whether the claim would
make consumers less likely
to seek professional advice:
Therapeutic Goods
Advertising Code 2007
. See also Review of Medicines and Medical Devices
Regulation,
Regulation of Complementary Medicines—Addendum to
Discussion Paper
(February 2015) 6.
28 Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [4.35].
Therapeutic Goods Regulations 1990
(Cth) r 10 (b) and sch 4
Items 3(d)(i) and 3(a)(i) provide that preparations are not listable if they
contain herbal substances derived from specified plants
(among which is
cannabis: sch 4
div 1) or if they are included in a schedule to the Poisons
Standard (cannabis is in Schedule 9).
30 Internationally, the requirements of GMP are not uniformly applied to
complementary medicines, with the United States, New Zealand
and Singapore among
the jurisdictions which apply different manufacturing standards to complementary
medicines: Lloyd Sansom, Will
Delaat and John Horvath,
Review of Medicines
and Medical Devices Regulation
Regulation of Complementary
Medicines—Addendum to Discussion Paper
(February 2015) 17. The
Australian complementary medicines industry has proposed the development of a
standard specific to complementary
medicines, and has suggested different
standards for, among other things, stability testing and validation testing:
of Medicines and Medical Devices Regulation,
Regulation of Complementary
Medicines—Addendum to Discussion Paper
2015) 17–18. The Review has asked for submissions on and will consider
whether a different set of GMP standards should be adopted
for complementary
medicines. See Submission from the Australian Self Medication Industry (Stage
2), Submission from Complementary
Medicines Australia (Stage 2).
Therapeutic Goods Act 1989
permits the Commonwealth
Minister for Health to determine written principles to be observed
in the manufacture of therapeutic goods. Through the
Therapeutic Goods
(Manufacturing Principles) Determination No. 1 of 2009
TGA has adopted the PIC/S ‘Guide to Good Manufacturing Practice for
Medicinal Products’ (PE 009-8, 15 January 2009) for
the purposes of
Through the operation of
and other provisions within the Act, the Guide has
legal force in Australia.
Therapeutic Goods (Manufacturing Principles) Determination No. 1 of
(Cth) s 5(4).
33 PIC/S ‘Guide to Good Manufacturing Practice for Medicinal
Products’ (PE 009-8, 15 January 2009) Annex 7, 48.
Other guidelines
7.20 International guidelines relevant to the production of herbal medicines
also exist,34 and various pharmacopoeias include guidance
on the production of
herbal drugs and extracts.35 Domestically, the TGA has developed the Australian
Regulatory Guidelines for Complementary
Medicines.36
Creating a framework for medicinal cannabis quality
7.21 Victoria should seek to make available a regulated source of medicinal
cannabis products—notwithstanding that they are
not proven,
pharmaceutical-grade products— while still providing appropriate
protections for vulnerable patients within the
If this structure were to replicate the rigour of the TGA’s assessment
process for pharmaceutical-grade products, there would
be no point in setting it
up. The alternative structure must sensibly be one which does not require the
same level of evidence to
be supplied, or there would be no expansion of the availability of medicinal
cannabis products within a satisfactory timeframe.
7.22 Equally, it is important that the products authorised under the
Victorian medicinal cannabis scheme do not directly compete with
or undermine
conventional pharmaceuticals. For the reason that they are not as tightly
regulated as products approved by the TGA,
the products available under the
Victorian medicinal cannabis scheme should be different from their
pharmaceutical counterparts,
including pharmaceuticals derived from cannabis.
Patients and doctors would have reasons for preferring pharmaceutical-grade,
tested cannabinoid products, and as a result the two categories of
product would not directly compete.37
7.23 It is important that, for the separate character of the Victorian
products to be preserved, and the pre-eminence of conventional
approval to be
maintained, the character of the products be distinctive. That is, the
government should not endorse these products
as replacements for conventional
pharmaceuticals. The equivocal evidence base, surveyed
in Chapter 2, shows this stance to be unavoidable. Therefore, it is the
Commission’s
view that medicinal cannabis products should be presented to patients as a
form of less- refined, herbal medicine.
7.24 The Commission considers that the regulation of medicinal cannabis
quality should be as follows:
• Medicinal cannabis products should not be required to be tested for
safety or efficacy prior to going to market, and patients
should be informed of
this fact when being supplied with products.38
• Medicinal cannabis products should be in the nature of herbal
extracts, in that they would contain a range of compounds found
in the plant,
not isolated cannabinoids.39
• The concentration of cannabinoids in medicinal cannabis products
should be permitted to vary within specified ranges. The
uncertainty potentially
generated by this would be addressed by requiring products to be tested, and
labelled accordingly.
34 For example: European Medicines Agency
Guideline on Stability Testing:
Stability Testing of Existing Active Substances and Related Finished Products
(CPMP/QWP/122/ 02, rev 1); European Medicines Agency
Quality of Herbal
Medicinal Products/Traditional Herbal Medicinal Products
(CPMP/QWP/2819/ 00
Rev. 2); European Medicines Agency
Test procedures and Acceptance Criteria
for Herbal Substances, Herbal Preparations and Herbal Medicinal
Products/Traditional Herbal
Medicinal Products
CPMP/QWP/2820 / 00 Rev.
35 See, eg, the monographs of the British Pharmacopoeia on ‘Herbal
Drugs’, ‘Herbal Drug Preparations’ and
‘Extracts’.
36 Currently published as version 5.2, May 2015.
37 That this is the case can be seen in the example of GW Pharmaceuticals.
Despite cannabis being widely available for medical and
recreational users in
the United States, the company is investing significant sums in trialling its
pharmaceutical-grade cannabinoid
products with a view to obtaining regulatory
approval for their sale in the United States. (Sativex is currently undergoing
trials for cancer pain, while Epidiolex is being trialled for Dravet
Syndrome and Lennox-Gastaut Syndrome.) See GW Pharmaceuticals
, Press Releases
http:// www.gwpharm.com
38 See [3.203] – [3.205].
39 This is consistent with the definition of ‘herbal substance’
Therapeutic Goods Regulations 1990
(Cth) r 2—’herbal
substance means all or part of a plant or substance (other than a pure chemical
or a substance of bacterial
origin): (a) that is obtained only by drying,
crushing, distilling, extracting, expressing, comminuting, mixing with an inert
substance or another herbal substance or mixing with water, ethanol,
glycerol or aqueous ethanol; and (b) that is not subjected to
treatment or process other than a treatment or process that is necessary for its
presentation in a pharmaceutical form.’
• Medicinal cannabis products should be subject to manufacturing
standards equivalent to those imposed on medicines approved
by the TGA.
7.25 The proposed regulation is less strict than for products approved by the
TGA, in that products would not be as rigorously assessed
or purified, but they
would still be subject to quality control. The government would fail to protect
patients if it were to endorse
the provision of products without taking steps to
ensure their quality. One objective
of legalising and regulating medicinal cannabis is to reduce the harms
associated with patients accessing cannabis for medical use
on the black market,
harms which include uncertainty about content, possibility of contamination and
an unreliable source of supply.40
7.26 Some submissions in support of a parallel system for the regulation of
the quality of medicinal cannabis supported this type
of regulation. Professor
David Penington stated he believes medicinal cannabis ‘will end [up] being
designated as a regulated
“herbal” product’.41 Along the same
lines, Laurence Mather, in his submission to the Senate Committee, endorsed
Dutch approach, of standardised herbal cannabis.42
7.27 It is acknowledged that cannabis is not free of risks, and in many ways
is quite distinct from the types of goods ordinarily
regulated as herbal
medicines. For this reason, the Commission does not suggest that Victoria merely
replicate the system of controls
for listed complementary medicines. As
described below and elsewhere in this report, herbal cannabis products should be
the following additional controls:
• Medicinal cannabis should only be made available to eligible
patients, namely those in defined ‘exceptional circumstances’
there is some evidence cannabis may assist.43
• Medicinal cannabis should only be supplied to and possessed by
someone who has been authorised by a medical practitioner.44
• Medicinal cannabis products should be batch tested prior to their
supply to patients, to quantify content and ensure the absence
contaminants.45
Quality standards
7.28 For the quality of medicinal cannabis products to be controlled, there
is a need to determine the set of standards to which they
will be held. Victoria
has the option
of drawing on internationally accepted standards for agricultural products
and drug manufacture, or developing its own set of standards,
specific to
medicinal cannabis.
7.29 There are sources on which the Victorian Government could draw to
establish the standards with which cultivators and manufacturers
• Good Agricultural and Collection Practice
• Good Manufacturing Practice
• Codes of practice with specific rules for medicinal cannabis.
40 Thus the Commission’s regulatory objective of ‘ensuring that
medicinal cannabis products are of reliable quality and
composition’.
See also Laurence Mather, Submission No 17 to Senate Legal and Constitutional
Affairs Committee,
Inquiry into the Regulator of Medicinal
Cannabis Bill 2014
, 9 March 2015.
41 Submission 24.
42 Laurence Mather, Submission No 17 to Senate Legal and Constitutional
Affairs Committee,
Inquiry into the Regulator of Medicinal Cannabis
, 9 March 2015, 8.
43 See Chapter 3.
44 See Chapter 3.
45 See [7.59] – [7.62].
Good Agricultural and Collection Practice
7.30 Good Agricultural and Collection Practice (GACP) is a set of procedures
that govern the cultivation, harvesting, processing and
storage of botanical
products used for the production of medicines. Their purpose has been described
as follows:
In the case of herbal preparations the production and primary processing of
the medicinal plant/herbal substance has a direct influence
on the quality of
the [active pharmaceutical ingredient]. Due to the inherent complexity of
naturally grown medicinal plants/herbal
substances and the limited analytical
techniques to characterise constituents solely by chemical or biological means,
reproducible
quality of starting materials of herbal origin requires an
adequate quality assurance system for the collection and/or cultivation,
and primary processing.46
7.31 In addition, GACP seeks to ensure that medicinal plants and herbal
substances are produced hygienically, reducing microbial contamination
minimum, and are handled with care, to avoid adversely affecting the herbal
substance during its collection, cultivation, processing
or storage.47
7.32 GACP comprises a set of procedures that producers of many types of plant
products should follow in order to ensure a safe finished
product for consumers.
There is, in fact, not one single version of GACP, but a number of guidelines
for different industries. The
standards most relevant to the production of
botanical medicines are those produced by the European Medicines Agency48 and
Health Organisation.49
7.33 Producers of medicinal plants in Australia are not directly required by
law to comply
with GACP. However, manufacturers using herbal ingredients are required to
undertake testing and treatment of botanical source materials,50
and must be
able to provide specifications for any herbal starting products.51 In this
respect, quality control of plant- derived
medicines is made the responsibility
of the manufacturer. In the case of the alkaloid poppy industry, for example,
cultivators licensed
by Victoria are not subject to any regulation of their
cultivation and harvesting practices from a quality perspective, with quality
obligations imposed solely on manufacturers through the licensing and approval
processes of the TGA and international pharmaceutical
regulators.52
7.34 Notwithstanding this, in the Commission’s view, cultivators in the
Victorian medicinal cannabis scheme should be required
to comply with standards
of some kind. UTT BioPharmaceuticals agreed with this, recommending that the
system regulate the finished
product, the botanical ingredients it contains, and
the cultivation process.53 While this would depart from the approach adopted
through the listing/registration processes in
Therapeutic Goods Act 1989
(Cth), the Commission considers that
the novelty of cannabis demands a cautious, transparent approach.
7.35 It should be noted that Victorian and Commonwealth legislation that
restricts the activities of all agricultural producers would
also apply to
cannabis cultivators.54
46 European Medicines Agency,
Guideline on Good Agricultural and
Collection Practice (GACP) for Starting Materials of Herbal Origin
(EMEA /HMPC/246816/2005) [1].
47 European Medicines Agency,
Guideline on Good Agricultural and
Collection Practice (GACP) for Starting Materials of Herbal Origin
(EMEA /HMPC/246816/2005) [2.2].
49 World Health Organisation,
WHO Guidelines On Good Agricultural and
Collection Practices (GACP) for Medicinal Plants
50 Annex 7 to the PIC/S ‘Guide to Good Manufacturing Practice for
Medicinal Products’ (PE 009-8, 15 January 2009) requires
manufacturers to
ensure botanical products are tested for constituents, pesticides, fungal
/microbial contamination, toxic metals
and foreign materials: clause 5. It also
highlights that treatments to reduce fungal /microbial contamination might be
51 European Medicines Agency
Test Procedures and Acceptance Criteria for
Herbal Substances, Herbal Preparations and Herbal Medicinal
Products/Traditional Herbal Medicinal Products
(EMA /CPMP/QWP/2820 /
52 Consultation 19.
53 Submission 60.
54 See, eg: the
Agricultural and Veterinary Chemicals (Control of Use) Act
(Vic), which restricts pesticides and other chemicals that may be used;
Environmental Protection Act 1970
(Vic) and policies associated with
it which restrict certain activities that have environmental impacts, such as
runoff, offensive
smells and waste disposal.
Recommendation
Licensed cultivators should be required to comply with
appropriate Good
Agricultural and Collection Practice.
Good Manufacturing Practice
7.36 In the Commission’s view, manufacturers in the Victorian medicinal
cannabis scheme should be required to comply with the
PIC/S Guide to Good
Manufacturing Practice
for Medicinal Products.55 Several submissions called for these standards to
be applied.56
As explained above, because they are worded in general terms, Good
Manufacturing Practice (GMP) can be applied to the manufacturers
of botanical
products just as they can to manufacturers of synthetic compounds. Relevant
international guidelines57 could also
be supplied to guide manufacturers.
Recommendation
Licensed manufacturers should be required to comply with Good
Manufacturing Practice, as reflected in the PIC/S Guide to Good Manufacturing
Practice for Medicinal Products.
Cannabis-specific codes of practice
7.37 In connection with the licensing of manufacturers, the TGA has detailed
protocols and a body of inspectors and officials with
specialised knowledge
in the Department of Health
and Human Services because the Department does not
have responsibility for the regulation of drug/herbal product manufacturers or
the enforcement of GMP.58 In
addition, the Department would need to determine how to apply the general
standards of GMP to cannabis production—for example,
the standards refer
to acceptable limits of pesticides and microbes, but there is no specification
of precisely what that level would
be.59 In summary, the supervision exercised
by the TGA over manufacturers cannot be replicated in the Victorian scheme
merely through
the application of the PIC/S Guide.
7.38 To address these possible practical difficulties, the Department could
prepare new rules, specifically for application to cannabis
production.60 This
would provide certainty to businesses seeking to participate in the scheme, and
to government inspectors in
determining whether licensees are compliant. The new rules could be used in
substitution for or in addition to GACP or GMP. If operating
alongside them, the
rules could function
to explain how GACP/GMP are considered to apply in the context of cannabis
production.
55 (PE 009-8) 15 January 2009.
56 Submissions 24 and 60, advisory committee (Meeting 2), Consultation 1.
57 Examples are given at [7.20].
58 The Department has a role in food safety, but this field applies a
different set of standards and relies on a different set of
59 Standards exist, but they are not contained in the PIC/S Guide to GMP.
Finished products regulated by the TGA must have microbial
levels below set
standards, laid out in the Therapeutic Goods Order No 77,
Microbiological
Standards for Medicines
(2008). TGA guidelines set out maximum levels of
pesticide and solvent residues in finished products: TGA,
Regulatory Guidelines for Complementary Medicines
(version 5.2, May 2015)
71. Even fresh produce is subject to maximum pesticide residue concentrations,
which are determined by Food
Standards Australia and New Zealand:
Standards Code
60 Comparative guidelines in Victoria are Codes of Practice in the dairy
Dairy Act 2000
) and the meat industry
Industry Act 1993
(Vic) ss 13A–13E).
This approach is adopted in the Netherlands.61 Cannabis-specific production
guidelines have also been adopted in, among other places,
Canada,62 Colorado
and Minnesota.63
Enforcing the standards
7.39 There are a number of tools through which the Victorian Government could
apply quality standards to manufacturers (from least
to most restrictive):
• allow the industry (licensed cultivators and manufacturers) to
self-regulate, and for optional accreditation schemes to give
information about the standards applied
• arrange for manufacturers to make cannabis products under contract to
the Victorian
Government, and make production standards terms of the contract
• make compliance with manufacturing standards a condition of the
licences held by cultivators and/or manufacturers
• set out rules in legislation.
7.40 Self-regulation would not be appropriate, as patient safety should be
paramount under the scheme. Conversely, setting out specific
legislation would be too restrictive, preventing the government from updating
procedures and standards as the industry develops.
Applying standards to
licensed manufacturers through contractual terms would not be sufficiently
transparent to give patients and
medical practitioners confidence in the scheme,
and would deprive inspectors of necessary enforcement powers.
7.41 In the Commission’s view, the GMP standards referred to above and
any local guidelines developed for cannabis should be
applied to manufacturers
and cultivators through incorporation of the relevant standards in regulations64
and through licence conditions.
7.42 Standards could be practically enforced through a combination of the
following mechanisms:
• inspections at the time of application to ensure facilities and
operators are set up to comply with GACP/GMP65
• requiring licensees to prepare and submit production plans66
• regular inspections throughout the period of the licence to ensure
ongoing compliance67
• record-keeping and reporting obligations imposed on licensees68
• audits conducted by third parties69
• infringement notices, improvement notices70 and licence variation
available where noncompliance is observed.
61 The Netherlands has produced a set of guidelines specific to cannabis,
which are applied to cultivators. The guidelines are based
on the European
Medicines Agency’s guidelines. See
Guidelines for Cultivating Cannabis
for Medicinal Purposes [Voorschriften voor de Verbouw van Cannabis voor
Medicinale Doeleinden]
, Annex to the Regulation of the Minister of Health,
Welfare and Sport of 9 January 2003, GMT/ BMC 2340685, English translation
in (2003) 3
Journal of Cannabis Therapeutics
62 Canada’s
Marihuana for Medical Purposes Regulations
/2013-119 set out procedures for the cultivation and processing of cannabis
which are based on the GMP provisions of the
Natural Health Product
Regulations
, SOR /2003-196 ss 52– 63; Part 3: Consultation 31.
63 Marijuana Enforcement Division (Colorado),
Sales, Manufacturing and
Dispensing of Medical Marijuana Rules
, 1 CCR 212-1;
Pertaining to Medical Cannabis Manufacturers
, Minnesota Rules
4700.0100-4770.2800.
64 Like the incorporation of the Guide at the Commonwealth level through
Therapeutic Goods Act 1989
(Cth): see [4.38] – [4.39].
65 Comparable to inspections of applicants for manufacturing licences under
Therapeutic Goods Act 1989
Dairy Act 2000
, under which certain
categories of licence holders can be required to have a food safety program,
setting out how the licence holder
will comply with the applicable Code of
Meat Industry Act 1993
, under which
licence holders can be required to have a quality assurance program.
67 By way of contrast, the TGA adopts a risk-based approach to inspections,
under which the frequency of inspections depends on the
risks associated with
the relevant product and process, together with the licensee’s compliance
history, while the duration
and conduct of inspections depends on the type of
processes used. See: Commonwealth Department of Health—Therapeutic Goods
Administration,
Manufacturer Inspections—An Overview
, (1 May 2013)
www.tga.gov.au
/manufacturer-inspections-overview
Meat Industry Act 1993
, imposing record keeping
obligations on licensees.
Dairy Act 2000
, under which Dairy Food Safety
Victoria can require licence holders to audit their food safety program;
Industry Act 1993
(Vic) s 12A.
Dairy Act 2000
, setting out the powers of authorised
officers to order licence holders to undertake cleaning, to shut down particular
to suspend delivery of orders, etc.
Efficacy testing
7.43 The approval process undertaken by the TGA evaluates products for
‘safety, quality and efficacy’.71 Sponsors seeking
to register a
therapeutic good must present to the TGA evidence that the good is efficacious
for the requested indication.72 The
less rigorous listing process does not
evaluate efficacy, but requires manufacturers to possess evidence supporting any
therapeutic
claims they wish to make.73
7.44 This raises the question of whether products should be permitted to be
sold under the scheme if they have not been specifically
tested in humans for
effect. One submission stated that it would be ‘unfair’ to apply the
efficacy criteria for registered
to medicinal cannabis products and argued that departure from ordinary
standards is justified where ‘medical science and regulatory
processes are
failing to meet the needs
of society’.74 However, a number of other submissions advocated for
clinical trials, on the basis that the efficacy of cannabis
was not yet
adequately established.75
7.45 In the Commission’s view, the scheme should operate on the basis
that the efficacy of Victorian medicinal cannabis products
has not been
established. The Victorian scheme should ensure a product is free of unsafe
components and its composition is sufficiently
known. However, it would not be
feasible or desirable for the scheme to make approval of a particular medicinal
cannabis product
contingent on proof (whether to conventional standards or
otherwise) that the product is effective to treat a given indication. Clinical
trials are costly and time-consuming to run, and placing similar barriers to
product approval as already exist under the TGA would
not facilitate access to
medicinal cannabis in any meaningful way.
7.46 Because their efficacy has not been specifically proven, products
offered under the medicinal cannabis scheme would be clinically
less useful than
those approved through conventional channels. While this would provide patients
and their treating medical practitioners
with fewer assurances than approval by
the TGA, this is a tolerable outcome because the scheme would complement, not
supplant, the
approval processes of the TGA, to allow access to less-proven
substances in exceptional circumstances.
7.47 There is a risk that products would be offered to patients despite
having no therapeutic value, or with their therapeutic value
overstated.76
However, as the government would be the sole distributor, there is no risk of a
third-party manufacturer making inaccurate
efficacy claims.
7.48 It is important for patients to be clearly informed when deciding to
take medicinal cannabis dispensed under the Victorian scheme
that the products
have not been subjected to the conventionally rigorous tests of efficacy imposed
by the TGA, and that other conventional
products exist which have that status.
By opting for the ‘alternative’ of medicinal cannabis, the patient
must be informed
that that the product may not be effective for them. There is a
risk that attaching the imprimatur of the state to these
regulated products would lead consumers to assume that they have been
clinically tested for efficacy. The advice given to patients
by doctors and the
government in authorising them to use cannabis would therefore be fundamental to
ensuring that patients’
consent to use such products is informed.77
Therapeutic Goods Act 1989
s 25(1)(d).
72 Therapeutic Goods Administration,
Product Regulation According to
, (28 October 2014),
http://www.tga.gov.au
Therapeutic Goods Act 1989
s 26A(2)(j).
74 Submission 43. Submission 95 also opposed the testing of efficacy for
cannabis products under a Victorian scheme.
75 Submissions 25 and 38.
76 Consumers of health products are frequently misled by overstated
therapeutic claims attached to unproven treatments. By way of
example, in 2013
the National Health and Medical Research Council issued a warning to patients
travelling overseas to seek treatment
with stem cell therapies, noting that
‘The science of stem cells offers great potential for treating a number of
conditions,
however in many cases further research is required to demonstrate
safety and effectiveness. ... Unproven stem cell treatments can
serious health complications such as infection, allergic reaction or immune
system rejection and in some cases, the development
of cancer. In addition to
the health and safety risks, these treatments often involve significant
financial costs. Undergoing unproven
treatments may also interfere with or delay
a patient accessing proven and potentially beneficial therapies or treatment
National Health and Medical Research Council, ‘NHMRC Warns
of the Risks Associated with Unproven Stem Cell Therapies in Australia
Overseas’, (Media Release, 19 December 2013)
http:// www.nhmrc.gov.au
77 See [3.203] – [3.205].
Clinical testing of side effects
7.49 For a therapeutic good to be included on the Australian Register
of Therapeutic Goods, its safety must be known. In the
case of listed goods,
safety is ensured by requiring that the product only contain ingredients already
known to be safe. In the case
of registered medicines, considered to be higher
risk, the sponsor must present evidence regarding
the product’s safety. That is, the medicine must have been tested for
side effects prior to obtaining approval.
7.50 The risks and side effects of cannabis are relatively few and minor.78
In addition, they are reasonably well documented, although
mostly not in a
clinical setting, and in
this sense cannabis is not comparable to a drug containing a new molecule.
Where a new complementary medicine is sought to be used,
its safety can be
established by documenting historical evidence of its use.79 Cannabis has been
extensively used and studied, and
while it is by no means completely safe or
free of side effects,
the Commission considers that quantifying cannabinoid content and
disseminating educational materials about known attributes and side
medicinal cannabis to medical practitioners would be sufficient to allow the
patient and their treating doctor to identify
risks for the patient, and render
safety testing of individual products unnecessary.
Product approval
7.51 Any Victorian medicinal cannabis scheme should only provide medicinal
cannabis products that have been approved by the government.
A list of approved
products would be publicly available, and new products could be added by the
Secretary of the Department of Health
and Human Services. A submission made on
behalf of the
cannabis community of Victoria opposed a scheme in which the available
products are limited by the government in this way, stating
that it would not
satisfy patient needs.80
The Commission considers, however, that this regulatory mechanism is
essential to give clarity to law enforcement, to satisfy doctors
products’ reliability and to maintain government control over the
available products.
7.52 By requiring that medicinal cannabis products be approved, the scheme
could draw a clear line between products that are lawful
and those that are not.
Amendments to
Drugs, Poisons and Controlled Substances Act 1981
(Vic) would
authorise medicinal cannabis patients to possess only the approved product
specified in the Authority to Dispense. Nominated
carers would be similarly
authorised.81
7.53 Medical practitioners issuing an Authority to Dispense would specify the
product to be dispensed, in a similar way to prescriptions
for conventional
medicines. To this end, the Department of Health and Human Services should make
available to medical practitioners
a list of approved products and their
properties.
7.54 A product approval should specify at least the following matters:
• its THC content, as a percentage
• its CBD content, as a percentage
• its formulation (for example: extraction, tincture, oil)
• permitted ingredients
• the brand name under which it will be sold
• the contents of its label.
78 See [2.145] – [2.164]. According to Laurence Mather, medicinal
cannabis has side effects, like all medicines, but they are
‘minimal and
acceptable’, and it ‘lacks life threatening acutely toxic effects
even in large overdoses’:
Laurence Mather, Submission No 17 to the Senate
Legal and Constitutional Affairs Committee, Parliament of Australia,
Regulator of Medicinal Cannabis Bill 2014
2015, 4, 7.
79 Therapeutic Goods Administration,
Australian Regulatory Guidelines for
Complementary Medicines
(version 5.2, May 2015) 76.
80 Submission 95.
81 See [3.198] , [3.215] , [3.222].
7.55 Upon taking possession of cannabis products from manufacturers, the
government should ensure that the product corresponds with
its approval. In
particular, through testing (detailed below), it should ensure that the
cannabinoid content of the product is consistent
with the approval, within a
specified tolerance range.82
7.56 Unlike the process for including new products on the Australian Register
of Therapeutic Goods, obtaining approval of a medicinal
cannabis product should
not be initiated by the proposed manufacturer, nor require the manufacturer to
test the product in clinical
trials before approval is granted. This is because
the design of the scheme is such that the government orders specific quantities
of designated cannabis products, which are then delivered to it by the licensed
manufacturers. That is, the government controls the
levels of supply and, correspondingly, should control the range of products
that are made available.83 However, the process for obtaining
new products would
involve consultation between the manufacturer and the Department, as the
introduction of a new product would depend
on the ability of the manufacturer(s)
to produce it safely and consistently.
7.57 The Secretary’s discretion to approve new products should be
unfettered. In practice, the Secretary would be likely to
take into account
scientific developments regarding the utility of different types of cannabis for
eligible conditions, patient demand
for new products, patient safety, and
pharmacological considerations regarding rate, intensity and duration of
absorption.
7.58 A process should be established by which products would be considered
for approval.
This should include consultation with the medical profession and the Expert
Advisory Committee on Medicinal Cannabis or a successor
advisory body.84 The
Department would issue guidelines regarding the product development and testing
which would need to
take place before the product is approved—for example, a manufacturer
may be asked to demonstrate their ability to control cannabinoid
concentration
before a particular product is approved.
Recommendations
The Secretary of the Department of Health and Human Services
should have the power to determine which medicinal cannabis products
manufactured under licence and dispensed in Victoria.
The Secretary of the Department of Health and Human Services
should establish and publish a register of medicinal cannabis products
for sale in Victoria. The register should specify, for each product:
(a) its THC and CBD content, as a percentage
(b) its formulation
(c) permitted ingredients
(d) the brand name under which it will be sold
(e) label contents.
82 In the Netherlands, cannabinoid content can vary from the specified
concentration by up to +/- 20%: Bedrocan BV, Submission No
Senate Legal and Constitutional Affairs Committee, Parliament of Australia,
Inquiry into the
Regulator of Medicinal Cannabis Bill 2014
13 March 2015.
83 This is the process adopted by the Office of Medicinal Cannabis in the
Netherlands: Consultation 28.
84 See [1.77] – [1.79].
Batch testing
7.59 Medicinal cannabis products would be tested for two reasons:
• to ensure the quality of products (namely, to ensure that the actual
quantity of cannabinoids in the product matches the concentration
listed on the
product approval)
• to ensure the safety of products (namely, to ensure that the product
contain unsafe concentrations of contaminants, such as moulds, microbes,
harmful or prohibited pesticides, solvent residue and so
7.60 Consistently with the requirements of the TGA, testing should be
conducted to ensure that any ‘quantitative claim’
made (that is, any
claim made regarding the THC or CBD content of a product) is verified, and this
testing should take place on
every batch produced.85 Testing should be performed
on the finished product (the oil, tincture or other product), not on the raw
plant matter.86 The specified cannabinoid content on the approval would need to
be within a prescribed tolerance, and failure to
do so would enable the
Secretary to reject the batch.87
7.61 Testing could either be performed by the manufacturer or by a third
party. For transparency reasons, the Commission considers
that testing by a
third party would be preferable.88 If internal testing is to be used, no
additional legislative change would be
required. If third parties are to be used
for testing, the legislation would need to authorise certain facilities to
possess medicinal
cannabis for the purpose of testing. It is suggested that the
provisions authorising certain facilities to undertake testing could
on current provisions empowering the Chief Commissioner of Police to declare
testing facilities to undertake forensic testing of drugs.89
7.62 In determining whether to authorise a particular facility, the Secretary
would have regard to whether it would use appropriate
technologies to give an
accurate indication of product strength.90 The technology used would need to be
adapted to the purpose of
the testing. While some testing technologies have as
their purpose determining which compounds are present in a sample, others are
intended to quantify the amount of
particular compounds present in a sample. A facility would need to be
properly equipped to test the potency91 of cannabis, and to
test for an
appropriate range of pesticides, solvents, heavy metals and microbial
contaminants.
Recommendation
The Secretary of the Department of Health and Human Services
have the power to authorise independent testing facilities in Victoria to
test medicinal cannabis products.
85 Therapeutic Goods Administration,
Australian Regulatory Guidelines for
Complementary Medicines
(version 5.2, May 2015) 125.
86 TGA guidelines allow botanical medicines to be ‘quantified by
input’ in certain circumstances—that is, it allows
the manufacturer
to omit testing of the finished product if the composition of its ingredients is
known. However, testing is required
where a ‘quantitative
is made on the product label. Because, as stated at [7.64] , the Commission
recommends that cannabis products be labelled with their
cannabinoid content,
testing of each batch would be required under the scheme: Therapeutic Goods
Administration,
Australian Regulatory Guidelines for Complementary Medicines
(version 5.2, May 2015) 123– 6.
87 This is the approach adopted in the Netherlands. There, cannabinoid
content is permitted to vary by +/- 20% of the set value for
the product,
consistently with European Medicines Agency guidelines: Consultation 28.
88 Submissions 60, 95.
Drugs, Poisons and Controlled Substances Act 1981
90 The Secretary should also ensure the facility is accredited by the
National Association of Testing Authorities.
91 In particular, the testing facility would need to be able to test cannabis
products for their concentration of THC and THCA, and
to be able to
differentiate the two cannabinoids when stating the concentration. Because only
THC is psychoactive, and it appears
is not metabolised to THC in the human body (see: Julia Jung et al,
‘Studies on the Metabolism of the Δ9-Tetrahydrocannabinol
Δ9-Tetrahydrocannabinolic Acid A (Δ9-THCA-A) in Rat Using LC-MS/
MS, LC-QTOF MS and GC-MS Techniques’ (2009) 44
Journal of Mass
Spectrometry
1423), an accurate statement of the potency of a cannabis
product must be capable of distinguishing THC from THCA. It has been asserted
that GC-MS, which heats the product sample in the testing process above the
temperature at which decarboxlyation occurs, converts
THCA in the sample into
THC, leading to results which overstate the concentration of THC in the finished
product, unless the sample
is ‘derivatised’ before testing: Luigi L
Romano and Arno Hazekamp, ‘Cannabis Oil: Chemical Evaluation of an
Cannabis- Based Medicine’ (2013) 7
Cannabinoids
Submission 95 also made this point.
Recommendation
All medicinal cannabis products manufactured under a Victorian
scheme should be subject to testing by an authorised testing facility
whether the cannabinoid content correlates with that specified on the label and
to identify the presence of any contaminants.
7.63 Submissions highlighted the value of labelling as a means of conveying
information about the product to patients.92 Matthew
Pallett submitted that
‘[a]ll commercial cannabis products should carry labelling stating
percentage of active constituents
so consumers can make an informed decision
7.64 As noted above, the scheme should allow for cannabinoid content to vary
slightly from the specified content on the approval.
Therefore, medicinal
cannabis products should be labelled with the precise cannabinoid content of the
product. Labels could also
convey warnings regarding the risk of driving,94 the
untested nature of the product, penalties attached to diversion and so on.
Post-market surveillance
7.65 Even cannabis products that have been subject to quality control
regulations could
later be found to be unsafe. For this reason, the regulation of therapeutic
goods always includes a system to monitor products after
they go onto the
market. This allows the regulator both to monitor rare or long-term adverse
effects, and to undertake recalls and
investigations if unexpected contamination
is detected.
7.66 The TGA has a system for reporting adverse events. Reports are primarily
made by patients, manufacturers, medical practitioners
and pharmacists. The
information received is logged, and may lead to further evaluation. Should a
safety concern be identified, the
TGA can take actions including information
bulletins, labelling changes, withdrawing or limiting a product’s
registration,
or requesting that further studies be undertaken.95 An analogous
system should be adopted in any medicinal cannabis scheme.96
Forms of medicinal cannabis
7.67 Submissions frequently argued for the scheme to make available a range
of medicinal cannabis products, to allow for the varying
preferences and medical
needs of patients.97
In addition to a variety of strains, the scheme should allow for a variety of
delivery modes. This is important as different patients
and conditions are
asserted to respond better to different products.
7.68 A considerable amount of knowledge exists, both in industry overseas and
in the Australian illicit market, regarding the composition
of cannabis, the
ways it can be refined and how products can be adapted to suit the needs of
patients. The Commission heard from
many people who had become expert on the
topic of medicinal cannabis, both through reviewing the literature and
cultivation experience.98
92 Submissions 59, 60, 69, 97.
93 Submission 59.
94 See [3.219].
95 Commonwealth Department of Health—Therapeutic Goods Administration,
Reporting Medicine and Vaccine Adverse Events
(28 October
2014) <https://
www.tga.gov.au
/reporting-medicine-and-vaccine-adverse-events-0
96 Consultation 25.
97 Submissions 19, 45, 59, 63, 74, 75, 84, 95; Consultations 6, 7. Members of
the Commission’s advisory committees also commented
upon the need for a
range of products to be made available: advisory committee (Meeting 3).
98 Submissions 29, 59, 93, 95; Consultation 7.
7.69 However, there is also a good deal to learn, and many assertions that
are frequently made regarding cultivation practices, extraction
methods and
pharmacology do not appear to
be based on science—indeed, this is not surprising given that there are
few legal means for this information to be tested and
Smoking should be avoided
7.70 Historically, cannabis has been commonly administered by
smoking.99 As discussed in the Issues Paper,100 smoking has
a number of
adverse health consequences and is an unreliable way of dosing. Many of the side
effects associated with smoking cannabis
are not observed for other modes of
administration.101 There is also the possibility of
accidental ingestion by third parties through passive smoking.102 A number
of submissions urged that smoking be discouraged or prevented
under the proposed
scheme, or remarked upon the harmful health effects of this mode of
administration.103 However, as noted by Cancer
Action Victoria, the risks
associated with smoking are of less importance for a person with a terminal
illness.104
7.71 In addition, over the past three decades governments have passed
increasingly restrictive laws aimed at protecting public health
by prohibiting
or discouraging smoking,105 while the not-for-profit sector has run extensive
public health campaigns to the same
A scheme which made cannabis available and enabled or encouraged smoking as a
delivery method would be inconsistent with the outcomes
and messages that
successive governments have worked hard to achieve in this area.
7.72 There are two distinct means by which a medicinal cannabis scheme could
seek to avoid the smoking of cannabis:
• by allowing dried cannabis (in addition to other forms) but
prohibiting or discouraging patients from consuming it by smoking
• by only allowing forms of cannabis that cannot be smoked.
Allowing dried cannabis but discouraging smoking
7.73 It would be possible to establish a scheme which provided dried cannabis
but did not promote smoking. The Victorian Government
could provide advice to
patients and
health professionals regarding other forms of delivery, such as vaporisation
and ingestion through food or tea. Pharmacists could
supply informational
material and be able to sell vaporisers, which heat cannabis without combusting
it, avoiding many of the negative
health effects observed with smoking.
Alternatively, legislation could be enacted which seeks to prevent or limit
smoking of cannabis
by users who have obtained it for medicinal use.
7.74 In the Netherlands, patients can only purchase dried cannabis, in the
form of whole dried flowers or flowers which have been
‘granulated’.
Government information programs encourage consumption by vaporisation, in a tea
or in edible/baked goods.106
However, in practice a large number of patients
administer their medicinal cannabis by smoking it—up to 80 per cent of
are estimated to do so.107
99 Smoking in a cigarette and smoking in a water pipe /bong are not
differentiated here.
100 See Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [3.81].
101 Ibid [3.81] – [3.85] , Submission 52.
102 Submission 52.
103 Submissions 38, 45, 47, 49, 52, 57, 63, 91, 99; Consultations 13, 16,
104 Submission 54.
105 Including location-based bans, advertising and marketing restrictions and
taxation policies. See M M Scollo and M H Winstanley
Tobacco in Australia: Facts & Issues
(4th ed, 2012, Cancer Council
http://www.tobaccoinaustralia.org.au
106 See Victorian Law Reform Commission,
Medicinal Cannabis Issues Paper
(2015) [6.12] – [6.13] , [6.23].
107 Consultation 28.
7.75 Several submissions called for dried plant matter to be among the forms
of cannabis available under the scheme.108 One expressed
the view that, if
dried cannabis were made available, few patients would smoke it in any
7.76 Cancer Council Victoria stated that it ‘would not support a scheme
where the smoking of cannabis is the predominant delivery
patients.’ It encouraged the consideration of models ‘where
alternative delivery methods, such as the use
of oils and vaporisers, are the
primary approach’.110
7.77 Victoria Police opposed the provision of dried plant cannabis to
patients, commenting that
‘[i]t would not be forensically possible to differentiate crude
cannabis grown illicitly from crude cannabis grown for medicinal
purposes.’111 Appropriately labelled, non-smokable cannabis would be more
easily differentiated from illicit cannabis by law
enforcement authorities.
7.78 While there are a range of educational measures and offence provisions
the government could adopt to discourage users from smoking
the dried plant form
of cannabis, and there are ways of administering the dried plant form which do
not involve smoking, the inevitable
reality is that if dried cannabis is
available, some patients will probably smoke it. A law which purported to
prohibit the act of
smoking medicinal cannabis, including on private property,
would not be enforceable. If Victoria wishes to prevent medicinal
cannabis supplied under the scheme from being smoked, an alternative approach
will be required.
Allowing only non-smokable forms
7.79 The Victorian Government could elect to only make available forms of
medicinal cannabis that cannot be smoked. Non-smokable forms
could include
extracts such as oils and concentrates, which can be swallowed or vaporised,
pills, capsules and tinctures.112
7.80 There are many challenges involved in allowing only non-smokable forms
of medicinal cannabis to be sold. Requiring producers
to refine cannabis before
it is sold would increase the cost of the product to the government113 and the
cost of administering the
regulatory system. Non-smokable extracts of cannabis
can be highly potent, much more so than dried cannabis, making the risk of
psychoactive effects much higher (this risk is heightened with oral
forms, due to the slow rate of onset).114 Finally, because patients
control over the way the cannabis is prepared and administered, prohibiting
smokable forms may reduce levels of engagement
with the system and promote
continued reliance on the black market.
108 Submissions 1, 3, 11, 12, 15, 16, 18, 19, 22, 24, 37, 57, 74, 84, 95.
109 Mullaways Medicinal Cannabis Pty Ltd observed that ‘[t]he future of
medicinal cannabis does not involve smoking cannabis.
Most patients will find
relief with other preparations ... very few if any will end up smoking it as a
medical option’: Submission
29. Marc Selan expressed a similar view in
Submission 74, while the submission made on behalf of the cannabis community of
observed that ‘long term use [of smoking] is rare’:
Submission 95.
110 Submission 57.
111 Submission 44.
112 Administration as a sublingual /buccal spray, as used for Sativex, may
not be available to be used in Victoria, as GW Pharmaceuticals
hold patents on,
among other things, the delivery of cannabinoids using a mouth spray: see, eg,
GW Pharmaceuticals, Cannabinoid Liquid
Formulations for Mucosal Administration,
Patent No 2009202434.
113 Submission 57.
114 Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
(2015) [2.39].
7.81 A further drawback to allowing only non-smokable forms of cannabis to be
sold is that patients would be deprived of safe administration
methods which
have a low production cost. Research and knowledge is growing about the use of
vaporisers (devices which
use heat to release cannabinoids and other volatile compounds) to administer
dried cannabis.115 Research indicates that this method
allows patients to
obtain the benefits of inhalation (fast uptake and short duration of effect)
while avoiding many of the harms
associated with smoking (bronchial irritation,
potential carcinogenesis and the effects of second-hand smoke on other
people).116
7.82 In addition, licit non-smokable cannabis products are very new, making
the task of regulating them difficult and uncertain. Information
on the safety
and efficacy of cannabis is limited, but the information that does exist mostly
pertains to dried cannabis. As a result,
the introduction of a scheme involving
only non-smokable forms is to some degree a foray into the unknown—indeed,
to the Commission’s
knowledge, only two jurisdictions (Minnesota and New
York) have introduced medicinal cannabis schemes
that do not allow the dried plant form, and only one scheme has so far
commenced. A number of states in the United States, however,
non-smokable forms of cannabis to be sold alongside dried plant cannabis, with
highly variable regulations imposed.
In addition, non-smokable forms are harder to regulate and the system for
licensing manufacturers outlined above would be largely
unnecessary if oils and
other extracts were not provided under the scheme.
7.83 Nonetheless, the Commission is persuaded that a scheme which allows
smoking should be avoided, and accepts that the only feasible
way of ensuring
this is through providing only non-smokable forms of medicinal cannabis. This
approach would also have the advantage
of enabling more accurate purity control
and dosing.
Formulations and delivery systems
7.84 A Victorian medicinal cannabis scheme should enable production of a
variety of formulations and delivery systems. Different patients
have different
needs and preferences in relation to medicinal cannabis – for example,
children will generally require a product
taken by mouth, for ease of
administration, while people affected by nausea and vomiting may not want a
product they need to swallow.117
115 Many submissions highlighted vaporisers as a useful mode of
administration, such as Submissions 24, 29, 45, 49, 61, 72, 74, 91,
Vaporising dried cannabis is said to be a ‘popular choice’ and
‘favoured by overseas Medicinal Cannabis Practitioners’:
116 See, eg, D I Abrams et al, ‘Vaporization as a Smokeless Cannabis
Delivery System: A Pilot Study’ (2007) 82
Clinical Pharmacology and
Therapeutics
572; Mallory Loflin and Mitch Earleywine, ‘No Smoke, No
Fire: What the Initial Literature Suggests Regarding Vapourized Cannabis
Respiratory Risk’ (2015) 51
Canadian Journal of Respiratory
Therapeutics
7. See also Submission 95.
117 Consultation 8.
7.85 Submissions called for the scheme to make available cannabis in the
following extracted forms:
• tinctures119
• edibles120
• tablets/capsules121
• creams/ointments122
• extracts123
• patches124
• raw cannabis.125
7.86 Many overseas jurisdictions allow the sale of
‘edibles’—foods such as chocolate and cookies that contain an
extract of cannabis—through their medicinal cannabis schemes. A number of
concerns were raised in submissions regarding such
products. One submission
argued that edible products should be strictly controlled on the basis that they
can cause bad publicity
for a medicinal cannabis scheme.126 Others observed
that edible products present a risk to children127 and to patients, who are
aware of the dose they are receiving.128 The Commission agrees and does not
recommend that they be included at
the outset of the scheme.
7.87 If dried cannabis is not supplied under the scheme, this precludes
patients from
‘vapourising’ cannabis, as explained above. The Commission heard
anecdotal reports that inhalation is a better mode of
delivery for people using
cannabis to treat pain129 and that its onset is quicker.130 So that the
inhalation route can be among those
available for some categories of patient,
the Secretary of the Department of Health and Human Services should evaluate the
and disadvantages of vaporisable concentrates, like those used in
e-cigarettes, as a means of delivery of medicinal cannabis.131
7.88 The government should ensure, through the licensee selection process and
selecting products for approval, that the range of available
products spans a
range of administration routes and pharmacological properties.
7.89 The cannabis plant comes in an extensive number of strains.132 These
strains, which represent particular subtypes of cannabis,
can be differentiated
using a number of characteristics, including the dominant species (sativa or
indica), the cannabinoid content
(THC, CBD and others) and the terpene
118 Submissions 1, 11, 12, 16, 18, 22, 24, 29, 31, 37, 45, 49, 59, 74, 80,
91, 95; Consultations 4, 13.
119 Submissions 1, 11, 12, 29, 37, 49, 74, 91, 95; Consultation 13.
120 Submissions 1, 16, 29, 37, 45, 74, 84, 91, 95.
121 Submissions 29, 45, 74; Consultation 13.
122 Submissions 12, 29, 74, 95.
123 Submissions 29, 54, 60. The submission on behalf of the cannabis
community of Victoria notes the distinction between ‘cold’
and converted extracts, and between those made with polar and nonpolar solvents:
Submission 95.
124 Submission 29.
125 Submissions 91, 95; Consultation 5.
126 Submission 55.
127 Submissions 27, 49.
128 Submission 22. In medical terms, it is difficult for patients to titrate
dosing, increasing the risk of under- or over-dosing:
Ryan Vandrey et al,
‘Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis
Products’ (2015) 313
Journal of the American Medical Association
129 Consultation 8.
130 Submission 95.
131 Vaporisable oils are made available by the two medicinal cannabis
suppliers in Minnesota, Leafline Labs LLC (see:
http://www.leaflinelabs. com /our-medicine
) and Minnesota Medical Solutions LLC (see:
http://www.minnesotamedicalsolutions.com /for-patients
132 Submission 59.
7.90 In some overseas jurisdictions, medicinal cannabis producers market many
ranges of strains to patients, under colourful and distinctive
strain names not
dissimilar to the branding for alcohol and food.133
7.91 A submission made on behalf of the cannabis community of Victoria
asserted that it:
does not support the idea of limiting forms of medicinal cannabis under the
operation of a proposed medicinal cannabis scheme for
Victoria. This submission
has promoted the unique applications and circumstances in which various forms of
cannabinoid medicines
serve particular patient ailments and needs. A
patient’s ability to access cannabis medicine is a key requirement of any
scheme. That implies that the medicine must be appropriate and in the
form appropriate for the patient.134
7.92 Professor Laurence Mather has also drawn attention to the complex nature
of cannabis products:
It is well known that medicinal preparations made from the cannabis plant
typically contain several hundreds of known chemical substances,
and many of
these demonstrate activity in relevant pharmacological models. Moreover, these
substances occur in varying concentrations
in different strains of cannabis
plants, with additional variations introduced by conditions of plant growing,
harvesting, storage
and processing. Thus ‘cannabis’ cannot be
regarded as a particular drug and therein lies an issue for regulatory bodies
and for intellectual property acquisition by pharmaceutical companies.135
7.93 Medicinal cannabis users often differentiate between strains of cannabis
based on the type of cannabis from which they are derived
dominant’, ‘indica dominant’ or
‘hybrid’). The species is perceived to affect the nature of the
psychoactive effects which the user experiences. The
indica strain is
considered, for example, to provide pain relief without the ‘high’.
However, the reason for the perceived
differences between sativa and indica
varieties of cannabis is as yet inadequately understood, and complicated to
assess due to
the number of potential compounds involved. Cannabinoid and
terpene content can vary as much within each category as between them.136
Increasingly, in the United States the distinctions between different strains
are complicated by commercial competition in the marketplace.
7.94 Notwithstanding this, producers respond to and influence consumer demand
by providing a number of strains in all three categories,
even where extracts
are supplied, allowing patients to try a range of strains to determine which
best addresses their symptoms. At
the start of its medicinal cannabis scheme, the Netherlands Office of
Medicinal Cannabis made available only sativa strains of cannabis;
response to patient demand, it introduced an indica strain (marketed as
‘Bedica’).137
7.95 The Commission agrees that the approval system put in place should allow
for producers to cultivate and market a range of strains.
There are many
compounds in the cannabis plant, and the quantities of each vary from strain to
strain. However, while the level of
strain variation seen in countries such as
Canada and the United States caters well to patient demand, in that it caters to
of preferences and allows them to look for
a strain that ‘works well for them’,138 it is difficult to
incorporate this level of variation
133 Canadian licensed producer Tweed Inc, for example, sells strains under
brand names including ‘Bogart’, ‘Mayberry’
‘Strangelove’.
Products vary in price per gram, and for each product, patients can view a
diagram showing the terpene balance of the plant (referred
‘terpography’), and view its percentage of THC and CBD. It also
sells blends of strains, designed to achieve
specific THC and CBD levels: Tweed
Inc, ‘Available Strains’
http://www.tweed.com /collections /available
134 Submission 95.
135 Laurence Mather, Submission No 17 to Senate Legal and Constitutional
Affairs Committee,
Inquiry into the Regulator of Medicinal Cannabis
, 9 March 2015, 2.
136 A Hazekamp and J T Fischedick, ‘Cannabis—From Cultivar to
Chemovar’ (2011) 4
Drug Testing and Analysis
660. The authors
analysed the cannabinoid and terpene ‘fingerprint’ of a number of
cannabis strains, finding similar profiles
137 Consultation 28.
138 In relation to the Dutch medicinal cannabis market, Hazekamp and
Fischedick observe: ‘An important reason for patients to
keep purchasing
their materials from illicit markets is the fact that, by trial and error, they
have found a strain that works optimally
for treatment of their specific
symptoms. With the limited choice of Cannabis varieties currently available from
official sources,
it is hard to deny the value of such choice.’ A Hazekamp
and J T Fischedick, ‘Cannabis—From Cultivar to Chemovar’
Drug Testing and Analysis
under the distribution model required by the
Single Convention on Narcotic
. That is, where the government is the sole purchaser of cannabis
products, there is no interface between the patient and the manufacturer,
limiting the extent to which the patient can communicate with them about their
needs.139 The Victorian Government will need to specify,
manufacturing licences, which products it wishes to procure. Further, were an
unlimited number of strains provided, doctors
would be incapable
of selecting the strain that is most therapeutically appropriate for patients
- this could only be determined through a process where
the patient had the
freedom to select their own product. Therefore the Commission considers that
only a modest number of strains
should be made available under the Victorian
scheme, described by neutral terminology.140
Cannabinoid content
7.96 Cannabis is known to contain between 80 and 100 cannabinoids. The
medicinal effects of these are only slowly coming to be understood,
hypothesising that the effect of certain cannabinoids is greater in combination
than in isolation (referred to as the ‘entourage
effect’).141 It
will be some time before the precise mechanism is known for many of the apparent
benefits observed by patients
using the plant form of cannabis or cannabis
7.97 Nonetheless, it is apparent that variation in cannabinoid levels between
different cannabis products results in differing patient
outcomes. The Victorian
scheme should therefore allow for cannabis products to be supplied that vary in
cannabinoid content. Under
the Minnesota medical cannabis scheme, by way of
example, manufacturers supply products with three or four different THC/CBD
concentrations.142
Similarly, in the Netherlands, Bedrocan supplies five
strains of cannabis, each with a specified level of THC and CBD.143
The Commission notes that the submission on behalf of the cannabis community
of Victoria opposed this model, stating that ‘[c]annabis
medicine cannot
be approached in this way. It must be specifically tailored for and to, a
patient’s individualized needs’.144
7.98 Some people called for products high in CBD and low in THC to be made
available on
the basis of their efficacy for certain conditions such as epilepsy.145 It
was noted in several submissions too that products with
very little THC would
have a minimal or non-existent psychoactive effect, and would therefore be of
limited interest for recreational
The Commission agrees with this perspective. In addition, the lack of
psychoactive effects means high-CBD products would have a better
safety profile
than high-THC products.147
As a result, the government may consider approving products high in CBD more
readily than those with a high level of THC.
7.99 Others called for products containing a balanced ratio of THC and CBD to
be made available.148 Professor David Penington submitted
that Victoria should
develop a product with equivalent levels of THC and CBD, drawing on evidence
showing that CBD
139 It should be acknowledged that the scheme operating in Israel uses a
state-aligned entity to distribute cannabis through pharmacies,
similarly to the
model proposed below, and does enable patients to access a variety of cannabis
strains. See Tikun Olam,
Our Strains
http://www.tikun-olam.info /our-Strains
. However, in Israel the doctor merely authorises a
patient’s use of cannabis, and does not determine the product they
supplied or the dose.
140 New York intends to make available non-smokable cannabis in a limited
number of approved product lines, each of which must be
sold under a
‘distinct name which has been approved by the department, consisting of
only letters and /or numbers’, which
must not ‘be coined or
fanciful’ or ‘include any “street”, slang or other
name’, to differentiate
it from other states where it is marketed with
evocative names: 8
NY Comp Codes R & Regs § 1004.11(c)(6).
141 See Ethan Russo, ‘Taming THC: Potential Cannabis Synergy and
Phytocannabinoid-Terpenoid Entourage Effects’ (2011)
Pharmacology
1344. Both cannabinoids and terpenes are posited as
contributing to the overall effects of cannabis products.
142 Leafline Labs supplies three ‘strengths’: Tangerine (THC >
CBD), Heather (THC = CBD) and Cobalt (THC < CBD).
Each strength is available
in a range of formats, including capsules, syrups /suspensions, oils for
vaporisation, tinctures and sublingual
sprays. Leafline Labs,
http://leaflinelabs.com /our-medicine /
. Minnesota Medical Solutions’ range was not
published at the time of writing.
143 Each of Bedrocan’s five strains has a specified approximate THC
(and in some cases CBD) concentration, which can be accessed
The strains are: Bedrocan (THC 22%, CBD <1%), Bedrobinol (THC 13.5%, CBD
<1%), Bediol (THC 6.5%, CBD 8%), Bedica (THC 14%, CBD
<1%) and Bedrolite
(THC 0.4%, CBD 9%).
144 Submission 95.
145 Submission 50; Consultation 8.
146 Submissions 46, 50.
147 See Therapeutic Goods Administration,
Australian Public Assessment
Report for Nabiximols
(September 2013).
148 Submissions 22, 59.
‘counteracts the negative effects of the potent and psychotogenic THC
on the brain’, reducing or eliminating its tendency
psychosis.149 Others also drew attention to the antipsychotic and
neuroprotective properties of CBD.150
7.100 Some submissions argued for products containing high levels of
tetrahydrocannabinolic acid (THCA) to be made available under
a Victorian
scheme.151 THCA is the precursor chemical to THC, and is not believed to be
psychoactive152 nor to be metabolised to
THC in the body.153 The cannabis plant
contains predominantly THCA, which is progressively converted to THC through the
drying process,
and can be converted further by heating. It has been asserted
that THCA is an effective treatment for the symptoms of epilepsy,154
diabetes155
and autism.156 However, the research on THCA, as distinct from THC, is at an
early stage. Studies have been carried out
on animals157 and in cultures,158
but rigorous human studies of the isolated cannabinoid are yet to be
conducted.159 Although the
accounts provided to the Commission regarding results
achieved with THCA tinctures have been strongly expressed,160 the lack of
on this compound means that the Commission cannot recommend that THCA
extracts be made available outside trials at this stage.
7.101 The Commission considers that the Victorian medicinal cannabis scheme
should be able to provide cannabis products with varying
quantities of the two
best-understood cannabinoids: THC and CBD.161 At this stage, there is
insufficient evidence to warrant the
provision of products that are
differentiated by other cannabinoids, and medical
practitioners would lack the ability to select an appropriate product. As
science develops and production methods improve, the Secretary
of the Department
of Health and Human Services may decide to approve further products.
7.102 The Secretary could ensure that a variety of cannabinoid compositions
are available under the scheme through the competitive
selection of licensees.
The Secretary could also
build incentives into the contract for the development of products, and allow
licensees to cultivate cannabis for experimental purposes
separately to their
medical allowance. A mechanism for obtaining expert advice should also be
incorporated.
149 Submission 24.
150 Consultation 23; Submission 22.
151 Submissions 29, 71.
152 E M Rock et al, ‘Tetrahydrocannabinolic Acid Reduces Nausea-Induced
Conditioned Gaping in Rats and Vomiting in
Suncus murinus
British Journal of Pharmacology
153 Julia Jung et al, ‘Studies on the Metabolism of the
9-Tetrahydrocannabinol Precursor 9-Tetrahydrocannabinolic Acid A
(Δ9-THCA-A)
Using LC-MS/ MS, LC-QTOF MS and GC-MS Techniques’ (2009) 44
of Mass Spectrometry
154 Submissions 29, 71.
155 Submission 71.
156 Submission 29.
157 E M Rock et al, ‘Tetrahydrocannabinolic Acid Reduces Nausea-Induced
Conditioned Gaping in Rats and Vomiting in
Suncus murinus
British Journal of Pharmacology
641; Kazuhito Watanabe et al,
‘Marijuana Extracts Possess the Effects Like the Endocrine Disrupting
Chemicals’ (2005) 206
158 R Moldzio et al, ‘Effects of Cannabinoids (9)
-tetrahydrocannabinol, (9) -Tetrahydrocannabinolic Acid and Cannabidiol in
Affected Murine Mesencephalic Cultures’ (2012) 19
Phytomedicine
819; Kitty C M Verhoeckx et al, ‘Unheated Cannabis Sativa Extracts and
its Major Compound THC-Acid Have Potential Immuno-Modulating
Properties Not
Mediated By CB1 And CB2 Receptor Coupled Pathways’ (2006) 6
International Immunopharmacology
159 No such studies were able to be located on PubMed or the
ClinicalTrials.gov portal. No published studies were drawn to the
Commission’s
attention in submissions (the submission on behalf of the
cannabis community of Victoria referred to a number of studies involving
but none of these involved trials in humans: Submission 95).
160 Submissions 29, 51, 71, 95. The submission on behalf of the cannabis
community of Victoria stated that ‘[t]here are many
children with
pediatric forms of epilepsy currently taking THC based cannabis medicine in
Australia, with great success’: Submission
95. Mullaways Medical Cannabis
Pty Ltd did, however, report the results of a patient survey, in which patients
reported results achieved
with a tincture reported to be high in THCA:
Submission 29.
161 A product range similar to that on offer in Minnesota might include
products with low THC, medium THC, high THC and predominantly
7.103 It would also be possible for rules to be made in legislation or
regulations, stipulating the maximum concentration of THC,
the minimum
concentration of CBD or the minimum THC:CBD ratio that Victorian medicinal
cannabis products would be permitted to contain.
This would enable the Secretary
to ensure that highly potent forms of cannabis are not available,162 and that
protective levels of
CBD are included. However, the Commission
does not consider that the government should adopt this approach. As stated
elsewhere, there is little scientific research on the
‘safe’ levels
of THC and CBD, so it would not be possible at this point to set outer limits of
this kind. As research
develops, the government should be in a position to
respond flexibly, and regulated concentration limits would present an obstacle
to this. The Secretary could address safety concerns by maintaining control over
the products approved.
Whole-plant medicines versus isolated cannabinoids
7.104 Several submissions called for only ‘whole plant’ or
‘natural’ cannabis to be provided, and for
‘pharmaceutical’
cannabis, or forms of cannabis which isolate one
cannabinoid or a few cannabinoids to be avoided.163 Others submitted that
cannabinoids
need to be extracted and studied in order for cannabis to be
studied.164
7.105 While not containing raw plant material, nonsmokable products made
available under a Victorian medicinal cannabis scheme would
be in the nature of
‘whole plant extracts’, in that they would contain a range of
cannabinoids and other substances,
not isolated or synthetic cannabinoids. At
the same time, though, they would be subject to strict controls regarding
cultivation
and manufacture, as set out above. This is consistent with their
regulation as a herbal product.165
Recommendation
Medicinal cannabis products supplied under any Victorian scheme
should: (a) not include products that can be smoked
(b) include a variety of delivery systems, such as tinctures, oils,
capsules, sprays and vaporisable liquids
(c) provide for variation in cannabinoid content
(d) be kept under review in view of developments in technology and medical
knowledge about the medicinal use of cannabis and specific
cannabinoids.
162 New, highly concentrated extracts of cannabis known as ‘wax’
and ‘shatter’, made from cannabis using hydrocarbon-based
techniques and taken by inhalation, have raised law enforcement concerns in
other jurisdiction and may present health
risks: Consultation
25. New Canadian regulations on cannabis oil have set an upper limit on the
amount of THC: Health Canada,
Section 56 Class Exemption for Licensed
Producers Under the Marihuana for Medical Purposes Regulations to Conduct
Activities with
(8 July 2015)
http:// www.hc-sc.gc.ca
163 Submissions 2, 6, 10, 30, 68, 69, 80, 93, 95; Consultations 5, 13. It is
important to note that ‘whole plant’ and
‘pharmaceutical’ cannabis preparations are not mutually exclusive.
For example, Sativex, produced by GW Pharmaceuticals,
is a botanical extract of
the cannabis plant. The plant matter is heated, then the cannabinoids are
extracted using liquid carbon
dioxide. The finished product achieves a 1:1 ratio
THC and CBD by blending together extracts from plants selectively bred to
express high concentrations of each cannabinoid. Importantly,
neither THC nor
CBD has been isolated from the plant to make the finished product, which
contains a range of other compounds found
in the cannabis plant (approximately
7%): Therapeutic Goods Administration,
Australian Public Assessment Report
for Nabiximols
2013) 12–13.
164 Submissions 26, 60.
165 See [7.23] above. It should be noted, though, that when extracts are
prepared, the cannabis used to produce them is commonly
‘decarboxylated’ first to convert the acids (THCA, CBDA) into
their corresponding form (THC, CBD). This heating causes
large amounts of
terpenes to be released as vapours, decreasing the terpene content of the
finished extract: Luigi Romano and Arno
Hazekamp, ‘Cannabis Oil: Chemical
Evaluation of an Upcoming Cannabis-Based Medicine’ (2013) 7
Cannabinoids
Research and
198 Introduction
199 Enabling research and drug development
202 Knowledge collection and information provision
204 Responsiveness to change
205 Scheme evaluation
8. Research and evaluation
Introduction
8.1 Victoria’s medicinal cannabis scheme should ensure that it fosters,
and responds to,
clinical knowledge about cannabis as a medicine. This regulatory objective,
recommended in Chapter 1, is designed to ensure that any
Victorian scheme
evolves in response to clinical developments and changes in the medicinal
cannabis industry.
8.2 Research into cannabinoids has been described as ‘one of the
fastest moving frontiers in pharmacology’.1 Research
using cannabis is
taking place around the world, in animal models, cell cultures and humans, with
new cannabinoids and uses for them
being discovered and evaluated.
8.3 In spite of this, as indicated in Chapter 2, there are limits on the
research that has been conducted in Australia and other countries,
researchers attributing this not to a lack of scientific interest but to
regulatory obstacles:
Over the past decade there has been immense international growth in this area
of research as the significance of the endocannabinoid
system in human health
and disease becomes increasingly apparent. Despite this, we conduct our research
in a tight regulatory environment
that makes sourcing, holding and administering
cannabinoids extremely difficult and expensive.2
8.4 Such obstacles to research activity give rise to a dilemma: without the
research basis, restrictions on cannabis production and
administration are
currently in place; because such restrictions persist, the research cannot take
place. Some obstacles are not
within the power of the Victorian Government to
address—for example, access to cannabinoids or cannabis through
importation,
and approval of clinical trials, are the responsibility of
the Commonwealth. Nonetheless, a Victorian scheme should seek, so far as is
possible, to break down the existing constraints on research
and allow inquiry
and innovation in this area to flourish.
8.5 To achieve this regulatory objective, so far as is possible by way of
changes to Victorian law, a number of recommendations are
made in this chapter
to promote research into medicinal cannabis. They are designed to enable
Victorian medicinal cannabis products
to be used in clinical research, and to ensure that decision making about
patient eligibility and use of medicinal cannabis would
be informed by a
developing evidence base. It also makes recommendations regarding how the scheme
could be responsive to scientific
and technological change, through review and
evaluation.
1 David Allsop et al, Submission No 52 to Senate Legal and Constitutional
Affairs Committee, Parliament of Australia,
Inquiry into the
Regulator of Medicinal Cannabis Bill 2014
Enabling research and drug development
8.6 Research and development of medicinal cannabis should be a central
consideration in the design of a Victorian medicinal
cannabis scheme. Patient
interests are much better served if research and product development continues
and, indeed, is encouraged.
8.7 Developing new cannabinoid-based drugs and running the necessary trials
to have them approved is a time-consuming and resource-intensive
exercise.3 In
addition, if left to the market, it relies on there being companies with a
sufficient interest in the development of
products for particular indications to
fund research. Much is made of the success of GW Pharmaceuticals in the United
Kingdom, and
their revolutionary development of cannabinoids at the
pharmaceutical grade.4 However, GW Pharmaceuticals could only
have developed their refined cultivation techniques, novel extraction systems
and delivery systems (over which they now hold an extensive
patent portfolio) in
an environment in which research and experimentation with the cannabis plant
were allowed and enabled.
8.8 Australian researchers should have the same opportunity to explore new
products and to test their potential, and the Victorian
scheme should set out to
foster technological innovation as the first step on this path, but
acknowledging that this can and will
occur at the same time as unrefined, unevaluated products are being supplied.
Andrew Katelaris made this point, calling for the scheme
to accommodate both
‘larger scale’ growing enterprises, supplying patients with products
tested for potency and quality,
and companies producing pharmaceutical
preparations, such as GW Pharmaceuticals.5
8.9 By contrast to jurisdictions with medicinal cannabis schemes, however,
the United Kingdom does not allow treatment with medicinal
cannabis other than
Sativex and like products. There is a risk that, by allowing access to medicinal
cannabis for certain groups
of patient before further research takes place, the
scheme could put a brake on research and drug development for those patients,6
because there is little incentive for patients
to sign up for a clinical trial if they can already access a satisfactory
product.7 In the Commission’s view, the best way of
controlling this risk
is to maintain a sharp distinction between the products accessible by eligible
patients under the Victorian
scheme (quality controlled but variable and
untested) and products approved or intended to be approved by the TGA
(standardised,
characterised and evaluated).
8.10 A range of government actions could be taken to facilitate and enable
research into cannabinoids and their application. Some
of these, such as funding
for clinical trials, participating in research, and offering research and
development grants, involve non-
legislative action, beyond the scope of the
Commission’s reference. Likewise, other actions which would enable trials
conducted more readily, such as the rescheduling of cannabis or a subset
thereof, amending the clinical trial approval process, or
restrictions on the importation of cannabinoids, are responsibilities of the
Commonwealth that Victoria has no power to control. Besides
these, though, there
are a number of legislative reforms available to Victoria which would enable and
facilitate research into cannabinoids
and development of pharmaceutical-grade
cannabinoid medications,
3 Cancer Council Australia and Clinical Oncology Society of Australia,
Position Statement—Medical Use of Cannabis
(21 May 2015)
http://www.cosa.org
4 Ethan Russo, ‘The Solution to the Medicinal Cannabis Problem’
in Michael Schatman,
Ethical Issues in Chronic Pain Management
5 Submission 30. See Appendix B for list of submissions.
6 ‘The flip side of those who passionately shout for the
“legalisation of cannabis” is that their call may inadvertently
hamper the medical development of cannabinoids, which is a shame’: Wai
Liu, ‘Why Anti-Cancer Properties in Cannabis Must
be Investigated’,
The Conversation
(online), 26 June 2015
http://theconversation.com /why-anti-cancer-properties-in-cannabis-must-be-investigated-42653
7 Consultation 32. See Appendix C for list of consultations.
• providing for licensed cultivators to supply cannabis to researchers
and manufacturers licensed by the TGA, and permitting
licensed cultivators to
cultivate cannabis for experimental purposes8
• ensuring that medical practitioners wishing to prescribe experimental
cannabinoid products within a clinical trial can access
treatment permits
without undue difficulty.
8.11 Importantly, by ensuring that the Victorian scheme is limited to the
manufacture and distribution of quality-controlled non-pharmaceutical
which are distinct from any pharmaceutical-grade products available, the
standards that apply to the development
and approval of pharmaceutical-grade products would remain within the control
Therapeutic Goods Administration.
Access to cannabis by researchers
8.12 The Commission understands that a key constraint on cannabinoid research
in Australia has been limited access to cannabinoid
products with which to
conduct research.9 The argument to relax these restrictions is particularly
compelling in light of the number
of non-psychoactive cannabinoids presently
generating research interest.10
8.13 A Victorian medicinal cannabis scheme should facilitate the development
of new cannabis strains and the transfer of these to
research institutes and
pharmaceutical companies for the purpose of research and development. Clearly,
research into cannabinoids
cannot take place without a source of cannabinoids,
such as raw cannabis.
8.14 Enabling pharmaceutical companies to access cannabis grown under a
Victorian scheme would require a simple addition to the cultivator
scheme recommended in Chapter 6. To limit the possibility of diversion of raw
cannabis, the Commission has recommended
that licensed cultivators be required,
through conditions on their licence, to deliver all the cannabis they produce to
a manufacturer
licensed under the Victorian scheme (with any remaining cannabis
to be destroyed) and at all times be party to a contract with a
manufacturer
licensed under the Victorian scheme.
8.15 To enable research to take place, cultivators should also be
permitted to deliver cannabis to TGA-licensed manufacturers,
universities and
research institutes. To control diversion, the scheme could require research
entities to apply for and obtain licences
analogous to the ‘processing
licences’ available under the alkaloid poppy scheme.11
8.16 It may be the case that researchers wish to cultivate cannabis
themselves, to exercise greater control over the breeding and
cultivation
process. The Victorian Government could consider issuing researchers
experimental licences to cultivate outside the scheme
for supply to patients.
These licences could equally be available to cultivators already licensed to
produce, to enable them to test
new strains and assess the impact of growing
conditions.12 Quantities of cannabis cultivated under an experimental
licence would be the subject of separate reporting to the International
Narcotics Control Board.
8 An example definition of ‘experimental purposes’ was included
in cl 20 (2) of the
Regulator of Medicinal Cannabis Bill 2014
included: ‘(a) developing and testing varieties of cannabis for medicinal
use; (b) improving methods of cultivating
cannabis for medicinal use; (c)
developing and testing cannabis products for medicinal use; (d) evaluating the
efficacy or safety
of cannabis products for medicinal use; (e) improving
methods of using or administering cannabis products for medicinal purposes;
performing tests, trials and other experiments for the purposes of making or
supporting an application under [the
Regulator of Medicinal Cannabis Bill 2014
Therapeutic Goods Act 1987
[sic] , or considering whether to make
such an application.’
9 David Allsop et al, Submission No 52 to Senate Legal and Constitutional
Affairs Committee, Parliament of Australia,
Inquiry into the
Regulator of Medicinal Cannabis Bill 2014
11 Governed by the
Drugs, Poisons and Controlled Substances Act 1981
Div 3. Processing licences for alkaloid poppies are issued to
the companies that are involved in converting the poppy straw into
pharmaceutical opiates. These entities must hold a current manufacturing licence
issued by the TGA (or a current export licence,
which would enable them to
export poppy straw to a manufacturer located overseas):
That is, the
Victorian ‘processing’ licence is held in parallel to a licence
allowing them to refine or export the poppy
12 These licences would be analogous to those available under
which permit a licence to cultivate alkaloid poppies to be granted for research
purposes not intended for therapeutic use. The
limitation regarding therapeutic
use would not, however, be appropriate for the creation of experimental drugs
used in human or animal
trials: see definition of ‘therapeutic use’
Drugs, Poisons and Controlled Substances Act 1981
Recommendation
Any Victorian medicinal cannabis scheme should foster research by
providing for:
(a) licensed cultivators to supply cannabis to appropriately licensed
manufacturers capable of producing or trialling pharmaceutical-grade
cannabis-derived products
(b) researchers and those holding commercial cultivation licences to
obtain experimental cultivation licences.
Treatment permits and clinical trials
8.17 Many medical practitioners urged that medicinal cannabis be made
available through a clinical trial framework. The Commission
agrees that
clinical trials can and should continue after any Victorian scheme is
introduced.
8.18 At present, a medical practitioner who wishes to administer, supply or
prescribe cannabis to a patient, including under the auspices
of a clinical
trial, requires a permit to prescribe cannabis to that patient, due to the
status of cannabis as a Schedule 9 poison.13
such permit, if granted, would be specific to the patient under treatment, in
would authorise treatment of that person alone. In practice, however,
Schedule 9 poison treatment permits are not sought in Victoria
and there are no
guidelines setting out when they may be issued.
8.19 Under any Victorian scheme there would be a need to ensure that people
can be treated with medicinal cannabis products within
a clinical trial, even if
they do not fall within
the eligibility criteria and/or the product has not yet been approved. For
this reason, the scheme should provide for a type of experimental
permit, which a specialist can obtain for any person. Such a permit could also
be used to facilitate the conduct of
so-called ‘n of 1’ trials, recommended to the Commission as a
means of testing the utility of cannabis in treating particular
patients or
conditions.14 The permit provisions could specifically apply to medicinal
cannabis, or be incorporated into an existing
treatment permit.15
8.20 At present, treatment permits for Schedule 9 poisons are required at all
times, with no exceptions. This contrasts with Schedule
8 poisons, where permits
are only required if the patient is drug dependent or the treatment lasts for
more than eight weeks.16 The
government may wish to consider simplifying the
process for obtaining experimental treatment permits for medicinal cannabis, or
them to particular situations only.17
Drugs, Poisons and Controlled Substances Act 1981
Unlike permits to administer, supply or prescribe Schedule 8 poisons, permits
are always required for Schedule 9 poisons, not just
in certain circumstances.
stating that Schedule 8 poison permits
are only required where the person is drug-dependent or where the duration of
use exceeds eight weeks, and
setting out a number of
exemptions.
14 N-of-1 or n =1 clinical trials are ‘empirical tests using a
within-patient randomised, double-blind, cross-over comparison
of drug and
placebo (or another drug), principally to study individual patients’
responses where there is uncertainty about
the effectiveness of a medication for
a chronic condition’: Jane Nikles et al, ‘Stakeholders’ Views
on the Routine
Use of N-of-1 Trials to Improve Clinical Care and to Make
Resource Allocation Decisions for Drug Use’ (2010) 34
Australian Health
131, 131. They involve a practitioner administering alternating
placebo (or other drug) and active (drug under investigation) treatment to a
patient and measuring their response, to test whether
the drug induces a
different response to the placebo /alternative. The alternating placebo /active
doses must be produced by a third
party, so that both the practitioner and the
patient are unaware of what is being administered (that is, the trial is
blind’): Consultation 32.
15 Medicinal cannabis may no longer be treated as a Schedule 9 poison,
depending on the model adopted.
Drugs, Poisons and Controlled Substances Act 1981
range of other exceptions to the permit requirement also apply:
17 For example, the
Drugs, Poisons and Controlled Substances Amendment
(Clinical Trials) Bill 2014
(Vic) would have simplified the process
for obtaining Schedule 9 treatment permits, by enabling medical practitioners
to seek a permit to treat a group of patients, not just
a single individual (as
is the case presently). The Cancer Council Victoria supported incorporating such
a measure into a medicinal
cannabis system: Submission 57.
Recommendation
The Secretary of the Department of Health and Human Services
should have the power to issue medical practitioners with permits to
patients other than those who are eligible under the scheme with medicinal
cannabis for trials and research.
8.21 An implementation issue for consideration by the Victorian Government is
when permits to treat patients with medicinal cannabis
within a clinical trial
should be granted. Clinical trials in Australia are generally required to be
conducted consistently with
national guidelines,18 and are permitted to be
conducted using unapproved goods if ethics committee approval is obtained.19
on the scope of any Commonwealth action giving Victoria authority over
the regulation of medicinal cannabis products, Victoria
could need to establish a procedure for the approval and supervision of
clinical trials using medicinal cannabis products.20
Knowledge collection and information provision
8.22 The government should ensure that any Victorian medicinal cannabis
scheme supports the development of knowledge and its dissemination
practitioners and researchers.21
8.23 The scheme could achieve this in a number of ways. Education of medical
practitioners would be essential, particularly as expertise
is presently very
limited. An important component of education is that it be continually updated
and improved, so the scheme should
also facilitate data collection and the
distribution of results to practitioners.22
8.24 In addition, as discussed in Chapter 3, medical practitioners enabling a
patient to be treated with medicinal cannabis would
first be required to seek a
permit from the Secretary of the Department of Health and Human Services. The
application for a permit
would be in a prescribed form,23 through which the
Secretary would have the ability to determine what information is collected
patients within the scheme. The collection and analysis of this
information would provide practitioners and researchers with a useful
data regarding those currently treated under the scheme.
Clinical registries
8.25 One way in which the data could be collected and analysed is through the
establishment by practitioners of a clinical registry.
These registries are
designed to allow practitioners in a field of medicine to compile data from
their patients in order to measure
the results of intervention.24
8.26 In the field of chronic pain, for example, Australian practitioners
have established the electronic Persistent Pain Outcomes
Collaboration (ePPOC)
data to the ePPOC about their
patients’ experience of pain and the manner in which that pain was
treated. The data are aggregated by the ePPOC and made publicly
available.25
18 Such as, National Health and Medical Research Council,
Statement on Ethical Conduct in Human Research
Therapeutic Goods Regulations 1990
(Cth) sch 5A, item 3.
20 For example, if only Victorian-approved medicinal cannabis products are
able to be supplied in Victoria without attracting the
provisions of the
Therapeutic Goods Act 1989
(Cth), any other products would need to comply
with TGA requirements for clinical trials.
21 Submissions 11, 22, 69, 76, 91, 99.
22 The education of medical practitioners is discussed in Chapter 3. See
[3.226] – [3.239] above.
Drugs, Poisons and Controlled Substances Regulations 2006
24 Several respondents to the Cancer Council Victoria’s clinician
survey recommended that a program be established to monitor
patient use,
responses and adverse effects: Submission 99.
25 Enterprise One Pain Management Service,
Patient Outcomes in Pain
(31 December 2014).
8.27 A registry of this kind could allow practitioners to share aggregated
information about how they had resolved problems around
the authorisation and
withdrawal of medicinal cannabis, which would inform the development of common
standards. For example, Associate
Professor Carolyn Arnold at Alfred Health
suggested that a ‘medical cannabis chronic pain treatment’ registry
include data about:
• if cannabis use is ceased, the reason and any adverse effects
• details of the specific medical cannabis form and dose used.26
8.28 As an alternative to condition-specific registries, Victorian health
practitioners could establish a general clinical registry
dedicated to the
general monitoring of all patients
who have been authorised to use medicinal cannabis. For example, the
Québec Cannabis Registry is intended to be a database
of all patients
authorised to use medicinal cannabis in Québec, to enable clinical
research into cannabis. This allows medical
practitioners to comply with their
professional obligations, as the position of the Collège des
Médecins du Québec
is that the prescription of cannabis is only
ethically authorised ‘within a research framework’.27 Accordingly,
Registry will seek to:
develop and answer future questions on the medical use of cannabis, such as
uses it, for what reasons, through which methods, and at what dose. ... [The
Registry] will be used to compile and store clinical
data collected directly
from patients who use medical marijuana. The data will be gathered from sites
and clinics across Quebec,
and each participant will provide data for four years
after recruitment. Any licensed doctor practising in the province wishing to
authorise cannabis for their adult patients can enrol participants in the
registry.28
8.29 The patient information collected through the issuing of permits, or in
creating and maintaining a clinical registry, could also
be used to invite
patients taking part in the scheme to be involved in clinical trials of
pharmaceutical-grade cannabinoids.
Recommendation
The Secretary of the Department of Health and Human Services
should collaborate with the clinical research community in developing
and protocols for collecting and sharing information about the incidence and
outcomes of treatment with medicinal cannabis
products under any Victorian
Dissemination of information
8.30 Subject to privacy requirements, data collected by the government could
be aggregated and disseminated to improve knowledge and
understanding among
practitioners. Data could also help support the production of guidelines and
information documents to be circulated
to practitioners, particularly where
adverse effects are observed. The data would also be used in any scheme
evaluation, discussed
26 Submission 98.
27 Collège des Médecins du Québec,
Concerning the Prescription of Dried Cannabis for Medical Purposes
28 Quebec Cannabis Registry, ‘World First: Launch of Quebec Registry
for Users of Medical Cannabis’ (Press Release, 11
May 2015, Montreal)
<https://registrecannabisquebec.com>.
Recommendation
The Secretary of the Department of Health and Human Services
(a) retain data collected on Permit applications and Authorities to
Dispense Medicinal Cannabis in a way that enables statistical
information about
the operation of the scheme to be compiled and used for evaluation purposes, and
for non-identifying information
to be made available for the purpose of research
into the efficacy of medicinal cannabis
(b) ensure that a privacy impact assessment is conducted when
the data collection and management systems in support of the medicinal
cannabis scheme, to safeguard the information privacy of patients,
carers, practitioners, pharmacists and other participants in the
Responsiveness to change
8.31 The science and technology around the use of medicinal cannabis is a
rapidly evolving field. Trials into the utility of cannabis
are ongoing and
commencing to deliver results which enable evaluations of efficacy to be made.
cannabis programs continue to develop
innovative delivery systems.29
8.32 Any Victorian scheme must therefore be sufficiently flexible to allow
for legal, scientific and technical change. As Mullaways
Medical Cannabis Pty
Ltd observed, ‘[t]he legislation must allow for research... Limiting the
scheme to current Australian
knowledge would leave a Victorian Medicinal
Cannabis Scheme stuck in the past based on outdated research.’30
8.33 In particular, as discussed in Chapter 3, the scheme should be
flexible enough to allow for new cannabis-based products
to be made available to
patients, and for new sets of conditions and symptoms, as new evidence emerges.
In addition, changes to Australian
or international law and the emergence of sources of cannabis overseas could
require the
Victorian scheme to respond.
Legal developments
8.34 There are a number of ways that laws and policies could change at the
Commonwealth level or in other states, necessitating alterations
Victorian scheme:
• medicinal cannabis schemes could be introduced in other Australian
states and territories
• ‘cannabis’ or a subset thereof could be moved to another
Schedule in the SUSMP
• the TGA could change its procedures to allow cannabis products to be
regulated as listed (herbal) medicines.
29 See, eg, the Syqe dose-controlled medical cannabis inhaler, supplying a
metered dose of vaporised cannabis
http://www.syqemedical. com
Pharmaceuticals’ lipophilic drug delivery technology, Alitra, used to
deliver a standardised dose of THC with high
bioavailability, under the name
http://www.echo-pharma.com
cannabis-based CBD-rich chewing gum
http://www.aximbiotech.com
30 Submission 29.
Alternative supply options
8.35 Medicinal cannabis schemes and industries in jurisdictions around the
world are in a state of flux. National policies on export
and import are subject
to change, meaning that in
the future, the products available for import may be quite different from
those available today. In addition, should other Australian
territories begin cultivating cannabis or manufacturing cannabis products, a
domestic source may become available. Likewise,
cannabis-based products (like
Sativex or Epidiolex) may be approved for sale in Australia through conventional
TGA channels.
8.36 A Victorian scheme should accommodate the potential supply of any such
While any importation would require the co-operation of the Commonwealth, the
scheme could allow, for example, for particular overseas-made
products to be
designated as approved medicinal cannabis products for the purposes of Victorian
Scheme evaluation
8.37 Research on, and the availability of, medicinal cannabis is constantly
changing and will continue to do so after the commencement
of the scheme.
Changes could include:
• clinical trials determine whether cannabis or cannabinoids are
effective in the treatment of conditions or symptoms not currently
statutory eligibility criteria
• new technologies for manufacturing cannabis extracts or administering
them to patients are developed
• international export opportunities emerge
• new cannabinoids are discovered
• new cannabis-based pharmaceuticals are approved by the TGA to be
sold in Australia.
8.38 The scheme should therefore be established in such a way that it is
subject to evaluation.
The evaluation should consider how well the scheme is meeting its objectives.
It should also consider the cost of the scheme and whether
it is functioning in
a sufficiently cost- effective way.
8.39 Specifically, the following matters should be taken into account in the
evaluation:
• participation rates in the scheme, including for each condition
• findings of the scheme regarding the efficacy and side effects of
• the cost of the scheme
• findings of clinical trials
• the availability (if any) of cannabinoid drugs approved by the TGA
and/or listed on the
Pharmaceutical Benefits Scheme
• legislative and regulatory changes (if any) at the Commonwealth
level and in other
States or Territories since the scheme was introduced.
Recommendation
The Minister for Health should cause an independent evaluation of
the scheme to take place no later than four years from its date
of commencement
and should be required to report to Parliament on the findings and
recommendations of the evaluation.
9. Conclusion
9.1 The Commission has been told that reform to Victoria’s laws to
allow people to be treated with medicinal cannabis in exceptional
circumstances
is both overdue and premature.
It is said to be overdue by those in the community who are already using it
to relieve the symptoms of a broad range of medical conditions,
some of which
are severely disabling and others of which are causing high levels of pain and
suffering. It is said
to be premature by those who caution against providing access to an otherwise
illegal drug before conventional and reliable clinical
evidence of its efficacy
in treating specific conditions, and its side effects, is comprehensively
9.2 In this report, the Commission has favoured an evidence-based approach to
determining the exceptional circumstances in which medicinal
cannabis would be
made available,
but for compassionate reasons one that extends in limited circumstances
beyond the exacting clinical standards that apply to the scheduling
prescription medicines. The recommended eligibility criteria encompass severe
conditions and symptoms regarding which there are
multiple examples of
significant improvement after patients have begun using cannabis, and where
returning to prescription medicines
presents an unacceptable risk to their
health and quality of life.
9.3 Thus, the Commission’s recommendations endeavour to balance
evidence of efficacy with knowledge of potential risks of side
effects and
abuse. The recommendations incorporate extension of compassion to take account
of the suffering arising from certain
medical conditions and to be responsive to
the wishes of patients and their carers in respect of conditions that impact
in often extreme ways.
9.4 The Commission’s recommendations give weight to research
assessments of the efficacy of medicinal cannabis but accord less
significance
to assertions and anecdotes. They
are framed on the basis of the legitimacy of the current preclusion of
recreational use
of cannabis and identify major deficits in the option of a grow your own
scheme which bypasses medical practitioners and is substantially
unregulated and
unmonitored. The Commission’s recommended approach looks to integrate
medicinal cannabis within the pharmacopoeia
available to medical practitioners.
It recognises that medicinal cannabis
is not a panacea; it is simply another pharmacological option with great
promise in some contexts and which is the subject of strong
levels of confidence
in some sectors within the community. It has the potential to play a
constructive role in the management of
some conditions and the alleviation of
pain and suffering.
9.5 These aspects of the Commission’s recommendations are a matter of
compromise.
They endorse and support a system of testing medications that protects the
community against foreseeable risks posed by untested preparations
that have the
potential to have a range of adverse consequences for patients. In addition,
they make only a modest and
controlled inroad upon the criminal status of using, possessing, cultivating
and trafficking
in cannabis. In this regard, it is acknowledged that many cannabis users,
including some who use it for medicinal purposes, will
be deeply disappointed
with the approach that the Commission has taken; they will continue to use
cannabis covertly and illegally
the involvement of medical practitioners.
9.6 However, it is the Commission’s view that it is important for a
medicinal cannabis scheme to be significantly weighted in
favour of strong
evidence bases; any other approach
is unlikely to secure the confidence and endorsement of the medical
profession. International experience has shown that, without
the support of a
significant percentage of medical practitioners, any medicinal cannabis scheme
will face significant hurdles as
a public health measure.
9.7 Australia’s medical practitioners are not ideologically averse to
the development of new medical options or to employment
of innovative measures
in difficult clinical scenarios where there is a high level of suffering by
their patients and those who care
for them and about them. However, for the
present they are divided on the question of whether medicinal cannabis is a
proper alternative
to orthodox prescription medications. They are reticent about
the provision of any medicinal cannabis products that have not
been approved by the Therapeutic Goods Administration. In addition, they have
little knowledge about the therapeutic properties of
medicinal cannabis in its
various forms and strengths, and do not have experience in administering it or
supervising its effects.
9.8 In order to elicit the confidence of the medical profession in a reform
to the law so as to permit access to cannabis for medicinal
purposes, it is
prudent to adopt a graduated and conservative approach to making it legally
available and to ensure that medical
practitioners (and pharmacists) are
assisted to provide the information necessary
for patients to provide informed consent. This means that under the
Commission’s recommended option medicinal cannabis would
not be legally
available for patients with some conditions and that there would be regulatory
oversight of the growing, manufacturing,
authorising and dispensing of medicinal
cannabis. These measures are
proposed as means to provide reassurance to medical practitioners,
pharmacists and the general community alike about what is a novel
medico-legal
step for Victoria.
9.9 Meanwhile, clinical evidence concerning the medical use of cannabis is
growing, as are medical breakthroughs in preventing and
treating many of the
diseases for which prescription medicines are only part of the therapeutic
answer. Experience in participating
in a medicinal cannabis scheme is likely to
provide an additional option for treating patients with serious conditions, to
the medical profession’s understanding about the use and effects of
medicinal cannabis, and to address the wishes of a significant
patients. The Commission considers it essential that the eligibility
and the scheme itself—are reviewed and modified as more and better
evidence of the efficacy, potential and side effects of cannabis
9.10 The legislative basis for a Victorian medicinal cannabis scheme should
rest upon regulatory objectives that would improve patients’
life through appropriate treatment without unreasonably inflating their
expectations of positive therapeutic effects or
exposing them to undue risks. It
needs to minimise any adverse consequences that
may arise from departing from the national frameworks for controlling
narcotic drugs and regulating therapeutic goods.
9.11 The Commission has considered the options proposed in submissions and
consultations and has concluded that an approach based
on the existing
regulation of the cultivation of alkaloid poppies, the production of poppy
straw, and the delivery of opioid replacement
therapy would be most likely to
achieve the regulatory objectives. This approach utilises well-trodden and
familiar regulatory paths
and thus does not involve the creation of a plethora
of new bodies to enable regulatory oversight. It is likely to generate a
availability of high quality medicinal cannabis whose properties are known.
In addition, it should enable medical practitioners to
titrate the strengths and
monitor the effects
in their patients of active constituents such as THC and CBD. This will
constitute a very significant safeguard against risks and
side effects from the
use of cannabis for medicinal purposes.
9.12 The way in which the Commission has structured its proposed scheme
enables Australia to satisfy its international obligations
and requires only a
modest set of enabling steps
by the Commonwealth in a collaborative partnership with Victoria. The
initiative that is recommended preserves the integrity of Australia’s
therapeutic regulatory framework
but caters compassionately and humanely to the needs of a vulnerable group of
patients whose suffering has been documented in Chapter
2 of this report.
9.13 The cost of establishing and operating a scheme that provides a limited
number of people affordable access to a prohibited substance
is likely to be
significant, although levels of uptake of the scheme cannot be forecast with
accuracy at this stage. Thus the scheme
needs to be carefully designed and well
managed to ensure that the cost is not disproportionate to its advantages and
efficiently run. The opportunity exists to reduce the unsatisfactory
incidence of resort to illegal medicinal cannabis of uncertain
quality and
strength and that does not incorporate medical oversight.
9.14 The potential outcome of the scheme recommended by the Commission is
the relief of high levels of suffering and avoidance of
the pressures and stigma
that currently attach to illegal procurement for therapeutic purposes of a drug
principally used recreationally
for its euphoriant effects. It will enable a
drug with significant medicinal potential to be used in properly and safely
circumstances under the supervision of medical practitioners, thereby
maximising its efficacy as a treatment and guarding against
potentially adverse
side effects.
212 Appendix A. Advisory committees
214 Appendix B. Submissions
216 Appendix C. Consultations
218 Appendix D. Tables of legislative amendments
Appendix A. Advisory committees
The terms of reference ask the Commission to appoint expert panels to assist
in its review, specifically to examine:
• prescribing practices for medicinal cannabis, including eligibility
criteria for access to medicinal cannabis and the role
of doctors in managing
the use of medicinal cannabis by patients
• the regulation of medicinal cannabis manufacture and distribution,
including which forms of medicinal cannabis should be permitted
It is the Commission’s usual practice to convene committees of
individuals with specialist expertise to assist in identifying
and exploring
issues and generating ideas for reform. Participation is by invitation.
For the medicinal cannabis reference, the Commission convened two advisory
committees:
• a medical advisory committee, to advise on prescribing practices that
could impact upon access to medicinal cannabis
• a regulation advisory committee, to advise on the regulation of the
potential manufacture and distribution of medicinal cannabis.
The individuals and organisations listed below accepted the
Commission’s invitation to participate on the committees.
Medical Advisory Committee
Individuals
Associate Professor Carolyn Arnold Laureate Professor Sam Berkovic AC
Associate Professor Noel Cranswick Dr Matthew Frei
Professor Carl Kirkpatrick Associate Professor Brian Le Dr Maurice Magner
Professor Paul Myles
Professor Ingrid Scheffer AO Professor Duncan Topliss Professor John Zalcberg
OAM Organisations
AMA Victoria
Australian Pain Society; Faculty of Pain Medicine of the Australian and New
Zealand College of
Anaesthetists; Pain Australia
Department of Health and Human Services (Victoria) Epilepsy Australia
MS Australia
Palliative Care Victoria
Regulation Advisory Committee
Individuals
Emeritus Professor Arie Freiberg AM Professor Margaret Hamilton AO Peter
Dr Kim Sweeny
Organisations
Department of Economic Development, Jobs, Transport and Resources (Victoria)
Department of Health and Human Services (Victoria)
Law Institute of Victoria
Office of Public Prosecutions
Office of the Chief Parliamentary Counsel
Royal Australia College of General Practitioners The Pharmacy Guild of
Australia—Victoria Victoria Legal Aid
Victoria Police
Victorian Therapeutics Advisory Group
The committees met separately and together on the following dates: Meeting
1: 1 April 2015 (Medical Advisory Committee)
Meeting 2: 2 April 2015 (Regulation Advisory Committee)
Meeting 3: 6 May 2015 (both committees).
Appendix B. Submissions
28. Confidential
29. Mullaways Medical Cannabis Pty Ltd
30. Dr Andrew Katelaris
31. Name withheld
32. Confidential
33. Aaron Johnson & Kelli Russell
34. Christian Business Men Australia, Macedon Ranges Group
35. The Australian Lawful Use of Cannabis
36. Les McDonald, Bebuybac the Concerned
Australians
37. Cannabis Policy Project
38. AMA Victoria
39. Confidential
40. Samuel Fair
41. Alkman Management Services Pty Ltd
42. Name withheld
43. Name withheld
44. Victoria Police
45. Confidential
46. Victorian Alcohol & Drug Association
47. Name withheld
48. Name withheld
49. Shirley Humphris
50. Cassie Batten & Rhett Wallace
51. Cheri O’Connell
52. The Royal Australian College of Physicians
53. Fred Andronikos
54. Cancer Action Victoria Inc
55. Name withheld
56. Confidential
57. Cancer Council Victoria
58. ACES Group
59. Matthew Pallett
60. UTT BioPharmaceuticals Pty Ltd
61. One World Cannabis Ltd
62. Derek & Elyse Spence
63. Law Institute of Victoria
64. Robert Wisbey
65. Name withheld
66. Jan Hartwich
67. Max & Diane Lock
68. Name withheld
69. Cannabis Science Australia Pty Ltd
70. Leah Bisiani
71. Michelle Whitelaw
72. Mark Eastick
73. Ivan Schparyk
74. Marc Selan
75. Australian Nursing & Midwifery Federation
(Victorian Branch)
76. EROS The Adults Only Association
77. Aboriginal Embassy Victoria
78. Joylene Donovan
79. Confidential
80. Natalie Vassallo
81. Lyn Cleaver
82. Confidential
83. Kevin Sammon
84. Loren W
85. Iain Fredin
86. Name withheld
87. Name withheld
88. Name withheld
89. Heather Marie Gladman
90. Belinda Doonar
91. Rangi Faulder
92. Lindsay Milton
94. Fred Andronikos
95. Michelle O’Dea, with the assistance of a working group of the
cannabis community of Victoria
97. Dr David Bearman
98. Associate Professor Carolyn Arnold
99. Cancer Council Victoria
Appendix C. Consultations
The Commission invited interested members of the public to attend meetings in
Melbourne and regional centres to discuss their views
on the legalisation of
medicinal cannabis, as listed below.
1. Melbourne (5 May 2015)
2. Geelong (8 May 2015)
3. Ballarat (18 May 2015)
4. Bendigo (19 May 2015)
5. Mildura (12 June 2015)
6. Wodonga (15 June 2015)
7. Shepparton (16 June 2015)
8. Bairnsdale (22 June 2015)
9. Morwell (23 June 2015)
The Commission consulted privately about the questions raised in the issues
paper with the people and organisations listed below in
chronological order.
10. Department of Health and Human Services (Victoria)
11. Health Law Committee, Law Institute of Victoria
12. Emeritus Professor David Penington AC
13. Cassie Batten and Rhett Wallace
14. Participants at a public symposium on the legalisation of medicinal
cannabis, organised by
Fred Andronikos and other members of the community in Melbourne
15. Department of Health (Commonwealth)
16. Dr Roger McLennan FRACP, FRCP, Clinical Haematologist and Medical
17. Glen Ludbrook, Central Highlands Community Legal Centre
18. David and Cheri O’Connell
19. Department of Economic Development, Jobs Training and Resources
20. Terry Roycroft, President, Medicinal Cannabis Resource Centre,
Vancouver, Canada
21. Victoria Police Drug Analysis Unit
22. Professor David Castle, Professor of Psychiatry at the University of
Melbourne and St Vincent’s
23. Melissa Lonsdale and Matthew Fulton, Sunraysia Community Health
24. Ester Vanhinnisdael, Charlotte Byrne (Gateway Health) and Ray Stephens
(Gateway Health)
25. Office of Medicinal Cannabis, Minnesota Department of Health
26. Colleen Garrick (Rumbalara Aboriginal Cooperative), Kaz Gurney (Goulburn
Valley Community Legal Centre), Sue Spence (FamilyCare),
Dr Zee Wan Wong
(Goulburn Valley Health) and staff from the Goulburn Valley Hospice
27. Canadian Medical Association
28. Office of Medicinal Cannabis, Netherlands
29. Arizona Department of Health Services
30. Bedrocan BV
31. Health Canada
32. Associate Professor Noel Cranswick
Appendix D. Tables of legislative amendments
The following tables list amendments that would support the
Commission’s recommended option for changes to the
Drugs, Poisons and
Controlled Substances Act 1981
(Vic), and to the
Drugs, Poisons and
Controlled Substances Regulations 2006
, to allow people to be treated with
medicinal cannabis in exceptional circumstances.
• Table 1: Cultivating and manufacturing medicinal cannabis
• Table 2: Treating medicinal cannabis as a class of poison or
controlled substance
• Table 3: Deeming classes of patients to be eligible to access
medicinal cannabis
• Table 4: Lawful possession of medicinal cannabis
• Table 5: Lawful supply of medicinal cannabis
• Table 6: Lawful storage of medicinal cannabis
• Table 7: Recording transactions in medicinal cannabis
• Table 8: Lawful administration of medicinal cannabis
• Table 9: Lawful destruction of medicinal cannabis
• Table 10: New offences under a Victorian medicinal cannabis
Table 1: Establishing a scheme for the lawful cultivation and manufacture
of medicinal cannabis products in the
Drugs, Poisons and Controlled
Substances Act 1981
Explanation
Define ‘cannabis’
It would be necessary to define ‘cannabis’ in order to identify
the raw product that cultivators and manufacturers are
licensed to turn
‘medicinal cannabis’ products. The Commission anticipates that
it is the process of cultivation, manufacturing, labelling
and quality testing
that turns cannabis into a product that is appropriate for medicinal consumption
and is as such ‘medicinal
The definition could refer to the definition of cannabis in section 70 of
the Act: ‘any fresh or dried parts of a plant of the
Explanation
‘Commonwealth licence to manufacture’
As in the poppy scheme, cannabis manufacturers would need to have a licence
Narcotic Drugs Act 1967
(Cth) and a definition is accordingly
The definition could draw upon the definition of ‘Commonwealth
licence to manufacture’ in s 69N of the Act: ‘a licence
manufacture narcotic drugs which relates to the manufacturing of cannabis,
cannabis resin, extracts or tinctures of cannabis under
Narcotic Drugs
of the Commonwealth’.
Create a ‘cannabis cultivation licence’
A division could deal with ‘cannabis cultivation licences’,
administered by the Secretary of the Department of Economic
Development, Jobs,
Transport and Resources. This division and associated definitions could be
modelled on Division 2 of
of the Act.
As in the poppy scheme, the activity of cultivation would have to be
defined. The definition could take on the meaning it is given
in s 70 of the
Act: to ‘sow a seed of a narcotic plant’, to ‘plant, grow,
tend, nurture or harvest a narcotic plant’
or to ‘graft, divide or
transplant a narcotic plant’.
Of particular importance is the requirement, following s 69OC(7), that the
holder of a cannabis cultivation licence is only permitted
to conduct activities
under a contract that has been registered in the
‘Cannabis register’.
Enable the Secretary of the Department
of Economic
Development,
Jobs, Transport and Resources to amend or suspend cannabis cultivation
This division would grant the Secretary of the Department of Economic
Development, Jobs, Transport and Resources powers to amend,
suspend or cancel
cannabis cultivation licences issued under the scheme. It could be modelled on
Division 4 of Part IVB of the Act.
Enable the Secretary of the Department
of Economic Development, Jobs, Transport and Resources to
appoint inspectors to supervise the activities of cannabis cultivation
licensees and the enforcement of breaches of
their licences or the provisions of the Act.
This division would grant the Secretary of the Department of Economic
Development, Jobs, Transport and Resources powers to appoint
inspectors to
conduct various functions under the scheme. Inspectors would have powers similar
to the powers conferred on inspectors
under the poppy scheme by s 69RB of the
The Division could be modelled on Division 5 of Part IVB of the Act.
Explanation
Create a ‘cannabis manufacturing licence’
It would be necessary to deal with ‘cannabis manufacturing
licences’, administered by the Secretary of the Department
of Health and
Human Services. This division and associated definitions could be modelled on
Division 3 of Part IVB of the Act.
‘Manufacturing’ could be defined with reference to the
definition in s 4(1) of the Act, providing that it ‘includes
any process
of refining, manipulating and mixing cannabis’.
Of particular importance is to create a requirement, following
s 69PC(8), that the holder of a cannabis manufacturing licence have a
current Commonwealth licence to manufacture.
Enable the Secretary of the Department of Health and Human Services to
or suspend cannabis manufacturing licences
This division would grant the Secretary of the Department of Health and
Human Services powers to amend, suspend or cancel cannabis
manufacturing
licences issued under the scheme.
The Division could be modelled on Division 4 of Part IVB of the Act.
Enable the Secretary of the Department of Health and Human Services to
authorise the inspection of the activities of cannabis manufacturing
and enforce breaches of their licences or the provisions of the Act.
This division would grant the Secretary of the Department of Health and
Human Services powers to authorise inspectors to conduct
various functions under the scheme relating to cannabis manufacture.
Inspectors would have powers similar to the powers conferred
on inspectors under
the poppy scheme by s 69RB of the Act.
The Division could be modelled on Division 5 of Part IVB of the Act.
Set out offences for non-compliance with various aspects of the
The division would impose penalties on licensed cannabis cultivators and
licensed cannabis manufacturers which failed to comply with
their statutory
obligations or licence conditions.
It could be modelled on Division 6 of Part IVB of the Act.
Establish a register for contracts between licensed cultivators and
licensed manufacturers of cannabis.
The Alkaloid Poppy Register is used to determine which contracts between
licensed processors and cultivators are compliant under the
scheme. Details of
the contract are kept on the Register, including the parties to the contract,
the location of cultivation and
the period of the contract.
It is a condition of every poppy cultivation licence that the cultivator
have a contract with a processor of poppy straw that is on
the Register.
A Cannabis Register, modelled on the Alkaloid Poppy Register, could be used
to monitor the existence and particulars of contractual
agreements and restrict
the range of contracts that are able to be acted on by licensees.
The provisions could be modelled on Division 7 of Part IVB of the
Explanation
Establish avenues for review by the Victorian Civil and Administrative
Under the poppy scheme, applicants may apply to VCAT for a review of
adverse decisions of a Secretary relating to licences under the
Act. A similar avenue of review should be permitted in respect of adverse
decisions about cannabis cultivation licences and cannabis
manufacturing
The provisions could be modelled on Division 8 of Part IVB of the
Create a register of medicinal cannabis products approved for sale in
The Commission recommends that a new register of approved products be
established, specifying a range of details about each registered
product, which
this new Division would establish.
The Division would set out the relevant rules and powers relating to that
approval. The Secretary of the Department of Health and
Human Services would be
granted the power to approve new products.
Create a process by which authorised officers are permitted to take
possession of medicinal cannabis
Under the medicinal cannabis scheme, authorised officers of the Victorian
Government would be required to take physical possession
of cannabis,
potentially arrange for it to be tested and labelled (rendering it
‘medicinal cannabis’) and deliver it
to participating pharmacies.
This Division would authorise those activities.
Confer power on the Governor in Council to make regulations
Section 69V of the Act provides that the Governor in Council may make
regulations with respect to a wide range of matters pertaining
to the poppy
Similar powers would be needed in respect of the cannabis scheme. This new
Division could confer upon the Governor in Council the
power to make enforceable
standards about the quality of cannabis cultivated or manufactured under the
The provisions could be modelled on Division 9 of Part IVB of the
Table 2: Treating medicinal cannabis as a class of poison or controlled
substance by amending the
Drugs, Poisons and Controlled Substances Act 1981
Explanation
Define ‘medicinal cannabis’
Medicinal cannabis products that are lawfully cultivated, manufactured and
labelled as such by the state under a Victorian scheme
need to be identified in s 4(1) of the Act.
The definition should make it clear that ‘medicinal cannabis’
‘cannabis’ and as such is a drug of dependence.
Include ‘drug of dependence’ in the definition of medicinal
This amendment is not strictly necessary, because ‘cannabis’ is
already identified in Schedule 11 of the Act as a drug
of dependence and should
be understood to include medicinal cannabis. However, for
the purposes of clarity it may be preferable to expressly identify the
medicinal cannabis products produced under the scheme as drugs
of dependence in
s 4(1) of the Act.
Explanation
Amend ‘poison or controlled substance’ to include medicinal
Various rules in the Act apply to ‘poisons and controlled
substances’
as a class, the definition applying to all scheduled medicines.
It is desirable for the bulk of these rules to also apply to medicinal
Where rules should not apply to medicinal cannabis, a specific exemption
has been suggested, as occurs with other scheduled medicines.
Exempt medicinal cannabis from the poisons schedules
The Commission regards it as appropriate to treat medicinal cannabis as a
wholly separate ‘schedule’ of medicine. This
allows rules applying
to different schedules of medicine to be applied to medicinal cannabis as is
desired, and also permits new
rules specific to medicinal cannabis to be
This could be achieved by introducing medicinal cannabis into Part 3 of the
Poisons List, in reliance on s 12A(1)(b) of the Act.
Exempt medicinal cannabis from the offences the Act imposes for breaching
the Commonwealth
Standard for the Uniform Scheduling
of Medicines and Poisons
’ rules with respect to the labelling,
containing,
storing and packaging, and advertising of poisons and controlled
Medicinal cannabis medicines should not be subject to the SUSMP’s
rules about labelling, containing, storing, packaging, and
advertising. New
rules will be created under the Victorian scheme.
This would require an additional provision to be introduced into s
of the Act.
Add medicinal cannabis to the rules about registered nurses administering
certain medicines to residents in aged care services who
are in high-level
residential care
Registered nurses are currently permitted to manage the administration of
drugs of dependence, Schedule 4, 8 and 9 poisons that have
been prescribed to
residents of aged care services who are in high-level residential care.
A new section may be required to ensure registered nurses can administer
medicinal cannabis. Section 36E refers to ‘prescription’
s 36F refers to national guidelines of the Nursing and Midwifery Board.
These may not be features of a Victorian medicinal cannabis
Exempt the medicinal cannabis scheme from the requirement that the
Secretary of the Department of Health maintain a public list
of persons holding licenses, permits or warrants.
Like the poppy scheme and the low-THC hemp scheme, it is not desirable to
require the Secretary to make public the details of licence-
holders under a
Victorian medicinal cannabis scheme.
Section 118 of the Act is used to exempt the poppy scheme and can be used
to similarly exempt medicinal cannabis licence-holders.
Table 3: Establishing a mechanism by which classes of patient may be
deemed eligible to access medicinal cannabis products under the
Poisons and Controlled Substances Act 1981
Explanation
Enable the Governor in Council to make regulations setting out categories
of eligibility to the scheme
The Commission has recommended that the conditions and symptoms that
entitle patients to access medicinal cannabis be set out in
regulations.
Table 4: Enabling medicinal cannabis to be lawfully possessed by amending
Drugs, Poisons and Controlled Substances Regulations 2006
Explanation
Enable a person who holds a licence to cultivate or
manufacture medicinal cannabis under the Act to possess medicinal cannabis
to the extent authorised by the licence.
If medicinal cannabis is exempted from the poisons schedules, it would be
necessary to re-apply certain regulations about possession
to medicinal
This would mean authorising the holder of a cannabis cultivation licence or
cannabis manufacturing licence, and their employees and
contractors, to possess
medicinal cannabis in the way permitted by the licence.
It could be achieved through amending r 5(1) item 1, or, more likely,
through the creation of a new regulation so as to better separate
out medicinal
cannabis licences from other licences, permits and warrants.
Enable the carriers or employees of a carrier to possess medicinal cannabis
for delivery to the person to whom
it is addressed, as consigned to them by a licence-holder or a medical
practitioner
If medicinal cannabis is exempted from the poisons schedules, it would be
necessary to re-apply certain regulations about possession
to medicinal
This would mean enabling a carrier service to transport medicinal cannabis
from a licence-holder, or a medical practitioner or pharmacist
to the person to
whom it is addressed.
It could be achieved through amending r 5(1) item 2, or through the
creation of a new regulation.
Enable a person to possess medicinal cannabis supplied to them by a
registered medical practitioner or pharmacist to the extent and
for the purpose
for which it supplied.
If medicinal cannabis is exempted from the poisons schedules, it would be
necessary to re-apply certain regulations about possession
to medicinal
This amendment would enable a person who has lawfully received medicinal
cannabis from a doctor or pharmacist to possess it for the
purpose intended,
most obviously medical use.
It could be achieved through amending r 5(1) item 3, or through the
creation of a new regulation.
Explanation
Enable a nurse to possess medicinal cannabis to the extent necessary for
administration to a
patient in accordance with the instructions
of a registered medical practitioner
If medicinal cannabis is exempted from the poisons schedules, it would be
necessary to re-apply certain regulations about possession
to medicinal
This would mean enabling a nurse to administer medicinal cannabis to their
patient on the instructions of a registered medical practitioner.
It could be achieved through amending r 5(2), or through the creation of a
new regulation.
Enable a nurse to possess medicinal cannabis while not under the direct
supervision of a registered medical practitioner, on determination
Secretary of the
Department of Health and Human Services.
If medicinal cannabis is exempted from the poisons schedules, it would be
necessary to re-apply certain regulations about possession
to medicinal
This amendment would enable a nurse to administer medicinal cannabis to
their patient while not being directly supervised by a medical
practitioner. The
power is only to be used by the Secretary of the Department of Health and Human
when necessary. It could be achieved
through amending rr 5(3) and (4), or
through the creation of a new regulation.
Enable a registered medical practitioner
to authorise treatment with medicinal cannabis
A new regulation should be inserted setting out the assessment to
be made by a medical practitioner about whether it is appropriate to
authorise the patient to access cannabis. Currently, r 8 requires
medical practitioner assess a patient’s therapeutic need for any drug of
dependence before prescribing it to the patient.
Amendments could use the same
wording or adopt a new test.
Prohibit a pharmacist from supplying medicinal cannabis
to a person for their therapeutic use otherwise than on the basis of an
Authority to Dispense.
Currently, r 12 requires that a pharmacist may supply a drug of dependence
to a person without a prescription after making an assessment
person’s therapeutic need.
The Commission has recommended that pharmacists be permitted to dispense
medicinal cannabis only upon receiving an Authority
to Dispense from a medical practitioner. Regulation 12 should be changed to
reflect this. The term ‘drug of dependence’
in r 12 should be
qualified by ‘other than medicinal cannabis’.
A new regulation should be inserted prohibiting a pharmacist from supplying
cannabis based on an assessment of a patient’s therapeutic
Enable a pharmacist to supply medicinal cannabis to a person who provides
them with an Authority to Dispense issued by a medical practitioner
in relation
to the person.
There is no regulation authorising pharmacists to administer, sell or
supply medicinal cannabis to patients. A new regulation is required
pharmacist to administer, sell or supply medicinal cannabis upon being presented
with an Authority to Dispense by a patient.
This could be achieved by amending r 15 or through the creation of a new
regulation.
Explanation
Enable the Secretary of the Department
of Health to issue permits to specialist medical practitioners
to authorise treatment with medicinal cannabis
There is no regulation authorising the Secretary to issue medicinal
cannabis permits to specialist medical practitioners. A new regulation
required granting the Secretary this power.
This could be achieved through amending r 22B or through the creation of a
new regulation.
Table 5: Enabling medicinal cannabis to be lawfully supplied by amending
Drugs, Poisons and Controlled Substances Regulations 2006
Explanation
Enable medical practitioners with the requisite permit
to authorise patients to obtain medicinal cannabis from pharmacists.
There is no regulation identifying the medical practitioners who can
authorise patients to access medicinal cannabis.
A new regulation is required enabling eligible medical practitioners who
are authorised by the requisite permit to authorise treatment
with medicinal
This would require a new regulation modelled on r 25.
Enable the Secretary of the Department
of Health and Human Services to determine the style and particulars of an
Authority to Dispense medicinal cannabis.
There is no regulation setting out the style and particulars of a medicinal
cannabis Authority to Dispense.
A new regulation is required enabling the Secretary of the Department of
Health and Human Services to establish the manner of writing
that constitutes a
valid Authority to Dispense, in the manner of r 26(1)(b). Like r 26(2), the
Secretary should have regard to security,
legibility and anything else the
Secretary regards as relevant.
Appropriately modified versions of subss (4) (prohibiting an Authority to
Dispense being in secret code) and (5) (prohibiting the
inclusion of particulars
that are false or misleading) should be incorporated into any new
regulation.
Require pharmacists to verify the details of an Authority to Dispense
before supplying medicinal cannabis.
There is no regulation requiring pharmacists to verify the details of an
Authority to Dispense medicinal cannabis. Such verification
is required for
prescriptions for medicines in Schedules 8 and 9.
A modified version of r 28 could require the pharmacist to take reasonable
steps to ensure the Authority to Dispense is from the eligible
medical practitioner from whom it purports to have been issued.
Require the suppliers of medicines to label medicinal cannabis products
with certain details.
There is no regulation requiring the supplier of a medicinal cannabis
product to label it with information about the name of the patient,
the date of
recording, the name, address and phone number of the supplier and the name of
the medicinal cannabis product.
A modified version of r 29 should indicate to pharmacists (in particular)
when they have to label medicinal cannabis products with
instructions about
Explanation
Require pharmacists to label medicinal cannabis products with details
when supplied and the date of the supply.
There is no regulation requiring the supplying pharmacist to identify that
a medicinal cannabis product has been supplied and mark
the date and premises of
the supply.
Further, r 30 prohibits the supply of a prescription medicine where more
than 12 months have passed since the date of the prescription
(in the case of a Schedule 4 poison) or 6 months have passed since the
prescription date (in the case of Schedule 8 and 9 poisons).
A modified version of r 30 should indicate to pharmacists how they must
label and date the supply of a medicinal cannabis product,
and the circumstances in which they must not supply it because the
Authority to Dispense is out of date.
Set out the circumstances where
a pharmacist must not supply on an Authority to Dispense
There is no regulation directing a pharmacist not to supply a medicinal
cannabis product when presented with an Authority to Dispense
that is forged,
altered, illegible, or concerns a product that has already
been supplied. Nor is there a requirement that a pharmacist not supply
medicinal cannabis products in excess of the Authority to Dispense.
A modified version of r 31 should require a pharmacist not to supply
medicinal cannabis products upon a defective Authority to Dispense
or in excess
of the amount authorised. Like r 31, a pharmacist should
be required to notify Victoria Police and the Secretary when presented with
a defective Authority to Dispense.
Alternatively, a supply of a medicinal cannabis product in excess of
the amount specified in the Authority to Dispense could be treated as
unauthorised supply of a drug of dependence as prohibited by
Part V of the
Require pharmacists to notify the authorising medical practitioner when
they believe a patient has sought multiple authorisations
from multiple medical
practitioners
There is no regulation requiring a pharmacist to notify a medical
practitioner when they believe the authorised patient has obtained
cannabis from them in the past eight weeks by using an Authority to Dispense
issued by another medical practitioner.
A modified version of r 32 could require the pharmacist to notify an
authorising medical practitioner if they believe multiple authorities
to dispense have been obtained. Such a requirement may not be necessary,
because the permit system proposed by the Commission may
adequately prevent
multiple authorities being sought by a patient.
Require pharmacists to retain Authority to Dispense
There is no regulation requiring pharmacists to take possession of and
retain an Authority to Dispense once all of the medicinal cannabis
it authorises
has been supplied.
A modified version of r 33 could impose this requirement, and require it to
be made available to authorised officers on request.
Table 6: Establishing rules for the lawful storage of medicinal cannabis
by amending the
Drugs, Poisons and Controlled Substances Regulations 2006
Explanation
Require anyone entitled to possess medicinal cannabis to store it as a
Schedule 8 or 9 poison
There is no regulation that specifically requires medicinal cannabis to be
stored. If medicinal cannabis is exempted from the poisons
schedules, it is
necessary to re-apply the rules around storage to medicinal cannabis.
Regulation 35 could be amended to include medicinal cannabis to be stored
similarly to Schedule 8 and 9 poisons.
Require anyone entitled to possess medicinal cannabis to fix and secure
their storage facility
There is no regulation requiring medicinal cannabis to be kept in a locked
storage facility that is fixed to the ground, as is required
with Schedule 8
and 9 poisons.
Regulation 36(1)(b) could be amended to extend these requirements
to medicinal cannabis. Amendments may also be required to r 36(2) to
clarify which people would be subject to the storage requirement.
Provide the Secretary with the power to require additional security for
medicinal cannabis
There is no regulation authorising the Secretary to direct persons who
store cannabis to provide additional security. This power should
be introduced
into the regulations. Medicinal cannabis would have to be incorporated into r 37
or a new regulation made.
Table 7: Establishing rules for recording transactions in medicinal
cannabis by amending the
Drugs, Poisons and Controlled Substances Regulations
Table 8: Establishing rules for administering medicinal cannabis by
amending the
Drugs, Poisons and Controlled Substances Regulations 2006
Explanation
Require a person supplied medicinal cannabis for treating
a specific person only to administer it to that person
Currently, persons are prohibited by r 45 from administering poisons in
Schedules 4, 8 and 9 to a person other than the person for
whom the poison was
supplied. These obligations should be extended to medicinal cannabis. In the
absence of such an extension, because
medicinal cannabis is a drug of
dependence, this administration could amount to unauthorised supply and fall
within Part V of the
Require orders for
the administration of medicinal cannabis to be legible and durable
A registered medical practitioner who orders the administration of a poison
in Schedules 4, 8 or 9 is required by regulation 46 to
do so in a way that is
legible and durable, and must date and sign the
order. These requirements should be extended to orders to administer
medicinal cannabis.
Set rules for the administration of medicinal cannabis by nurses
Regulation 47(1) sets out the circumstances in which a nurse may administer
a Schedule 9 poison consistently with the directions for
use or instructions by
a registered medical practitioner. These rules should be adapted to the
administration of medicinal cannabis
by a nurse.
If a new regulation on the possession of medicinal cannabis were inserted,
attention would have to be given to r 47(1)(e), which refers
to r 5(2) and (3)
to determine when a nurse may administer cannabis.
Restrict the self- administration and prohibiting the self- authorisation
and self- supply of medicinal cannabis
Regulation 48 restricts the circumstances in which a person can
self-administer poisons in Schedules 4, 8 and 9. It prohibits medical
practitioners from self-prescribing or self-administering cannabis.
prohibitions on Schedule 9 poisons should be extended to medicinal cannabis. In
adapting r 48(a), it would be necessary to reflect
that cannabis is not
‘prescribed’ like a Schedule 9 poison, but is authorised.
Because medicinal cannabis is a drug of dependence, self- administration
by a medical practitioner would be unauthorised supply and
also fall within Part
V of the Act.
Prohibit the supply or administration of medicinal cannabis to support drug
Regulation 49 prohibits persons from administering,
‘prescribing’, selling or supplying drugs of dependence merely for
the purpose of supporting a person’s drug dependence.
In adapting r 49, it would be necessary to reflect that medicinal cannabis
is not ‘prescribed’ like a Schedule 9 poison,
authorised.
Table 9: Establishing rules for the destruction of medicinal cannabis by
amending the
Drugs, Poisons and Controlled Substances Regulations 2006
Explanation
Prohibit the wilful destruction of medicinal cannabis
Currently, r 50 prohibits persons from wilfully destroying poisons in
Schedules 8 and 9. This prohibition should be extended to medicinal
Create exceptions to the rule that medicinal cannabis must not be wilfully
Regulation 51 creates a number of exemptions allowing poisons in Schedules
8 and 9 to be destroyed in certain circumstances. These
exemptions should be
extended to medicinal cannabis.
Table 10: New offences under a Victorian medicinal cannabis scheme to be
provided in the
Drugs, Poisons and Controlled Substances Act 1981
Drugs, Poisons and Controlled Substances Regulations 2006
Conduct to be prohibited
Section capturing conduct
Explanation
An authorised patient supplies medicinal cannabis to an unauthorised
Section 71AC
No new offence required
An authorised patient would only be authorised to possess and use medicinal
cannabis; if they supplied it to another person they would
be trafficking
without being authorised.
A carer supplies medicinal cannabis to an unauthorised person
Section 71AC
No new offence required
A nominated carer would only be authorised to possess medicinal cannabis
and to administer it to their registered patient; if they
supplied to another
person they would be trafficking without being authorised.
A patient misleads or deceives medical practitioner in order
to obtain an Authority to Dispense to obtain medicinal cannabis
Amendment required
Additions may be required to reflect the
‘Authority to Dispense’ procedure proposed for medicinal
cannabis – presently references are only to prescriptions
A doctor seeks a permit in relation to a patient who is not eligible for
medicinal cannabis
Closest offence is r 8
New offence is required
An amendment or new provision would be required because regulation 8 refers
‘prescription’.
Medicinal practitioners who issued an Authority to Dispense medicinal
cannabis would not be required to ‘prescribe’. Authorising
who is ineligible should still be penalised.
A pharmacist supplies cannabis products which were not made under
government licence
Sections 71 to 71AC
No new offence required
Pharmacists would only be authorised to possess and supply ‘medicinal
cannabis products’ made under licence and supplied
by the Secretary of the
Department of Health and Human Services. Supply of other products would
contravene the prohibition on trafficking.
A person other than
a pharmacist supplies cannabis products (whether or not made under
government licence)
Sections 27, 71 to
No new offence required
Only pharmacists would be authorised to supply medicinal cannabis products.
Anyone else who does so would engage in:
• the sale of a poison or controlled substance when not authorised or
licensed to do so, and
• trafficking.
Conduct to be prohibited
Section capturing conduct
Explanation
A person other than a licensed cultivator grows cannabis for medicinal
Sections 72 to 72B
No new offence required
Under the scheme, only licensed cultivators would be authorised to
cultivate cannabis for medicinal purposes. Anyone else who does
so engages in
cultivating a narcotic plant without being authorised or licensed to do
A person other than a licensed manufacturer produces medicinal cannabis
Sections 23, 71 to
No new offence required
Under the scheme, only licensed manufacturers would be authorised to
manufacture medicinal cannabis products. Anyone else who did
so would engage
• trafficking a drug of dependence in contravention of s 71AC
(manufacture is within the meaning of traffick)
• and the manufacture of a poison or controlled substance when not
authorised or licensed to do so in contravention of s 23.
If the manufacturer did not have a licence from the Commonwealth, they
would also probably breach the
Narcotic Drugs Act
An employee of a cultivator or manufacturer misappropriates cannabis
without authority of the employer or outside of the terms of
statutory authorisation
Crimes Act 1958
No new offence required
This would be theft. If the cannabis was sold or given to a third party it
would also be trafficking.
A licensed cultivator or manufacturer supplies cannabis to someone other
than a licensed manufacturer/the Office of Medicinal Cannabis
Sections 71
No new offence required
This conduct would be outside what cultivators and manufacturers are
licensed to do, and would therefore amount to trafficking in
dependence.
A person represents that a product they are selling is an approved
medicinal cannabis product when it is not.
The closest offence is that of ‘trafficking’ in
sections 71
New offence could be created
This conduct would punish persons who sold unapproved medicinal cannabis
products under false pretences. Such conduct would be trafficking
dependence in a way that is unauthorised by the Act and captured by ss 71
If the government wished to punish this offence differently or make the
fault elements of the offence clearer, it could create a new
offence covering
this conduct.
Bibliography
Bibliography
2012 Symposium: ‘Practical, Legal, and Ethical Perspectives on Medical
Marijuana (Transcription of
Speakers’ Remarks)’ (2012) 16
Michigan State University
Journal of Medicine and Law
Abrams, D I et al, ‘Vaporization as a Smokeless Cannabis Delivery
System: A Pilot Study’ (2007) 82
Clinical Pharmacology and Therapeutics
ACON and others,
Submission to NSW Legislative Council Inquiry into the
Use of Cannabis for
Medical Purposes
(February 2013)
Allsop, David et al,
Submission No 52 to the Senate Legal and
Constitutional Affairs Legislation Committee, Parliament of Australia, Inquiry
Regulator of Medicinal Cannabis Bill 2014
(March 2015)
American Academy of Neurology, ‘Epidiolex (Cannabidiol) in Treatment
Resistant Epilepsy’, Abstract of presentation to
the American Academy of
Neurology 67th Annual Meeting,
22 April 2015
American Glaucoma Society,
Position Statement on Marijuana and the
Treatment of Glaucoma
10 August 2009 <
www.americanglaucomasociety.net
American Psychiatric Association,
Diagnostic and Statistical Manual of
Mental Disorders
(5th ed, 2013)
Arizona Department of Health Services,
Arizona Medical Marijuana Act
(AMMA) End of Year
www.azdhs.gov
Armentano, Paul, ‘Cannabis and Psychomotor Performance: A Rational
Review of the Evidence and
Implications for Public Policy’ (2012) 5
Drug Testing and Analysis
Australian and New Zealand College of Anaesthetists Faculty of Pain Medicine,
Statement on
Patients’ Rights to Pain Management and Associated Responsibilities
(Position Statement No 45,
www.fpm.anzca.edu.au
Australian Health Ministers’ Advisory Council
, Scheduling Policy
Framework for Medicines and
Australian Lawyers Alliance,
Submission No 55 to the Senate Legal and
Constitutional Affairs
Legislation Committee, Parliament of Australia, Inquiry into the
of Medicinal Cannabis Bill
(March 2015)
Bachhuber, Marcus A et al, ‘Medical Cannabis Laws and Opioid Analgesic
Overdose Mortality in the United States, 1999–2010’
JAMA Internal Medicine
Backes, Michael,
Cannabis Pharmacy
(Black Dog & Leventhal,
Baron, E P, ‘Comprehensive Review of Medicinal Marijuana, Cannabinoids
and Therapeutic
Implications in Medicine and Headache: What a Strange Trip It’s
Been...’ (June 2015) 55
Bedrocan BV,
Submission No 48 to the Senate Legal and Constitutional
Affairs Legislation Committee, Parliament of Australia, Inquiry into the
Regulator of Medicinal Cannabis Bill 2014
(March 2015)
Belendiuk, Katherine A, Lisa L Baldini and Marcel O Bonn-Miller,
‘Narrative Review of the Safety and Efficacy of Marijuana
Treatment of Commonly State-Approved Medical and Psychiatric Disorders’
(2015) 10(10)
Addiction Science & Clinical Practice
Bewley-Taylor, David,
International Drug Control: Consensus Fractured
(Cambridge University Press,
Blake, D R, ‘Preliminary Assessment of the Efficacy, Tolerability and
Safety of a Cannabis- Based Medicine (Sativex) in the
Treatment of Pain Caused
by Rheumatoid Arthritis’ (2006)
Rheumatology
Bloor, Roger et al ‘Ammonia Release from Heated “Street”
Cannabis Leaf and Its Potential Toxic
Effects on Cannabis Users’ (2008) 103
Bonn-Miller, M O et al, ‘Posttraumatic Stress Symptom Severity Predicts
Marijuana Use Coping
Motives Among Traumatic Event-Exposed Marijuana Users’ (2007) 20
Journal of Traumatic Stress
Bostwick, Michael J, ‘Blurred Boundaries: The Therapeutics and Politics
of Medical Marijuana’ (2012) 87
Mayo Clinic Proceedings
Brenner, Michelle,
Conversations on Compassion
(Create Space,
Burns, Patricia B, Rod J Rohrich and Kevin C Chung, ‘The Levels of
Evidence and Their Role in
Evidence-Based Medicine’ (2011) 128
Plastic Reconstructive Surgery
Canada Border Services Agency
, Importation and Exportation of Controlled
Substances and
Canadian Medical Association,
CMA Statement Authorizing Marijuana for
Medical Purposes
(Update 2015)
Canadian Medical Protective Association,
Medical Marijuana: New
Regulations, New College
Guidance for Canadian Doctors
, (Document number W14-005-E, May 2014,
revised July 2015)
www.cmpa-acpm.ca
Cancer Council Australia and Clinical Oncology Society of Australia
— Submission No 37 to the Senate Legal and
Constitutional Affairs Legislation Committee, Parliament of Australia, Inquiry
Regulator of Medicinal Cannabis Bill 2014
— Position Statement—Medical Use of Cannabis
, 21 May 2015
www.cosa.org
Cancer Research UK,
A Trial Looking at Sativex with Temozolomide for
Glioblastoma Multiforme
Brain Tumour (GWCA1208)
, 29 May 2015 <
www.cancerresearchuk.org
Caplan, Gerald, ‘Medical Marijuana: A Study of Unintended
Consequences’ (2012) 43
Carter, G T et al, ‘Cannabis and Amyotrophic Lateral Sclerosis:
Hypothetical and Practical Applications, and a Call for Clinical
American Journal of Hospice and Palliative Care
Carter, Gregory T and Bill S Rosen, ‘Marijuana in the Management of
Amyotrophic Lateral
Sclerosis’ (2001) 18
American Journal of Hospice & Palliative
Castle, David, Robin M Murray and Deepak Cyril D’Souza (eds),
Marijuana and Madness
, (2nd ed, Cambridge University Press, 2012)
Caulkins, Jonathan et al,
Considering Marijuana Legalisation: Insights for
Vermont and Other
(RAND Corporation, 2015)
Caulkins, Jonathan P et al,
Marijuana Legislation: What Everyone Needs to
(Oxford University
Press, 2012)
Chu, Yu-Wei, ‘The Effects of Medical Marijuana Laws on Illegal
Marijuana Use’ (2014) 38
Journal of Health Economics
ClinicalTrials.Gov,
A Study: Pure CBD as a Single-Agent for Solid Tumor
(NCT02255292
1 October 2014, <
www.clinicaltrials.gov
Collège des Médecins du Québec,
Guidelines Concerning
the Prescription of Dried Cannabis for
Medical Purposes
(April 2014)
College of Family Physicians of Canada
— Authorizing Dried Cannabis for Chronic Pain or Anxiety:
Preliminary Guidance
(September 2014)
— Statement on Health Canada’s Proposed Changes to Medical
Marijuana Regulations
(Position Statement, February 2013)
College of Physicians and Surgeons of British Columbia,
Professional
Standards and Guidelines: Marijuana for Medical Purposes
(5 May 2015)
Collett, Stephen C, Tom Gariffo, Marisa Hernandez-Morgan,
Evaluation of
the Medical Marijuana Program in Washington, DC
, University of California,
Los Angeles Luskin School of Public Affairs (2013)
Collier, Joe, ‘Paediatric Prescribing: Using Unlicensed Drugs and
Medicines Outside Their Licensed
Indications’ (1999) 48
British Journal of Clinical Pharmacology
Colorado Department of Public Health & Environment,
Medical Marijuana
Registry Program
, 30 June 3015 <
www.colorado.gov
> Commonwealth Department
— Medicinal Cannabis
(27 May 2015) <
www.health.gov.au
— Submission No 67 to the Legal and Constitutional Affairs
Legislation Committee, Inquiry into
Regulator of Medicinal Cannabis Bill 2014
— The National Strategy for Quality Use of Medicines: Executive
(2002) Commonwealth Department of Health—Therapeutic Goods
Administration
— About the Work of the TGA—A Risk Management Approach
August 2011)
— Access to Unapproved Therapeutic Goods via the Special Access
— Access to Unapproved Therapeutic Goods: Personal Importation
— Australian Public Assessment Report for Nabiximols
September 2013)
— Australian Regulatory Guidelines for Complementary Medicines
(version 5.2, May 2015)
— Australian Requirements and Recommendations for Pharmacovigilance
Responsibilities of
Sponsors of Medicines
(4 June 2014)
— Authorised Prescribers
(14 July 2015)
— Benefits Versus Risks Approach to Regulating Therapeutic Goods
(8 February 2015)
— Good Manufacturing Practice
(29 April 2013)
— Mandatory Requirements for an Effective Application
— Manufacturer Inspections—An Overview
(1 May 2013)
— Reporting Medicine and Vaccine Adverse Events
(28 October
— Medicines and Vaccines Post-Market Vigilance—Statistics for
(26 May 2015)
— Medicines Regulation and the TGA
— Role of the Sponsor
(28 March 2013)
— TGA Labelling and Packaging Regulatory Framework
October 2014)
— The Therapeutic Goods Administration’s Risk Management
Approach to the Regulation of
Therapeutic Goods
Commonwealth Department of Health—Therapeutic Goods Administration
(Advisory Committee on Medicines Scheduling),
Final Decisions and Reasons for
Decisions by Delegates of the Secretary to the Department of Health, March 2015
(19 March 2015)
Commonwealth Department of Infrastructure and Regional Development,
Australian Government, Fact Sheet:
Answers to Your Questions from the
Information Sessions
Cougle, J R et al, ‘Posttraumatic Stress Disorder and Cannabis Use in a
Nationally Representative
Sample’ (2011) 25
Psychologically Addictive Behaviors
Council of Australian Therapeutics Advisory Groups,
Rethinking Medicines
Decision-Making in
Public Hospitals: Guiding Principles for the Quality Use of Off-Label
(November 2013)
Cridge, Belinda J and Rhonda J Rosengren, ‘Critical Appraisal of the
Potential Use of Cannabinoids in Cancer Management’
Management and Research
Curtis, Adrienne, Carl E Clarke and Hugh E Rickards, ‘Cannabinoids
for Tourette’s Syndrome’ (2009) 4
Cochrane Database of Systematic
Decorte, Tom, ‘Cannabis Social Clubs in Belgium: Organisational
Strengths and Weaknesses, and
Threats to the Model’ (2014) 26
International Journal of Drug Policy
Decorte, Tom et al (eds)
World Wide Weed: Global Trends in Cannabis
Cultivation and Its Control
(Ashgate, 2011)
Deepak Cyril D’Souza and Mohini Ranganathan, ‘Medical Marijuana:
Is the Cart Before the Horse?’ (2015) 313
Journal of the American
Medical Association
Degenhardt, Louisa and Wayne D Hall, ‘The Adverse Effects of
Cannabinoids: Implications for
Use of Medical Marijuana’ (2008) 178(13)
Canadian Medical
Association Journal
Delourme, J et al, ‘Respiratory Consequences of Inhalation of
Adulterated Cannabis’ (2009) 26
La Revue des Maladies Respiratoires
552 (French)
Delsys Research Group,
Final Report: Cost-Benefit Analysis of Regulatory
Changes for Access to
Marihuana for Medical Purposes
Dhanapal, Raghu, T R Saraswathi and Rajkumar N Govind, ‘Cancer
Cachexia’ (2011) 15
Oral and Maxillofacial Pathology
Downey, L A et al, ‘The Effects of Cannabis and Alcohol in Simulated
Driving: Influences of Dose and Experience’ (2013)
Accident Analysis
and Prevention
Drummer, Olaf et al, ‘The Involvement of Drugs in Drivers of Motor
Vehicles Killed in Australian
Road Traffic Crashes’ (2003) 943
Accident Analysis and Prevention
Dyer, Owen, ‘The Growth of Medical Marijuana’ (2013)
Medical Journal
Enterprise One Pain Management Service,
Patient Outcomes in Pain
(31 December 2014)
Epilepsy Australia,
Medical Marijuana in the Treatment of Epilepsy
October 2014)
European Medicines Agency
— Guideline on Good Agricultural and Collection Practice (GACP) for
Starting Materials of
Herbal Origin
(EMEA/HMPC/246816/2005)
— Guideline on Stability Testing: Stability Testing of Existing
Active Substances and Related
Finished Products
(CPMP/QWP/122/02, rev 1)
— Quality of Herbal Medicinal Products/Traditional Herbal Medicinal
(CPMP/ QWP/2819/00 Rev. 2)
— Test Procedures and Acceptance Criteria for Herbal Substances,
Herbal Preparations and Herbal Medicinal Products/Traditional
Herbal Medicinal
(EMA/CPMP/ QWP/2820/00 Rev 2)
Faculty of Pain Medicine, Australian and New Zealand College of
Anaesthetists,
Statement on
‘Medicinal Cannabis’ with Particular Reference to its Use in
the Management of Patients with
Chronic Non-Cancer Pain
(PM 10, 2015)
Families and Friends for Drug Law Reform,
Submission No 82 to the ACT
Standing Committee
on Health, Ageing, Community and Social Services, Exposure Draft of the
Drugs of Dependence
(Cannabis Use for Medical Purposes) Amendment Bill 2014
, 16 February
Farrell, Michael, Rachelle Buchbinder and Wayne Hall, ‘Should Doctors
Prescribe Cannabinoids?’ (2014) 348
British Medical Journal
Federal Institute for Drugs and Medical Devices (Germany),
Fitzcharles, Mary-Ann et al, ‘The Dilemma of Medical Marijuana Use by
Rheumatology Patients’ (2014) 66
Arthritis Care & Research
Flach, A J, ‘ Delta-9-tetrahydrocannabinol (THC) in the Treatment of
End-Stage Open-Angle
Glaucoma’ (2002) 100
Transactions of the American Ophthalmological
Forrester, Kim, Debra Griffiths,
Essentials of Law for Medical
Practitioners
Freckelton, Ian, ‘Medicinal Cannabis Law Reform: Lessons from Canadian
Litigation’ (2015) 22
Journal of Law and Medicine
Frezza, Claire, ‘Medical Marijuana: A Drug Without a Medical
Model’ (2013) 101
Georgetown Law
Galloway, Kevin T et al, ‘War on Pain: Multimodal and
Multidisciplinary Therapy for Pain
Management’ (2011) 6(9)
American Nurse Today
www.americannursetoday.com
General Purpose Standing Committee No 4, Legislative Council of the
Parliament of New South
The Use of Cannabis for Medical Purposes
Gloss, G and B Vickrey, ‘Cannabinoids for Epilepsy: Review’
Cochrane Database of
Systematic Reviews
Grant, I et al, ‘Non-Acute (Residual) Neurocognitive Effects of
Cannabis Use: A Meta-Analytic
Study’ (2003) 9
Journal of the International Neuropsychological
Green, Keith, ‘Marijuana Smoking vs Cannabinoids for Glaucoma
Therapy’ (1998) 116
Archives of
Ophthalmology
Gregorio, Joseph, ‘Physicians, Medical Marijuana and the Law’
Virtual Mentor
Grotenhermen, Franjo and Ethan Russo (eds)
Cannabis and Cannabinoids:
Pharmacology, Toxicology, and Therapeutic Potential
(Haworth Press,
GW Pharmaceuticals
, Cancer Pain
www.gwpharm.com
Hakkarainen, Pekka et al, ‘Growing Medicine: Small-Scale Cannabis
Cultivation for Medical
Purposes in Six Different Countries’ (2015) 26
International Journal
of Drug Policy
Hall, Wayne, ‘What has Research Over the Past Two Decades Revealed
Effects of Recreational Cannabis Use?’ (2014) 110
Hamadeh, R et al, ‘Fatal Aspergillosis Associated with Smoking
Contaminated Marijuana, in a
Marrow Transplant Recipient’ (1988) 94
Hartman, Rebecca and Marilyn Huestis, ‘Cannabis Effects on Driving
Skills’ (2013) 59
Hasin, Debra S et al, ‘Medical Marijuana Laws and Adolescent Marijuana
Use in the USA from
1991 to 2014: Results from Annual, Repeated Cross-sectional Surveys’
The Lancet Psychiatry
http://dx.doi.org/10.1016/S2215-0366(15)00217-5
Hazekamp, A and J T Fischedick, ‘Cannabis—From Cultivar to
Chemovar’ (2011) 4
Drug Testing and Analysis
Hazekamp, Arno, ‘An Evaluation of the Quality of Medicinal Grade
Cannabis in the Netherlands’ (2006) 1
Cannabinoids
Health Canada
— Approval of Sativex with Conditions: Fact Sheet
— Authorization with Conditions of Sativex
(1 August 2007)
— Import and Export of Marijuana by Licensed
Producers—Information Bulletin
, 8 June 2015
— Information for Health Care Professionals: Cannabis (Marihuana,
Marijuana) and the
Cannabinoids
(February 2013)
— Medical Marihuana Regulatory Reform 2011 Consultations
— Proposed Improvements to Health Canada’s Marihuana Medical
Access Program
(31 March 2013)
— Section 56 Class Exemption for Licensed Producers Under the
Marihuana for Medical
Purposes Regulations to Conduct Activities with Cannabis
— Statement on Supreme Court of Canada Decision in R v Smith
Hillig, Karl W, ‘Genetic Evidence for Speciation in Cannabis
(Cannabaceae)’ (2005) 52
Resources and Crop Evolution
House of Commons Science and Technology Committee, United Kingdom Parliament,
Check 2: Homeopathy
(HC 45) Fourth Report of Session 2009–10
(2010) IASP Task Force on Taxonomy,
Classification of Chronic Pain
ed, 1994) International Narcotics Control Board
— Contribution to the High-Level Review of the Implementation by
Member States of the Political Declaration and Plan of Action
on International
Cooperation Towards an Integrated and Balanced Strategy to Counter the World
Drug Problem
— Guide on Estimating Requirements for Substances under
International Control
— Report of the International Narcotics Control Board for 2014
(E/INCB/2014/1)
John Ramsay & Associates,
Review of the Tasmanian Poppy Industry
Regulation: Report
(July 2013) Jung, Julia et al, ‘Studies on the
Metabolism of the Δ9-Tetrahydrocannabinol Precursor Δ9-
Tetrahydrocannabinolic Acid A (Δ9-THCA-A) in Rat Using LC-MS/MS, LC-QTOF
MS and GC-MS
Techniques’ (2009) 44
Journal of Mass Spectrometry
Kahan, Meldon et al, ‘Prescribing Smoked Cannabis for Chronic Noncancer
Pain: Preliminary
Recommendations’ (2014) 60
Canadian Family Physician
Kalant, Harold and Amy J Porath-Waller, ‘Medical Use of Cannabis and
Cannabinoids’ (2014)
Canadian Centre on Substance Abuse Clearing the Smoke on Cannabis
(Report Series No 5, 2014)
Kehl, L J, ‘A Cannabinoid Agonist Differentially Attenuates Deep Tissue
Hyperalgesia in Animal
Models of Cancer and Inflammatory Muscle Pain’ (2003) 103
Kondrad, Elin and Alfred Reid, ‘Colorado Family Physicians’
Attitudes Toward Medical Marijuana’ (2013) 26
Journal of the American
Board of Family Medicine
Koppel, B S et al, ‘Systematic Review: Efficacy and Safety of Medical
Marijuana in Selected Neurological Disorders: Report
of the Guideline
Subcommittee of the American Academy of Neurology’ (2014) 82
Kramer, Joan, ‘Medical Marijuana for Cancer’ (2015) 65
Cancer Journal for Clinicians
Lal, S et al, ‘Cannabis Use Among Patients with Inflammatory Bowel
Disease’ (2011) 23
Journal of Gastroenterological & Hepatology
Legislative Council General Purpose Standing Committee No 4, Parliament of
New South Wales,
The Use of Cannabis for Medical Purposes
Legislative Council Government Administration Committee ‘A’,
Parliament of Tasmania
Report on Legalised Medicinal Cannabis
Lenné, M G et al, ‘The Effects of Cannabis and Alcohol on
Simulated Arterial Driving: Influences of Driving Experience
Demand’ (2010) 42
Accident Analysis and Prevention
Lenné, Michael, Tom Triggs and Michael Regan,
Cannabis and Road
Safety: A Review of Recent Epidemiological Driver Impairment, and Drug Screening
’ Report No 23, Monash University Accident Research Centre
Linger, P, A Ostwald and J Haensler, ‘Cannabis Sativa L. Growing on
Heavy Metal Contaminated
Soil: Growth, Cadmium Uptake and Photosynthesis’ (2005) 49
Liu, Wai, ‘Why Anti-Cancer Properties in Cannabis Must be
Investigated’,
The Conversation UK
26 June 2015
Loflin, Mallory and Mitch Earleywine, ‘No Smoke, No Fire: What the
Initial Literature Suggests Regarding Vapourized Cannabis
and Respiratory
Risk’ (2015) 51
Canadian Journal of Respiratory Therapeutics
Lucas, Philippe, ‘It Can’t Hurt to Ask; A Patient-Centred Quality
of Service Assessment of Health
Canada’s Medical Cannabis Policy and Program’, (2012) 9
Reduction Journal
Lynch, Mary E and Fiona Campbell, ‘Cannabinoids for Treatment of
Chronic Non-Cancer Pain;
A Systematic Review of Randomised Trials’ (2011) 72
British Journal
of Clinical Pharmacology
Mack, Alison and Janet Joy,
Marijuana as Medicine? The Science Beyond the
Controversy
(National Academy Press, 2001)
Maisto, Stephen, Mark Galizio and Gerard Connors,
Drug Use and Abuse
(Cengage Learning,
Marcoux, Rita, E Paul Larrat and F Randy Vogenberg, ‘Medical Marijuana
and Related Legal
Aspects’ (2013) 38
Pharmacy and Therapeutics
Marks, Amber,
The Legal Landscape for Cannabis Social Clubs in Spain
(Observatorio Civil De
Drogas, 2015)
Martin-Sanchez, E et al, ‘Systematic Review and Meta-Analysis of
Cannabis Treatment for
Chronic Pain’ (2009) 10
Pain Medicine
Mather, Laurence,
Submission No 17 to the Senate Legal and Constitutional
Affairs Legislation Committee, Parliament of Australia, Inquiry into the
Regulator of Medicinal Cannabis Bill 2014
Mather, Laurence, Alex Wodak and William Notcutt, ‘Re: Should Doctors
Prescribe Cannabinoids?’
www.bmj.com/content/348/bmj.g2737/rr/701867
Mather, Laurence E et al, ‘(Re)introducing Medicinal Cannabis’
Medical Journal of
Mathern, Gary W, Laurie Beninig and Astrid Nehlig, ‘Fewer Specialists
Support Using Medical Marijuana and CBS in Treating Epilepsy
Patients Compared
with Other Medical Professionals and Patients: Results of Epilepsia’s
Survey’ (2014) 56
McLaren, Jennifer et al, ‘Cannabis Potency and Contamination: A Review
of the Literature’ (2008)
McLoughlin, B C et al, ‘Cannabis and Schizophrenia’ (2015) 41
Schizophrenia Bulletin
McLoughlin, B C et al, ‘Cannabis and Schizophrenia: Review’
Cochrane Database of
Systematic Reviews
McPartland, J M and P L Pruitt, ‘Medical Marijuana and Its Use by the
Immunocompromised’ (1997) 3
Alternative Therapies in Health and
Medical Board of Australia,
Good Medical Practice: A Code of Conduct for
Doctors in Australia
(March 2014)
Menetrey, A, M Augsburger, B Favrat et al, ‘Assessment of Driving
Capability Through the Use of Clinical and Psychomotor Tests
in Relation to
Blood Cannabinoids Levels Following Oral Administration of 20 mg Dronabinol or
of a Cannabis Decoction Made with 20
or 60 mg Delta9- THC’ (2005) 29
Journal of Analytical Toxicology
Moldzio, R et al, ‘ Effects of Cannabinoids Δ(9)
-Tetrahydrocannabinol, Δ(9)Tetrahydrocannabinolic
Acid and Cannabidiol in MPP+ Affected Murine Mesencephalic Cultures’
Phytomedicine
Munson, A E et al, ‘Antineoplastic Activity of Cannabinoids’
Journal of the National
Cancer Institute
Naftali, T et al, ‘Cannabis Induces a Clinical Response in Patients
with Crohn’s Disease: A Prospective Placebo-Controlled
Study’ (2013)
Clinical Gastroenterological & Hepatology
Naftali, T et al, ‘Treatment of Crohn’s Disease with Cannabis: An
Observational Study’ (2011) 13
Israel Medical Association Journal
National Cancer Institute,
Cannabis and Cannabinoids
, 6 November 2014
www.cancer.gov
> National Cannabis
Prevention and Information Centre
— Cannabis Withdrawal
(1 November 2011)
— Driving Under the Influence of Cannabis: A Brief Review of the
National Health and Medical Research Council,
National Statement on
Ethical Conduct in Human
Netherlands Minister for Health, Welfare and Sport,
Guidelines for
Cultivating Cannabis for Medicinal Purposes
[Voorschriften voor de Verbouw
van Cannabis voor Medicinale Doeleinden], Annex to the Regulation of the
Minister of Health, Welfare
and Sport of 9 January 2003, GMT/ BMC 2340685,
English translation reproduced in (2003) 3
Journal of Cannabis Therapeutics
New South Wales Health,
Role of Drug and Therapeutics Committee in the
Evaluation and
Approval of Medicines for Use in Public Hospitals
(Policy Directive No
PD2008_037)
New South Wales Working Party on the Use of Cannabis for Medical Purposes,
Report of the
Working Party on the Use of Cannabis for Medical Purposes
Nikles, Jane et al, ‘Stakeholders’ Views on the Routine Use of
N-of-1 Trials to Improve Clinical Care and to Make Resource
Allocation Decisions
for Drug Use’ (2010) 34
Australian Health Review
Nolan, Jim, ‘Employee Privacy in the Electronic Workplace Pt 2: Drug
Testing, Out of Hours
Conduct and References’ (2000) 7
Nurmikko, Turo J et al, ‘Sativex Successfully Treats Neuropathic Pain
Characterised by Allodynia: A Randomised, Double-Blind
Placebo-Controlled
Clinical Trial’ (2007) 133
Nurnberg, Helen et al, ‘An Analysis of Applicants Presenting to a
Medical Marijuana Specialty
Practice in California’ (2011) 4
Journal of Drug Policy Analysis
O’Connell, Cheri,
Submission No 109 to the Senate Legal and
Constitutional Affairs Legislation
Committee, Parliament of Australia, Inquiry into the
Regulator of
Medicinal Cannabis Bill 2014
Patel, Anup, ‘Medical Marijuana in Pediatric Neurological
Disorders’ (2015)
Journal of Child
Neurology (advance)
<jcn.sagepub.com>
Penington, David, ‘Medicinal Cannabis: Time for Clear Thinking’
Medical Journal of
Pertwee, Roger (ed)
Handbook of Cannabis
(Oxford University Press,
Pharmaceutical Benefits Advisory Committee
, Public Summary Document:
(July 2013) Pharmaceutical Benefits Scheme,
Nabiximols, Oral
Spray, 10 mL, Sativex
, July 2013
Pharmacy Board of Australia
— Background on the Regulation of Compounding by Pharmacists
(March 2015)
— Guidelines on Compounding of Medicines
(April 2015)
Phillips, Jennan A, Michael G Holland, Debra D Baldwin, ‘Marijuana in
the Workplace: Guidance for Occupational Health Professionals
and Employers.
Joint Guidance Statement of the American Association of Occupational Health
Nurses and the American College of Occupational
and Environmental
Medicine’ (2015) 57
Journal of Environmental Medicine
Phillips, Tudor J C et al, ‘Pharmacological Treatment of Painful
HIV-Associated Sensory Neuropathy: A Systematic Review and
Meta-Analysis of
Randomised Controlled Trials’ (2010) 5(12)
Pharmaceutical Inspection Convention: Pharmaceutical Inspection Co-Operation
Good Manufacturing Practice for Medicinal Products
(PE 009-8, 15
January 2009)
Porcella, Anna et al, ‘The Human Eye Expresses High Levels of CB1
Cannabinoid Receptor mRNA
and Protein’ (2001) 12
European Journal of Neuroscience
Potter, C M et al, ‘Posttraumatic Stress Disorder and Cannabis Use in a
Nationally Representative
Sample’ (2011) 25
Journal of Anxiety Disorders
Public Health Association of Australia,
Position Statement: Medicinal
Cannabis in Australia
Raman, C et al, ‘Amyotrophic Lateral Sclerosis: Delayed Disease
Progression in Mice by Treatment with a Cannabinoid’ (2004)
Other Motor Neuron Disorders
Rasheed, Arun, Sravya Reddy B and Roja C, ‘A Review on Standardisation
of Herbal Formulation’ (2012) 2
International Journal of Phytotherapy
Review of Medicines and Medical Devices Regulation,
Regulation of
Complementary Medicines— Addendum to Discussion Paper
Rock, E M et al, ‘Tetrahydrocannabinolic Acid Reduces Nausea-Induced
Conditioned Gaping in
Rats and Vomiting in Suncus Murinus’ (2013) 170
British Journal of
Pharmacology
Rom, Slava and Yuri Persidsky, ‘Cannabinoid Receptor 2: Potential Role
in Immunomodulation and
Neuroinflammation’ (2013) 8
Journal of Neuroimmune Pharmacology
Romano, Luigi and Arno Hazekamp, ‘Cannabis Oil: Chemical Evaluation of
an Upcoming
Cannabis-Based Medicine’ (2013) 7
Cannabinoids
Russo, Ethan
— ‘Taming THC: Potential Cannabis Synergy and
Phytocannabinoid-Terpenoid Entourage
Effects’ (2011) 163
British Journal of Pharmacology
The Solution to ‘the Medicinal Cannabis Problem’
in Michael Schatman
, Ethical Issues in
Chronic Pain Management
(Informa, 2007)
Sackett, David L et al, ‘Evidence-Based Medicine: What It Is and What
It Isn’t’ (1996) 312
Medical Journal
Sansom, Lloyd, Will Delaat and John Horvath,
Review of Medicines and
Medical Devices Regulation
Scollo, M M and M H Winstanley (eds),
Tobacco in Australia: Facts &
(4th ed, 2012, Cancer
Council Victoria)
Senate Legal and Constitutional Affairs Committee, Parliament of
, Inquiry into the
Regulator of Medicinal Cannabis Bill 2014
Seppala, Emma, ‘The Compassionate Mind’ (2013) 26
Association
for Psychological Science
www.psychologicalscience.org
Sewell, Andrew R, James Poling and Mehmet Soluoglu, ‘The Effect of
Cannabis Compared with
Alcohol on Driving’ (2009) 18
American Journal of Addiction
Standing Committee on Health, Aging, Community and Social Services, ACT
Legislative Assembly,
Inquiry into Exposure Draft of the Drugs of Dependence
(Cannabis Use for Medical Purposes) Amendment Bill 2014 and Related Discussion
(March 2015)
Tomida, I et al, ‘Effect of Sublingual Application of Cannabinoids on
Intraocular Pressure: A Pilot
Study’ (2006) 15
Journal of Glaucoma
Tomida, I, R G Pertwee and A Azuara-Blanco, ‘Cannabinoids and
Glaucoma’ (2004) 88
Journal of Ophthalmology
Tramèr, Martin R et al, ‘Cannabinoids for Control of Chemotherapy
Induced Nausea and Vomiting: Quantitative Systematic
Review’ (2001) 323
British Medical Journal
Triantafyllidi, Aikaterini et al, ‘Herbal and Plant Therapy in Patients
with Inflammatory Bowel
Disease’ (2015) 28
Annals of Gastroenterology
Vandrey, Ryan et al, ‘Cannabinoid Dose and Label Accuracy in Edible
Medical Cannabis Products’ (2015) 313
Journal of the American Medical
Association
Verhoeckx, Kitty C M et al, ‘Unheated Cannabis Sativa Extracts and Its
Major Compound THC-acid Have Potential Immuno-Modulating
Properties Not Mediated
by CB1 and CB2 Receptor Coupled Pathways’ (2006) 6
International
Immunopharmacology
Victorian Department of Health,
Policy for Maintenance Pharmacotherapy for
Opioid Dependence
Victorian Law Reform Commission,
Medicinal Cannabis: Issues Paper
Victorian Public Sector Commission,
Legal Form and Governance Arrangements
for Public Entities: Guidelines
Wachtel, Boaz,
International Medical Cannabis Policy
(11 March 2013)
http://www.slideshare.net/ SafeAccess/asa-2013-medical-cannabis-in-israel-v3
Wade, Derick T, ’A Preliminary Controlled Study to Determine Whether
Whole-Plant Cannabis
Extracts Can Improve Intractable Neurogenic Symptoms’ (2003) 17
Clinical Rehabilitation
Wang, Tongtong et al, ‘Adverse Effects of Medical Cannabinoids: A
Systematic Review’ (2008) 178
Canadian Medical Association Journal
Ware, Mark A et al, ‘Smoked Cannabis for Chronic Neuropathic Pain: A
Randomized Controlled
Trial’ (2010) 182
Canadian Medical Association Journal
Ware, Mark and Vivianne Tawfik, ‘Safety Issues Concerning the Medical
Use of Cannabis and
Cannabinoids’ (2005) 10
Pain Research and Management
Warr, David, ‘Chemotherapy- and Cancer-Related Nausea and
Vomiting’ (2008) 15
Warrell, David, Timothy M. Cox, John D Firth (eds),
Oxford Textbook of
University Press, 2003)
Watanabe, Kazuhito et al, ‘Marijuana Extracts Possess the Effects Like
the Endocrine Disrupting
Chemicals’ (2005) 206
Welty, Timothy E, Adrienne Luebke and Barry E Gidal, ‘Cannabidiol:
Promise and Pitfalls’ (2014)
Epilepsy Currents
Western Australian Department of Health and Victorian Department of Health,
Application to
Amend the Poisons Standard (Substance: Cannabidiol)
, 6 October
Whiting, Penny F et al, ‘Cannabinoids for Medical Use: A Systematic
Review and Meta-Analysis’
Journal of the American Medical
Association
Wilsey, Barth et al, ‘Low-Dose Vaporized Cannabis Significantly
Improves Neuropathic Pain’ (2012)
Journal of Pain
World Health Organisation
— Ensuring Balance in National Policies on Controlled Substances:
Guideline for Availability and
Accessibility of Controlled Medicines
— WHO Guidelines on Good Agricultural and Collection Practices
(GACP) for Medicinal Plants
Yarnell, Stephanie, ‘Marijuana for Posttraumatic Stress Disorder: A
Review of the Current Literature’ (2015) 17(3)
Primary Care Companion
for CNS Disorders
http://www.psychiatrist.com
Zajicek, J P et al , ‘Multiple Sclerosis and Extract of Cannabis:
Results of the MUSEC Trial’ (2012) 83
Journal of Neurology, Neurosurgery and Psychiatry
Zaller, N et al, ‘Profiles of Medicinal Cannabis Patients Attending
Compassion Centers in Rhode
Island’ (2015) 47
Journal of Psychoactive Drugs
Reports published by the
Victorian Law Reform Commission
1 Criminal Liability for Workplace Death
and Serious Injury in the Public Sector (2002)
2 Disputes between Co-owners (2002)
3 Failure to Appear in Court in Response to Bail
4 People with Intellectual Disabilities at Risk:
A Legal Framework for Compulsory Care (2003)
5 Sexual Offences (2004)
6 Defences to Homicide (2004)
7 Workplace Privacy (2005)
8 Implementing the
Evidence Act 1995
9 Uniform Evidence Law (2006)
10 Review of Family Violence Laws (2006)
11 Residential Tenancy Databases (2006)*
12 Assisted Reproductive Technology and Adoption
13 Review of the
Bail Act 1997
14 Civil Justice Review (2008)
15 Law of Abortion (2008)
16 Assistance Animals (2008)*
17 Jury Directions (2009)
18 Surveillance in Public Places (2010)
19 Protection Applications in the Children’s Court
20 Review of the
Property Law Act 1958
21 Supporting Young People in Police Interviews
22 Easements and Covenants (2010)
23 Sex Offenders Registration (2011)
24 Guardianship (2012)
25 Birth Registration and Birth Certificates (2013)*
26 Succession Laws (2013)
27 Jury Empanelment (2014)
28 Review of the
Crimes (Mental Impairment and Unfitness to be Tried) Act
29 The Forfeiture Rule (2014)
30 Trading Trusts—Oppression Remedies (2015)
31 Photographing and Filming Tenants’ Possessions for Advertising
Purposes (2015)*
32 Medicinal Cannabis (2015)
* community law reform
For a full list of publications see
www.lawreform.vic.gov.au
Medicinal Cannabis
r e p o r t
GPO Box 4637
Victoria 3001
333 Queen Street Melbourne Victoria 3000
+61 3 8608 7800
1300 666 555
(within Victoria)
+61 3 8608 7888
law.reform@lawreform.vic.gov.au
www.lawreform.vic.gov.au
Print (pretty)
Print (eco-friendly)
RTF format (4.02 MB)
PDF format (1.68 MB)
LawCite records
NoteUp references
Join the discussion
Tweet this page
Follow @AustLII on Twitter